[
  {
    "raw_text": "What is the main cause of hiv-1 infection in children?",
    "new_text": "What is the main [Etiology aspects] / cause of [Human immunodeficiency virus I infection] / hiv - 1 infection in [Child] / children ?",
    "n_kge": 3
  },
  {
    "raw_text": "What plays the crucial role in the mother to child transmission of hiv-1 and what increases the risk?",
    "new_text": "What [Play] / plays the crucial [Social Role] / role in the [Maternal-Fetal Infection Transmission] / mother to child transmission of [HIV-1] / hiv - 1 and what [Increased] / increases the [Risk] / risk ?",
    "n_kge": 6
  },
  {
    "raw_text": "How many children were infected by hiv-1 in 2008-2009, worldwide?",
    "new_text": "How many [Child] / children were [Infected] / infected by [HIV-1] / hiv - 1 in 2008 - 2009 , worldwide ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the role of c-c motif chemokine ligand 3 like 1 (ccl3l1) in mother to child transmission of hiv-1?",
    "new_text": "What is the [Social Role] / role of c - c [Protein Domain] / motif chemokine ligand 3 like 1 [Present] / in [Maternal-Fetal Infection Transmission] / mother to child transmission of [HIV-1] / hiv - 1 ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is dc-genr and where is it expressed?",
    "new_text": "What is dc - genr and where is it expressed ?",
    "n_kge": 0
  },
  {
    "raw_text": "How does the presence of dc-signr affect the mtct of hiv-1?",
    "new_text": "How does the [Present] / presence of [CLEC4M gene] / dc - signr [Affect (mental function)] / affect the mtct of [HIV-1] / hiv - 1 ?",
    "n_kge": 4
  },
  {
    "raw_text": "Why do low levels of dc-signr enhance mother to child transmission of hiv-1?",
    "new_text": "Why do low levels of [CLEC4M gene] / dc - signr enhance [Maternal-Fetal Infection Transmission] / mother to child transmission of [HIV-1] / hiv - 1 ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the percentage of mother to child transmission of hiv-1, when there is no intervention?",
    "new_text": "What is the [Percent (qualifier value)] / percentage of [Maternal-Fetal Infection Transmission] / mother to child transmission of [HIV-1] / hiv - 1 , when there is no [Interventional procedure] / intervention ?",
    "n_kge": 4
  },
  {
    "raw_text": "Does c-c chemokine receptor type 5 (ccr5) affect the transmission of hiv-1?",
    "new_text": "Does [CCR5 protein, human] / c - c chemokine receptor type 5 [Affect (mental function)] / affect the [disease transmission qualifier] / transmission of [HIV-1] / hiv - 1 ?",
    "n_kge": 4
  },
  {
    "raw_text": "How does mannanose binding lectin (mbl) affect elimination of hiv-1 pathogen?",
    "new_text": "How does mannanose binding [Lectin] / lectin [Affect (mental function)] / affect [Excretory function] / elimination of [HIV-1] / hiv - 1 [Pathogenic organism] / pathogen ?",
    "n_kge": 5
  },
  {
    "raw_text": "How can ccr5's effect in hiv-1 transmission be reduced?",
    "new_text": "How can ccr5's effect in [HIV-1] / hiv - 1 [disease transmission qualifier] / transmission be reduced ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is ifitm?",
    "new_text": "What is ifitm ?",
    "n_kge": 0
  },
  {
    "raw_text": "How many cysteine residues are contained in the first transmembrane domain of ifitm3?",
    "new_text": "How many [cysteine] / cysteine residues are contained in the first transmembrane domain of [IFITM3 gene] / ifitm3 ?",
    "n_kge": 2
  },
  {
    "raw_text": "What inhibits s-palmitoylation?",
    "new_text": "What inhibits s - palmitoylation ?",
    "n_kge": 0
  },
  {
    "raw_text": "What interaction is inhibited by the presence of 2-bromopalmitic acid (2bp)?",
    "new_text": "What interaction is inhibited by the [Present] / presence of 2 - bromopalmitic [Acids] / acid ( 2bp ) ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is a function associated with ifitm5?",
    "new_text": "What is a [physiological aspects] / function associated with [IFITM5 gene] / ifitm5 ?",
    "n_kge": 2
  },
  {
    "raw_text": "What regulates the antiviral activity of ifitm3?",
    "new_text": "What regulates the antiviral activity of [IFITM3 gene] / ifitm3 ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is another name for ifitm5?",
    "new_text": "What is another [Name] / name for [IFITM5 gene] / ifitm5 ?",
    "n_kge": 2
  },
  {
    "raw_text": "Why is the expression of ifitm5 not promoted by interferons?",
    "new_text": "Why is the [Expression procedure] / expression of [IFITM5 gene] / ifitm5 not promoted by [Interferons] / interferons ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the amino acid similarity between ifitm5 and the other ifitm proteins?",
    "new_text": "What is the [Amino Acids] / amino acid similarity between [IFITM5 gene] / ifitm5 and the other ifitm [Proteins] / proteins ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the amino acid similarity between ifitm 1, ifitm 2, and ifitm 3?",
    "new_text": "What is the [Amino Acids] / amino acid similarity between ifitm 1 , ifitm 2 , and ifitm 3 ?",
    "n_kge": 1
  },
  {
    "raw_text": "What amino acid might be involved in calcium binding in the c-terminal region of a protein?",
    "new_text": "What [Amino Acids] / amino acid might be [Involvement with] / involved [Present] / in calcium binding [Present] / in the c - terminal region of [Staphylococcal Protein A] / a protein ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is the size of bovine coronavirus?",
    "new_text": "What is the [size] / size of [Bovine coronavirus] / bovine coronavirus ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the molecular structure of bovine coronavirus?",
    "new_text": "What is the [Molecular Structure] / molecular structure of [Bovine coronavirus] / bovine coronavirus ?",
    "n_kge": 2
  },
  {
    "raw_text": "How many nucleotides does bovine coronavirus contain?",
    "new_text": "How many [Nucleotides] / nucleotides does [Bovine coronavirus] / bovine coronavirus contain ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the size of the orf1ab gene in bovine coronavirus?",
    "new_text": "What is the [size] / size of the orf1ab [Genes] / gene in [Bovine coronavirus] / bovine coronavirus ?",
    "n_kge": 3
  },
  {
    "raw_text": "Is the orf1ab gene at the 3' or 5' end of the bovine coronavirus genome?",
    "new_text": "Is the orf1ab [Genes] / gene at the 3 ' or 5 ' end of the [Bovine coronavirus] / bovine coronavirus [Genome] / genome ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is a significant cause of influenze like illness among healthy adolescents and adults presenting for medical evaluation?",
    "new_text": "What is a [Statistical Significance] / significant [Etiology aspects] / cause of influenze [Like] / like [Illness (finding)] / illness among healthy adolescents and [Adult] / adults [Presentation] / presenting for medical evaluation ?",
    "n_kge": 6
  },
  {
    "raw_text": "What is the most common species of human coronavirus among adults?",
    "new_text": "What is the most common species of [Human coronavirus] / human coronavirus among [Adult] / adults ?",
    "n_kge": 2
  },
  {
    "raw_text": "Which human coronavirus showed species specific clinical characteristics of its infection?",
    "new_text": "Which [Human coronavirus] / human coronavirus showed species specific clinical characteristics of its [Communicable Diseases] / infection ?",
    "n_kge": 2
  },
  {
    "raw_text": "What causes the outbreak of sars and mers?",
    "new_text": "What [Etiology aspects] / causes the [Disease Outbreaks] / outbreak of [Severe Acute Respiratory Syndrome] / sars and [Middle East Respiratory Syndrome] / middle east respiratory syndrome ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is the case fatality rate of sars and mers?",
    "new_text": "What is the [Case Fatality Rate] / case fatality rate of [Severe Acute Respiratory Syndrome] / sars and [Middle East Respiratory Syndrome] / middle east respiratory syndrome ?",
    "n_kge": 3
  },
  {
    "raw_text": "What were the common hcov strains in the 5 year usa study?",
    "new_text": "What were the common hcov [Muscle strain] / strains in the 5 year [United States] / usa study ?",
    "n_kge": 2
  },
  {
    "raw_text": "Which species are more prevalent but less severe?",
    "new_text": "Which species are [More] / more prevalent but less [Severe (severity modifier)] / severe ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is required for a hepatitis b infection in cells?",
    "new_text": "What is required for a hepatitis b [Communicable Diseases] / infection in [Cell Count] / cells ?",
    "n_kge": 2
  },
  {
    "raw_text": "What regulates the broad, but less specific, virus-cell interaction in a hepatitis b infection?",
    "new_text": "What regulates the broad , but less specific , virus - cell interaction in a hepatitis b infection ?",
    "n_kge": 0
  },
  {
    "raw_text": "Which protein domain of the hepatitis b envelope is necessary for infection?",
    "new_text": "Which [Protein Domain] / protein domain of the [Hepatitis B] / hepatitis b envelope is necessary for [Communicable Diseases] / infection ?",
    "n_kge": 3
  },
  {
    "raw_text": "Where is ntcp located in the body?",
    "new_text": "Where is [SLC10A1 gene] / ntcp located in the [Human body] / body ?",
    "n_kge": 2
  },
  {
    "raw_text": "What does the ntcp protein mediate?",
    "new_text": "What does the [SLC10A1 gene] / ntcp [Proteins] / protein mediate ?",
    "n_kge": 2
  },
  {
    "raw_text": "Is ntcp sufficient to allow hbv infection?",
    "new_text": "Is [SLC10A1 gene] / ntcp sufficient [Tryptophanase] / to allow hbv infection ?",
    "n_kge": 2
  },
  {
    "raw_text": "Why is ntcp thought to not be sufficient for hbv infection?",
    "new_text": "Why is [SLC10A1 gene] / ntcp [Thinking, function] / thought [Tryptophanase] / to not be sufficient for hbv infection ?",
    "n_kge": 3
  },
  {
    "raw_text": "What kinds of viruses are japanese encephalitis virus(jev), tick-borne encephalitis virus(tbev), eastern equine encephalitis virus (eeev), sindbis virus(sv), and dengue virus(dv)?",
    "new_text": "What kinds of [Virus] / viruses are [Japanese encephalitis virus] / japanese encephalitis virus ( jev ) , [Tick-Borne Encephalitis Viruses] / tick - borne encephalitis virus ( [Tick-Borne Encephalitis Virus] / tbev ) , [Encephalitis Virus, Eastern Equine] / eastern equine encephalitis virus , [Sindbis Virus] / sindbis virus ( [El Salvador] / sv ) , and [Dengue Virus] / dengue virus ( [dianhydrogalactitol/etoposide] / dv ) ?",
    "n_kge": 9
  },
  {
    "raw_text": "What are the current clinically-available methods to detect encephalitis viral antigens?",
    "new_text": "What are the current clinically - available [Methods] / methods [Tryptophanase] / to detect [Encephalitis] / encephalitis [Antigens, Viral] / viral antigens ?",
    "n_kge": 4
  },
  {
    "raw_text": "What methods exist for detecting multiple antigens simultaneously in a one-sample, laboratory test?",
    "new_text": "What [Methods] / methods exist for detecting [Numerous] / multiple [Antigens] / antigens simultaneously in a [One] / one - [Specimen] / sample , [Laboratory Procedures] / laboratory test ?",
    "n_kge": 6
  },
  {
    "raw_text": "How many antigens could be detected by liew's multiplex elisa test?",
    "new_text": "How many [Antigens] / antigens could be detected by liew's multiplex [Enzyme-Linked Immunosorbent Assay] / elisa [Laboratory Procedures] / test ?",
    "n_kge": 3
  },
  {
    "raw_text": "What kind of antibodies were used in the elisa-array assay?",
    "new_text": "What [Type - attribute] / kind of [Antibodies] / antibodies were [Used by] / used in the elisa - [Array] / array assay ?",
    "n_kge": 4
  },
  {
    "raw_text": "How was the elisa assay validated?",
    "new_text": "How was the [Enzyme-Linked Immunosorbent Assay] / elisa assay validated ?",
    "n_kge": 1
  },
  {
    "raw_text": "What capture antibodies were used in the study?",
    "new_text": "What capture [Antibodies] / antibodies were used in the study ?",
    "n_kge": 1
  },
  {
    "raw_text": "What was the spotting concentration range for the capture antibodies?",
    "new_text": "What was the [Metrorrhagia] / spotting concentration range for the capture [Antibodies] / antibodies ?",
    "n_kge": 2
  },
  {
    "raw_text": "How was the proper spotting concentration determined?",
    "new_text": "How was the proper [Metrorrhagia] / spotting [Mental concentration] / concentration determined ?",
    "n_kge": 2
  },
  {
    "raw_text": "How was cross reaction detection determined?",
    "new_text": "How was [Cross Reactions] / cross reaction [Detection] / detection determined ?",
    "n_kge": 2
  },
  {
    "raw_text": "How was the elisa-array assay validated?",
    "new_text": "How was the elisa - [Array] / array assay validated ?",
    "n_kge": 1
  },
  {
    "raw_text": "In 2010, how many cases of tuberculosis were estimated in china?",
    "new_text": "In 2010 , how [Numerous] / many [Case (situation)] / cases of [Tuberculosis] / tuberculosis were [Estimated] / estimated in [China] / china ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is the population of shandong province?",
    "new_text": "What is the [geographic population] / population of shandong province ?",
    "n_kge": 1
  },
  {
    "raw_text": "What was the purpose of this study?",
    "new_text": "What was the purpose of this study ?",
    "n_kge": 0
  },
  {
    "raw_text": "What was the age range for the people surveyed?",
    "new_text": "What was the [Age] / age range for the [Persons] / people surveyed ?",
    "n_kge": 2
  },
  {
    "raw_text": "How was the survey designed?",
    "new_text": "How was the survey designed ?",
    "n_kge": 0
  },
  {
    "raw_text": "Was was the sample size?",
    "new_text": "Was was the sample size ?",
    "n_kge": 0
  },
  {
    "raw_text": "How were the clusters selected?",
    "new_text": "How were the clusters selected ?",
    "n_kge": 0
  },
  {
    "raw_text": "How many people were in a community cluster?",
    "new_text": "How many [Persons] / people were in a [Community] / community cluster ?",
    "n_kge": 2
  },
  {
    "raw_text": "Who was excluded from the study?",
    "new_text": "Who was excluded from the study ?",
    "n_kge": 0
  },
  {
    "raw_text": "When was the study conducted?",
    "new_text": "When was the study conducted ?",
    "n_kge": 0
  },
  {
    "raw_text": "Who conducted the study?",
    "new_text": "Who conducted the study ?",
    "n_kge": 0
  },
  {
    "raw_text": "What medium was used to collect the sputum samples?",
    "new_text": "What [Communications Media] / medium was [Used by] / used [Tryptophanase] / to collect the sputum samples ?",
    "n_kge": 3
  },
  {
    "raw_text": "What was the response rate for the study?",
    "new_text": "What was the [Frequency of Responses] / response rate for the study ?",
    "n_kge": 1
  },
  {
    "raw_text": "What was the average age of a study participant?",
    "new_text": "What was the average [Age] / age of a [Study Subject] / study participant ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was the prevalence rate in shandong in 2010 for sputum positive cases of tuberculosis?",
    "new_text": "What was the prevalence rate [Present] / in shandong [Present] / in 2010 for [Sputum] / sputum [percent positive cells] / positive [Case (situation)] / cases of [Tuberculosis] / tuberculosis ?",
    "n_kge": 6
  },
  {
    "raw_text": "What was the most striking finding of the study regarding tuberculosis patients?",
    "new_text": "What was the most [Strikes, Employee] / striking [Signs and Symptoms] / finding of the study regarding [Tuberculosis] / tuberculosis [Patients] / patients ?",
    "n_kge": 4
  },
  {
    "raw_text": "How many cases of sputum positive tuberculosis patients had no persistent cough?",
    "new_text": "How [Numerous] / many [Case (situation)] / cases of [Sputum] / sputum [percent positive cells] / positive [Tuberculosis] / tuberculosis [Patients] / patients had no persistent cough ?",
    "n_kge": 6
  },
  {
    "raw_text": "How many tuberculosis patients in shandong were over 65 years old?",
    "new_text": "How [Numerous] / many [Tuberculosis] / tuberculosis [Patients] / patients in shandong were over 65 years old ?",
    "n_kge": 3
  },
  {
    "raw_text": "What enzymes have been reported to be linked with severity of infection and various pathological conditions caused by microorganisms?",
    "new_text": "What [Enzymes] / enzymes have been [Report (document)] / reported [Tryptophanase] / to be linked with severity of infection and various pathological conditions caused by [Microorganism] / microorganisms ?",
    "n_kge": 4
  },
  {
    "raw_text": "At what temperatures was the assay completed?",
    "new_text": "At what [Temperature] / temperatures was the [Biological Assay] / assay [Complete] / completed ?",
    "n_kge": 3
  },
  {
    "raw_text": "What criteria sets the guideline for drug-like properties?",
    "new_text": "What criteria sets the [Guidelines] / guideline for [Pharmaceutical Preparations] / drug - like [Property (attribute)] / properties ?",
    "n_kge": 3
  },
  {
    "raw_text": "What could be novel candidates as potent inhibitors of papain like cysteine proteases in resistant microorganisms?",
    "new_text": "What could be [New] / novel candidates as potent inhibitors of papain like cysteine proteases in resistant [Microorganism] / microorganisms ?",
    "n_kge": 2
  },
  {
    "raw_text": "What method is useful in administering small molecules for systemic delivery to the body?",
    "new_text": "What [Methods] / method is useful in [Administration procedure] / administering small molecules for [Systemic] / systemic [Obstetric Delivery] / delivery to the [Human body] / body ?",
    "n_kge": 5
  },
  {
    "raw_text": "Why is the nasal mucosa useful in the delivery of small molecules into the body?",
    "new_text": "Why is the [Structure of mucous membrane of nose] / nasal mucosa useful in the [Obstetric Delivery] / delivery of small molecules into the [Human body] / body ?",
    "n_kge": 3
  },
  {
    "raw_text": "What are the most common methods of inhaled delivery of medications?",
    "new_text": "What are the most common methods of [Inspiration function] / inhaled delivery of [Pharmaceutical Preparations] / medications ?",
    "n_kge": 2
  },
  {
    "raw_text": "What medications have shown good promise to in vivo delivery via dry powder inhalers?",
    "new_text": "What [Pharmaceutical Preparations] / medications have shown good promise to in vivo [Obstetric Delivery] / delivery via [Dry Powder Inhaler (device)] / dry powder inhalers ?",
    "n_kge": 3
  },
  {
    "raw_text": "How are sirnas typically delivered for systemic effect?",
    "new_text": "How are sirnas typically delivered for [Systemic] / systemic effect ?",
    "n_kge": 1
  },
  {
    "raw_text": "What structures form the human airway?",
    "new_text": "What structures form the [Homo sapiens] / human airway ?",
    "n_kge": 1
  },
  {
    "raw_text": "What size of particle has been shown to be most effective in the delivery to the lower airway?",
    "new_text": "What size of particle has been shown [Tryptophanase] / to be most [Effectiveness] / effective in the [Obstetric Delivery] / delivery [Tryptophanase] / to the lower airway ?",
    "n_kge": 4
  },
  {
    "raw_text": "What are the essential conditions in sirna delivery to effectively produce gene silencing in the lungs?",
    "new_text": "What are the essential [Condition] / conditions in [RNA, Small Interfering] / sirna [Obstetric Delivery] / delivery to effectively produce [Gene Silencing] / gene silencing in the [Lung] / lungs ?",
    "n_kge": 5
  },
  {
    "raw_text": "How long is the saibk gene?",
    "new_text": "How [Long] / long is the saibk [Genes] / gene ?",
    "n_kge": 2
  },
  {
    "raw_text": "How many open reading frames are in the saibk gene?",
    "new_text": "How many [Open Reading Frames] / open reading frames are in the saibk [Genes] / gene ?",
    "n_kge": 2
  },
  {
    "raw_text": "What virus has the closest genetic identity with the saibk gene?",
    "new_text": "What [Virus] / virus has the closest genetic identity with the saibk gene ?",
    "n_kge": 1
  },
  {
    "raw_text": "How many surgical masks or respirators have past studies projected will be required for a pandemic in the united states?",
    "new_text": "How many surgical masks or [Mechanical Ventilator] / respirators have [In the past] / past studies [Projections and Predictions] / projected will be required for a [Pandemics] / pandemic in the [United States] / united states ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is the acronym mers-cov?",
    "new_text": "What is the [Acronyms] / acronym [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are the critical factors that determine the effect of an epidemic?",
    "new_text": "What are the critical factors that determine the effect of an [Epidemic] / epidemic ?",
    "n_kge": 1
  },
  {
    "raw_text": "When did the world health organization (who) officially declare the 2019-ncov epidemic as a public health emergency of international concern?",
    "new_text": "When did the [World Health Organization] / world health organization officially declare the [2019 novel coronavirus] / 2019 - ncov [Epidemic] / epidemic as a [public health medicine (field)] / public health [Emergency Situation] / emergency of international concern ?",
    "n_kge": 5
  },
  {
    "raw_text": "What influenza virus was identified in china in 2013?",
    "new_text": "What [Orthomyxoviridae] / influenza virus was identified in [China] / china in 2013 ?",
    "n_kge": 2
  },
  {
    "raw_text": "What past research has been done on severe, single-wave pandemics?",
    "new_text": "What [In the past] / past [research] / research has been [Done (qualifier value)] / done on [Severe (severity modifier)] / severe , [Unmarried person] / single - wave [Pandemics] / pandemics ?",
    "n_kge": 6
  },
  {
    "raw_text": "What is a clinical attack rate?",
    "new_text": "What is a clinical [Incidence Proportion] / attack rate ?",
    "n_kge": 1
  },
  {
    "raw_text": "What was the clinical attack rate in the 2009 h1n1 pandemic?",
    "new_text": "What was the clinical [Incidence Proportion] / attack rate in the 2009 [H1N1] / h1n1 [Pandemics] / pandemic ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the estimated r0 of covid-19?",
    "new_text": "What is the [Estimated] / estimated r0 of [COVID-19] / covid - 19 ?",
    "n_kge": 2
  },
  {
    "raw_text": "How many ventilators have past studies projected will be required for a pandemic in the united states?",
    "new_text": "How many [Ventilator - respiratory equipment] / ventilators have [In the past] / past studies [Projections and Predictions] / projected will be required for a [Pandemics] / pandemic in the [United States] / united states ?",
    "n_kge": 5
  },
  {
    "raw_text": "How is exhaled breath condensate used in viral research?",
    "new_text": "How is [Exhaled breath condensate (substance)] / exhaled breath condensate [Used by] / used in [Viral] / viral [research] / research ?",
    "n_kge": 4
  },
  {
    "raw_text": "How many patients were i this study?",
    "new_text": "How many [Patients] / patients were [Iodides] / i this study ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was the conclusion of this study?",
    "new_text": "What was the conclusion of this study ?",
    "n_kge": 0
  },
  {
    "raw_text": "How long did the patient breath into the rtube?",
    "new_text": "How [Long] / long did the [Patients] / patient [Breath] / breath into the rtube ?",
    "n_kge": 3
  },
  {
    "raw_text": "What followed the reverse transcription step in the analysis?",
    "new_text": "What [Followed by] / followed the [Reverse Transcription] / reverse transcription step in the analysis ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was the last step in the analysis?",
    "new_text": "What was the last step in the analysis ?",
    "n_kge": 0
  },
  {
    "raw_text": "What percentage of the patients were between 20 and 30 years old in this study?",
    "new_text": "What [Percent (qualifier value)] / percentage of the [Patients] / patients were between 20 and 30 years old in this study ?",
    "n_kge": 2
  },
  {
    "raw_text": "Why is ebc an attractive method for screening?",
    "new_text": "Why is ebc [Aniridia type 1] / an attractive method for screening ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the leading cause of death among children after the age of 1 month?",
    "new_text": "What is the [Before] / leading cause of death among children after the [Age] / age of 1 [Monthly (qualifier value)] / month ?",
    "n_kge": 3
  },
  {
    "raw_text": "How has the number of childhood pneumonia been reduced?",
    "new_text": "How has the [Numbers] / number of childhood pneumonia been reduced ?",
    "n_kge": 1
  },
  {
    "raw_text": "What percentage of childhood deaths are due to pneumonia?",
    "new_text": "What [Percent (qualifier value)] / percentage of [Childhood] / childhood [Cessation of life] / deaths are [Due to] / due to [Pneumonia] / pneumonia ?",
    "n_kge": 5
  },
  {
    "raw_text": "How has the childhood population grown in the last two decades?",
    "new_text": "How has the [Childhood] / childhood [geographic population] / population grown in the last [Two] / two decades ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the reduction in the number of childhood pneumonia cases?",
    "new_text": "What is the [Reduction (chemical)] / reduction in the [Numbers] / number of childhood pneumonia [Case (situation)] / cases ?",
    "n_kge": 3
  },
  {
    "raw_text": "How much is the reduction in the childhood pneumonia deaths?",
    "new_text": "How much is the [Reduction (chemical)] / reduction in the childhood [Pneumonia] / pneumonia deaths ?",
    "n_kge": 2
  },
  {
    "raw_text": "Childhood pneumonia rate for high income countries vs low and middle income countries?",
    "new_text": "Childhood pneumonia rate for high income countries vs low and [Middle] / middle [Income] / income [Country] / countries ?",
    "n_kge": 3
  },
  {
    "raw_text": "What percentage of childhood pneumonia deaths occur outside hospital in low and middle income countries?",
    "new_text": "What [Percent (qualifier value)] / percentage of childhood pneumonia [Cessation of life] / deaths occur [Extrinsic] / outside [Hospitals] / hospital in low and [Middle] / middle [Income] / income [Country] / countries ?",
    "n_kge": 7
  },
  {
    "raw_text": "Case fatality rates for childhood pneumonia in high income vs low and middle income countries?",
    "new_text": "[Case Fatality Rate] / Case fatality rates for childhood pneumonia in [High] / high [Income] / income vs low and [Middle] / middle [Income] / income [Country] / countries ?",
    "n_kge": 6
  },
  {
    "raw_text": "How can childhood pneumonia affect the subsequent health of a person?",
    "new_text": "How can childhood pneumonia [Affect (mental function)] / affect the [Following] / subsequent health of a person ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the increase in the risk of respiratory disease after having childhood pneumonia?",
    "new_text": "What is the [Increase] / increase in the [Risk] / risk of [Respiration Disorders] / respiratory disease after having childhood pneumonia ?",
    "n_kge": 3
  },
  {
    "raw_text": "Which is the best method to identify pneumonia in a person?",
    "new_text": "Which is the best [Methods] / method [Tryptophanase] / to identify [Pneumonia] / pneumonia in a [Persons] / person ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is responsible for the reduction of radiologic pneumonia?",
    "new_text": "What is [Responsible to (attribute)] / responsible for the [Reduction (chemical)] / reduction of [Radiology Specialty] / radiologic [Pneumonia] / pneumonia ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is the percentage reduction in pneumonia cases due to vaccination?",
    "new_text": "What is the [Percent (qualifier value)] / percentage [Reduction (chemical)] / reduction in [Pneumonia] / pneumonia [Case (situation)] / cases due to [Vaccination] / vaccination ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is the revised who definition of bacterial pneumonia?",
    "new_text": "What is the revised [World Health Organization] / world health organization definition of [Pneumonia, Bacterial] / bacterial pneumonia ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the reduction in bacterial pneumonia under the revised who definition of bacterial pneumonia?",
    "new_text": "What is the [Reduction (chemical)] / reduction in [Pneumonia, Bacterial] / bacterial pneumonia [Inferior] / under the revised [World Health Organization] / world health organization definition of [Pneumonia, Bacterial] / bacterial pneumonia ?",
    "n_kge": 5
  },
  {
    "raw_text": "What caused the increase in the incidence of empyema in children in the recent past?",
    "new_text": "What caused the [Increase] / increase in the [Incidence] / incidence of [Empyema] / empyema in [Child] / children in the [Recent] / recent past ?",
    "n_kge": 5
  },
  {
    "raw_text": "How have the incidence empyema been reduced?",
    "new_text": "How have the [Incidence] / incidence [Empyema] / empyema been reduced ?",
    "n_kge": 2
  },
  {
    "raw_text": "What pneumonia related or chest conditions indicate the need for child radiography?",
    "new_text": "What pneumonia related or chest conditions indicate the need for [Child] / child radiography ?",
    "n_kge": 1
  },
  {
    "raw_text": "What chest diseases and pneumonia were identified as leading causes prior to the availability of vaccines?",
    "new_text": "What chest diseases and [Pneumonia] / pneumonia were identified as [Before] / leading [Etiology aspects] / causes [Before] / prior to the availability of [Vaccines] / vaccines ?",
    "n_kge": 5
  },
  {
    "raw_text": "Why has pertussis immunity in infants has decreased in infants?",
    "new_text": "Why has [Pertussis] / pertussis [Immune response] / immunity in [Infant] / infants has [Decreased] / decreased in [Infant] / infants ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is the effect of childhood tuberculosis in childhood pneumonia?",
    "new_text": "What is the effect of childhood tuberculosis in [Childhood] / childhood pneumonia ?",
    "n_kge": 1
  },
  {
    "raw_text": "What are the risk factors in childhood pneumonia?",
    "new_text": "What are the [risk factors] / risk factors in childhood pneumonia ?",
    "n_kge": 1
  },
  {
    "raw_text": "How does air pollution affect the incidence of childhood pneumonia?",
    "new_text": "How does air pollution [Affect (mental function)] / affect the [Incidence] / incidence of childhood pneumonia ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the strongest risk factor for childhood pneumonia?",
    "new_text": "What is the strongest [risk factors] / risk factor for childhood pneumonia ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the global coverage of influenza and pneumonia vaccines?",
    "new_text": "What is the global coverage of [Influenza] / influenza and [Pneumonia] / pneumonia [Vaccines] / vaccines ?",
    "n_kge": 3
  },
  {
    "raw_text": "Is influenza vaccination during pregnancy safe and how long does it protect the child?",
    "new_text": "Is influenza vaccination during [Pregnancy] / pregnancy safe and how [Long] / long does it protect the [Child] / child ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is emphyema?",
    "new_text": "What is emphyema ?",
    "n_kge": 0
  },
  {
    "raw_text": "How is the term end point consolidation described with regard to pneumonia diagnosis?",
    "new_text": "How is the [Term Birth] / term [End Point] / end point [Lung consolidation] / consolidation described with regard to [Pneumonia] / pneumonia [Diagnosis] / diagnosis ?",
    "n_kge": 5
  },
  {
    "raw_text": "What factors make h5n1 a worldwide threat to public health?",
    "new_text": "What factors make [Influenza in Birds] / h5n1 a worldwide threat to [public health medicine (field)] / public health ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are the symptoms of h5n1 infection in humans?",
    "new_text": "What are the symptoms of h5n1 infection in [Homo sapiens] / humans ?",
    "n_kge": 1
  },
  {
    "raw_text": "Name some medications used to treat influenza?",
    "new_text": "[Name] / Name some [Pharmaceutical Preparations] / medications [Used by] / used [Tryptophanase] / to [Therapeutic procedure] / treat [Influenza] / influenza ?",
    "n_kge": 6
  },
  {
    "raw_text": "Why have antiretrovirals medications had limited benefit in treating influenza?",
    "new_text": "Why have antiretrovirals [Pharmaceutical Preparations] / medications had limited benefit in treating [Influenza] / influenza ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the focus of the current study?",
    "new_text": "What is the [Focal] / focus of the current study ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the result of the current study?",
    "new_text": "What is the result of the current study ?",
    "n_kge": 0
  },
  {
    "raw_text": "How do the polysaccharides in plants effect the immune response?",
    "new_text": "How do the [Polysaccharides] / polysaccharides in [Plants] / plants effect the [Immune response] / immune response ?",
    "n_kge": 3
  },
  {
    "raw_text": "What does this study demonstrate?",
    "new_text": "What does this study demonstrate ?",
    "n_kge": 0
  },
  {
    "raw_text": "In this study, how did treatment of eap after infection affect survival?",
    "new_text": "In this study , how did [therapeutic aspects] / treatment of [phosphoethanolamine] / eap after [Communicable Diseases] / infection [Affect (mental function)] / affect [Continuance of life] / survival ?",
    "n_kge": 5
  },
  {
    "raw_text": "What viruses have been responsible for most common childhood acute respiratory track infections (arti)?",
    "new_text": "What [Virus] / viruses have been [Responsible to (attribute)] / responsible for most common [Childhood] / childhood acute respiratory [Track (course)] / track infections ?",
    "n_kge": 4
  },
  {
    "raw_text": "Are there any vaccines against to protect against respiratory viral infections?",
    "new_text": "Are there any [Vaccines] / vaccines against [Tryptophanase] / to protect against respiratory viral infections ?",
    "n_kge": 2
  },
  {
    "raw_text": "Which type of bacteria are implicated in carrying genes of drug resistance?",
    "new_text": "Which [Type - attribute] / type of bacteria are implicated in carrying genes of drug resistance ?",
    "n_kge": 1
  },
  {
    "raw_text": "What may be a likely cause of sink-to-sink spreading of pathogens in the hospital setting?",
    "new_text": "What may be a [Probable diagnosis] / likely [Etiology aspects] / cause of sink - to - sink [Spreading (qualifier value)] / spreading of pathogens in the [Hospitals] / hospital setting ?",
    "n_kge": 4
  },
  {
    "raw_text": "What types of acute respiratory infections can be screened and diagnosed with multiplex pcr?",
    "new_text": "What types of acute respiratory infections can be screened and [Diagnosis] / diagnosed with multiplex pcr ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the role of antibodies during infection?",
    "new_text": "What is the [Social Role] / role of [Antibodies] / antibodies during [Communicable Diseases] / infection ?",
    "n_kge": 3
  },
  {
    "raw_text": "How can antibodies also create health problems?",
    "new_text": "How can [Antibodies] / antibodies also create [Health] / health problems ?",
    "n_kge": 2
  },
  {
    "raw_text": "Which technology invention produced antibodies that are clones of a unique parent cell?",
    "new_text": "Which [Technology] / technology [Inventions] / invention produced [Antibodies] / antibodies that are clones of a unique parent cell ?",
    "n_kge": 3
  },
  {
    "raw_text": "What mechanism is responsible for the creation of diversified repertoire for antibodies?",
    "new_text": "What [Mechanism (attribute)] / mechanism is [Responsible to (attribute)] / responsible for the [Surgical construction] / creation of diversified repertoire for [Antibodies] / antibodies ?",
    "n_kge": 4
  },
  {
    "raw_text": "What developments have been made possible by the study of b-cell repertoire?",
    "new_text": "What developments have been made possible by the study of [B-Lymphocytes] / b - cell repertoire ?",
    "n_kge": 1
  },
  {
    "raw_text": "What motivates the study of the rare b-cells that produce broadly neutralizing antibodies (bnab)?",
    "new_text": "What motivates the study of the rare [B-Lymphocytes] / b - cells that produce broadly neutralizing antibodies ?",
    "n_kge": 1
  },
  {
    "raw_text": "How has the study of b-cells helped the treatment for respiratory syncytial virus (rsv)?",
    "new_text": "How has the study of [B-Lymphocytes] / b - cells helped the [therapeutic aspects] / treatment for [Respiratory syncytial virus] / respiratory syncytial virus ?",
    "n_kge": 3
  },
  {
    "raw_text": "How are the studies on b-cells helping the development of a universal influenza vaccine?",
    "new_text": "How are the studies on [B-Lymphocytes] / b - cells helping the development of a universal influenza vaccine ?",
    "n_kge": 1
  },
  {
    "raw_text": "What role b-cell play in malaria infection and prevention?",
    "new_text": "What [Social Role] / role [B-Lymphocytes] / b - cell [Play] / play in [Malaria] / malaria [Communicable Diseases] / infection and [Prophylactic treatment] / prevention ?",
    "n_kge": 6
  },
  {
    "raw_text": "How can the study of b-cells help in the prevention and treatment of autoimmune diseases?",
    "new_text": "How can the study of [B-Lymphocytes] / b - cells help in the [Prophylactic treatment] / prevention and [therapeutic aspects] / treatment of [Autoimmune Diseases] / autoimmune diseases ?",
    "n_kge": 4
  },
  {
    "raw_text": "When was the middle east respiratory syndrome coronavirus isolated first?",
    "new_text": "When was the [Middle East Respiratory Syndrome Coronavirus] / middle east respiratory syndrome coronavirus isolated first ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the case fatality rate for mers coronavirus?",
    "new_text": "What is the [Case Fatality Rate] / case fatality rate for [Middle East Respiratory Syndrome Coronavirus] / middle east respiratory syndrome coronavirus ?",
    "n_kge": 2
  },
  {
    "raw_text": "How does gender influence mers-cov infection?",
    "new_text": "How does [Gender] / gender influence [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov [Communicable Diseases] / infection ?",
    "n_kge": 3
  },
  {
    "raw_text": "Which is the source animal for the mers-cov?",
    "new_text": "Which is the [Source] / source [Animals] / animal for the [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the median time until death in mers-cov?",
    "new_text": "What is the median time until death in [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the incubation period for mers-cov?",
    "new_text": "What is the incubation period for [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the treatment for mers-cov?",
    "new_text": "What is the [therapeutic aspects] / treatment for [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov ?",
    "n_kge": 2
  },
  {
    "raw_text": "What age group had the most mers-cov infections?",
    "new_text": "What [Human Age Group] / age group had the most [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov [Infection] / infections ?",
    "n_kge": 3
  },
  {
    "raw_text": "Why are nucleosides analogs used for chemotheraphy?",
    "new_text": "Why are nucleosides analogs [Used by] / used for chemotheraphy ?",
    "n_kge": 1
  },
  {
    "raw_text": "What nucleoside analog is the focus of the current study?",
    "new_text": "What nucleoside analog is the [Focal] / focus of the current study ?",
    "n_kge": 1
  },
  {
    "raw_text": "Gemcitabine has been shown to have antiviral activity against which viruses?",
    "new_text": "[gemcitabine] / Gemcitabine has been shown [Tryptophanase] / to have antiviral activity against which viruses ?",
    "n_kge": 2
  },
  {
    "raw_text": "How does gemcitabine disrupt viral activity?",
    "new_text": "How does [gemcitabine] / gemcitabine disrupt viral activity ?",
    "n_kge": 1
  },
  {
    "raw_text": "Why are cotton rats considered a strong animal model for biomedical research?",
    "new_text": "Why are [Rats, Cotton] / cotton rats considered a strong animal model for biomedical research ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the structure of the cd40 ligand?",
    "new_text": "What is the structure of the [CD40 Ligand] / cd40 ligand ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the effect of cd40l on dendritic cells?",
    "new_text": "What is the effect of [CD40 Ligand, human] / cd40l on [Dendritic Cells] / dendritic cells ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the effect of cd40l on b cells?",
    "new_text": "What is the effect of [CD40 Ligand, human] / cd40l on [B-Lymphocytes] / b cells ?",
    "n_kge": 2
  },
  {
    "raw_text": "What factor may influence viral replication and gene expression?",
    "new_text": "What [Factor] / factor may influence viral replication and [Gene Expression] / gene expression ?",
    "n_kge": 2
  },
  {
    "raw_text": "What accounts for the variation of codon usage among open reading frameworks?",
    "new_text": "What accounts for the variation of codon usage among open [Reading (activity)] / reading frameworks ?",
    "n_kge": 1
  },
  {
    "raw_text": "What conditions are considered upper respiratory tracts infections?",
    "new_text": "What conditions are considered upper respiratory tracts infections ?",
    "n_kge": 0
  },
  {
    "raw_text": "What conditions are considered lower respiratory tract infections?",
    "new_text": "What conditions are considered [Lower respiratory tract infection] / lower respiratory tract infections ?",
    "n_kge": 1
  },
  {
    "raw_text": "What immune cells are primarily involved in eliminating virus-infected cells?",
    "new_text": "What immune cells are primarily [Involvement with] / involved in eliminating virus - infected [Cell Count] / cells ?",
    "n_kge": 2
  },
  {
    "raw_text": "What molecules have been shown to hinder t cell responses to viral infections?",
    "new_text": "What [Molecule] / molecules have been shown to hinder [T-Lymphocyte] / t cell responses to viral infections ?",
    "n_kge": 2
  },
  {
    "raw_text": "The accumulation of what molecule hinders phagocytic activity in t cells?",
    "new_text": "The accumulation of what [Molecule] / molecule hinders phagocytic activity in t cells ?",
    "n_kge": 1
  },
  {
    "raw_text": "When did the last director general of the who resign?",
    "new_text": "When did the last director general of the [World Health Organization] / world health organization resign ?",
    "n_kge": 1
  },
  {
    "raw_text": "Why might an organization like the who be necessary?",
    "new_text": "Why might [Aniridia type 1] / an organization like the [World Health Organization] / world health organization be necessary ?",
    "n_kge": 2
  },
  {
    "raw_text": "Where should the next director general for the who come from?",
    "new_text": "Where should the next director general for the [World Health Organization] / world health organization come from ?",
    "n_kge": 1
  },
  {
    "raw_text": "What traits should the new director general of the who have?",
    "new_text": "What [Trait] / traits should the [New] / new director general of the [World Health Organization] / world health organization have ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the hepatitis c virus?",
    "new_text": "What is the [Hepatitis C] / hepatitis c virus ?",
    "n_kge": 1
  },
  {
    "raw_text": "How many people have persistent hepatitis c virus?",
    "new_text": "How many [Persons] / people have [Persistent] / persistent [Hepatitis C] / hepatitis c virus ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the long-term risk of chronic hepatitis c infection?",
    "new_text": "What is the long - term risk of [Hepatitis C, Chronic] / chronic hepatitis c infection ?",
    "n_kge": 1
  },
  {
    "raw_text": "What antiviral treatments are used for hepatitis c infection?",
    "new_text": "What [Antiviral Agents] / antiviral [Therapeutic procedure] / treatments are [Used by] / used for hepatitis c infection ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the main cause of death in the neonatal period of calves?",
    "new_text": "What is the main cause of death [Present] / in the neonatal period of calves ?",
    "n_kge": 1
  },
  {
    "raw_text": "Where was hepcidin first discovered?",
    "new_text": "Where was [hepcidin] / hepcidin first discovered ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is hepcidin?",
    "new_text": "What is [hepcidin] / hepcidin ?",
    "n_kge": 1
  },
  {
    "raw_text": "What organ produces hepcidin?",
    "new_text": "What [Organ] / organ produces [hepcidin] / hepcidin ?",
    "n_kge": 2
  },
  {
    "raw_text": "What stimulates the release of hepcidin?",
    "new_text": "What stimulates the [Patient Discharge] / release of [hepcidin] / hepcidin ?",
    "n_kge": 2
  },
  {
    "raw_text": "What element does hepcidin play a roles in regulating during metabolism?",
    "new_text": "What [Elements] / element does [hepcidin] / hepcidin [Play] / play a [Social Role] / roles in regulating during [Metabolism] / metabolism ?",
    "n_kge": 5
  },
  {
    "raw_text": "Is hepcidin toxic?",
    "new_text": "Is [hepcidin] / hepcidin toxic ?",
    "n_kge": 1
  },
  {
    "raw_text": "Why is iron critical to bacteria?",
    "new_text": "Why is [iron] / iron critical to bacteria ?",
    "n_kge": 1
  },
  {
    "raw_text": "How does hepcidin work in the duodenum?",
    "new_text": "How does [hepcidin] / hepcidin [Work] / work in the [Duodenum] / duodenum ?",
    "n_kge": 3
  },
  {
    "raw_text": "How does hepcidin affect macrophages?",
    "new_text": "How does [hepcidin] / hepcidin [Affect (mental function)] / affect [macrophage] / macrophages ?",
    "n_kge": 3
  },
  {
    "raw_text": "What leads to oxidative stress in the body?",
    "new_text": "What leads to [Oxidative Stress] / oxidative stress in the [Human body] / body ?",
    "n_kge": 2
  },
  {
    "raw_text": "What parameter is used to measure antioxidant levels?",
    "new_text": "What [Parameter Value] / parameter is [Used by] / used [Tryptophanase] / to [Measures] / measure [Antioxidants] / antioxidant [Levels (qualifier value)] / levels ?",
    "n_kge": 6
  },
  {
    "raw_text": "What is acute hemorrhagic encephalomyelitis?",
    "new_text": "What is [Leukoencephalitis, Acute Hemorrhagic] / acute hemorrhagic encephalomyelitis ?",
    "n_kge": 1
  },
  {
    "raw_text": "What are the salient findings in acute hemorrhagic encephalomyelitis?",
    "new_text": "What are the salient findings in [Leukoencephalitis, Acute Hemorrhagic] / acute hemorrhagic encephalomyelitis ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is ranbp2?",
    "new_text": "What is ranbp2 ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the suggested role of ranbp2 in the cell?",
    "new_text": "What is the suggested [Social Role] / role of ranbp2 in the [Cells] / cell ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the hallmark finding of acute necrotizing encephalopathy?",
    "new_text": "What is the hallmark [Signs and Symptoms] / finding of acute necrotizing encephalopathy ?",
    "n_kge": 1
  },
  {
    "raw_text": "What could trigger acute necrotizing encephalopathy?",
    "new_text": "What could [Precipitating Factors] / trigger acute necrotizing encephalopathy ?",
    "n_kge": 1
  },
  {
    "raw_text": "When did she present with rapidly progressive right-hand weakness?",
    "new_text": "When did she present with rapidly progressive [Structure of right hand] / right - hand weakness ?",
    "n_kge": 1
  },
  {
    "raw_text": "Compounds from what framework have shown promising anticancer and antiviral properties?",
    "new_text": "Compounds from what framework have shown promising anticancer and [Antiviral Agents] / antiviral [Property (attribute)] / properties ?",
    "n_kge": 2
  },
  {
    "raw_text": "The replication of what virus is strongly inhibited by 2-(4-hydroxybenzyl)quinazolin-4(3h)-one (1)?",
    "new_text": "The replication of what virus is strongly inhibited by 2 - ( 4 - hydroxybenzyl ) quinazolin - 4 ( 3h ) - [One] / one ( 1 ) ?",
    "n_kge": 1
  },
  {
    "raw_text": "How many samples were obtained?",
    "new_text": "How many samples were obtained ?",
    "n_kge": 0
  },
  {
    "raw_text": "What percentage of patients were positive for at least one respiratory pathogen?",
    "new_text": "What [Percent (qualifier value)] / percentage of [Patients] / patients were [percent positive cells] / positive for at least [One] / one respiratory pathogen ?",
    "n_kge": 4
  },
  {
    "raw_text": "What percentage of patients tested positive for hbov1?",
    "new_text": "What [Percent (qualifier value)] / percentage of [Patients] / patients [Tests (qualifier value)] / tested [percent positive cells] / positive for hbov1 ?",
    "n_kge": 4
  },
  {
    "raw_text": "When was hbov1 first identified?",
    "new_text": "When was hbov1 first identified ?",
    "n_kge": 0
  },
  {
    "raw_text": "What are the symptoms of hbov1 infection?",
    "new_text": "What are the symptoms of hbov1 [Communicable Diseases] / infection ?",
    "n_kge": 1
  },
  {
    "raw_text": "What are the ages of the patients in this study?",
    "new_text": "What are the ages of the patients in this study ?",
    "n_kge": 0
  },
  {
    "raw_text": "What was the male to female ratio for this study?",
    "new_text": "What was the [Males] / male to [Woman] / female [Ratio] / ratio for this study ?",
    "n_kge": 3
  },
  {
    "raw_text": "What causes acute respiratory illness in young children?",
    "new_text": "What [Etiology aspects] / causes acute respiratory illness in young children ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the molecular structure of the human metapneumovirus (hmpv)?",
    "new_text": "What is the [Molecular Structure] / molecular structure of the [Human Metapneumovirus] / human metapneumovirus ?",
    "n_kge": 2
  },
  {
    "raw_text": "What virus is closely related to the human respiratory syncytial virus (rsv)?",
    "new_text": "What [Virus] / virus is closely [Relationships] / related to the [Human respiratory syncytial virus] / human respiratory syncytial virus ( [Respiratory syncytial virus] / respiratory syncytial virus ) ?",
    "n_kge": 4
  },
  {
    "raw_text": "What diseases are caused by hmpv?",
    "new_text": "What [Disease] / diseases are caused by [Human Metapneumovirus] / human metapneumovirus ?",
    "n_kge": 2
  },
  {
    "raw_text": "How large is the hmpv genome?",
    "new_text": "How large is the human metapneumovirus genome ?",
    "n_kge": 0
  },
  {
    "raw_text": "How many open reading frames are in the hmpv genome?",
    "new_text": "How many [Open Reading Frames] / open reading frames are in the [Human Metapneumovirus] / human metapneumovirus [Genome] / genome ?",
    "n_kge": 3
  },
  {
    "raw_text": "What are the two major genotypes of hmpv?",
    "new_text": "What are the [Two] / two [Severe (severity modifier)] / major genotypes of human metapneumovirus ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the most common subgroup of hmpv?",
    "new_text": "What is the most common subgroup of [Human Metapneumovirus] / human metapneumovirus ?",
    "n_kge": 1
  },
  {
    "raw_text": "Who accounted for 44% of hmpv positive cases in kenya between 2007 and 2011?",
    "new_text": "Who accounted for 44 % of [Human Metapneumovirus] / human metapneumovirus [percent positive cells] / positive [Case (situation)] / cases in [Kenya] / kenya between 2007 and 2011 ?",
    "n_kge": 4
  },
  {
    "raw_text": "What does this study describe?",
    "new_text": "What does this study describe ?",
    "n_kge": 0
  },
  {
    "raw_text": "What was the difference in the group a and b genomes?",
    "new_text": "What was the difference in the group a and b [Genome] / genomes ?",
    "n_kge": 1
  },
  {
    "raw_text": "What was the purpose of this study?",
    "new_text": "What was the purpose of this study ?",
    "n_kge": 0
  },
  {
    "raw_text": "How many control samples were used in this study?",
    "new_text": "How many control samples were used in this study ?",
    "n_kge": 0
  },
  {
    "raw_text": "What was the prevalence of coinfection?",
    "new_text": "What was the [Statistical Prevalence] / prevalence of [Coinfection] / coinfection ?",
    "n_kge": 2
  },
  {
    "raw_text": "What risks factors were associated with lower rtis?",
    "new_text": "What [Risk] / risks factors were associated with lower rtis ?",
    "n_kge": 1
  },
  {
    "raw_text": "What tests can simultaneously identify and subtype multiple respiratory viruses?",
    "new_text": "What [Laboratory Procedures] / tests can simultaneously identify and subtype [Numerous] / multiple respiratory viruses ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was the definition for an immunocompromised state in this study?",
    "new_text": "What was the definition for an [Immunocompromised Host] / immunocompromised [Geographic state] / state in this study ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was the length of the study?",
    "new_text": "What was the length of the study ?",
    "n_kge": 0
  },
  {
    "raw_text": "How many patients had acute rtis?",
    "new_text": "How many [Patients] / patients had [acute] / acute rtis ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was the most frequent coinfection?",
    "new_text": "What was the most frequent [Coinfection] / coinfection ?",
    "n_kge": 1
  },
  {
    "raw_text": "What health regulations were changes due to the outbreak of c burnetti?",
    "new_text": "What [Health] / health regulations were [Changing] / changes [Due to] / due to the [Disease Outbreaks] / outbreak of c burnetti ?",
    "n_kge": 4
  },
  {
    "raw_text": "What was the median seropresence of c burnetti in sheep flocks not linked to human outbreaks?",
    "new_text": "What was the median seropresence of c burnetti in [Sheep] / sheep flocks not linked to [Homo sapiens] / human [Disease Outbreaks] / outbreaks ?",
    "n_kge": 3
  },
  {
    "raw_text": "What important risk factors to infection were found during the second case-controlled study?",
    "new_text": "What important risk factors to infection were [Present] / found during the second case - controlled study ?",
    "n_kge": 1
  },
  {
    "raw_text": "What was the interquartile range of the incubation period?",
    "new_text": "What was the interquartile range of the incubation period ?",
    "n_kge": 0
  },
  {
    "raw_text": "How many controls were used in the second case study?",
    "new_text": "How many controls were [Used by] / used in the second [Case Study] / case study ?",
    "n_kge": 2
  },
  {
    "raw_text": "What public event was linked with the outbreak?",
    "new_text": "What public [Event] / event was linked with the [Disease Outbreaks] / outbreak ?",
    "n_kge": 2
  },
  {
    "raw_text": "What causes q fever?",
    "new_text": "What [Etiology aspects] / causes [Q Fever] / q fever ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is coxiella burnetii?",
    "new_text": "What is [Coxiella burnetii] / coxiella burnetii ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the primary reservoir for coxiella burnetii?",
    "new_text": "What is the primary reservoir for [Coxiella burnetii] / coxiella burnetii ?",
    "n_kge": 1
  },
  {
    "raw_text": "How are humans typically infected with coxiella burnetii?",
    "new_text": "How are [Homo sapiens] / humans typically [Infected] / infected with [Coxiella burnetii] / coxiella burnetii ?",
    "n_kge": 3
  },
  {
    "raw_text": "What are critical to regulate cellular biological processes?",
    "new_text": "What are critical [Tryptophanase] / to regulate [Cells] / cellular biological processes ?",
    "n_kge": 2
  },
  {
    "raw_text": "How is the hetesim measured used?",
    "new_text": "How is the hetesim [Measured] / measured [Used by] / used ?",
    "n_kge": 2
  },
  {
    "raw_text": "What kind of data is included in the string database?",
    "new_text": "What [Type - attribute] / kind of [Data] / data is included in the string database ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the function of malat1?",
    "new_text": "What is the [physiological aspects] / function of [MALAT1 gene] / malat1 ?",
    "n_kge": 2
  },
  {
    "raw_text": "What test can detect reduced anticoccidial efficacy in the field?",
    "new_text": "What [Laboratory Procedures] / test can detect reduced anticoccidial [Effectiveness] / efficacy in the field ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is toltrazuril used to treat?",
    "new_text": "What is toltrazuril [Used by] / used [Tryptophanase] / to [Therapeutic procedure] / treat ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is multiple evanescent white dot syndrome?",
    "new_text": "What is [Multiple Evanescent White Dot Syndrome] / multiple evanescent white dot syndrome ?",
    "n_kge": 1
  },
  {
    "raw_text": "What precedes about half of the reported cases of mewds?",
    "new_text": "What precedes about half of the [Report (document)] / reported [Case (situation)] / cases of [Multiple Evanescent White Dot Syndrome] / multiple evanescent white dot syndrome ?",
    "n_kge": 3
  },
  {
    "raw_text": "What types of viruses can be diagnosed through serological testing?",
    "new_text": "What types of viruses can be [Diagnosis] / diagnosed through serological [Testing] / testing ?",
    "n_kge": 2
  },
  {
    "raw_text": "What type of clinical test can differentiate multiple evanescent white dot syndrome (mewds) from optic neuritis?",
    "new_text": "What type of clinical test can [Well Differentiated] / differentiate [Multiple Evanescent White Dot Syndrome] / multiple evanescent white dot syndrome from [Optic Neuritis] / optic neuritis ?",
    "n_kge": 3
  },
  {
    "raw_text": "What were the most common viruses sampled from nasal swabs in ilorin, nigeria?",
    "new_text": "What were the most common [Virus] / viruses [Sampling - Surgical action] / sampled from nasal swabs in ilorin , [Nigeria] / nigeria ?",
    "n_kge": 3
  },
  {
    "raw_text": "What was the most common virus detected in community members in this sample?",
    "new_text": "What was the most common [Virus] / virus detected in [Community] / community [member] / members in this [Specimen] / sample ?",
    "n_kge": 4
  },
  {
    "raw_text": "How bad is the burden of disease in developing countries?",
    "new_text": "How bad is the burden of disease in developing countries ?",
    "n_kge": 0
  },
  {
    "raw_text": "Where do the majority of all infectious disease outbreaks happen?",
    "new_text": "Where do the majority of all infectious disease outbreaks happen ?",
    "n_kge": 0
  },
  {
    "raw_text": "What are some risk factors for countries to experience a high prevalence of acute respiratory infections?",
    "new_text": "What are some [risk factors] / risk factors for [Country] / countries [Tryptophanase] / to [Practice Experience] / experience a high prevalence of [Acute respiratory infections] / acute respiratory infections ?",
    "n_kge": 5
  },
  {
    "raw_text": "What symptoms are associated with acute respiratory infections?",
    "new_text": "What symptoms are associated with [Acute respiratory infections] / acute respiratory infections ?",
    "n_kge": 1
  },
  {
    "raw_text": "What was the most common virus detected in community samples in ilorin, nigeria?",
    "new_text": "What was the most common [Virus] / virus detected in [Community] / community samples in ilorin , [Nigeria] / nigeria ?",
    "n_kge": 3
  },
  {
    "raw_text": "What was the prevalence of coronavirus oc43 in community samples in ilorin, nigeria?",
    "new_text": "What was the [Statistical Prevalence] / prevalence of coronavirus oc43 [Present] / in [Community] / community samples [Present] / in ilorin , [Nigeria] / nigeria ?",
    "n_kge": 5
  },
  {
    "raw_text": "What was the prevalence of coronavirus oc 229 e/nl63 in clinical subjects in ilorin, nigeria?",
    "new_text": "What was the [Statistical Prevalence] / prevalence of coronavirus oc 229 e / nl63 [Present] / in clinical subjects [Present] / in ilorin , [Nigeria] / nigeria ?",
    "n_kge": 4
  },
  {
    "raw_text": "What was the difference between community and clinic cases of acute respiratory infections?",
    "new_text": "What was the difference between [Community] / community and [Ambulatory Care Facilities] / clinic [Case (situation)] / cases of [Acute respiratory infections] / acute respiratory infections ?",
    "n_kge": 4
  },
  {
    "raw_text": "How can countries enhance public health surveillance?",
    "new_text": "How can [Country] / countries enhance public health surveillance ?",
    "n_kge": 1
  },
  {
    "raw_text": "Why do respiratory tract infections pose major public health problems?",
    "new_text": "Why do [Respiratory Tract Infections] / respiratory tract infections pose [Severe (severity modifier)] / major [public health medicine (field)] / public health problems ?",
    "n_kge": 3
  },
  {
    "raw_text": "How much of a greater risk are children than adults to viral infections?",
    "new_text": "How much of a greater [Risk] / risk are children than adults to [Virus Diseases] / viral infections ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the most common infection in childhood?",
    "new_text": "What is the most common [Communicable Diseases] / infection in [Childhood] / childhood ?",
    "n_kge": 2
  },
  {
    "raw_text": "What can respiratory viruses cause?",
    "new_text": "What can respiratory viruses [Etiology aspects] / cause ?",
    "n_kge": 1
  },
  {
    "raw_text": "When do respiratory infections usually happen?",
    "new_text": "When do [Respiratory Tract Infections] / respiratory infections usually happen ?",
    "n_kge": 1
  },
  {
    "raw_text": "What are the most common viruses?",
    "new_text": "What are the most common [Virus] / viruses ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the most common viral infection for infants up to 3 months old?",
    "new_text": "What is the most common [Virus Diseases] / viral infection for [Infant] / infants up to 3 months old ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the incidence of rsv in children older than 3 years of age?",
    "new_text": "What is the [Incidence] / incidence of [Respiratory syncytial virus] / respiratory syncytial virus in [Child] / children older than 3 years of age ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the distance between the p4 7 and p12 7 genes in the irish versus japanese equine coronavirus variants?",
    "new_text": "What is the [Distance] / distance between the [EXOSC10 gene] / p4 7 and [CDKN2A gene] / p12 7 [Genes] / genes in the irish versus japanese [Equine coronavirus] / equine coronavirus variants ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is the difference between the tokachi09 and irish coronavirus genomic sequences?",
    "new_text": "What is the difference between the tokachi09 and irish [Genus: Coronavirus] / coronavirus [Genome] / genomic [DNA Sequence] / sequences ?",
    "n_kge": 3
  },
  {
    "raw_text": "What suggests that irish equine coronaviruses may have a low genetic diversity?",
    "new_text": "What suggests that irish [Equine coronavirus] / equine coronaviruses may have a low [Variation (Genetics)] / genetic diversity ?",
    "n_kge": 2
  },
  {
    "raw_text": "Where have most outbreaks of equine coronavirus occurred in the united states?",
    "new_text": "Where have most [Disease Outbreaks] / outbreaks of [Equine coronavirus] / equine coronavirus occurred in the [United States] / united states ?",
    "n_kge": 3
  },
  {
    "raw_text": "What kind of pertussis vaccine is used in middle and high income countries?",
    "new_text": "What [Type - attribute] / kind of [pertussis vaccine] / pertussis vaccine is [Used by] / used in [Middle] / middle and high income countries ?",
    "n_kge": 4
  },
  {
    "raw_text": "Where is the highest rate of childhood pertussis globally?",
    "new_text": "Where is the highest rate of [Childhood] / childhood [Pertussis] / pertussis globally ?",
    "n_kge": 2
  },
  {
    "raw_text": "What type of pertussis vaccine has been recently recommended by the who?",
    "new_text": "What type of pertussis vaccine has been [Recent] / recently recommended by the [World Health Organization] / world health organization ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are the clinical symptoms of pertussis?",
    "new_text": "What are the clinical symptoms of [Pertussis] / pertussis ?",
    "n_kge": 1
  },
  {
    "raw_text": "What type of swabs are used to sample patients with pertussis?",
    "new_text": "What [Type - attribute] / type of [Swab specimen] / swabs are [Used by] / used [Tryptophanase] / to [Specimen] / sample [Patients] / patients with [Pertussis] / pertussis ?",
    "n_kge": 7
  },
  {
    "raw_text": "How frequently do pertussis outbreaks peak?",
    "new_text": "How frequently do [Pertussis] / pertussis [Disease Outbreaks] / outbreaks peak ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the who criteria for a pertussis infection?",
    "new_text": "What is the [World Health Organization] / world health organization criteria for a [Pertussis] / pertussis [Communicable Diseases] / infection ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is used by the canadian public health system to identify periods of influenza activity?",
    "new_text": "What is used by the canadian public health system [Tryptophanase] / to identify periods of [Influenza] / influenza activity ?",
    "n_kge": 2
  },
  {
    "raw_text": "Why is laboratory confirmation of influenza infection not commonly performed?",
    "new_text": "Why is laboratory confirmation of [Influenza] / influenza infection not commonly [Performed] / performed ?",
    "n_kge": 2
  },
  {
    "raw_text": "What types of viral infections are monitored through canada's respiratory virus detection surveillance system (rvdss)?",
    "new_text": "What types of viral infections are monitored through canada's respiratory virus detection surveillance system ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is discussed in this publication?",
    "new_text": "What is discussed in this [Publications] / publication ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is discussed in this publication?",
    "new_text": "What is discussed in this [Publications] / publication ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is reported in this publication?",
    "new_text": "What is [Report (document)] / reported in this [Publications] / publication ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the conclusion regarding ire1 and rnasel proteins?",
    "new_text": "What is the conclusion regarding [ERN1 gene] / ire1 and [RNASEL gene] / rnasel [Proteins] / proteins ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the structure of an echovirus?",
    "new_text": "What is the structure of an [Echovirus] / echovirus ?",
    "n_kge": 1
  },
  {
    "raw_text": "What diseases are associated with echoviruses?",
    "new_text": "What [Disease] / diseases are associated with [Echovirus] / echoviruses ?",
    "n_kge": 2
  },
  {
    "raw_text": "In california, to where are meningitis cases reported according to the california code of regulations?",
    "new_text": "In [California] / california , to where are [Meningitis] / meningitis [Case (situation)] / cases [Report (document)] / reported according to the [California] / california code of regulations ?",
    "n_kge": 5
  },
  {
    "raw_text": "According to the california code of regulations, when should a meningitis case be reported?",
    "new_text": "According to the [California] / california code of regulations , when should a [Meningitis] / meningitis [Case (situation)] / case be [Report (document)] / reported ?",
    "n_kge": 4
  },
  {
    "raw_text": "Where is the viral and rickettsial disease laboratory located?",
    "new_text": "Where is the [Viral] / viral and [Rickettsia Infections] / rickettsial disease [Laboratory] / laboratory located ?",
    "n_kge": 3
  },
  {
    "raw_text": "What type of reference genome was used in the study?",
    "new_text": "What [Type - attribute] / type of reference [Genome] / genome was used in the study ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was the read coverage for the e-30 genome in this study?",
    "new_text": "What was the [Reading (activity)] / read coverage for the e - 30 [Genome] / genome in this study ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are the structural regions of the enterovirus polyprotein in this study?",
    "new_text": "What are the structural regions of the [Enterovirus Infections] / enterovirus polyprotein in this study ?",
    "n_kge": 1
  },
  {
    "raw_text": "What can nuclear receptors regulate?",
    "new_text": "What can [Receptors, Nuclear] / nuclear receptors regulate ?",
    "n_kge": 1
  },
  {
    "raw_text": "What are associated with cancer, diabetes, inflammatory disease, and osteoporosis?",
    "new_text": "What are associated with [Malignant Neoplasms] / cancer , diabetes , [Inflammatory disorder] / inflammatory disease , and [Osteoporosis] / osteoporosis ?",
    "n_kge": 3
  },
  {
    "raw_text": "What are nuclear receptors (nrs)?",
    "new_text": "What are [Receptors, Nuclear] / nuclear receptors ( [Receptors, Nuclear] / nuclear receptor ) ?",
    "n_kge": 2
  },
  {
    "raw_text": "What biological factors for nuclear receptors regulate?",
    "new_text": "What [Biological Factors] / biological factors for [Receptors, Nuclear] / nuclear receptors regulate ?",
    "n_kge": 2
  },
  {
    "raw_text": "How many families are in the nr superfamily?",
    "new_text": "How many families are in the [Nauru] / nr superfamily ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is a prerequisite to make a molecular docking study feasible?",
    "new_text": "What is a prerequisite [Tryptophanase] / to make a molecular docking study feasible ?",
    "n_kge": 1
  },
  {
    "raw_text": "What tool can be used to determine the 3d structure of proteins?",
    "new_text": "What tool can be [Used by] / used [Tryptophanase] / to determine the 3d structure of proteins ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are the shortcomings of x-ray crystallography?",
    "new_text": "What are the shortcomings of [Crystallography, X-Ray] / x - ray crystallography ?",
    "n_kge": 1
  },
  {
    "raw_text": "What types of proteins are difficult to crystallize?",
    "new_text": "What [Type - attribute] / types of [Proteins] / proteins are [Difficult (qualifier value)] / difficult [Tryptophanase] / to crystallize ?",
    "n_kge": 4
  },
  {
    "raw_text": "Where were the data collected for this study?",
    "new_text": "Where were the [Data] / data collected for this study ?",
    "n_kge": 1
  },
  {
    "raw_text": "Who performed the sampling procedures?",
    "new_text": "Who [Performed] / performed the sampling procedures ?",
    "n_kge": 1
  },
  {
    "raw_text": "When were the fecal samples collected?",
    "new_text": "When were the [Feces] / fecal samples collected ?",
    "n_kge": 1
  },
  {
    "raw_text": "What reference genome was used in the study?",
    "new_text": "What reference [Genome] / genome was used in the study ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the length of the replicase gene orf1ab?",
    "new_text": "What is the length of the replicase gene orf1ab ?",
    "n_kge": 0
  },
  {
    "raw_text": "What type of coronavirus was detected in r affinis and r sinicus species?",
    "new_text": "What [Type - attribute] / type of [Genus: Coronavirus] / coronavirus was detected in [Right] / r affinis and [Right] / r sinicus species ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is a natural reservoir of coronavirus?",
    "new_text": "What is a [Natural] / natural reservoir of [Genus: Coronavirus] / coronavirus ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the genome size of the coronavirus?",
    "new_text": "What is the genome size of the [Genus: Coronavirus] / coronavirus ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the structure of the coronavirus?",
    "new_text": "What is the structure of the [Genus: Coronavirus] / coronavirus ?",
    "n_kge": 1
  },
  {
    "raw_text": "What animals do gamma and delta coronavirus mainly infect?",
    "new_text": "What [Animals] / animals do [Gamma Rays] / gamma and delta [Genus: Coronavirus] / coronavirus mainly [Infected] / infect ?",
    "n_kge": 4
  },
  {
    "raw_text": "How many types of coronaviruses are known to cause human disease?",
    "new_text": "How [Numerous] / many [Type - attribute] / types of [Genus: Coronavirus] / coronaviruses are [Known] / known [Tryptophanase] / to [Etiology aspects] / cause [Homo sapiens] / human [Disease] / disease ?",
    "n_kge": 8
  },
  {
    "raw_text": "What plays a role in regulating the immune response to a viral infection?",
    "new_text": "What [Play] / plays a [Social Role] / role in regulating the immune response to a viral infection ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the conclusion of the coronavirus long-term surveillance studies?",
    "new_text": "What is the conclusion of the [Genus: Coronavirus] / coronavirus long - term surveillance studies ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the cause of feline infectious peritonitis (fip)?",
    "new_text": "What is the [Etiology aspects] / cause of [Feline infectious peritonitis] / feline infectious peritonitis ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the molecular structure of feline infectious peritonitis virus?",
    "new_text": "What is the [Molecular Structure] / molecular structure of [Feline infectious peritonitis virus] / feline infectious peritonitis virus ?",
    "n_kge": 2
  },
  {
    "raw_text": "How is fecv detected in cats?",
    "new_text": "How is [Coronavirus, Feline] / fecv detected in [Felis catus] / cats ?",
    "n_kge": 2
  },
  {
    "raw_text": "What type of vaccine is used to protect against fipv infection?",
    "new_text": "What type of vaccine is [Used by] / used [Tryptophanase] / to protect against [Feline infectious peritonitis virus] / fipv [Communicable Diseases] / infection ?",
    "n_kge": 4
  },
  {
    "raw_text": "Why is their controversy surrounding the fipv vaccine?",
    "new_text": "Why is their controversy [Surrounding (qualifier value)] / surrounding the [Feline infectious peritonitis virus] / fipv [Vaccines] / vaccine ?",
    "n_kge": 3
  },
  {
    "raw_text": "For how long was the denatured polyacrylamide gel polymerized?",
    "new_text": "For how [Long] / long was the denatured polyacrylamide gel [Polymerization] / polymerized ?",
    "n_kge": 2
  },
  {
    "raw_text": "How was the binding strength measured?",
    "new_text": "How was the binding [Physical Strength] / strength [Measured] / measured ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was the focus of this study?",
    "new_text": "What was the [Focal] / focus of this study ?",
    "n_kge": 1
  },
  {
    "raw_text": "What do neuroaminidase inhibitors target?",
    "new_text": "What do neuroaminidase inhibitors target ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the function of neuroaminidase in the influenza virus?",
    "new_text": "What is the [physiological aspects] / function of neuroaminidase in the [Orthomyxoviridae] / influenza virus ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is tamiflu?",
    "new_text": "What is [Tamiflu] / tamiflu ?",
    "n_kge": 1
  },
  {
    "raw_text": "What was the test for the level of cytotoxicity used in this study?",
    "new_text": "What was the test for the [Levels (qualifier value)] / level of cytotoxicity used in this study ?",
    "n_kge": 1
  },
  {
    "raw_text": "What method was used to measure the inhibition of viral replication?",
    "new_text": "What [Methods] / method was [Used by] / used [Tryptophanase] / to [Measures] / measure the inhibition of viral replication ?",
    "n_kge": 4
  },
  {
    "raw_text": "What was the conclusion of this study?",
    "new_text": "What was the conclusion of this study ?",
    "n_kge": 0
  },
  {
    "raw_text": "Why have nucleic acid amplification tests been restricted to laboratory settings?",
    "new_text": "Why have [Nucleic Acid Amplification Tests] / nucleic acid amplification tests been restricted to [Laboratory] / laboratory settings ?",
    "n_kge": 2
  },
  {
    "raw_text": "What screening method was evaluated in this study?",
    "new_text": "What screening method was [Evaluation] / evaluated in this study ?",
    "n_kge": 1
  },
  {
    "raw_text": "What was used to measure the performance of the nina heaters?",
    "new_text": "What was [Used by] / used [Tryptophanase] / to [Measures] / measure the performance of the nina heaters ?",
    "n_kge": 3
  },
  {
    "raw_text": "What percentage of hiv-infected people go undetected in the united states?",
    "new_text": "What [Percent (qualifier value)] / percentage of hiv - infected [Persons] / people [GORAB gene] / go undetected in the [United States] / united states ?",
    "n_kge": 4
  },
  {
    "raw_text": "What percentage of patients do not return for followup after hiv testing?",
    "new_text": "What [Percent (qualifier value)] / percentage of [Patients] / patients do not return for [Follow-up status] / followup after hiv testing ?",
    "n_kge": 3
  },
  {
    "raw_text": "What statistical tests were used to compare categorical variables?",
    "new_text": "What [Statistical Test] / statistical tests were [Used by] / used [Tryptophanase] / to compare categorical variables ?",
    "n_kge": 3
  },
  {
    "raw_text": "What was a severe limitation of this study?",
    "new_text": "What was a [Severe (severity modifier)] / severe limitation of this study ?",
    "n_kge": 1
  },
  {
    "raw_text": "What followup is needed to confirm the results of the current study?",
    "new_text": "What [Follow-up status] / followup is needed [Tryptophanase] / to confirm the results of the current study ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the conclusion of this study?",
    "new_text": "What is the conclusion of this study ?",
    "n_kge": 0
  },
  {
    "raw_text": "What suggests that ip-10 plays a significant role on the pathogenesis of pneumonia?",
    "new_text": "What suggests that ip - 10 [Play] / plays a [Statistical Significance] / significant [Social Role] / role on the pathogenesis of [Pneumonia] / pneumonia ?",
    "n_kge": 4
  },
  {
    "raw_text": "What cell types help prevent pneumococcal and influenza infection in the lungs?",
    "new_text": "What [Cells] / cell types help prevent [Streptococcus pneumoniae] / pneumococcal and [Influenza] / influenza infection in the lungs ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the most common, clinically-relevant multiresistant pathogen in both healthcare and community acquired infections?",
    "new_text": "What is the most common , clinically - relevant multiresistant [Pathogenic organism] / pathogen in both [Health care facility] / healthcare and [Community-Acquired Infections] / community acquired infections ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the treatment of choice for mrsa infections?",
    "new_text": "What is the treatment of choice for mrsa infections ?",
    "n_kge": 0
  },
  {
    "raw_text": "What enzyme is essential for the metabolism of fatty acids?",
    "new_text": "What [Enzymes] / enzyme is essential for the [Metabolism] / metabolism of fatty acids ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was the purpose of this research?",
    "new_text": "What was the [Purpose] / purpose of this [research] / research ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the conclusion of the study?",
    "new_text": "What is the conclusion of the study ?",
    "n_kge": 0
  },
  {
    "raw_text": "Why makes the marmoset an appropriate animal model for pathogen research?",
    "new_text": "Why makes the [Callithrix] / marmoset [Aniridia type 1] / an appropriate animal model for [Pathogenic organism] / pathogen research ?",
    "n_kge": 3
  },
  {
    "raw_text": "How can the efficacy of daas be diminished?",
    "new_text": "How can the [Effectiveness] / efficacy of daas be [Decreased] / diminished ?",
    "n_kge": 2
  },
  {
    "raw_text": "Was is the response rate of the hepatitis c virus to direct-acting antiviral treatments?",
    "new_text": "Was is the response rate of the [Hepatitis C] / hepatitis c virus to direct - acting antiviral treatments ?",
    "n_kge": 1
  },
  {
    "raw_text": "How do nonnucleoside ns5b polymerase inhibitors work?",
    "new_text": "How do nonnucleoside ns5b [Polymerase] / polymerase inhibitors [Work] / work ?",
    "n_kge": 2
  },
  {
    "raw_text": "How many patients were studied?",
    "new_text": "How many [Patients] / patients were studied ?",
    "n_kge": 1
  },
  {
    "raw_text": "Was written consent obtained?",
    "new_text": "Was written consent obtained ?",
    "n_kge": 0
  },
  {
    "raw_text": "How much of the rna template was in the reverse transcription reaction mixture?",
    "new_text": "How much of the [RNA] / rna template [Wiskott-Aldrich Syndrome] / was in the [Reverse Transcription] / reverse transcription [Reaction] / reaction mixture ?",
    "n_kge": 4
  },
  {
    "raw_text": "How many rass to ns5a inhibitors were identified?",
    "new_text": "How [Numerous] / many rass to ns5a inhibitors were identified ?",
    "n_kge": 1
  },
  {
    "raw_text": "Why is the substitution e62d important in drug resistance?",
    "new_text": "Why is the [Missense Mutation] / substitution e62d important in [Drug resistance] / drug resistance ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are the key factors preventing the elimination of hcv infection in some patients?",
    "new_text": "What are the key factors preventing the [Excretory function] / elimination of [Hepatitis C] / hcv infection in some [Patients] / patients ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is needed to direct genetic mutations in rna viruses?",
    "new_text": "What is needed [Tryptophanase] / to [Direct type of relationship] / direct genetic mutations in [RNA Viruses] / rna viruses ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the structure of the pestivirus?",
    "new_text": "What is the structure of the [Pestivirus] / pestivirus ?",
    "n_kge": 1
  },
  {
    "raw_text": "What sequences are critical for the autonomous replication of the pestivirus genome?",
    "new_text": "What sequences are critical for the autonomous replication of the [Pestivirus] / pestivirus [Genome] / genome ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are the 4 structural proteins of the pestivirus polyprotein?",
    "new_text": "What are the 4 [Structural protein] / structural proteins of the [Pestivirus] / pestivirus polyprotein ?",
    "n_kge": 2
  },
  {
    "raw_text": "The bac differed from the parental cdna sequence by what amino acid substitutions?",
    "new_text": "The bac differed from the [parent] / parental cdna sequence by what amino acid substitutions ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the purpose of this research study?",
    "new_text": "What is the purpose of this research study ?",
    "n_kge": 0
  },
  {
    "raw_text": "Why are ssis important to the overall burden on the healthcare system?",
    "new_text": "Why are ssis important to the overall burden on the [Health Care Systems] / healthcare system ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the \"never event\" policy?",
    "new_text": "What is the \" never event \" [Policy] / policy ?",
    "n_kge": 1
  },
  {
    "raw_text": "Patients from how many medical centers were studied?",
    "new_text": "[Patients] / Patients from how many medical centers were studied ?",
    "n_kge": 1
  },
  {
    "raw_text": "Which patients were excluded from the study?",
    "new_text": "Which [Patients] / patients were excluded from the study ?",
    "n_kge": 1
  },
  {
    "raw_text": "What are the limitations of a deterministic model?",
    "new_text": "What are the [Limitation] / limitations of a deterministic [Model] / model ?",
    "n_kge": 2
  },
  {
    "raw_text": "How does pedv spread?",
    "new_text": "How does [Porcine epidemic diarrhea virus] / pedv [Spreading (qualifier value)] / spread ?",
    "n_kge": 2
  },
  {
    "raw_text": "How does pedv cause illness?",
    "new_text": "How does [Porcine epidemic diarrhea virus] / pedv [Etiology aspects] / cause [Illness (finding)] / illness ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the size of the pedv genome?",
    "new_text": "What is the size of the [Porcine epidemic diarrhea virus] / pedv genome ?",
    "n_kge": 1
  },
  {
    "raw_text": "Which viruses are part of the old world complex of arenaviridae?",
    "new_text": "Which [Virus] / viruses are part of the old world [Complex] / complex of [Arenaviridae] / arenaviridae ?",
    "n_kge": 3
  },
  {
    "raw_text": "How can old world and new world arenaviruses be differentiated?",
    "new_text": "How can old world and new world arenaviruses be [Cell Differentiation process] / differentiated ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the incubation period for arenavirus?",
    "new_text": "What is the incubation period for [Arenavirus] / arenavirus ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the structure of the arenavirus?",
    "new_text": "What is the structure of the [Arenavirus] / arenavirus ?",
    "n_kge": 1
  },
  {
    "raw_text": "What proteins does the arenavirus produce?",
    "new_text": "What [Proteins] / proteins does the [Arenavirus] / arenavirus produce ?",
    "n_kge": 2
  },
  {
    "raw_text": "What diagnostic test has been show to have excellent sensitivity in detecting viral infections?",
    "new_text": "What [Diagnostic tests] / diagnostic test has been show [Tryptophanase] / to have excellent [Hypersensitivity] / sensitivity in detecting [Virus Diseases] / viral infections ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is the effect of oseltamivir and zanamivir?",
    "new_text": "What is the effect of [oseltamivir] / oseltamivir and [zanamivir] / zanamivir ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is glycyrrhizin?",
    "new_text": "What is [glycyrrhizic acid] / glycyrrhizin ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the effect of glycyrrhizin in viral infections?",
    "new_text": "What is the effect of [glycyrrhizic acid] / glycyrrhizin in [Virus Diseases] / viral infections ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is another word for hypercytokinaemia?",
    "new_text": "What is another word for hypercytokinaemia ?",
    "n_kge": 0
  },
  {
    "raw_text": "What has been correlated with the pathogenicity of the h5n1 infection?",
    "new_text": "What has been correlated with the [Pathogenicity Aspects] / pathogenicity of the h5n1 infection ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the conclusion of the study?",
    "new_text": "What is the conclusion of the study ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the mean duration of time from single lobe consolidation to bilateral multilobar lung infiltrates in human adenovirus type 55 (hadv-55)?",
    "new_text": "What is the mean [Duration (temporal concept)] / duration of [Time] / time from single lobe consolidation to [Bilateral] / bilateral multilobar lung [Infiltration] / infiltrates in human adenovirus [Type - attribute] / type 55 ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is the mean duration of time from first positive chest x-ray to bilateral multilobar lung infiltrates in human adenovirus type 55 (hadv-55)?",
    "new_text": "What is the mean [Duration (temporal concept)] / duration of [Time] / time from first [percent positive cells] / positive [Plain chest X-ray] / chest x - ray to bilateral multilobar lung [Infiltration] / infiltrates in human adenovirus [Type - attribute] / type 55 ( human adenovirus [Type - attribute] / type 55 ) ?",
    "n_kge": 7
  },
  {
    "raw_text": "What are the most frequent clinical manifestations of human adenovirus type 55 (hadv-55) induced ards?",
    "new_text": "What are the most frequent clinical manifestations of human adenovirus [Type - attribute] / type 55 ( human adenovirus [Type - attribute] / type 55 ) induced [Respiratory Distress Syndrome, Adult] / acute respiratory distress syndrome ?",
    "n_kge": 3
  },
  {
    "raw_text": "What do we know about the genomics of human adenovirus type 55 (hadv-55)?",
    "new_text": "What do we know about the [Genomics] / genomics of human adenovirus [Type - attribute] / type 55 ( human adenovirus [Type - attribute] / type 55 ) ?",
    "n_kge": 3
  },
  {
    "raw_text": "What are the clinical symptoms of human adenovirus type 55 (hadv-55)?",
    "new_text": "What are the clinical symptoms of human adenovirus [Type - attribute] / type 55 ( human adenovirus [Type - attribute] / type 55 ) ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the mean time from onset of symptoms to dyspnea in human adenovirus type 55 (hadv-55)?",
    "new_text": "What is the mean time from onset of symptoms [Tryptophanase] / to dyspnea in human adenovirus [Type - attribute] / type 55 ( human adenovirus [Type - attribute] / type 55 ) ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the mean time of onset of symptoms to icu admission in human adenovirus type 55 (hadv-55)?",
    "new_text": "What is the mean time of onset of symptoms [Tryptophanase] / to [intensive care unit] / icu [Hospital admission] / admission in human adenovirus [Type - attribute] / type 55 ( human adenovirus [Type - attribute] / type 55 ) ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is the mean rate of respiration upon admission to the icu when admitted for human adenovirus type 55 (hadv-55)?",
    "new_text": "What is the mean rate of respiration upon [Hospital admission] / admission to the [intensive care unit] / icu when [Hospital admission] / admitted for human adenovirus [Type - attribute] / type 55 ( human adenovirus [Type - attribute] / type 55 ) ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is the white blood cell count in severe cases of human adenovirus type 55 (hadv-55)?",
    "new_text": "What is the white blood cell count in [Severe (severity modifier)] / severe [Case (situation)] / cases of [Adenoviruses, Human] / human adenovirus [Type - attribute] / type [55] / 55 ( [Adenoviruses, Human] / human adenovirus [Type - attribute] / type [55] / 55 ) ?",
    "n_kge": 8
  },
  {
    "raw_text": "What does a chest x-ray look like for a patient with a severe case of human adenovirus type 55 (hadv-55)?",
    "new_text": "What does a [Plain chest X-ray] / chest x - ray [Personal appearance] / look like for a [Patients] / patient with a [Severe (severity modifier)] / severe [Case (situation)] / case of human adenovirus [Type - attribute] / type [55] / 55 ( human adenovirus [Type - attribute] / type [55] / 55 ) ?",
    "n_kge": 9
  },
  {
    "raw_text": "What are the high resolution pulmonary ct scan findings for patients with severe cases of human adenovirus type 55 (hadv-55)?",
    "new_text": "What are the high resolution [Lung] / pulmonary computed tomography scan findings for [Patients] / patients with [Severe (severity modifier)] / severe [Case (situation)] / cases of human adenovirus [Type - attribute] / type 55 ( human adenovirus [Type - attribute] / type 55 ) ?",
    "n_kge": 6
  },
  {
    "raw_text": "Where could a clinician acquire a positive viral sample in severe cases of human adenovirus type 55 (hadv-55)?",
    "new_text": "Where could a [Clinician] / clinician acquire a [percent positive cells] / positive [Viral] / viral [Specimen] / sample in [Severe (severity modifier)] / severe [Case (situation)] / cases of human adenovirus [Type - attribute] / type [55] / 55 ( human adenovirus [Type - attribute] / type [55] / 55 ) ?",
    "n_kge": 10
  },
  {
    "raw_text": "How long did it take for patients with positive human adenovirus type 55 (hadv-55) endotracheal aspirates to develop a measurable viremia?",
    "new_text": "How [Long] / long did it take for [Patients] / patients with [percent positive cells] / positive human adenovirus [Type - attribute] / type 55 ( human adenovirus [Type - attribute] / type 55 ) endotracheal aspirates [Tryptophanase] / to develop a measurable [Viremia] / viremia ?",
    "n_kge": 7
  },
  {
    "raw_text": "Does blood type play a role in the severity of human adenovirus type 55 (hadv-55) infection?",
    "new_text": "Does [Blood Group (classification)] / blood type [Play] / play a [Social Role] / role in the [Severities] / severity of human adenovirus [Type - attribute] / type [55] / 55 ( human adenovirus [Type - attribute] / type [55] / 55 ) [Communicable Diseases] / infection ?",
    "n_kge": 9
  },
  {
    "raw_text": "What are the most common clinical manifestations of severe human adenovirus type 55 (hadv-55) induced ards?",
    "new_text": "What are the most common clinical manifestations of [Severe (severity modifier)] / severe human adenovirus [Type - attribute] / type 55 ( human adenovirus [Type - attribute] / type 55 ) induced [Respiratory Distress Syndrome, Adult] / acute respiratory distress syndrome ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is the mortality rate of severe ards from human adenovirus type 55 (hadv-55)?",
    "new_text": "What is the mortality rate of [Severe (severity modifier)] / severe acute respiratory distress syndrome from human adenovirus [Type - attribute] / type 55 ( human adenovirus [Type - attribute] / type 55 ) ?",
    "n_kge": 3
  },
  {
    "raw_text": "What role does t-cell count play in severe human adenovirus type 55 (hadv-55) infection?",
    "new_text": "What [Social Role] / role does t - cell count [Play] / play in [Severe (severity modifier)] / severe human adenovirus [Type - attribute] / type 55 ( human adenovirus [Type - attribute] / type 55 ) [Communicable Diseases] / infection ?",
    "n_kge": 6
  },
  {
    "raw_text": "How successful are the use of invasive mechanical ventilation (imv) and non-invasive positive pressure ventilation (nppv) in the treatment of severe ards from human adenovirus type 55 infection?",
    "new_text": "How [Success] / successful are the use of invasive mechanical ventilation and non - invasive positive pressure ventilation in the [therapeutic aspects] / treatment of severe acute respiratory distress syndrome from human adenovirus [Type - attribute] / type [55] / 55 infection ?",
    "n_kge": 4
  },
  {
    "raw_text": "How many patients were analyzed in the study?",
    "new_text": "How many [Patients] / patients were analyzed in the study ?",
    "n_kge": 1
  },
  {
    "raw_text": "How many patients with community-acquired pneumonia are hospitalized each year?",
    "new_text": "How [Numerous] / many [Patients] / patients with [Community acquired pneumonia] / community - acquired pneumonia are [Patient in hospital] / hospitalized each year ?",
    "n_kge": 4
  },
  {
    "raw_text": "What chest x-ray findings are typically indicative of community-acquired pneumonia?",
    "new_text": "What [Plain chest X-ray] / chest x - ray findings are typically indicative of [Community acquired pneumonia] / community - acquired pneumonia ?",
    "n_kge": 2
  },
  {
    "raw_text": "When did who declare a pandemic of ph1n1/2009v influenza?",
    "new_text": "When did [World Health Organization] / world health organization declare a [Pandemics] / pandemic of ph1n1 / 2009v influenza ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the classical cutoff value for antibody titers?",
    "new_text": "What is the [Conventional] / classical cutoff value for [Antibody titer measurement] / antibody titers ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is meant by a protective hia titer?",
    "new_text": "What is meant by a protective hia titer ?",
    "n_kge": 0
  },
  {
    "raw_text": "What are the results of the study?",
    "new_text": "What are the results of the study ?",
    "n_kge": 0
  },
  {
    "raw_text": "What was the interpretation for the crossreactive antibodies?",
    "new_text": "What was the [Interpretation Process] / interpretation for the crossreactive antibodies ?",
    "n_kge": 1
  },
  {
    "raw_text": "How long did the ph1n1/2009 viral outbreak last?",
    "new_text": "How [Long] / long did the ph1n1 / 2009 [Viral] / viral [Disease Outbreaks] / outbreak last ?",
    "n_kge": 3
  },
  {
    "raw_text": "What were the aims of this study?",
    "new_text": "What were the aims of this study ?",
    "n_kge": 0
  },
  {
    "raw_text": "What network of physicians provides real-time clinical data on the spread of influenza in france?",
    "new_text": "What [Social Networks] / network of [Physicians] / physicians provides real - time clinical data on the [Spreading (qualifier value)] / spread of [Influenza] / influenza in [France] / france ?",
    "n_kge": 5
  },
  {
    "raw_text": "What are the criteria used to define an influenza-like illness in france?",
    "new_text": "What are the criteria [Used by] / used [Tryptophanase] / to define [Aniridia type 1] / an [Influenza-like symptoms] / influenza - like illness in [France] / france ?",
    "n_kge": 5
  },
  {
    "raw_text": "What virus was the most common among the h1n1v negative patients?",
    "new_text": "What [Virus] / virus was the most common among the h1n1v [Negative] / negative [Patients] / patients ?",
    "n_kge": 3
  },
  {
    "raw_text": "What was the aim of this study?",
    "new_text": "What was the aim of this study ?",
    "n_kge": 0
  },
  {
    "raw_text": "Where is the bearded vulture (gypaetus barbatus) commonly found?",
    "new_text": "Where is the bearded vulture ( [Lammergeier] / gypaetus barbatus ) commonly [Present] / found ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was the focus of this study?",
    "new_text": "What was the [Focal] / focus of this study ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the third most prevalent cancer in females in the united states?",
    "new_text": "What is the third most prevalent [Malignant Neoplasms] / cancer in [Females] / females in the [United States] / united states ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the 1-year survival rate for colorectal cancer patients?",
    "new_text": "What is the 1 - year [Survival Rate] / survival rate for [Colorectal Carcinoma] / colorectal cancer [Patients] / patients ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the 5-year survival rate for colorectal cancer patients?",
    "new_text": "What is the 5 - year survival rate for [Colorectal Carcinoma] / colorectal cancer [Patients] / patients ?",
    "n_kge": 2
  },
  {
    "raw_text": "How were nuclear morphological changes in ht-29 cells measured?",
    "new_text": "How were nuclear morphological changes in [HT29 Cells] / ht - 29 cells [Measured] / measured ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is directly related to nuclear condensation?",
    "new_text": "What is directly [Relationships] / related to nuclear condensation ?",
    "n_kge": 1
  },
  {
    "raw_text": "What morphological cell changes are most associated with apoptosis?",
    "new_text": "What morphological [Cells] / cell changes are most associated with [Apoptosis] / apoptosis ?",
    "n_kge": 2
  },
  {
    "raw_text": "What types of cells are suitable for colon cancer studies?",
    "new_text": "What types of cells are suitable for [Malignant tumor of colon] / colon cancer studies ?",
    "n_kge": 1
  },
  {
    "raw_text": "What was the goal of this study?",
    "new_text": "What was the [objective (goal)] / goal of this study ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the conclusion of this study?",
    "new_text": "What is the conclusion of this study ?",
    "n_kge": 0
  },
  {
    "raw_text": "What was the conclusion of this study?",
    "new_text": "What was the conclusion of this study ?",
    "n_kge": 0
  },
  {
    "raw_text": "What are the implications of the novel fermentation-based glycosylation strategy described in this study?",
    "new_text": "What are the implications of the [New] / novel [Fermentation] / fermentation - based [glycosylation] / glycosylation strategy described in this study ?",
    "n_kge": 3
  },
  {
    "raw_text": "What characteristics does glycosylation have on flavonoids?",
    "new_text": "What [Characteristics] / characteristics does [glycosylation] / glycosylation have on [Flavonoids] / flavonoids ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is fibrinogen-like protein 2 (fgi2)?",
    "new_text": "What is fibrinogen - like protein 2 ( fgi2 ) ?",
    "n_kge": 0
  },
  {
    "raw_text": "What represses murine hepatitis virus strain 3 (mhv-3) infection?",
    "new_text": "What represses murine hepatitis virus [Muscle strain] / strain 3 infection ?",
    "n_kge": 1
  },
  {
    "raw_text": "What was the goal of this study?",
    "new_text": "What was the [objective (goal)] / goal of this study ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is fulminant hepatitis?",
    "new_text": "What is [Fulminant Hepatitis] / fulminant hepatitis ?",
    "n_kge": 1
  },
  {
    "raw_text": "How does prothrombinase fgl2 affect the coagulation process?",
    "new_text": "How does [Thromboplastin] / prothrombinase [FGL2 gene] / fgl2 [Affect (mental function)] / affect the coagulation process ?",
    "n_kge": 3
  },
  {
    "raw_text": "How long after mhv-3 infection were liver samples taken?",
    "new_text": "How [Long] / long after murine hepatitis virus [Muscle strain] / strain 3 infection were liver samples taken ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the relationship between urbanization and risk of emergence of flu-like diseases?",
    "new_text": "What is the [Relationships] / relationship between [Urbanization] / urbanization and risk of emergence of flu - like diseases ?",
    "n_kge": 2
  },
  {
    "raw_text": "What factors and characteristics of semi-urban landscapes promote viral transmission?",
    "new_text": "What factors and [Characteristics] / characteristics of semi - urban landscapes [Promotion (action)] / promote viral transmission ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the relationship between hin1 viral transmission and poultry production?",
    "new_text": "What is the [Relationships] / relationship between [SCGB3A1 gene] / hin1 viral transmission and [Fowls, Domestic] / poultry production ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the principle behind infection convergence model ?",
    "new_text": "What is the principle behind [Communicable Diseases] / infection convergence [Model] / model ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the boosted regression tree method?",
    "new_text": "What is the boosted regression [Trees (plant)] / tree method ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the advantage of boosted regression tree method?",
    "new_text": "What is the advantage of boosted regression [Trees (plant)] / tree method ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the relationship between land use and emergence of hpai h5n1?",
    "new_text": "What is the [Relationships] / relationship between land use and emergence of hpai [Influenza in Birds] / h5n1 ?",
    "n_kge": 2
  },
  {
    "raw_text": "Where is the highest risk of hpai h5n1 like disease emergence?",
    "new_text": "Where is the highest risk of hpai [Influenza in Birds] / h5n1 like [Disease] / disease emergence ?",
    "n_kge": 2
  },
  {
    "raw_text": "How does land use fragmentation increase the risk of flu-like diseases?",
    "new_text": "How does land use fragmentation [Increase] / increase the risk of flu - like diseases ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the relationship between the outbreak of hpai h5n1 like diseases and rice cultivation?",
    "new_text": "What is the [Relationships] / relationship between the [Disease Outbreaks] / outbreak of hpai [Influenza in Birds] / h5n1 like [Disease] / diseases and [Rice (Dietary)] / rice cultivation ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is the relationship between aquaculture and spread of h5n1 like diseases?",
    "new_text": "What is the [Relationships] / relationship between aquaculture and [Spreading (qualifier value)] / spread of [Influenza in Birds] / h5n1 like [Disease] / diseases ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is the relationship between proximity ofwater bodies to agricultural lands and spread of h5n1 like diseases?",
    "new_text": "What is the [Relationships] / relationship between proximity ofwater [Human body] / bodies to agricultural lands and [Spreading (qualifier value)] / spread of [Influenza in Birds] / h5n1 like [Disease] / diseases ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is the effect of diversity of chicken flock on h5n1 disease?",
    "new_text": "What is the effect of [Diversity] / diversity of [Chickens] / chicken [Flock] / flock on [Influenza in Birds] / h5n1 [Disease] / disease ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is compound topological index and how is it related to the risk of disease transmission?",
    "new_text": "What is compound topological index and how is it [Relationships] / related to the [Risk] / risk of disease transmission ?",
    "n_kge": 2
  },
  {
    "raw_text": "In vitro comparison of antiviral activity of chloroquine(cq) and hydroxychloroquine(hcq) against covid-19?",
    "new_text": "In vitro comparison of antiviral activity of [chloroquine] / chloroquine ( cq ) and [hydroxychloroquine] / hydroxychloroquine ( [hydroxychloroquine] / hcq ) against [COVID-19] / covid - 19 ?",
    "n_kge": 4
  },
  {
    "raw_text": "What will be the drug of choice for treating covid-19 between chloroquine and remdesivir?",
    "new_text": "What will be the [Pharmaceutical Preparations] / drug of [Choice Behavior] / choice for treating [COVID-19] / covid - 19 between [chloroquine] / chloroquine and [remdesivir] / remdesivir ?",
    "n_kge": 5
  },
  {
    "raw_text": "Mechanism of action of chloroquine(cq) and hydroxychloroquine(hcq) against covid-19?",
    "new_text": "Mechanism of action of [chloroquine] / chloroquine ( cq ) and [hydroxychloroquine] / hydroxychloroquine ( [hydroxychloroquine] / hcq ) against [COVID-19] / covid - 19 ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is the effect of chloroquine(cq) and hydroxychloroquine(hcq) on endosomal maturation and endocytosis in covid-19 treatment?",
    "new_text": "What is the effect of [chloroquine] / chloroquine ( cq ) and [hydroxychloroquine] / hydroxychloroquine ( [hydroxychloroquine] / hcq ) on endosomal [Biologic Development] / maturation and [Endocytosis] / endocytosis in covid - 19 treatment ?",
    "n_kge": 5
  },
  {
    "raw_text": "Evidence of hydroxychloroquine(hcq) being anti inflammatory in sars-cov-2 critically ill patients with elevated plasma cytokines?",
    "new_text": "Evidence of [hydroxychloroquine] / hydroxychloroquine ( [hydroxychloroquine] / hcq ) being [Anti-Inflammatory Agents] / anti inflammatory in [2019 novel coronavirus] / sars - cov - 2 [Critical Illness] / critically ill [Patients] / patients with [High] / elevated [Plasma] / plasma [cytokine] / cytokines ?",
    "n_kge": 9
  },
  {
    "raw_text": "What proportion of healthcare workers reported symptoms of depression?",
    "new_text": "What proportion of [Health Personnel] / healthcare workers [Report (document)] / reported symptoms of depression ?",
    "n_kge": 2
  },
  {
    "raw_text": "What proportion of healthcare workers reported symptoms of anxiety?",
    "new_text": "What proportion of [Health Personnel] / healthcare workers [Report (document)] / reported symptoms of anxiety ?",
    "n_kge": 2
  },
  {
    "raw_text": "What proportion of healthcare workers reported symptoms of insomnia?",
    "new_text": "What proportion of [Health Personnel] / healthcare workers [Report (document)] / reported symptoms of [Sleeplessness] / insomnia ?",
    "n_kge": 3
  },
  {
    "raw_text": "What proportion reported distress?",
    "new_text": "What proportion [Report (document)] / reported [Distress] / distress ?",
    "n_kge": 2
  },
  {
    "raw_text": "What were the generalized anxiety disorder scale scores?",
    "new_text": "What were the generalized anxiety disorder scale [Score] / scores ?",
    "n_kge": 1
  },
  {
    "raw_text": "What were the insomnia severity index scores ?",
    "new_text": "What were the insomnia severity index scores ?",
    "n_kge": 0
  },
  {
    "raw_text": "What were the impact of event scale\u2013revised scores?",
    "new_text": "What were the impact of event scale revised [Score] / scores ?",
    "n_kge": 1
  },
  {
    "raw_text": "What were the results of analysis?",
    "new_text": "What were the results of analysis ?",
    "n_kge": 0
  },
  {
    "raw_text": "What were the results of analysis?",
    "new_text": "What were the results of analysis ?",
    "n_kge": 0
  },
  {
    "raw_text": "What are the conclusions of this study?",
    "new_text": "What are the conclusions of this study ?",
    "n_kge": 0
  },
  {
    "raw_text": "What are microtubule severing enzymes?",
    "new_text": "What are microtubule severing [Enzymes] / enzymes ?",
    "n_kge": 1
  },
  {
    "raw_text": "What genetic mutation is associated with hereditary spastic paraplegia?",
    "new_text": "What genetic mutation is associated with [Spastic Paraplegia, Hereditary] / hereditary spastic paraplegia ?",
    "n_kge": 1
  },
  {
    "raw_text": "What genetic mutation is associated with cerebral malformations?",
    "new_text": "What genetic mutation is associated with cerebral malformations ?",
    "n_kge": 0
  },
  {
    "raw_text": "What genetic mutation is associated with autism?",
    "new_text": "What genetic mutation is associated with [Autistic Disorder] / autism ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is katnal1?",
    "new_text": "What is [KATNAL1 gene] / katnal1 ?",
    "n_kge": 1
  },
  {
    "raw_text": "What organ is most associated with the katnal1 gene?",
    "new_text": "What [Organ] / organ is most associated with the katnal1 gene ?",
    "n_kge": 1
  },
  {
    "raw_text": "What cns functions can be measured by studying the movement of mice in a t-maze?",
    "new_text": "What cns functions can be [Measured] / measured by studying the [Movement] / movement of [House mice] / mice in [Tonsillectomy and adenoidectomy] / a t - [amsacrine/azacitidine/etoposide] / maze ?",
    "n_kge": 5
  },
  {
    "raw_text": "What cns functions are changed by mutations in the katnal1 gene?",
    "new_text": "What cns functions are [Changing] / changed by [Mutation] / mutations in the katnal1 gene ?",
    "n_kge": 2
  },
  {
    "raw_text": "How is japanese encephalitis transmitted?",
    "new_text": "How is [Japanese Encephalitis] / japanese encephalitis [disease transmission] / transmitted ?",
    "n_kge": 2
  },
  {
    "raw_text": "What element is essential to promoting jev infection?",
    "new_text": "What [Elements] / element is essential to [Promotion (action)] / promoting jev [Communicable Diseases] / infection ?",
    "n_kge": 3
  },
  {
    "raw_text": "Where is q130 located in the ns4b protein?",
    "new_text": "Where is q130 located in the ns4b [Proteins] / protein ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the mechanism of action for manidipine?",
    "new_text": "What is the mechanism of action for manidipine ?",
    "n_kge": 0
  },
  {
    "raw_text": "How many different pathogens are members of the flaviviridae family of virus?",
    "new_text": "How many different pathogens are [member] / members of the flaviviridae family of [Virus] / virus ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the size of a flavivirus?",
    "new_text": "What is the [size] / size of a [Flavivirus] / flavivirus ?",
    "n_kge": 2
  },
  {
    "raw_text": "How many open reading frames are in the flavivirus genome?",
    "new_text": "How many [Open Reading Frames] / open reading frames are in the [Flavivirus] / flavivirus [Genome] / genome ?",
    "n_kge": 3
  },
  {
    "raw_text": "What are the structural protein elements of a flavivirus?",
    "new_text": "What are the structural protein elements of a [Flavivirus] / flavivirus ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the function of the nonstructural protein elements of the flavivirus?",
    "new_text": "What is the function of the nonstructural protein [Elements] / elements of the [Flavivirus] / flavivirus ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are rvps?",
    "new_text": "What are rvps ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is hts?",
    "new_text": "What is [Saline Solution, Hypertonic] / hts ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the selective index in high throughput screening?",
    "new_text": "What is the selective index in [High-Throughput Screening] / high throughput screening ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the structure of a recombiant viral particle?",
    "new_text": "What is the structure of a recombiant viral particle ?",
    "n_kge": 0
  },
  {
    "raw_text": "What measure is used in high-throughput screening to identify potential antiviral compounds?",
    "new_text": "What [Measures] / measure is [Used by] / used in [High-Throughput Screening] / high - throughput screening [Tryptophanase] / to identify potential [Antiviral Agents] / antiviral compounds ?",
    "n_kge": 5
  },
  {
    "raw_text": "How many known species of rotavirus exist?",
    "new_text": "How [Numerous] / many [Known] / known species of rotavirus exist ?",
    "n_kge": 2
  },
  {
    "raw_text": "Is rotavirus single or double-stranded?",
    "new_text": "Is [Rotavirus] / rotavirus [Unmarried person] / single or double - stranded ?",
    "n_kge": 2
  },
  {
    "raw_text": "What structural proteins are coded by rotavirus?",
    "new_text": "What [Structural protein] / structural proteins are coded by [Rotavirus] / rotavirus ?",
    "n_kge": 2
  },
  {
    "raw_text": "What non-structural proteins are coded by rotavirus?",
    "new_text": "What non - structural proteins are coded by [Rotavirus] / rotavirus ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is qrt-pcr?",
    "new_text": "What is [Quantitative Reverse Transcriptase PCR] / qrt - pcr ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is required to establish a secondary immune response to a viral infection?",
    "new_text": "What is required [Tryptophanase] / to establish a [Immunologic Memory] / secondary immune response [Tryptophanase] / to a [Virus Diseases] / viral infection ?",
    "n_kge": 4
  },
  {
    "raw_text": "What do immunoglobulin isotype recombination and somatic hyper mutation depend on?",
    "new_text": "What do immunoglobulin isotype [Recombination, Genetic] / recombination and somatic hyper mutation depend on ?",
    "n_kge": 1
  },
  {
    "raw_text": "What was used to quantify the amount of igm secreting cells?",
    "new_text": "What was [Used by] / used [Tryptophanase] / to quantify the [Quantity] / amount of igm secreting cells ?",
    "n_kge": 3
  },
  {
    "raw_text": "Where was the coronavirus discovered?",
    "new_text": "Where was the [Genus: Coronavirus] / coronavirus discovered ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the number of confirmed cases reached on 8 february 2020?",
    "new_text": "What is the [Numbers] / number of confirmed cases reached on 8 february 2020 ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is presented in this study?",
    "new_text": "What is [Presentation] / presented in this study ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the proposed model?",
    "new_text": "What is the proposed [Model] / model ?",
    "n_kge": 1
  },
  {
    "raw_text": "When is ssa generally employed?",
    "new_text": "When is ssa generally employed ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the main idea behind the proposed model?",
    "new_text": "What is the main idea behind the proposed [Model] / model ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the proposed model called?",
    "new_text": "What is the proposed [Model] / model called ?",
    "n_kge": 1
  },
  {
    "raw_text": "How is fpassa-anfis model evaluated?",
    "new_text": "How is fpassa - adaptive neuro - fuzzy inference system [Model] / model [Evaluation] / evaluated ?",
    "n_kge": 2
  },
  {
    "raw_text": "What did the comparison of the fpassa-anfis model with several existing models, show?",
    "new_text": "What did the comparison of the fpassa - adaptive neuro - fuzzy inference system model with [Numerous] / several existing [Model] / models , show ?",
    "n_kge": 2
  },
  {
    "raw_text": "How was the proposed model tested?",
    "new_text": "How was the proposed [Model] / model [Tests (qualifier value)] / tested ?",
    "n_kge": 2
  },
  {
    "raw_text": "What were the outcomes of the test?",
    "new_text": "What were the outcomes of the test ?",
    "n_kge": 0
  },
  {
    "raw_text": "What are the large family of viruses, called coronaviruses?",
    "new_text": "What are the large family of [Virus] / viruses , called [Genus: Coronavirus] / coronaviruses ?",
    "n_kge": 2
  },
  {
    "raw_text": "Among whom are the coronaviruses distributed?",
    "new_text": "Among whom are the [Genus: Coronavirus] / coronaviruses distributed ?",
    "n_kge": 1
  },
  {
    "raw_text": "In what the adaptive neuro-fuzzy inference system (anfis) [22] is widely applied?",
    "new_text": "In what the adaptive neuro - fuzzy inference system [ 22 ] is widely applied ?",
    "n_kge": 0
  },
  {
    "raw_text": "What does anfis offer?",
    "new_text": "What does adaptive neuro - fuzzy inference system offer ?",
    "n_kge": 0
  },
  {
    "raw_text": "In which applications has it been applied?",
    "new_text": "In which [Application procedure] / applications has it been applied ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is si?",
    "new_text": "What is si ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is pso?",
    "new_text": "What is pso ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is sca?",
    "new_text": "What is [Cardiac Arrest] / sca ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is mvo?",
    "new_text": "What is mvo ?",
    "n_kge": 0
  },
  {
    "raw_text": "For what sca algorithm was applied to improve the anfis model ?",
    "new_text": "For what [Cardiac Arrest] / sca [algorithm] / algorithm was applied [Tryptophanase] / to improve the adaptive neuro - fuzzy inference system [Model] / model ?",
    "n_kge": 4
  },
  {
    "raw_text": "What may be a problem with individual si algorithm?",
    "new_text": "What may be a [Problem] / problem with [Persons] / individual si [algorithm] / algorithm ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is owa?",
    "new_text": "What is owa ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is proposed in the current study?",
    "new_text": "What is proposed in the current study ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the fpa optimization algorithm inspired by?",
    "new_text": "What is the fpa optimization [algorithm] / algorithm [Inspiration function] / inspired by ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the ssa optimization algorithm inspired by?",
    "new_text": "What is the ssa optimization [algorithm] / algorithm [Inspiration function] / inspired by ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the proposed fpassa method?",
    "new_text": "What is the proposed fpassa [Methods] / method ?",
    "n_kge": 1
  },
  {
    "raw_text": "How does the proposed fpassa start?",
    "new_text": "How does the proposed fpassa [Beginning] / start ?",
    "n_kge": 1
  },
  {
    "raw_text": "What do the authors propose?",
    "new_text": "What do the [Author] / authors propose ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is vacuolar-type h(+)-atpase (v-atpase)?",
    "new_text": "What is vacuolar - [Type - attribute] / type h ( + ) - [Adenosine Triphosphatases] / atpase ( v - atpase ) ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is archazolid?",
    "new_text": "What is archazolid ?",
    "n_kge": 0
  },
  {
    "raw_text": "How many complexes are within v-atpase?",
    "new_text": "How many complexes are within v - atpase ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the role of v-atpase in the plasma membrane of osteoclasts and renal epithelial cells?",
    "new_text": "What is the [Social Role] / role of v - atpase [Present] / in the plasma membrane of osteoclasts and renal epithelial cells ?",
    "n_kge": 2
  },
  {
    "raw_text": "What does angiogenesis depend on?",
    "new_text": "What does [Angiogenic Process] / angiogenesis depend on ?",
    "n_kge": 1
  },
  {
    "raw_text": "How were untreated mda-mb-231 cells labeled?",
    "new_text": "How were untreated [3,4-Methylenedioxyamphetamine] / mda - mb - 231 [Cell Count] / cells labeled ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was the goal of the study?",
    "new_text": "What was the [objective (goal)] / goal of the study ?",
    "n_kge": 1
  },
  {
    "raw_text": "What was the reported infection rate for influenza?",
    "new_text": "What was the [Report (document)] / reported infection rate for [Influenza] / influenza ?",
    "n_kge": 2
  },
  {
    "raw_text": "How many times more likely was an infection found in patients over 85 years old?",
    "new_text": "How many [Time] / times more [Probable diagnosis] / likely was an [Communicable Diseases] / infection [Present] / found in [Patients] / patients over [85] / 85 years old ?",
    "n_kge": 6
  },
  {
    "raw_text": "What can be the main challenges in managing a hospital outbreak of covid-19?",
    "new_text": "What can be the main [Challenge] / challenges in [Management procedure] / managing a [Hospitals] / hospital [Disease Outbreaks] / outbreak of covid - 19 ?",
    "n_kge": 4
  },
  {
    "raw_text": "Why early identification of covid-19 patients can be difficult?",
    "new_text": "Why early identification of [COVID-19] / covid - 19 [Patients] / patients can be [Difficult (qualifier value)] / difficult ?",
    "n_kge": 3
  },
  {
    "raw_text": "What are the steps that a hospital should take after covid-19 outbreak?",
    "new_text": "What are the steps that a [Hospitals] / hospital should take after [COVID-19] / covid - 19 [Disease Outbreaks] / outbreak ?",
    "n_kge": 3
  },
  {
    "raw_text": "Why exposure risk of covid-19 is very high for icu staff and what precautions should be taken?",
    "new_text": "Why [Injury due to exposure to external cause] / exposure [Risk] / risk of [COVID-19] / covid - 19 is very high for [intensive care unit] / icu staff and what precautions should be taken ?",
    "n_kge": 4
  },
  {
    "raw_text": "Use of sir/seir model in statistics-based predictions of coronavirus epidemic spreading?",
    "new_text": "Use of sir / seir [Model] / model [Present] / in statistics - based [Prediction] / predictions of [Genus: Coronavirus] / coronavirus [Epidemic] / epidemic [Spreading (qualifier value)] / spreading ?",
    "n_kge": 6
  },
  {
    "raw_text": "What virus are used by the most successful neuronal circuit tracing methods?",
    "new_text": "What [Virus] / virus are used by the most [Success] / successful neuronal circuit tracing [Methods] / methods ?",
    "n_kge": 3
  },
  {
    "raw_text": "In what direction does the vesicular stomatitis virus spread through the nervous system?",
    "new_text": "In what [Direction] / direction does the vesicular stomatitis virus [Spreading (qualifier value)] / spread through the [Nervous system structure] / nervous system ?",
    "n_kge": 3
  },
  {
    "raw_text": "What determines the whether the spread of vesicular stomatitis virus is monosynaptic or polysynaptic?",
    "new_text": "What determines the whether the [Spreading (qualifier value)] / spread of vesicular stomatitis virus is monosynaptic or polysynaptic ?",
    "n_kge": 1
  },
  {
    "raw_text": "What types of viruses can be used to study the connectivity of neuronal circuitry?",
    "new_text": "What types of viruses can be [Used by] / used [Tryptophanase] / to study the connectivity of neuronal circuitry ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is carrageenan?",
    "new_text": "What is carrageenan ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is a potential therapeutic benefit of carageenan?",
    "new_text": "What is a potential [Therapeutic procedure] / therapeutic benefit of carageenan ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the optimal window for initiating treatment with carageenan and zanamivir?",
    "new_text": "What is the optimal window for initiating [therapeutic aspects] / treatment with carageenan and [zanamivir] / zanamivir ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was the mortality rate of influenza a virus subtype h7n9 (avian or bird flu)?",
    "new_text": "What was the [Mortality Vital Statistics] / mortality rate of influenza a virus subtype h7n9 ( [Aves] / avian or [Influenza in Birds] / bird flu ) ?",
    "n_kge": 3
  },
  {
    "raw_text": "How many human cases were there of influenza a virus subtype h7n9?",
    "new_text": "How many [Homo sapiens] / human [Case (situation)] / cases were there of influenza a virus subtype h7n9 ?",
    "n_kge": 2
  },
  {
    "raw_text": "How did most patients contract influenza a virus subtype h7n9?",
    "new_text": "How did most [Patients] / patients [Contract agreement] / contract influenza a virus subtype h7n9 ?",
    "n_kge": 2
  },
  {
    "raw_text": "Can influenza a virus subtype h7n9 be transmit human to human?",
    "new_text": "Can influenza a virus subtype h7n9 be transmit [Homo sapiens] / human to [Homo sapiens] / human ?",
    "n_kge": 2
  },
  {
    "raw_text": "What kind of disease is caused by influenza?",
    "new_text": "What [Type - attribute] / kind of [Disease] / disease is caused by [Influenza] / influenza ?",
    "n_kge": 3
  },
  {
    "raw_text": "How many severe cases are there for annual influenza epidemics?",
    "new_text": "How many [Severe (severity modifier)] / severe [Case (situation)] / cases are there for [Annual] / annual influenza epidemics ?",
    "n_kge": 3
  },
  {
    "raw_text": "How many deaths occur annually as a result of annual influenza epidemics?",
    "new_text": "How many [Cessation of life] / deaths occur [Annual] / annually as a [Result] / result of [Annual] / annual influenza [Epidemic] / epidemics ?",
    "n_kge": 5
  },
  {
    "raw_text": "Is coinfection common in influenza infection?",
    "new_text": "Is [Coinfection] / coinfection common in [Influenza] / influenza [Communicable Diseases] / infection ?",
    "n_kge": 3
  },
  {
    "raw_text": "What percentage of people infected with influenza have a viral coinfection?",
    "new_text": "What [Percent (qualifier value)] / percentage of [Persons] / people [Infected] / infected with [Influenza] / influenza have a [Viral] / viral [Coinfection] / coinfection ?",
    "n_kge": 6
  },
  {
    "raw_text": "What are common concamitant infections during the course of influenza infection?",
    "new_text": "What are common concamitant [Infection] / infections during the [Course] / course of [Influenza] / influenza infection ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the anti-viral mechanism of action for carrageenan?",
    "new_text": "What is the [Antiviral Agents] / anti - viral mechanism of action for carrageenan ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the hypothetical mechanical benefit for carageenan in preventing and treating upper respiratory infections?",
    "new_text": "What is the hypothetical mechanical benefit for carageenan in preventing and treating [Upper Respiratory Infections] / upper respiratory infections ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is carageenan?",
    "new_text": "What is carageenan ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the recovery benefit of carageenan in patients with any respiratory virus?",
    "new_text": "What is the recovery benefit of carageenan [Present] / in [Patients] / patients with any respiratory virus ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the anti-influenza benefit of carageenan?",
    "new_text": "What is the anti - influenza benefit of carageenan ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the association between influenza viral load and carageenan?",
    "new_text": "What is the [Mental association] / association between [Influenza] / influenza [Viral Load result] / viral load and carageenan ?",
    "n_kge": 3
  },
  {
    "raw_text": "Is oseltamivir effective when taken intranasally?",
    "new_text": "Is [oseltamivir] / oseltamivir [Effectiveness] / effective when taken intranasally ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the effect of intranasal zanamivir on laboratory confirmed infleunza infection?",
    "new_text": "What is the effect of intranasal [zanamivir] / zanamivir on [Laboratory] / laboratory confirmed infleunza [Communicable Diseases] / infection ?",
    "n_kge": 3
  },
  {
    "raw_text": "Do carageenan and zanamivir delivered intranasally have a benefit when taken for influenza subtype h7n7 infection?",
    "new_text": "Do carageenan and [zanamivir] / zanamivir delivered intranasally have a benefit when taken for [Influenza] / influenza subtype h7n7 [Communicable Diseases] / infection ?",
    "n_kge": 3
  },
  {
    "raw_text": "Do carageenan and zanamivir delivered intranasally have a benefit when taken for influenza subtype h1n1 infection?",
    "new_text": "Do carageenan and [zanamivir] / zanamivir delivered intranasally have a benefit when taken for influenza subtype h1n1 [Communicable Diseases] / infection ?",
    "n_kge": 2
  },
  {
    "raw_text": "Is there a dose-dependent response to carageenan and zanamavir intranasal therapy?",
    "new_text": "Is there a dose - dependent response to carageenan and zanamavir intranasal [therapeutic aspects] / therapy ?",
    "n_kge": 1
  },
  {
    "raw_text": "Do carageenan and zanamavir together have a greater benefit than either in monotherapy?",
    "new_text": "Do carageenan and zanamavir together have a greater benefit than either in monotherapy ?",
    "n_kge": 0
  },
  {
    "raw_text": "Did the use of carageenan play a role in pandemic's caused by novel viruses?",
    "new_text": "Did the use of carageenan [Play] / play a [Social Role] / role in pandemic's caused by [New] / novel [Virus] / viruses ?",
    "n_kge": 4
  },
  {
    "raw_text": "How was ili defined?",
    "new_text": "How was [Isolated limb perfusion] / ili defined ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is this assay based on?",
    "new_text": "What is this [Biological Assay] / assay based on ?",
    "n_kge": 1
  },
  {
    "raw_text": "How was random sampling performed?",
    "new_text": "How was random sampling [Performed] / performed ?",
    "n_kge": 1
  },
  {
    "raw_text": "What used to detect pathogens?",
    "new_text": "What [Used by] / used [Tryptophanase] / to detect pathogens ?",
    "n_kge": 2
  },
  {
    "raw_text": "What does the retrospective study use?",
    "new_text": "What does the [Retrospective Studies] / retrospective study [utilization qualifier] / use ?",
    "n_kge": 2
  },
  {
    "raw_text": "How many swabs were randomly selected and analyzed?",
    "new_text": "How many [Swab specimen] / swabs were randomly selected and analyzed ?",
    "n_kge": 1
  },
  {
    "raw_text": "How were the swabs analyzed?",
    "new_text": "How were the [Swab specimen] / swabs analyzed ?",
    "n_kge": 1
  },
  {
    "raw_text": "What viruses were detected?",
    "new_text": "What [Virus] / viruses were detected ?",
    "n_kge": 1
  },
  {
    "raw_text": "What co-infections were found?",
    "new_text": "What [Coinfection] / co - infections were [Present] / found ?",
    "n_kge": 2
  },
  {
    "raw_text": "What seasonal differences were found?",
    "new_text": "What [Seasonal course] / seasonal differences were [Present] / found ?",
    "n_kge": 2
  },
  {
    "raw_text": "What does the study highlight?",
    "new_text": "What does the study highlight ?",
    "n_kge": 0
  },
  {
    "raw_text": "What does the study show?",
    "new_text": "What does the study show ?",
    "n_kge": 0
  },
  {
    "raw_text": "Which are identified as major viruses mostly responsible for ili and pneumonia in several studies?",
    "new_text": "Which are identified as [Severe (severity modifier)] / major [Virus] / viruses mostly [Responsible to (attribute)] / responsible for [Isolated limb perfusion] / ili and pneumonia in several studies ?",
    "n_kge": 4
  },
  {
    "raw_text": "What percentage of these infections are identified?",
    "new_text": "What [Percent (qualifier value)] / percentage of these [Infection] / infections are identified ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is reunion island?",
    "new_text": "What is reunion island ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the number of inhabitants of reunion island?",
    "new_text": "What is the [Numbers] / number of inhabitants of reunion island ?",
    "n_kge": 1
  },
  {
    "raw_text": "Where is reunion island located?",
    "new_text": "Where is reunion island located ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the island's health care system similar to?",
    "new_text": "What is the island's [Health Care Systems] / health care system similar to ?",
    "n_kge": 1
  },
  {
    "raw_text": "When does influenza activity increase?",
    "new_text": "When does [Influenza] / influenza activity [Increase] / increase ?",
    "n_kge": 2
  },
  {
    "raw_text": "When does the influenza vaccination campaign in reunion island start?",
    "new_text": "When does the [Influenza] / influenza vaccination campaign in reunion island [Beginning] / start ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the clinical and biological influenza surveillance has been based on?",
    "new_text": "What is the clinical and [biology (field)] / biological [Influenza] / influenza surveillance has been based on ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is this network composed of?",
    "new_text": "What is this [Social Networks] / network composed of ?",
    "n_kge": 1
  },
  {
    "raw_text": "How are the influenza tests carried out?",
    "new_text": "How are the [Influenza] / influenza [Laboratory Procedures] / tests carried out ?",
    "n_kge": 2
  },
  {
    "raw_text": "What do 40-50% of the samples test positive for?",
    "new_text": "What do 40 - 50 % of the samples [Laboratory Procedures] / test [percent positive cells] / positive for ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are the ili samples wich test negative for influence?",
    "new_text": "What are the [Isolated limb perfusion] / ili samples [WIPF2 gene] / wich [Laboratory Procedures] / test [Negative] / negative for influence ?",
    "n_kge": 4
  },
  {
    "raw_text": "What tool has been developed to identify several viruses simultaneously?",
    "new_text": "What tool has been developed [Tryptophanase] / to identify [Numerous] / several [Virus] / viruses simultaneously ?",
    "n_kge": 3
  },
  {
    "raw_text": "What are the objectives of the study?",
    "new_text": "What are the objectives of the study ?",
    "n_kge": 0
  },
  {
    "raw_text": "On which system the reverse transcription and preamplification steps were performed?",
    "new_text": "On which [Drug Delivery Systems] / system the [Reverse Transcription] / reverse transcription and preamplification steps were [Performed] / performed ?",
    "n_kge": 3
  },
  {
    "raw_text": "Which two seasons were identified for trends in virus circulation?",
    "new_text": "Which [Two] / two [Seasons] / seasons were identified for [trends qualifier] / trends in [Virus] / virus [Blood Circulation] / circulation ?",
    "n_kge": 5
  },
  {
    "raw_text": "Which were the most frequently identified respiratory pathogens?",
    "new_text": "Which were the most frequently identified respiratory pathogens ?",
    "n_kge": 0
  },
  {
    "raw_text": "What were detected only in summer?",
    "new_text": "What were detected [Singular] / only in [Summer] / summer ?",
    "n_kge": 2
  },
  {
    "raw_text": "What viruses were identified only in winter?",
    "new_text": "What [Virus] / viruses were identified [Singular] / only in [Winter] / winter ?",
    "n_kge": 3
  },
  {
    "raw_text": "Respiratory viral pathogens were present in what percentage of samples?",
    "new_text": "Respiratory [Viral] / viral pathogens were [Present] / present in what [Percent (qualifier value)] / percentage of samples ?",
    "n_kge": 3
  },
  {
    "raw_text": "What did the study highlight?",
    "new_text": "What did the study highlight ?",
    "n_kge": 0
  },
  {
    "raw_text": "How many swabs remained without etiology?",
    "new_text": "How many [Swab specimen] / swabs remained without [Etiology aspects] / etiology ?",
    "n_kge": 2
  },
  {
    "raw_text": "What hypotheses can explain this result?",
    "new_text": "What hypotheses can explain this [Result] / result ?",
    "n_kge": 1
  },
  {
    "raw_text": "What could not be tested for?",
    "new_text": "What could not be [Tests (qualifier value)] / tested for ?",
    "n_kge": 1
  },
  {
    "raw_text": "What does this study highlight?",
    "new_text": "What does this study highlight ?",
    "n_kge": 0
  },
  {
    "raw_text": "What does the study show?",
    "new_text": "What does the study show ?",
    "n_kge": 0
  },
  {
    "raw_text": "What would be interesting to do?",
    "new_text": "What would be [Interested] / interesting to do ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is it most similar to?",
    "new_text": "What is it most similar to ?",
    "n_kge": 0
  },
  {
    "raw_text": "How many people were affected as of feb 10, 2020?",
    "new_text": "How many [Persons] / people were [Affecting] / affected as of feb 10 , 2020 ?",
    "n_kge": 2
  },
  {
    "raw_text": "How is the sars-cov-2 referred to?",
    "new_text": "How is the [2019 novel coronavirus] / sars - cov - 2 [Patient referral] / referred [Tryptophanase] / to ?",
    "n_kge": 3
  },
  {
    "raw_text": "How much similarity the sars-cov-2 genome sequence has with sars-cov?",
    "new_text": "How much similarity the [2019 novel coronavirus] / sars - cov - 2 genome sequence [HAS1 gene] / has with [SARS coronavirus] / sars - cov ?",
    "n_kge": 3
  },
  {
    "raw_text": "What similarity human sars-cov and palm civet sarslike cov share?",
    "new_text": "What similarity [Homo sapiens] / human [SARS coronavirus] / sars - cov and [Palmar surface] / palm civet sarslike cov share ?",
    "n_kge": 3
  },
  {
    "raw_text": "How much is the difference between the human sars-cov-2 and the bat ratg13-cov?",
    "new_text": "How much is the difference between the [Homo sapiens] / human [2019 novel coronavirus] / sars - cov - 2 and the [Chiroptera] / bat ratg13 - cov ?",
    "n_kge": 3
  },
  {
    "raw_text": "Why is it highly unlikely that ratg13 cov is the immediate source of sars-cov-2?",
    "new_text": "Why is it [High] / highly unlikely that ratg13 cov is the [Immediate] / immediate [Source] / source of [2019 novel coronavirus] / sars - cov - 2 ?",
    "n_kge": 4
  },
  {
    "raw_text": "What are the most revealing signs that sars-cov-2 evolved by natural evolution?",
    "new_text": "What are the most revealing signs that [2019 novel coronavirus] / sars - cov - 2 evolved by [Natural] / natural [Biological Evolution] / evolution ?",
    "n_kge": 3
  },
  {
    "raw_text": "What did the nature medicine paper report?",
    "new_text": "What did the [Nature] / nature [Pharmaceutical Preparations] / medicine paper report ?",
    "n_kge": 2
  },
  {
    "raw_text": "Why does the claim lack any scientific basis?",
    "new_text": "Why does the claim lack any [Science] / scientific basis ?",
    "n_kge": 1
  },
  {
    "raw_text": "How was the mouse-adapted sars virus (ma15) generated?",
    "new_text": "How was the [House mice] / mouse - [Adaptation] / adapted [SARS coronavirus] / sars virus ( ma15 ) generated ?",
    "n_kge": 3
  },
  {
    "raw_text": "How did the sars-cov gain elevated replication and lung pathogenesis in aged mice ?",
    "new_text": "How did the [SARS coronavirus] / sars - cov gain [High] / elevated [DNA Replication] / replication and lung pathogenesis in [Age] / aged mice ?",
    "n_kge": 4
  },
  {
    "raw_text": "Why is it likely that ma15 is highly attenuated to replicate in human cells?",
    "new_text": "Why is it [Probable diagnosis] / likely that ma15 is [High] / highly attenuated [Tryptophanase] / to replicate in [Human cells] / human cells ?",
    "n_kge": 4
  },
  {
    "raw_text": "Why were civets proposed to be an intermediate host of the bat-covs, capable of spreading sars cov to humans?",
    "new_text": "Why were civets proposed [Tryptophanase] / to be [Aniridia type 1] / an [Intermediate Host] / intermediate host of the [Chiroptera] / bat - covs , capable of [Spreading (qualifier value)] / spreading [SARS coronavirus] / sars cov [Tryptophanase] / to [Homo sapiens] / humans ?",
    "n_kge": 8
  },
  {
    "raw_text": "What was the finding in 2013?",
    "new_text": "What was the [Signs and Symptoms] / finding in 2013 ?",
    "n_kge": 1
  },
  {
    "raw_text": "Why is it proposed that some bat sl-covs may be able to directly infect human hosts?",
    "new_text": "Why is it proposed that some [Chiroptera] / bat sl - covs may be [Ability] / able to directly [Infected] / infect [Homo sapiens] / human [Host (organism)] / hosts ?",
    "n_kge": 5
  },
  {
    "raw_text": "What was done to test if an intermediate host may not be necessary and that some bat sl-covs may be able to directly infect human hosts t?",
    "new_text": "What was done [Tryptophanase] / to [Laboratory Procedures] / test if an [Intermediate Host] / intermediate host may not be necessary and that some [Chiroptera] / bat sl - covs may be [Ability] / able [Tryptophanase] / to directly [Infected] / infect [Homo sapiens] / human [Host (organism)] / hosts t ?",
    "n_kge": 9
  },
  {
    "raw_text": "What were the results of this test?",
    "new_text": "What were the results of this test ?",
    "n_kge": 0
  },
  {
    "raw_text": "Why were experiments with sl-shc014-ma15 chimeric virus were later restricted?",
    "new_text": "Why were experiments with sl - shc014 - ma15 [Chimera organism] / chimeric [Virus] / virus were later restricted ?",
    "n_kge": 2
  },
  {
    "raw_text": "Why is there no credible evidence to support the claim that the sars-cov-2 is derived from the chimeric sl-shc014-ma15 virus?",
    "new_text": "Why is there no credible evidence [Tryptophanase] / to support the claim that the [2019 novel coronavirus] / sars - cov - 2 is derived from the [Chimera organism] / chimeric sl - shc014 - ma15 [Virus] / virus ?",
    "n_kge": 4
  },
  {
    "raw_text": "What did the rumour that the virus was made by humans in the lab, claim?",
    "new_text": "What did the rumour that the [Virus] / virus was made by [Homo sapiens] / humans in the [Laboratory] / lab , claim ?",
    "n_kge": 3
  },
  {
    "raw_text": "What was reported in a rebuttal paper led by an hiv-1 virologist dr feng gao?",
    "new_text": "What was reported in a rebuttal paper led by an [HIV-1] / hiv - 1 virologist [Physicians] / dr feng gao ?",
    "n_kge": 2
  },
  {
    "raw_text": "What happened to the report with initial claims?",
    "new_text": "What happened to the [Report (document)] / report with initial claims ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the difference between evolution and synthetic constructs?",
    "new_text": "What is the difference between [Biological Evolution] / evolution and synthetic constructs ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the conclusion of this report?",
    "new_text": "What is the conclusion of this [Report (document)] / report ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the conclusion of this report?",
    "new_text": "What is the conclusion of this [Report (document)] / report ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the clinical manifestation similar to?",
    "new_text": "What is the clinical [Manifest] / manifestation similar to ?",
    "n_kge": 1
  },
  {
    "raw_text": "What was the purpose of the research?",
    "new_text": "What was the [Purpose] / purpose of the [research] / research ?",
    "n_kge": 2
  },
  {
    "raw_text": "What preventative measure has been taken to decrease the incidence of diarrhea in children?",
    "new_text": "What [Prophylactic treatment] / preventative [Measures] / measure has been taken [Tryptophanase] / to decrease the [Incidence] / incidence of diarrhea in [Child] / children ?",
    "n_kge": 5
  },
  {
    "raw_text": "What led to a great increase in their study among virologists worldwide?",
    "new_text": "What led to a great [Increase] / increase [Present] / in their study among [Virologists] / virologists worldwide ?",
    "n_kge": 3
  },
  {
    "raw_text": "How many hantaviral genotypes have been described?",
    "new_text": "How many hantaviral [Genotype] / genotypes have been described ?",
    "n_kge": 1
  },
  {
    "raw_text": "How many of them are pathogenic for humans?",
    "new_text": "How [Numerous] / many of them are [Pathogenic organism] / pathogenic for [Homo sapiens] / humans ?",
    "n_kge": 3
  },
  {
    "raw_text": "What do hantaviruses cause in their reservoir hosts?",
    "new_text": "What do [Hantavirus] / hantaviruses [Etiology aspects] / cause in their reservoir hosts ?",
    "n_kge": 2
  },
  {
    "raw_text": "What does hantavirus human disease manifest as?",
    "new_text": "What does [Hantavirus] / hantavirus [Homo sapiens] / human [Disease] / disease [Manifest] / manifest as ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is the case-fatality ratios, for the most common viral serotypes?",
    "new_text": "What is the case - fatality ratios , for the most common [Viral] / viral [Serotype] / serotypes ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are among the factors that may have increased the human caseload of hcps between 1993 and the present?",
    "new_text": "What are among the factors that may have [Increased] / increased the [Homo sapiens] / human caseload of hcps between 1993 and the [Present] / present ?",
    "n_kge": 3
  },
  {
    "raw_text": "What do authors consider in this study?",
    "new_text": "What do [Author] / authors consider in this study ?",
    "n_kge": 1
  },
  {
    "raw_text": "What do authors consider in this study?",
    "new_text": "What do [Author] / authors consider in this study ?",
    "n_kge": 1
  },
  {
    "raw_text": "Which diseases are a major concern among scientists studying infectious diseases?",
    "new_text": "Which [Disease] / diseases are a [Severe (severity modifier)] / major concern among [Scientist] / scientists studying [Communicable Diseases] / infectious diseases ?",
    "n_kge": 4
  },
  {
    "raw_text": "What may alter population disease dynamics and lead to the emergence of zoonotic infections?",
    "new_text": "What may alter population [Disease] / disease dynamics and [lead] / lead to the emergence of zoonotic infections ?",
    "n_kge": 2
  },
  {
    "raw_text": "Which are among the conspicuous examples which challenge prevention and control measures of public health systems?",
    "new_text": "Which are among the conspicuous examples which [Challenge:Type:Point in time:^Patient:Nominal] / challenge [Prophylactic treatment] / prevention and control [Measures] / measures of public health systems ?",
    "n_kge": 3
  },
  {
    "raw_text": "More recently, what did outbreaks of several viral-related diseases that have emerged or re-emerged, involve?",
    "new_text": "[More] / More [Recent] / recently , what did [Disease Outbreaks] / outbreaks of several viral - [Relationships] / related diseases that have emerged or re - emerged , involve ?",
    "n_kge": 4
  },
  {
    "raw_text": "What did, in the last century, outbreaks of viral-related diseases that have emerged or re-emerged, involve?",
    "new_text": "What did , in the last century , [Disease Outbreaks] / outbreaks of viral - [Relationships] / related diseases that have emerged or re - emerged , involve ?",
    "n_kge": 2
  },
  {
    "raw_text": "Among zoonotic diseases, what are hosts of several pathogenic rna viruses?",
    "new_text": "Among [Zoonoses] / zoonotic diseases , what are [Host (organism)] / hosts of several [Pathogenic organism] / pathogenic [RNA Viruses] / rna viruses ?",
    "n_kge": 4
  },
  {
    "raw_text": "Which pathogenic rna viruses are hosted by small mammals?",
    "new_text": "Which [Pathogenic organism] / pathogenic [RNA Viruses] / rna viruses are hosted by [Small] / small [Mammals] / mammals ?",
    "n_kge": 4
  },
  {
    "raw_text": "When did hantavirus infections became a concern in the americas?",
    "new_text": "When did hantavirus infections became a concern in the americas ?",
    "n_kge": 0
  },
  {
    "raw_text": "What was the hantavirus cardiopulmonary syndrome, hcps (or hantavirus pulmonary syndrome), linked to?",
    "new_text": "What was the hantavirus cardiopulmonary syndrome , hcps ( or [Hantavirus Pulmonary Syndrome] / hantavirus pulmonary syndrome ) , linked [Tryptophanase] / to ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was identified as the reservoir of snv?",
    "new_text": "What was identified as the reservoir of [Single Nucleotide Variant] / snv ?",
    "n_kge": 1
  },
  {
    "raw_text": "What did a review of ancient chinese writings in 960 ad, reveal?",
    "new_text": "What did a review of ancient chinese writings in [960] / 960 [Alzheimer disease, familial, type 3] / ad , reveal ?",
    "n_kge": 2
  },
  {
    "raw_text": "How was hfrs first brought to the attention of western medicine ?",
    "new_text": "How was [Hemorrhagic Fever with Renal Syndrome] / hfrs first brought to the [Attention] / attention of western medicine ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is htnv?",
    "new_text": "What is htnv ?",
    "n_kge": 0
  },
  {
    "raw_text": "Where was htnv isolated from?",
    "new_text": "Where was htnv isolated from ?",
    "n_kge": 0
  },
  {
    "raw_text": "Which new genus was the virus later found to represent?",
    "new_text": "Which [New] / new genus was the [Virus] / virus later [Present] / found [Tryptophanase] / to represent ?",
    "n_kge": 4
  },
  {
    "raw_text": "Which was the first hantavirus to be isolated?",
    "new_text": "Which was the first [Hantavirus] / hantavirus [Tryptophanase] / to be isolated ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the categorization of hantaviruses as belonging to the family bunyaviridae due in part to?",
    "new_text": "What is the [Classification] / categorization of [Hantavirus] / hantaviruses [artesunate] / as belonging to the family bunyaviridae [Due to] / due in [Part] / part to ?",
    "n_kge": 5
  },
  {
    "raw_text": "What was the hairpin morphology first described for?",
    "new_text": "What was the hairpin morphology first described for ?",
    "n_kge": 0
  },
  {
    "raw_text": "How is the the precursor form gpc processed, during virus maturation?",
    "new_text": "How is the the precursor form [GYPC gene] / gpc [Process] / processed , during virus maturation ?",
    "n_kge": 2
  },
  {
    "raw_text": "When does the cleavage appear to be signaled?",
    "new_text": "When does the [Cytokinesis] / cleavage [Appearance] / appear [Tryptophanase] / to be signaled ?",
    "n_kge": 3
  },
  {
    "raw_text": "Why must the two proteins gn and gc be co-expressed?",
    "new_text": "Why must the [Two] / two [Proteins] / proteins [Guinea (geographic area)] / gn and gc be co - expressed ?",
    "n_kge": 3
  },
  {
    "raw_text": "Which two distinct cellular receptors the glycoproteins are the known or presumed ligands for?",
    "new_text": "Which [Two] / two distinct cellular receptors the [Glycoproteins] / glycoproteins are the [Known] / known or presumed [Ligands] / ligands for ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is the underlying premise for many of these studies?",
    "new_text": "What is the underlying premise for many of these studies ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the premise for apathogenic forms to blunt any pathological response in the host?",
    "new_text": "What is the premise for apathogenic forms to blunt any [Pathology] / pathological response in the host ?",
    "n_kge": 1
  },
  {
    "raw_text": "Which proteins and mrnas prominently induced by hantaviruses include?",
    "new_text": "Which [Proteins] / proteins and mrnas prominently induced by [Hantavirus] / hantaviruses include ?",
    "n_kge": 2
  },
  {
    "raw_text": "What have hantaviruses been identified as adversely affect?",
    "new_text": "What have [Hantavirus] / hantaviruses been identified as adversely [Affect (mental function)] / affect ?",
    "n_kge": 2
  },
  {
    "raw_text": "What have hantaviruses been identified in potentiating?",
    "new_text": "What have [Hantavirus] / hantaviruses been identified in potentiating ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is n-protein?",
    "new_text": "What is [Measles Virus Nucleoprotein] / n - protein ?",
    "n_kge": 1
  },
  {
    "raw_text": "What does the n-protein, as an rna-binding protein, do?",
    "new_text": "What does the [Measles Virus Nucleoprotein] / n - protein , as an [RNA-Binding Proteins] / rna - binding protein , do ?",
    "n_kge": 2
  },
  {
    "raw_text": "As an rna-binding protein that engages the hairpin termini of the genomic segments, what does the n-protein of hantavirus do?",
    "new_text": "As an [RNA-Binding Proteins] / rna - binding protein that engages the hairpin termini of the genomic segments , what does the [Measles Virus Nucleoprotein] / n - protein of [Hantavirus] / hantavirus do ?",
    "n_kge": 3
  },
  {
    "raw_text": "As an rna-binding protein that engages the hairpin termini of the genomic segments, what does the n-protein of hantavirus do?",
    "new_text": "As an [RNA-Binding Proteins] / rna - binding protein that engages the hairpin termini of the genomic segments , what does the [Measles Virus Nucleoprotein] / n - protein of [Hantavirus] / hantavirus do ?",
    "n_kge": 3
  },
  {
    "raw_text": "What does the n-protein act as?",
    "new_text": "What does the [Measles Virus Nucleoprotein] / n - protein [Adoptive Immunotherapy] / act as ?",
    "n_kge": 2
  },
  {
    "raw_text": "What can some of the other activities of n have, be linked to?",
    "new_text": "What can some of the other activities of n have , be linked [Tryptophanase] / to ?",
    "n_kge": 1
  },
  {
    "raw_text": "What can some of the other activities of n have, be linked to?",
    "new_text": "What can some of the other activities of n have , be linked [Tryptophanase] / to ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is n also reported to interact with?",
    "new_text": "What is [N not otherwise specified Antibody] / n also [Report (document)] / reported [Tryptophanase] / to interact with ?",
    "n_kge": 3
  },
  {
    "raw_text": "How do the viral rnas become concentrated in p bodies during hantavirus infection?",
    "new_text": "How do the viral rnas become concentrated in p [Human body] / bodies during hantavirus infection ?",
    "n_kge": 1
  },
  {
    "raw_text": "What have confocal microscopy and biochemical-inhibitor studies shown?",
    "new_text": "What have [Microscopy, Confocal] / confocal microscopy and biochemical - [Inhibitor] / inhibitor studies shown ?",
    "n_kge": 2
  },
  {
    "raw_text": "What have confocal microscopy and biochemical-inhibitor studies shown on what n tracks?",
    "new_text": "What have [Microscopy, Confocal] / confocal microscopy and biochemical - [Inhibitor] / inhibitor studies shown on what n [Track (course)] / tracks ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the ultimate destination for n, for its assembly into viral particles?",
    "new_text": "What is the ultimate [Destination] / destination for n , for its assembly into viral particles ?",
    "n_kge": 1
  },
  {
    "raw_text": "How does it traffic?",
    "new_text": "How does it traffic ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is a dominant negative inhibitor?",
    "new_text": "What is a dominant negative [Inhibitor] / inhibitor ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is dynamitin associated with?",
    "new_text": "What is [DCTN2 gene] / dynamitin associated with ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is dynamitin associated with?",
    "new_text": "What is [DCTN2 gene] / dynamitin associated with ?",
    "n_kge": 1
  },
  {
    "raw_text": "What does recent data indicate?",
    "new_text": "What does [Recent] / recent [Data] / data indicate ?",
    "n_kge": 2
  },
  {
    "raw_text": "Why have hantavirus diseases of man been suspected of having an immunopathogenic basis?",
    "new_text": "Why have hantavirus diseases of [Male population group] / man been suspected of having an immunopathogenic basis ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is a critical feature of both?",
    "new_text": "What is a critical [Characteristics] / feature of both ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the character of he resulting leakage?",
    "new_text": "What is the [Personality Character] / character of [helium] / he [Due to] / resulting [Extravasation] / leakage ?",
    "n_kge": 4
  },
  {
    "raw_text": "Which is an especially attractive candidate as an important in vivo receptor for hantaviruses?",
    "new_text": "Which is [Aniridia type 1] / an especially attractive candidate as [Aniridia type 1] / an important in vivo [receptor] / receptor for [Hantavirus] / hantaviruses ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is the likely way that hantaviruses arrive at their target tissues?",
    "new_text": "What is the [Probable diagnosis] / likely way that [Hantavirus] / hantaviruses arrive at their target tissues ?",
    "n_kge": 2
  },
  {
    "raw_text": "What does the virus seed?",
    "new_text": "What does the [Virus] / virus [Plant seeds] / seed ?",
    "n_kge": 2
  },
  {
    "raw_text": "What happens with the viral seeding at the local endothelium?",
    "new_text": "What happens with the [Viral] / viral seeding at the [Local] / local [Endothelium] / endothelium ?",
    "n_kge": 3
  },
  {
    "raw_text": "How long does the process of giving rise to primary viremia for hantavirus infections?",
    "new_text": "How [Long] / long does the process of giving rise to primary [Viremia] / viremia for hantavirus infections ?",
    "n_kge": 2
  },
  {
    "raw_text": "What happens by the time that secondary viremia emerges?",
    "new_text": "What happens by the [Time] / time that [Neoplasm Metastasis] / secondary [Viremia] / viremia emerges ?",
    "n_kge": 3
  },
  {
    "raw_text": "How is the the expression of proinflammatory cytokines induced?",
    "new_text": "How is the the [Expression procedure] / expression of proinflammatory cytokines induced ?",
    "n_kge": 1
  },
  {
    "raw_text": "For hcps, what does that expression favor?",
    "new_text": "For hcps , what does that [Expression procedure] / expression favor ?",
    "n_kge": 1
  },
  {
    "raw_text": "For hcps, what does that expression spare?",
    "new_text": "For hcps , what does that [Expression procedure] / expression spare ?",
    "n_kge": 1
  },
  {
    "raw_text": "What happens for hfrs?",
    "new_text": "What happens for [Hemorrhagic Fever with Renal Syndrome] / hfrs ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is considered to be a requirement for the development of systemic disease symptoms?",
    "new_text": "What is considered [Tryptophanase] / to be a requirement for the development of [Systemic disease] / systemic disease symptoms ?",
    "n_kge": 2
  },
  {
    "raw_text": "What do those abnormalities sometimes culminate in?",
    "new_text": "What do those [Congenital Abnormality] / abnormalities sometimes culminate in ?",
    "n_kge": 1
  },
  {
    "raw_text": "What leads to death in most fatal cases of hcps?",
    "new_text": "What leads to [Cessation of life] / death [Present] / in most [Fatal] / fatal [Case (situation)] / cases of hcps ?",
    "n_kge": 4
  },
  {
    "raw_text": "What leads to death in most fatal cases of hcps?",
    "new_text": "What leads to [Cessation of life] / death [Present] / in most [Fatal] / fatal [Case (situation)] / cases of hcps ?",
    "n_kge": 4
  },
  {
    "raw_text": "What potential mechanism, could be presumed to underlie the pathogenesis of hcps?",
    "new_text": "What potential [Mechanism (attribute)] / mechanism , could be presumed [Tryptophanase] / to underlie the pathogenesis of hcps ?",
    "n_kge": 2
  },
  {
    "raw_text": "What potential mechanism, could be presumed to underlie the pathogenesis of hcps?",
    "new_text": "What potential [Mechanism (attribute)] / mechanism , could be presumed [Tryptophanase] / to underlie the pathogenesis of hcps ?",
    "n_kge": 2
  },
  {
    "raw_text": "What potential mechanism, could be presumed to underlie the pathogenesis of hcps?",
    "new_text": "What potential [Mechanism (attribute)] / mechanism , could be presumed [Tryptophanase] / to underlie the pathogenesis of hcps ?",
    "n_kge": 2
  },
  {
    "raw_text": "What explanation have some investigators favored for much of the capillary leak?",
    "new_text": "What explanation have some [Research Personnel] / investigators favored for much of the capillary leak ?",
    "n_kge": 1
  },
  {
    "raw_text": "What animal models exist for both the asymptomatic carriage of puuv and snv?",
    "new_text": "What [Animal Model] / animal models exist for both the [Asymptomatic (finding)] / asymptomatic carriage of puuv and [Single Nucleotide Variant] / snv ?",
    "n_kge": 3
  },
  {
    "raw_text": "For what can the syrian hamster model used?",
    "new_text": "For what can the [Mesocricetus auratus] / syrian hamster [Model] / model [Used by] / used ?",
    "n_kge": 3
  },
  {
    "raw_text": "What does the hamster model for hcps caused by?",
    "new_text": "What does the [Hamsters] / hamster [Model] / model for hcps caused by ?",
    "n_kge": 2
  },
  {
    "raw_text": "Typically how long do the hamsters die post-inoculation?",
    "new_text": "Typically how [Long] / long do the [Hamsters] / hamsters die post - inoculation ?",
    "n_kge": 2
  },
  {
    "raw_text": "What does the microscopic examination of the lung reveal, as with human hcps?",
    "new_text": "What does the microscopic examination of the [Lung] / lung reveal , [artesunate] / as with [Homo sapiens] / human hcps ?",
    "n_kge": 3
  },
  {
    "raw_text": "What do andv-infected hamsters fitted with physiologic monitoring devices exhibit?",
    "new_text": "What do andv - [Infected] / infected [Hamsters] / hamsters [Seizures] / fitted with physiologic monitoring [Medical Devices] / devices [Exhibits as Topic] / exhibit ?",
    "n_kge": 5
  },
  {
    "raw_text": "What do diminished pulse pressures, tachycardia, and hypotension in andv infected hamsters appear to closely mimic?",
    "new_text": "What do diminished pulse pressures , [Tachycardia] / tachycardia , and [Hypotension] / hypotension in andv [Infected] / infected [Hamsters] / hamsters [Appearance] / appear [Tryptophanase] / to closely mimic ?",
    "n_kge": 6
  },
  {
    "raw_text": "Compared to humans, what do andv infected hamsters exhibit?",
    "new_text": "Compared to [Homo sapiens] / humans , what do andv [Infected] / infected [Hamsters] / hamsters [Exhibits as Topic] / exhibit ?",
    "n_kge": 4
  },
  {
    "raw_text": "With what have three studies correlated plasma viral rna?",
    "new_text": "With what have [Three] / three studies correlated [Plasma] / plasma viral rna ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are examples of delivery vectors for commercial anti-salmonella vaccines?",
    "new_text": "What are examples of [Obstetric Delivery] / delivery [Cloning Vectors] / vectors for commercial anti - salmonella vaccines ?",
    "n_kge": 2
  },
  {
    "raw_text": "What can be a factor in using common vectors for the delivery of vaccines?",
    "new_text": "What can be a factor in [Use of] / using common [Cloning Vectors] / vectors for the delivery of vaccines ?",
    "n_kge": 2
  },
  {
    "raw_text": "Is a pre-existing immune response to commonly used delivery vector an advantage or a disadvantage?",
    "new_text": "Is a pre - existing [Immune response] / immune response to commonly [Used by] / used [Obstetric Delivery] / delivery [Disease Vectors] / vector an advantage or a disadvantage ?",
    "n_kge": 4
  },
  {
    "raw_text": "What bacterial delivery vectors have been tested in animal hosts?",
    "new_text": "What bacterial [Obstetric Delivery] / delivery [Cloning Vectors] / vectors have been [Tests (qualifier value)] / tested in [Animals] / animal [Host (organism)] / hosts ?",
    "n_kge": 5
  },
  {
    "raw_text": "Which bacteial delivery vectors have gained favor for vaccines?",
    "new_text": "Which bacteial [Obstetric Delivery] / delivery [Cloning Vectors] / vectors have gained favor for [Vaccines] / vaccines ?",
    "n_kge": 3
  },
  {
    "raw_text": "Why are e coli and lactic acid are safe choices as delivery vectors for vaccines?",
    "new_text": "Why are [Escherichia coli] / e coli and [lactic acid] / lactic acid are safe [Choice Behavior] / choices as [Obstetric Delivery] / delivery [Cloning Vectors] / vectors for [Vaccines] / vaccines ?",
    "n_kge": 6
  },
  {
    "raw_text": "What is listeria?",
    "new_text": "What is [Listeria] / listeria ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the advantage of listeria as a delivery vector for vaccines?",
    "new_text": "What is the advantage of [Listeria] / listeria [artesunate] / as a delivery [Disease Vectors] / vector for vaccines ?",
    "n_kge": 3
  },
  {
    "raw_text": "What are examples of viral vectors for delivering vaccines?",
    "new_text": "What are examples of viral vectors for delivering [Vaccines] / vaccines ?",
    "n_kge": 1
  },
  {
    "raw_text": "Which viral vaccine delivery vector was first licensed?",
    "new_text": "Which viral vaccine delivery vector was first [License] / licensed ?",
    "n_kge": 1
  },
  {
    "raw_text": "What are examples of attenuated poxvirus vaccine delivery vectors?",
    "new_text": "What are examples of attenuated poxvirus vaccine delivery vectors ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the connection between chicken and salmonella?",
    "new_text": "What is the [Connection] / connection between [Chickens] / chicken and [Salmonella] / salmonella ?",
    "n_kge": 3
  },
  {
    "raw_text": "Why are some poxvirus ideally suited as vaccine delivery vectors?",
    "new_text": "Why are some [Poxviridae] / poxvirus ideally suited as vaccine delivery [Cloning Vectors] / vectors ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the advantage of adenovirus as vaccine delivery vector?",
    "new_text": "What is the advantage of [Adenoviruses] / adenovirus as vaccine delivery [Disease Vectors] / vector ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are important criteria for selecting vaccine delivery vectors?",
    "new_text": "What are important criteria for selecting vaccine delivery [Cloning Vectors] / vectors ?",
    "n_kge": 1
  },
  {
    "raw_text": "What are important criteria for selecting vaccine delivery vectors?",
    "new_text": "What are important criteria for selecting vaccine delivery [Cloning Vectors] / vectors ?",
    "n_kge": 1
  },
  {
    "raw_text": "What are important criteria for selecting vaccine delivery vectors?",
    "new_text": "What are important criteria for selecting vaccine delivery [Cloning Vectors] / vectors ?",
    "n_kge": 1
  },
  {
    "raw_text": "What happens when a recipient of a vaccine has immune response to the delivery vector?",
    "new_text": "What happens when a [Recipient] / recipient of a [Vaccines] / vaccine has [Immune response] / immune response to the [Obstetric Delivery] / delivery [Disease Vectors] / vector ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is the effect of host immune response to the delivery vector on the efficacy of vaccination?",
    "new_text": "What is the effect of host immune response [Tryptophanase] / to the delivery [Disease Vectors] / vector on the [Effectiveness] / efficacy of vaccination ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the effect of host immune response to the delivery vector on the efficacy of vaccination?",
    "new_text": "What is the effect of host immune response [Tryptophanase] / to the delivery [Disease Vectors] / vector on the [Effectiveness] / efficacy of vaccination ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is an example of the effect of immunity to the delivery vector on the efficacy of vaccination?",
    "new_text": "What is [Aniridia type 1] / an example of the effect of [Immune response] / immunity [Tryptophanase] / to the delivery [Disease Vectors] / vector on the [Effectiveness] / efficacy of vaccination ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is the effect of host immune response to viral delivery vectors in the efficacy of vaccination?",
    "new_text": "What is the effect of host immune response [Tryptophanase] / to viral [Obstetric Delivery] / delivery [Cloning Vectors] / vectors in the [Effectiveness] / efficacy of vaccination ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is the effect of host immune response to the viral delivery vector on the efficacy of vaccination?",
    "new_text": "What is the effect of host immune response [Tryptophanase] / to the viral [Obstetric Delivery] / delivery vector on the [Effectiveness] / efficacy of [Vaccination] / vaccination ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is the effect of host immune response to the delivery vector on the efficacy of vaccination?",
    "new_text": "What is the effect of host immune response [Tryptophanase] / to the delivery [Disease Vectors] / vector on the [Effectiveness] / efficacy of vaccination ?",
    "n_kge": 3
  },
  {
    "raw_text": "What are methods to avoid the effect vector immunity on the efficacy of vaccination?",
    "new_text": "What are [Methods] / methods [Tryptophanase] / to avoid the effect vector [Immune response] / immunity on the [Effectiveness] / efficacy of vaccination ?",
    "n_kge": 4
  },
  {
    "raw_text": "What are methods to avoid the effect of vector immune response on the efficacy of vaccination?",
    "new_text": "What are [Methods] / methods [Tryptophanase] / to avoid the effect of [Disease Vectors] / vector [Immune response] / immune response on the [Effectiveness] / efficacy of [Vaccination] / vaccination ?",
    "n_kge": 6
  },
  {
    "raw_text": "How does cell-mediated immunity to viral delivery vector, reduce the immune response to vaccine?",
    "new_text": "How does [Cellular Immunity] / cell - mediated immunity to viral [Obstetric Delivery] / delivery vector , reduce the [Immune response] / immune response to [Vaccines] / vaccine ?",
    "n_kge": 4
  },
  {
    "raw_text": "How can vectors for which host has immunity, be used differently to increase the efficacy of vaccination?",
    "new_text": "How can [Cloning Vectors] / vectors for which [Host (organism)] / host has [Immune response] / immunity , be [Used by] / used differently [Tryptophanase] / to [Increase] / increase the [Effectiveness] / efficacy of [Vaccination] / vaccination ?",
    "n_kge": 8
  },
  {
    "raw_text": "How does the ped virus transmit between animals?",
    "new_text": "How does the [OCA2 wt Allele] / ped [Virus] / virus transmit between [Animals] / animals ?",
    "n_kge": 3
  },
  {
    "raw_text": "How can bacilius subtilis be used as an oral vaccine?",
    "new_text": "How can bacilius subtilis be used as an oral [Vaccines] / vaccine ?",
    "n_kge": 1
  },
  {
    "raw_text": "What cells are infected by the ped virus?",
    "new_text": "What [Cell Count] / cells are [Infected] / infected by the [OCA2 wt Allele] / ped [Virus] / virus ?",
    "n_kge": 4
  },
  {
    "raw_text": "What kind of immune responses are most effective in preventing ped virus?",
    "new_text": "What [Type - attribute] / kind of [Immune response] / immune responses are most [Effectiveness] / effective in preventing [OCA2 wt Allele] / ped [Virus] / virus ?",
    "n_kge": 5
  },
  {
    "raw_text": "What intestinal factors may reduce the effectiveness of orally-administered immunizations?",
    "new_text": "What [Intestines] / intestinal factors may reduce the [Effectiveness] / effectiveness of orally - administered [Immunization] / immunizations ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is bacillus subtilis?",
    "new_text": "What is [Bacillus subtilis] / bacillus subtilis ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the role of dendritic cells in the immune response?",
    "new_text": "What is the [Social Role] / role of [Dendritic Cells] / dendritic cells in the [Immune response] / immune response ?",
    "n_kge": 3
  },
  {
    "raw_text": "Where do dendritic cells exist in the body?",
    "new_text": "Where do [Dendritic Cells] / dendritic cells exist in the [Human body] / body ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are the components of the gut-associated lymphoid tissue?",
    "new_text": "What are the components of the [Gut associated lymphoid tissue] / gut - associated lymphoid tissue ?",
    "n_kge": 1
  },
  {
    "raw_text": "What type of cells form the intestinal mucosal barrier?",
    "new_text": "What type of cells form the intestinal mucosal barrier ?",
    "n_kge": 0
  },
  {
    "raw_text": "What factors determine an effective mucosal immune response?",
    "new_text": "What factors determine an [Effectiveness] / effective mucosal immune response ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is an effective indicator of a vaccine's ability to generate an immune response?",
    "new_text": "What is [Aniridia type 1] / an [Effectiveness] / effective indicator of a vaccine's [Ability] / ability [Tryptophanase] / to generate [Aniridia type 1] / an [Immune response] / immune response ?",
    "n_kge": 6
  },
  {
    "raw_text": "What is interleukin-1beta?",
    "new_text": "What is [interleukin-1, beta] / interleukin - 1beta ?",
    "n_kge": 1
  },
  {
    "raw_text": "When was the first case of covid-19 identified?",
    "new_text": "When was the first [Case (situation)] / case of [COVID-19] / covid - 19 identified ?",
    "n_kge": 2
  },
  {
    "raw_text": "Where did sars-cov-2 originate?",
    "new_text": "Where did [2019 novel coronavirus] / sars - cov - 2 originate ?",
    "n_kge": 1
  },
  {
    "raw_text": "In what year did the first sars epidemic occur?",
    "new_text": "In what year did the first [Severe Acute Respiratory Syndrome] / sars [Epidemic] / epidemic occur ?",
    "n_kge": 2
  },
  {
    "raw_text": "When was world health organization (who) first notified about the sars-cov-2 epidemic in wuhan city, china?",
    "new_text": "When was [World Health Organization] / world health organization ( [World Health Organization] / world health organization ) first notified about the [2019 novel coronavirus] / sars - cov - 2 [Epidemic] / epidemic in wuhan city , [China] / china ?",
    "n_kge": 5
  },
  {
    "raw_text": "When did we discover that sars-cov-2, which causes covid-19, was a novel coronavirus?",
    "new_text": "When did we discover that [2019 novel coronavirus] / sars - cov - 2 , which [Etiology aspects] / causes [COVID-19] / covid - 19 , was a [2019 novel coronavirus] / novel coronavirus ?",
    "n_kge": 4
  },
  {
    "raw_text": "How long did it take to identify the cause of covid-19?",
    "new_text": "How [Long] / long did it take [Tryptophanase] / to identify the [Etiology aspects] / cause of [COVID-19] / covid - 19 ?",
    "n_kge": 4
  },
  {
    "raw_text": "What type of test was initially developed to screen for sars-cov-2?",
    "new_text": "What type of test was initially developed [Tryptophanase] / to screen for [2019 novel coronavirus] / sars - cov - 2 ?",
    "n_kge": 2
  },
  {
    "raw_text": "How big was the temporary hospital built in wuhan city for treatment of covid-19 patients?",
    "new_text": "How big was the [Transitory] / temporary hospital built in wuhan city for treatment of covid - 19 patients ?",
    "n_kge": 1
  },
  {
    "raw_text": "How long did it take china to build the temporary hospital in wuhan for covid-19 patients?",
    "new_text": "How [Long] / long did it take [China] / china [Tryptophanase] / to build the [Transitory] / temporary [Hospitals] / hospital in wuhan for [COVID-19] / covid - 19 [Patients] / patients ?",
    "n_kge": 7
  },
  {
    "raw_text": "What is a key factor in managing emerging infectious disease threats?",
    "new_text": "What is a key factor in [Management procedure] / managing [Communicable Diseases, Emerging] / emerging infectious disease threats ?",
    "n_kge": 2
  },
  {
    "raw_text": "In what year did the mers epidemic occur?",
    "new_text": "In what year did the [Middle East Respiratory Syndrome] / middle east respiratory syndrome [Epidemic] / epidemic occur ?",
    "n_kge": 2
  },
  {
    "raw_text": "How long did it take to publish the full genomic sequence of sars-cov-2 after it was identified?",
    "new_text": "How [Long] / long did it take [Tryptophanase] / to publish the full [Genome] / genomic [Base Sequence] / sequence of [2019 novel coronavirus] / sars - cov - 2 after it was identified ?",
    "n_kge": 5
  },
  {
    "raw_text": "What was the fatality rate for sars-cov?",
    "new_text": "What was the fatality rate for [SARS coronavirus] / sars - cov ?",
    "n_kge": 1
  },
  {
    "raw_text": "What was the fatality rate for mers?",
    "new_text": "What was the fatality rate for [Middle East Respiratory Syndrome] / middle east respiratory syndrome ?",
    "n_kge": 1
  },
  {
    "raw_text": "What are some challenges associated with using media and social media to capture information about an emerging epidemic?",
    "new_text": "What are some challenges associated with [Use of] / using [Communications Media] / media and [Social Media] / social media [Tryptophanase] / to capture [Information] / information about an emerging [Epidemic] / epidemic ?",
    "n_kge": 6
  },
  {
    "raw_text": "What are the risks of health workers failing to wash hands?",
    "new_text": "What are the [Risk] / risks of [Health Workforce] / health workers failing to wash hands ?",
    "n_kge": 2
  },
  {
    "raw_text": "Who is at risk when health workers fail to wash their hands?",
    "new_text": "Who is at risk when [Health Workforce] / health workers fail [Tryptophanase] / to [Wash (cleansing action)] / wash their [Hand] / hands ?",
    "n_kge": 4
  },
  {
    "raw_text": "What was the r0 of sars in absence of control measures?",
    "new_text": "What was the r0 of [Severe Acute Respiratory Syndrome] / sars [Present] / in absence of control [Measures] / measures ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is superspreading?",
    "new_text": "What is superspreading ?",
    "n_kge": 0
  },
  {
    "raw_text": "How many people may have left wuhan before travel restrictions were imposed?",
    "new_text": "How many [Persons] / people may have [Left] / left wuhan before [travel] / travel restrictions were imposed ?",
    "n_kge": 3
  },
  {
    "raw_text": "How many severe cases of influenza-related illnesses are reported per year?",
    "new_text": "How [Numerous] / many [Severe (severity modifier)] / severe [Case (situation)] / cases of [Influenza] / influenza - [Relationships] / related [Illness (finding)] / illnesses are [Report (document)] / reported per year ?",
    "n_kge": 7
  },
  {
    "raw_text": "How many influenza-related deaths are reported each year?",
    "new_text": "How many [Influenza] / influenza - related deaths are [Report (document)] / reported each year ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the mortality rate of the h5n1 strain of influenza?",
    "new_text": "What is the [Mortality Vital Statistics] / mortality rate of the h5n1 strain of [Influenza] / influenza ?",
    "n_kge": 2
  },
  {
    "raw_text": "What cells are the main target of the influenza a virus in the lungs?",
    "new_text": "What [Cell Count] / cells are the main target of the [influenza A virus] / influenza a virus in the [Lung] / lungs ?",
    "n_kge": 3
  },
  {
    "raw_text": "How many extracellular domains are in the ceamcam1 protein?",
    "new_text": "How many extracellular domains are in the ceamcam1 [Proteins] / protein ?",
    "n_kge": 1
  },
  {
    "raw_text": "Where is ceacam1 expressed in the body?",
    "new_text": "Where is ceacam1 expressed in the [Human body] / body ?",
    "n_kge": 1
  },
  {
    "raw_text": "What motifs are absent in the short form of ceacam1 protein?",
    "new_text": "What motifs are absent in the short form of ceacam1 [Proteins] / protein ?",
    "n_kge": 1
  },
  {
    "raw_text": "What are the most common isoforms of ceacam1?",
    "new_text": "What are the most common [Protein Isoforms] / isoforms of ceacam1 ?",
    "n_kge": 1
  },
  {
    "raw_text": "How do ceacam1 and ceacam5 interact?",
    "new_text": "How do ceacam1 and [CEACAM5 protein, human] / ceacam5 interact ?",
    "n_kge": 1
  },
  {
    "raw_text": "What are the src-family of kinases?",
    "new_text": "What are the src - family of kinases ?",
    "n_kge": 0
  },
  {
    "raw_text": "What triggers the release of pro-inflammatory cytokines/chemokines to assist in viral clearance?",
    "new_text": "What [Precipitating Factors] / triggers the [Patient Discharge] / release of pro - inflammatory [cytokine] / cytokines / [chemokine] / chemokines [Tryptophanase] / to [Helping Behavior] / assist in [Viral] / viral [Clearance] / clearance ?",
    "n_kge": 8
  },
  {
    "raw_text": "What mediates the anti-apoptosis of neutrophils?",
    "new_text": "What mediates the anti - apoptosis of neutrophils ?",
    "n_kge": 0
  },
  {
    "raw_text": "How do natural killer cells fight influenza viruses?",
    "new_text": "How do [Natural Killer Cells] / natural killer cells fight [Orthomyxoviridae] / influenza viruses ?",
    "n_kge": 2
  },
  {
    "raw_text": "How do influenza viruses escape binding by the natural killer cell activating receptors?",
    "new_text": "How do [Orthomyxoviridae] / influenza viruses escape binding by the natural killer cell activating receptors ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is enfuvirtide?",
    "new_text": "What is [enfuvirtide] / enfuvirtide ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is labeled in red?",
    "new_text": "What is labeled in [Redness] / red ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is marked in blue?",
    "new_text": "What is marked in [Blue color] / blue ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is marked in green?",
    "new_text": "What is marked in [Green color] / green ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is labeled in pink?",
    "new_text": "What is labeled in [Pink color] / pink ?",
    "n_kge": 1
  },
  {
    "raw_text": "How many times was the experiment repeated?",
    "new_text": "How many [Time] / times was the experiment repeated ?",
    "n_kge": 1
  },
  {
    "raw_text": "What was the main finding in the study?",
    "new_text": "What was the main [Signs and Symptoms] / finding in the study ?",
    "n_kge": 1
  },
  {
    "raw_text": "What do the results suggest?",
    "new_text": "What do the results suggest ?",
    "n_kge": 0
  },
  {
    "raw_text": "What enhanced anti-hiv1 activity?",
    "new_text": "What enhanced anti - hiv1 activity ?",
    "n_kge": 0
  },
  {
    "raw_text": "What figure shows that ap3 exhibited higher inhibitory activities on infection by hiv-1 iiib and hiv-1 bal strains?",
    "new_text": "What figure shows that ap3 exhibited higher inhibitory activities on [Communicable Diseases] / infection by [HIV-1] / hiv - 1 iiib and [HIV-1] / hiv - 1 bal [Muscle strain] / strains ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is the serum half-life of t20?",
    "new_text": "What is the [Serum] / serum [Half-Life] / half - life of t20 ?",
    "n_kge": 2
  },
  {
    "raw_text": "What kind of model best describes the pharmacokinetic profiles of ap3 and ap2?",
    "new_text": "What [Type - attribute] / kind of [Model] / model best describes the [Pharmacokinetic study] / pharmacokinetic profiles of ap3 and [FABP4 wt Allele] / ap2 ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is the in vivo elimination half-life of ap3?",
    "new_text": "What is the in vivo elimination half - life of ap3 ?",
    "n_kge": 0
  },
  {
    "raw_text": "Why did the t20/n36 complex not show a typical alpha helical conformation?",
    "new_text": "Why did the t20 / [N36] / n36 [Complex] / complex not show a typical alpha helical [Molecular Conformation] / conformation ?",
    "n_kge": 3
  },
  {
    "raw_text": "What mutations have been typically associated with t20-resistant hiv-1 variants?",
    "new_text": "What [Mutation] / mutations have been typically associated with t20 - resistant [HIV-1] / hiv - 1 variants ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are main steps for mitigating the covid -19 transmission during transport of suspected and confirmed patients?",
    "new_text": "What are main steps for mitigating the covid - 19 [disease transmission qualifier] / transmission during [Biological Transport] / transport of suspected and confirmed [Patients] / patients ?",
    "n_kge": 3
  },
  {
    "raw_text": "How many deaths each year are caused by gastroenteritis?",
    "new_text": "How many [Cessation of life] / deaths each year are caused by [Gastroenteritis] / gastroenteritis ?",
    "n_kge": 2
  },
  {
    "raw_text": "What percentage of sporadic diarrhea are caused by norovirus?",
    "new_text": "What [Percent (qualifier value)] / percentage of sporadic diarrhea are caused by [Norovirus] / norovirus ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the most common cause of viral gastroenteritis in children?",
    "new_text": "What is the most common [Etiology aspects] / cause of viral gastroenteritis in [Child] / children ?",
    "n_kge": 2
  },
  {
    "raw_text": "Which types of adenovirus are associated with diarrhea?",
    "new_text": "Which types of adenovirus are associated with diarrhea ?",
    "n_kge": 0
  },
  {
    "raw_text": "When was the first tissue culture system developed?",
    "new_text": "When was the first tissue culture system developed ?",
    "n_kge": 0
  },
  {
    "raw_text": "What are the most common dna-based techniques for detecting viruses?",
    "new_text": "What are the most common [DNA] / dna - based techniques for detecting [Virus] / viruses ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is universal primer-pcr used for in viral studies?",
    "new_text": "What is universal [Oligonucleotide Primers] / primer - [Polymerase Chain Reaction] / pcr [Used by] / used for in [Viral studies (procedure)] / viral studies ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is koch's first postulate?",
    "new_text": "What is koch's first postulate ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is koch's second postulate?",
    "new_text": "What is koch's second postulate ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is koch's third postulate?",
    "new_text": "What is koch's third postulate ?",
    "n_kge": 0
  },
  {
    "raw_text": "If all 3 of koch's postulates are met, what does this indicate?",
    "new_text": "If [All] / all 3 of koch's postulates are [Methionine measurement] / met , what does this indicate ?",
    "n_kge": 2
  },
  {
    "raw_text": "Is koch's postulate applicable to enteric viruses?",
    "new_text": "Is koch's postulate applicable to enteric viruses ?",
    "n_kge": 0
  },
  {
    "raw_text": "What changes do viruses make to be unrecognizable to previously neutralizing antibodies?",
    "new_text": "What [Changing] / changes do [Virus] / viruses make [Tryptophanase] / to be unrecognizable [Tryptophanase] / to previously [Antibodies, Neutralizing] / neutralizing antibodies ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is hepatitis c?",
    "new_text": "What is [Hepatitis C] / hepatitis c ?",
    "n_kge": 1
  },
  {
    "raw_text": "How large is the hcv genome?",
    "new_text": "How large is the [Hepatitis C] / hcv [Genome] / genome ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are the non-structural proteins encoded by the hcv genome?",
    "new_text": "What are the non - structural proteins encoded by the [Hepatitis C] / hcv [Genome] / genome ?",
    "n_kge": 2
  },
  {
    "raw_text": "Why has it been difficult to develop a therapy for the hepatitis c virus?",
    "new_text": "Why has it been [Difficult (qualifier value)] / difficult [Tryptophanase] / to develop a [therapeutic aspects] / therapy for the hepatitis c virus ?",
    "n_kge": 3
  },
  {
    "raw_text": "An antibody response to which proteins correlates with reduced hcv levels?",
    "new_text": "[Aniridia type 1] / An antibody response to which proteins correlates with reduced [Hepatitis C] / hcv [Levels (qualifier value)] / levels ?",
    "n_kge": 3
  },
  {
    "raw_text": "How are type a, b, and c viruses determined?",
    "new_text": "How are type a , b , and c viruses determined ?",
    "n_kge": 0
  },
  {
    "raw_text": "Which type of influenza causes epidemics and pandemics?",
    "new_text": "Which [Type - attribute] / type of [Influenza] / influenza [Etiology aspects] / causes [Epidemic] / epidemics and [Pandemics] / pandemics ?",
    "n_kge": 5
  },
  {
    "raw_text": "When did lions first occupy europe?",
    "new_text": "When did [Panthera leo] / lions first occupy [Europe] / europe ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was the purpose of this study?",
    "new_text": "What was the purpose of this study ?",
    "n_kge": 0
  },
  {
    "raw_text": "What has been the application of phage display technology?",
    "new_text": "What has been the [Application procedure] / application of phage display [Technology] / technology ?",
    "n_kge": 2
  },
  {
    "raw_text": "What makes phage display technology useful for other applications?",
    "new_text": "What makes phage display [Technology] / technology useful for other [Application procedure] / applications ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are the advantages of phage as a vaccine carrier?",
    "new_text": "What are the advantages of [Bacteriophages] / phage as a [Vaccines] / vaccine [Genetic Carriers] / carrier ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the potential of phage for infectious and chronic diseases?",
    "new_text": "What is the potential of [Bacteriophages] / phage for infectious and [Chronic disease] / chronic diseases ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the regularity of the virion major coat protein lattice useful for?",
    "new_text": "What is the regularity of the [Virion] / virion [Severe (severity modifier)] / major [GOLPH3 gene] / coat protein lattice useful for ?",
    "n_kge": 3
  },
  {
    "raw_text": "Why is the phage ab excellent model system for directed protein evolution?",
    "new_text": "Why is the [Bacteriophages] / phage ab excellent [Biological Models] / model system for directed [Proteins] / protein evolution ?",
    "n_kge": 3
  },
  {
    "raw_text": "What are filamentous bacteriophages genera inovirua and plectrovirus?",
    "new_text": "What are filamentous bacteriophages genera inovirua and [Plectrovirus] / plectrovirus ?",
    "n_kge": 1
  },
  {
    "raw_text": "What invention has made bacteriophage useful for research?",
    "new_text": "What [Inventions] / invention has made [Bacteriophages] / bacteriophage useful for [research] / research ?",
    "n_kge": 3
  },
  {
    "raw_text": "What has the bacteriphage technology and the library of folded protein variants enabled?",
    "new_text": "What has the bacteriphage [Technology] / technology and the [Libraries] / library of folded protein variants enabled ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are the potential novel applications of the filamentous phage?",
    "new_text": "What are the potential [New] / novel [Application procedure] / applications of the filamentous phage ?",
    "n_kge": 2
  },
  {
    "raw_text": "What themes are common in the applications of filamentous phage?",
    "new_text": "What themes are common in the [Application procedure] / applications of filamentous phage ?",
    "n_kge": 1
  },
  {
    "raw_text": "What do applications of filamentous phage depend on?",
    "new_text": "What do [Application procedure] / applications of filamentous phage depend on ?",
    "n_kge": 1
  },
  {
    "raw_text": "What characteristics are determined by the display mode?",
    "new_text": "What [Characteristics] / characteristics are determined by the display mode ?",
    "n_kge": 1
  },
  {
    "raw_text": "How may the display be achieved?",
    "new_text": "How may the display be achieved ?",
    "n_kge": 0
  },
  {
    "raw_text": "What does the term \"phage display\" refer to?",
    "new_text": "What does the [Term Birth] / term \" phage display \" refer [Tryptophanase] / to ?",
    "n_kge": 2
  },
  {
    "raw_text": "What does the term \"phage displayed library\" refer to?",
    "new_text": "What does the [Term Birth] / term \" [Bacteriophages] / phage displayed [Libraries] / library \" refer [Tryptophanase] / to ?",
    "n_kge": 4
  },
  {
    "raw_text": "What characteristic of filamentous phage has been demonstrated?",
    "new_text": "What [Characteristics] / characteristic of filamentous phage has been demonstrated ?",
    "n_kge": 1
  },
  {
    "raw_text": "What application is a natural extension of the ability to display recombinant exogenous sequences on its surface?",
    "new_text": "What [Application procedure] / application is a [Natural] / natural extension of the [Ability] / ability [Tryptophanase] / to display recombinant [Extrinsic] / exogenous [DNA Sequence] / sequences on its [Surface] / surface ?",
    "n_kge": 7
  },
  {
    "raw_text": "What makes it an attractive vaccine carrier?",
    "new_text": "What makes it an attractive [Vaccines] / vaccine [Genetic Carriers] / carrier ?",
    "n_kge": 2
  },
  {
    "raw_text": "What does the display mode determine?",
    "new_text": "What does the display mode determine ?",
    "n_kge": 0
  },
  {
    "raw_text": "Why are antibody epitope based peptide vaccines are no longer an active research area?",
    "new_text": "Why are [Antibodies] / antibody [Epitopes] / epitope based peptide vaccines are no longer an active [research] / research [Geographic Locations] / area ?",
    "n_kge": 4
  },
  {
    "raw_text": "What phage may be useful in allergy immunotherapy?",
    "new_text": "What [Bacteriophages] / phage may be useful in [Allergy Specialty] / allergy [Biological Response Modifiers] / immunotherapy ?",
    "n_kge": 3
  },
  {
    "raw_text": "Which are some phage based contraceptive vaccines for animals?",
    "new_text": "Which are some [Bacteriophages] / phage based contraceptive vaccines for [Animals] / animals ?",
    "n_kge": 2
  },
  {
    "raw_text": "Which are some phage based contraceptive vaccines for animals?",
    "new_text": "Which are some [Bacteriophages] / phage based contraceptive vaccines for [Animals] / animals ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is one reason for the lack of success of immunization phage displayed peptides with native protein?",
    "new_text": "What is [One] / one [Indication of (contextual qualifier)] / reason for the lack of [Success] / success of immunization phage displayed peptides with native protein ?",
    "n_kge": 3
  },
  {
    "raw_text": "Despite shortcomings, what has the filamentous phage has been useful for?",
    "new_text": "Despite shortcomings , what has the filamentous phage has been useful for ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the result of all species tests of phage particles?",
    "new_text": "What is the [Result] / result of all species [Laboratory Procedures] / tests of [Bacteriophages] / phage particles ?",
    "n_kge": 3
  },
  {
    "raw_text": "What are the results of filamentous phage immunizations in mice?",
    "new_text": "What are the results of filamentous phage [Immunization] / immunizations in [House mice] / mice ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the primary antibody response against the phage?",
    "new_text": "What is the primary [Antibody Formation] / antibody response against the [Bacteriophages] / phage ?",
    "n_kge": 2
  },
  {
    "raw_text": "Why is phage self-adjuvanting?",
    "new_text": "Why is [Bacteriophages] / phage self - adjuvanting ?",
    "n_kge": 1
  },
  {
    "raw_text": "On what does the antibody response to phage depend on?",
    "new_text": "On what does the [Antibody Formation] / antibody response to [Bacteriophages] / phage depend on ?",
    "n_kge": 2
  },
  {
    "raw_text": "What do biodistribution studies of the phage after intravenous injection show?",
    "new_text": "What do biodistribution studies of the [Bacteriophages] / phage after [Intravenous Injections] / intravenous injection show ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are the merits of the filamentous phage carriers?",
    "new_text": "What are the merits of the filamentous phage [Genetic Carriers] / carriers ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is a future potential of filamentous phage?",
    "new_text": "What is a future potential of filamentous phage ?",
    "n_kge": 0
  },
  {
    "raw_text": "What were more potent inhibitors of staphylococcus aureus growth than high-concentration free chloramphenicol?",
    "new_text": "What were [More] / more potent inhibitors of [Staphylococcus aureus] / staphylococcus aureus growth than [High] / high - [Mental concentration] / concentration free chloramphenicol ?",
    "n_kge": 4
  },
  {
    "raw_text": "What killed prostate cancer cells in vitro?",
    "new_text": "What [Killing] / killed [Malignant neoplasm of prostate] / prostate cancer [Cell Count] / cells in vitro ?",
    "n_kge": 3
  },
  {
    "raw_text": "What was the effect of phage displaying peptides on tumor?",
    "new_text": "What was the effect of phage displaying [Peptides] / peptides on tumor ?",
    "n_kge": 1
  },
  {
    "raw_text": "Why is the phage displaying an scfv against \u03b2-amyloid fibrils is a good diagnostic for alzheimers and parkinson's disease?",
    "new_text": "Why is the [Bacteriophages] / phage displaying [Aniridia type 1] / an [Single-Chain Antibodies] / scfv against \u03b2 - amyloid fibrils is a good [Diagnosis] / diagnostic for alzheimers and parkinson's disease ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is the structure of a filamentous phage particle?",
    "new_text": "What is the structure of a filamentous phage particle ?",
    "n_kge": 0
  },
  {
    "raw_text": "What makes filamentous phage ideal scaffold for bioconjugation?",
    "new_text": "What makes filamentous phage ideal scaffold for bioconjugation ?",
    "n_kge": 0
  },
  {
    "raw_text": "What trials have been done to demonstrate the potential of phage in applications for nanomaterials?",
    "new_text": "What trials have been done [Tryptophanase] / to demonstrate the potential of [Bacteriophages] / phage [Present] / in [Application procedure] / applications for [Nanostructured Materials] / nanomaterials ?",
    "n_kge": 5
  },
  {
    "raw_text": "What trials have been done to demonstrate the potential of phage in applications for nanomaterials?",
    "new_text": "What trials have been done [Tryptophanase] / to demonstrate the potential of [Bacteriophages] / phage [Present] / in [Application procedure] / applications for [Nanostructured Materials] / nanomaterials ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is the filamentous phage varion is made of?",
    "new_text": "What is the filamentous phage varion is made of ?",
    "n_kge": 0
  },
  {
    "raw_text": "What demonstrate the potential of phage in applications for nanomaterials?",
    "new_text": "What demonstrate the potential of [Bacteriophages] / phage [Present] / in [Application procedure] / applications for [Nanostructured Materials] / nanomaterials ?",
    "n_kge": 4
  },
  {
    "raw_text": "What was investigated in this study?",
    "new_text": "What was investigated in this study ?",
    "n_kge": 0
  },
  {
    "raw_text": "What was the range of genomic sequencing depths?",
    "new_text": "What was the range of genomic sequencing [Deep (qualifier value)] / depths ?",
    "n_kge": 1
  },
  {
    "raw_text": "Which q-score reads were eliminated from the analysis?",
    "new_text": "Which q - [Score] / score [Reading (activity)] / reads were eliminated from the analysis ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was the mean length of the sequenced read?",
    "new_text": "What was the mean length of the sequenced read ?",
    "n_kge": 0
  },
  {
    "raw_text": "Which strain was similar to other belgian porcine kobuvirus isolates?",
    "new_text": "Which [Muscle strain] / strain was similar to other belgian [Family suidae] / porcine [Kobuvirus] / kobuvirus isolates ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is clodstridium difficile?",
    "new_text": "What is clodstridium difficile ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is sporulation?",
    "new_text": "What is sporulation ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the key regulator to sporulation?",
    "new_text": "What is the key regulator to sporulation ?",
    "n_kge": 0
  },
  {
    "raw_text": "What are the main virulence factors in c difficle?",
    "new_text": "What are the main [Virulence Factors] / virulence factors in c difficle ?",
    "n_kge": 1
  },
  {
    "raw_text": "What laboratory test can be used to monitor protein expression?",
    "new_text": "What [Laboratory Procedures] / laboratory test can be [Used by] / used [Tryptophanase] / to [Patient Monitoring] / monitor protein expression ?",
    "n_kge": 4
  },
  {
    "raw_text": "How is venezuelan equine encephalitis virus transmitted?",
    "new_text": "How is [Venezuelan equine encephalitis virus] / venezuelan equine encephalitis virus [disease transmission] / transmitted ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are the symptoms of venezuelan equine encephalitis virus?",
    "new_text": "What are the symptoms of [Venezuelan equine encephalitis virus] / venezuelan equine encephalitis virus ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the mortality rate of venezuelan equine encephalitis virus in children?",
    "new_text": "What is the [Mortality Vital Statistics] / mortality rate of [Venezuelan equine encephalitis virus] / venezuelan equine encephalitis virus in [Child] / children ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the mortality rate of venezuelan equine encephalitis virus in adults?",
    "new_text": "What is the [Mortality Vital Statistics] / mortality rate of [Venezuelan equine encephalitis virus] / venezuelan equine encephalitis virus in [Adult] / adults ?",
    "n_kge": 3
  },
  {
    "raw_text": "What vaccine can be used to prevent venezuelan equine encephalitis virus?",
    "new_text": "What [Vaccines] / vaccine can be [Used by] / used [Tryptophanase] / to prevent [Venezuelan equine encephalitis virus] / venezuelan equine encephalitis virus ?",
    "n_kge": 4
  },
  {
    "raw_text": "What can rna sequencing be used to monitor?",
    "new_text": "What can rna sequencing be [Used by] / used [Tryptophanase] / to [Patient Monitoring] / monitor ?",
    "n_kge": 3
  },
  {
    "raw_text": "What activates the upr pathway in the cell?",
    "new_text": "What activates the upr pathway in the cell ?",
    "n_kge": 0
  },
  {
    "raw_text": "What indicators does the upr pathway use to regulate protein folding and secretion in the cell?",
    "new_text": "What indicators does the upr pathway [utilization qualifier] / use [Tryptophanase] / to regulate [protein folding] / protein folding and secretion in the cell ?",
    "n_kge": 3
  },
  {
    "raw_text": "Where does egr1 accumulate in the cell?",
    "new_text": "Where does [EGR1 gene] / egr1 accumulate in the [Cells] / cell ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is egr1?",
    "new_text": "What is [EGR1 gene] / egr1 ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is disease resilience?",
    "new_text": "What is [Disease] / disease resilience ?",
    "n_kge": 1
  },
  {
    "raw_text": "What family of virus does sars reside in?",
    "new_text": "What [Family] / family of [Virus] / virus does [Severe Acute Respiratory Syndrome] / sars reside in ?",
    "n_kge": 3
  },
  {
    "raw_text": "What family of virus does mers reside in?",
    "new_text": "What [Family] / family of [Virus] / virus does [Middle East Respiratory Syndrome] / middle east respiratory syndrome reside in ?",
    "n_kge": 3
  },
  {
    "raw_text": "When was sars-cov first identified?",
    "new_text": "When was [SARS coronavirus] / sars - cov first identified ?",
    "n_kge": 1
  },
  {
    "raw_text": "How many people did sars-cov infect?",
    "new_text": "How many [Persons] / people did [SARS coronavirus] / sars - cov [Infected] / infect ?",
    "n_kge": 3
  },
  {
    "raw_text": "What percentage of people infected with mers-cov died?",
    "new_text": "What [Percent (qualifier value)] / percentage of [Persons] / people [Infected] / infected with [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov [Cessation of life] / died ?",
    "n_kge": 5
  },
  {
    "raw_text": "What percentage of people infected with sars-cov died?",
    "new_text": "What [Percent (qualifier value)] / percentage of [Persons] / people [Infected] / infected with [SARS coronavirus] / sars - cov [Cessation of life] / died ?",
    "n_kge": 5
  },
  {
    "raw_text": "What was the reservoir for sars-cov and mers-cov?",
    "new_text": "What was the reservoir for [SARS coronavirus] / sars - cov and [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was the primary threatening clinical finding in patients infected with sars-cov and mers-cov?",
    "new_text": "What was the primary threatening clinical finding in [Patients] / patients [Infected] / infected with [SARS coronavirus] / sars - cov and [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is the relationship between sars-cov and acute lung injury (ali)?",
    "new_text": "What is the [Relationships] / relationship between [SARS coronavirus] / sars - cov and [Acute Lung Injury] / acute lung injury ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the relationship between sars-cov and acute respiratory distress syndrome (ards)?",
    "new_text": "What is the [Relationships] / relationship between [SARS coronavirus] / sars - cov and [Respiratory Distress Syndrome, Adult] / acute respiratory distress syndrome ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is required for a person to survive a serious sars-cov infection?",
    "new_text": "What is required for a [Persons] / person [Tryptophanase] / to survive a serious sars - cov infection ?",
    "n_kge": 2
  },
  {
    "raw_text": "How does cell-entry differ between sars-cov and mers-cov?",
    "new_text": "How does [Cells] / cell - entry differ between [SARS coronavirus] / sars - cov and [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is a major difference in clinical progression between sars-cov and mers-cov?",
    "new_text": "What is a major difference in clinical [Disease Progression] / progression between [SARS coronavirus] / sars - cov and [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov ?",
    "n_kge": 3
  },
  {
    "raw_text": "How does transmission differ between sars-cov and mers-cov?",
    "new_text": "How does [disease transmission qualifier] / transmission differ between [SARS coronavirus] / sars - cov and [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov ?",
    "n_kge": 3
  },
  {
    "raw_text": "How do sars-cov and mers-cov evade the immune system sensing it's genome?",
    "new_text": "How do [SARS coronavirus] / sars - cov and [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov evade the [Immune system] / immune system sensing it's [Genome] / genome ?",
    "n_kge": 4
  },
  {
    "raw_text": "What role does initial viral titer play in the prognosis of sars-cov and mers-cov?",
    "new_text": "What [Social Role] / role does initial viral titer [Play] / play in the [Forecast of outcome] / prognosis of [SARS coronavirus] / sars - cov and [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is the timeline of the type i interferon (ifn) response in sars-cov infection?",
    "new_text": "What is the timeline of the [Interferon Type I] / type i interferon ( ifn ) response in sars - cov infection ?",
    "n_kge": 1
  },
  {
    "raw_text": "How do sars-cov viral proteins interact with the immune response?",
    "new_text": "How do [SARS coronavirus] / sars - cov [Viral Proteins] / viral proteins interact with the [Immune response] / immune response ?",
    "n_kge": 3
  },
  {
    "raw_text": "What was the role of corticosteroid use in hospitalized patients with sars-cov?",
    "new_text": "What was the [Social Role] / role of [Adrenal Cortex Hormones] / corticosteroid use [Present] / in hospitalized patients with [SARS coronavirus] / sars - cov ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is the role of interferon's (ifns) in the treatment of sars-cov?",
    "new_text": "What is the [Social Role] / role of interferon's [Present] / in the [therapeutic aspects] / treatment of [SARS coronavirus] / sars - cov ?",
    "n_kge": 4
  },
  {
    "raw_text": "What are some negative effects of decreasing immunopathology by immunomodulation?",
    "new_text": "What are some negative effects of decreasing [immunopathology specialty] / immunopathology by [Immunoregulation] / immunomodulation ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the role of topoisomerase i in improving host resilience in viral lung infections?",
    "new_text": "What is the [Social Role] / role of [DNA Topoisomerases, Type I] / topoisomerase i [Present] / in improving [Host (organism)] / host resilience [Present] / in viral [Lung] / lung infections ?",
    "n_kge": 6
  },
  {
    "raw_text": "What is the role of complement 5a (c5a) in increasing host resilience to viral lung infection?",
    "new_text": "What is the [Social Role] / role of complement 5a [Present] / in increasing host resilience to viral lung infection ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the role of statins in increasing host resilience to viral lung infections?",
    "new_text": "What is the [Social Role] / role of [Hydroxymethylglutaryl-CoA Reductase Inhibitors] / statins [Present] / in increasing [Host (organism)] / host resilience to viral [Lung] / lung infections ?",
    "n_kge": 5
  },
  {
    "raw_text": "Which medical comorbidities most profoundly influenced mers-cov outcomes?",
    "new_text": "Which medical [Comorbidity] / comorbidities most profoundly influenced [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov outcomes ?",
    "n_kge": 2
  },
  {
    "raw_text": "Which immune factors were associated with increased sars-cov morbidity and mortality?",
    "new_text": "Which [Immunologic Factors] / immune factors were associated with [Increased] / increased [SARS coronavirus] / sars - cov [Morbidity - disease rate] / morbidity and [Mortality Vital Statistics] / mortality ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is the prognostic role of coinfection in sars-cov and mers-cov infections?",
    "new_text": "What is the prognostic [Social Role] / role of [Coinfection] / coinfection in [SARS coronavirus] / sars - cov and [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov [Infection] / infections ?",
    "n_kge": 5
  },
  {
    "raw_text": "Can host resilience be predicted?",
    "new_text": "Can [Host (organism)] / host resilience be [Prediction] / predicted ?",
    "n_kge": 2
  },
  {
    "raw_text": "Can biomarkers be used to predict outcomes in acute respiratory distress (ards) patients?",
    "new_text": "Can [Biological Markers] / biomarkers be [Used by] / used [Tryptophanase] / to predict outcomes in acute respiratory distress ( [Respiratory Distress Syndrome, Adult] / acute respiratory distress syndrome ) [Patients] / patients ?",
    "n_kge": 5
  },
  {
    "raw_text": "What work has been carried out this study?",
    "new_text": "What [Work] / work has been carried out this study ?",
    "n_kge": 1
  },
  {
    "raw_text": "How many confirmed cases were identified in february 2020?",
    "new_text": "How many confirmed cases were identified in february 2020 ?",
    "n_kge": 0
  },
  {
    "raw_text": "What was the case fatality rate?",
    "new_text": "What was the [Case Fatality Rate] / case fatality rate ?",
    "n_kge": 1
  },
  {
    "raw_text": "Who are the majority of cases?",
    "new_text": "Who are the majority of [Case (situation)] / cases ?",
    "n_kge": 1
  },
  {
    "raw_text": "What are the symptoms at the onset?",
    "new_text": "What are the symptoms at the onset ?",
    "n_kge": 0
  },
  {
    "raw_text": "What type of virus is 2019-ncov?",
    "new_text": "What type of virus is [2019 novel coronavirus] / 2019 - ncov ?",
    "n_kge": 1
  },
  {
    "raw_text": "What clade does it belong to?",
    "new_text": "What clade does it belong [Tryptophanase] / to ?",
    "n_kge": 1
  },
  {
    "raw_text": "What other betacoronaviruses are zoonotic in origin?",
    "new_text": "What other [Betacoronavirus] / betacoronaviruses are zoonotic in origin ?",
    "n_kge": 1
  },
  {
    "raw_text": "How does the pathogenicity of 2019-ncov compare with other viruses?",
    "new_text": "How does the [Pathogenicity Aspects] / pathogenicity of [2019 novel coronavirus] / 2019 - ncov compare with other [Virus] / viruses ?",
    "n_kge": 3
  },
  {
    "raw_text": "How does the transmissibility of 2019-ncov compare with other viruses?",
    "new_text": "How does the transmissibility of [2019 novel coronavirus] / 2019 - ncov compare with other [Virus] / viruses ?",
    "n_kge": 2
  },
  {
    "raw_text": "Which electronic databases were used for this study?",
    "new_text": "Which electronic databases were used for this study ?",
    "n_kge": 0
  },
  {
    "raw_text": "What was the purpose of the search?",
    "new_text": "What was the [Purpose] / purpose of the search ?",
    "n_kge": 1
  },
  {
    "raw_text": "What topics were searched for?",
    "new_text": "What topics were searched for ?",
    "n_kge": 0
  },
  {
    "raw_text": "What studies were excluded?",
    "new_text": "What studies were excluded ?",
    "n_kge": 0
  },
  {
    "raw_text": "What did the searches yield?",
    "new_text": "What did the searches yield ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the the primary means for diagnosing the new virus strain?",
    "new_text": "What is the the primary [Means] / means for [Diagnosis] / diagnosing the [New] / new virus strain ?",
    "n_kge": 3
  },
  {
    "raw_text": "What are roles of the period and type of specimens?",
    "new_text": "What are [Social Role] / roles of the period and type of specimens ?",
    "n_kge": 1
  },
  {
    "raw_text": "What are some of the other diagnostic methods?",
    "new_text": "What are some of the other diagnostic methods ?",
    "n_kge": 0
  },
  {
    "raw_text": "How does rt-lamp compare with other methods?",
    "new_text": "How does rt - lamp compare with other [Methods] / methods ?",
    "n_kge": 1
  },
  {
    "raw_text": "How do rt-iipcr and a one-step rrt-pcr compare with other methods?",
    "new_text": "How do [Structure of right thigh] / rt - iipcr and a one - step [Quantitative Reverse Transcriptase PCR] / rrt - pcr compare with other [Methods] / methods ?",
    "n_kge": 3
  },
  {
    "raw_text": "Why is rt-pcr not the best method sometimes?",
    "new_text": "Why is [Reverse Transcriptase Polymerase Chain Reaction] / rt - pcr not the best [Methods] / method sometimes ?",
    "n_kge": 2
  },
  {
    "raw_text": "What did the comparison between the molecular test and serological test show?",
    "new_text": "What did the comparison between the molecular [Laboratory Procedures] / test and [Serologic tests] / serological test show ?",
    "n_kge": 2
  },
  {
    "raw_text": "What enhancements to the molecular tests were looked at?",
    "new_text": "What enhancements to the molecular [Laboratory Procedures] / tests were looked at ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the threshold sensitivity of real time pcr?",
    "new_text": "What is the [Threshold] / threshold [Hypersensitivity] / sensitivity of real time pcr ?",
    "n_kge": 2
  },
  {
    "raw_text": "How is the reproducibility of real time pcr?",
    "new_text": "How is the reproducibility of real time pcr ?",
    "n_kge": 0
  },
  {
    "raw_text": "What are potential vaccines based on?",
    "new_text": "What are potential [Vaccines] / vaccines based on ?",
    "n_kge": 1
  },
  {
    "raw_text": "Which kit is currently used in china?",
    "new_text": "Which kit is currently [Used by] / used in [China] / china ?",
    "n_kge": 2
  },
  {
    "raw_text": "Why were only four studies included?",
    "new_text": "Why were [Singular] / only [Four] / four studies included ?",
    "n_kge": 2
  },
  {
    "raw_text": "Which four studies were included?",
    "new_text": "Which [Four] / four studies were included ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is te safety of the vaccines?",
    "new_text": "What is [tellurium] / te [Safety] / safety of the [Vaccines] / vaccines ?",
    "n_kge": 3
  },
  {
    "raw_text": "What was the performance of the vaccine candidates?",
    "new_text": "What was the performance of the [Vaccines] / vaccine candidates ?",
    "n_kge": 1
  },
  {
    "raw_text": "How many clinical trials are registered?",
    "new_text": "How many [Clinical Trials] / clinical trials are registered ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the status of the nine trials?",
    "new_text": "What is the [Status] / status of the [Nine] / nine trials ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are the results on seroconversion?",
    "new_text": "What are the results on [Seroconversion] / seroconversion ?",
    "n_kge": 1
  },
  {
    "raw_text": "What were the results on antibodies?",
    "new_text": "What were the results on [Antibodies] / antibodies ?",
    "n_kge": 1
  },
  {
    "raw_text": "What were the t-cell responses?",
    "new_text": "What were the [T-Lymphocyte] / t - cell responses ?",
    "n_kge": 1
  },
  {
    "raw_text": "What were the differences in immune responses?",
    "new_text": "What were the differences in [Immune response] / immune responses ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the observed benefit of the molecules?",
    "new_text": "What is the observed benefit of the [Molecule] / molecules ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the ongoing randomized trial investigating?",
    "new_text": "What is the [Continuous] / ongoing [Clinical Trials, Randomized] / randomized trial investigating ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are the many prospective and restrospective studies conducted on?",
    "new_text": "What are the many [Longitudinal Studies] / prospective and restrospective studies conducted on ?",
    "n_kge": 1
  },
  {
    "raw_text": "What was the result of the phase 1 trial of igg immunoglobin?",
    "new_text": "What was the [Result] / result of the phase 1 trial of igg immunoglobin ?",
    "n_kge": 1
  },
  {
    "raw_text": "What role rapid diagnostics plays?",
    "new_text": "What [Social Role] / role rapid diagnostics [Play] / plays ?",
    "n_kge": 2
  },
  {
    "raw_text": "What other measures rapid diagnostics facilitates?",
    "new_text": "What other [Measures] / measures rapid diagnostics facilitates ?",
    "n_kge": 1
  },
  {
    "raw_text": "What are ways to perform laboratory diagnostics?",
    "new_text": "What are ways [Tryptophanase] / to [Performed] / perform laboratory diagnostics ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are key limtations of genetic detection?",
    "new_text": "What are key limtations of [gene therapy] / genetic [Detection] / detection ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is a key limitation of serological testing?",
    "new_text": "What is a key limitation of serological [Testing] / testing ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the limitation in virus testing?",
    "new_text": "What is the limitation in [Virus] / virus [Testing] / testing ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was the result of the treatment?",
    "new_text": "What was the result of the treatment ?",
    "n_kge": 0
  },
  {
    "raw_text": "What superiority did the treatment with integrative chinese and western medicine treatment have compared with using control treatment alone?",
    "new_text": "What superiority did the [therapeutic aspects] / treatment with integrative chinese and western medicine [therapeutic aspects] / treatment have compared with [Use of] / using control [therapeutic aspects] / treatment [Singular] / alone ?",
    "n_kge": 5
  },
  {
    "raw_text": "What was a characteristic of sars-cov and mers-cov, specimens collected from the lower respiratory tract such as sputum and tracheal aspirates?",
    "new_text": "What was a [Characteristics] / characteristic of [SARS coronavirus] / sars - cov and [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov , [Specimen] / specimens collected from the [Lower respiratory tract structure] / lower respiratory tract such as [Sputum] / sputum and tracheal aspirates ?",
    "n_kge": 6
  },
  {
    "raw_text": "How do severe cases compare with mild cases?",
    "new_text": "How do [Severe (severity modifier)] / severe [Case (situation)] / cases compare with [Mild (qualifier value)] / mild [Case (situation)] / cases ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is the disadvantage of upper respiratory tract specimens?",
    "new_text": "What is the disadvantage of [Upper respiratory tract] / upper respiratory tract [Specimen] / specimens ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are the existing practices in detecting genetic material of viruses?",
    "new_text": "What are the existing [Practice Experience] / practices in detecting [Genetic Materials] / genetic material of [Virus] / viruses ?",
    "n_kge": 3
  },
  {
    "raw_text": "Why are nucleic amplification tests (naat) usually preferred as in the case of mers-cov diagnosis?",
    "new_text": "Why are [Cell Nucleus] / nucleic amplification [Laboratory Procedures] / tests usually preferred [artesunate] / as in the [Case (situation)] / case of [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov [Diagnosis] / diagnosis ?",
    "n_kge": 6
  },
  {
    "raw_text": "Where was the first validated diagnostic test designed?",
    "new_text": "Where was the first validated [Diagnostic tests] / diagnostic test designed ?",
    "n_kge": 1
  },
  {
    "raw_text": "How were the assays selected ?",
    "new_text": "How were the assays selected ?",
    "n_kge": 0
  },
  {
    "raw_text": "How were the assays used?",
    "new_text": "How were the assays [Used by] / used ?",
    "n_kge": 1
  },
  {
    "raw_text": "What were the results?",
    "new_text": "What were the results ?",
    "n_kge": 0
  },
  {
    "raw_text": "What did the trial on sab-301 demonstrate?",
    "new_text": "What did the [Clinical Trials] / trial on [Spinal Anesthesia] / sab - 301 demonstrate ?",
    "n_kge": 2
  },
  {
    "raw_text": "What conditions are caused by staphylococcus aureus?",
    "new_text": "What conditions are caused by [Staphylococcus aureus] / staphylococcus aureus ?",
    "n_kge": 1
  },
  {
    "raw_text": "What percentage of healthy adults are asymptotically colonized by pneumococcus bacteria?",
    "new_text": "What [Percent (qualifier value)] / percentage of healthy adults are asymptotically colonized by [Streptococcus pneumoniae] / pneumococcus bacteria ?",
    "n_kge": 2
  },
  {
    "raw_text": "What types of cells follow epithelial cells in the immune response to infections in the lung?",
    "new_text": "What types of cells [Followed by] / follow [Epithelial Cells] / epithelial cells in the [Immune response] / immune response [Tryptophanase] / to infections in the lung ?",
    "n_kge": 4
  },
  {
    "raw_text": "What enhances the expression of type i interferon?",
    "new_text": "What enhances the [Expression procedure] / expression of [Interferon Type I] / type i interferon ?",
    "n_kge": 2
  },
  {
    "raw_text": "What reduces the antimicrobial activities of alveolar macrophages?",
    "new_text": "What reduces the antimicrobial activities of [Macrophages, Alveolar] / alveolar macrophages ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is pneumolysin?",
    "new_text": "What is pneumolysin ?",
    "n_kge": 0
  },
  {
    "raw_text": "What factors make bacterial and viral co-infections so lethal?",
    "new_text": "What factors make bacterial and viral co - infections so lethal ?",
    "n_kge": 0
  },
  {
    "raw_text": "What are inovirus-associated vectors?",
    "new_text": "What are [Inovirus] / inovirus - [Associated with] / associated [Cloning Vectors] / vectors ?",
    "n_kge": 3
  },
  {
    "raw_text": "How can random peptide libraries be used in applications?",
    "new_text": "How can random peptide libraries be [Used by] / used in [Application procedure] / applications ?",
    "n_kge": 2
  },
  {
    "raw_text": "Which lactobacililus casei strain does not have the cholera toxin subunit a1 (cta1) on the surface?",
    "new_text": "Which lactobacililus casei [Muscle strain] / strain does not have the [Cholera Toxin] / cholera toxin [Protein Subunits] / subunit [Unknown GENC] / a1 ( cta1 ) on the [Surface] / surface ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is the most effective treatment against influenza?",
    "new_text": "What is the most effective treatment against [Influenza] / influenza ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the percentage decrease in influenza antibodies after 8 months after inoculation with the inactivated vaccine?",
    "new_text": "What is the [Percent (qualifier value)] / percentage decrease in influenza antibodies [Status post] / after 8 months [Status post] / after [Vaccination] / inoculation with the inactivated vaccine ?",
    "n_kge": 4
  },
  {
    "raw_text": "Why is matrix protein 2 (m2) an attractive target for a universal influenza vaccine?",
    "new_text": "Why is matrix protein 2 ( m2 ) [Aniridia type 1] / an attractive target for a universal influenza vaccine ?",
    "n_kge": 1
  },
  {
    "raw_text": "Why have m2-based vaccines been ineffective?",
    "new_text": "Why have m2 - based [Vaccines] / vaccines been ineffective ?",
    "n_kge": 1
  },
  {
    "raw_text": "Why are lactic acid bacteria considered an attractive delivery system for a live influenza vaccine?",
    "new_text": "Why are lactic acid bacteria considered [Aniridia type 1] / an attractive delivery system for a live influenza vaccine ?",
    "n_kge": 1
  },
  {
    "raw_text": "What primer pairs were used for pcr?",
    "new_text": "What [Oligonucleotide Primers] / primer pairs were [Used by] / used for [Polymerase Chain Reaction] / pcr ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is considered essential to boost the interaction of the influenza vaccine with the mucosal immune system?",
    "new_text": "What is considered essential [Tryptophanase] / to [Boost] / boost the interaction of the [Influenza virus vaccine] / influenza vaccine with the [Mucous Membrane] / mucosal [Immune system] / immune system ?",
    "n_kge": 5
  },
  {
    "raw_text": "Name some adjuvants that have been used with an influenza vaccine?",
    "new_text": "[Name] / Name some adjuvants that have been [Used by] / used with an [Influenza virus vaccine] / influenza vaccine ?",
    "n_kge": 3
  },
  {
    "raw_text": "What was found in the lungs of the control mice in this study?",
    "new_text": "What was [Present] / found in the lungs of the control mice in this study ?",
    "n_kge": 1
  },
  {
    "raw_text": "What did this study show?",
    "new_text": "What did this study show ?",
    "n_kge": 0
  },
  {
    "raw_text": "What regulates the secretion of proinflammatory cytokines?",
    "new_text": "What regulates the secretion of proinflammatory cytokines ?",
    "n_kge": 0
  },
  {
    "raw_text": "Where does the nlrp3 inflammasome activate after a sars-cov infection?",
    "new_text": "Where does the [NLRP3 gene] / nlrp3 inflammasome activate after a sars - cov infection ?",
    "n_kge": 1
  },
  {
    "raw_text": "What ion channel is essential for 3a-mediated il-1beta secretion?",
    "new_text": "What ion channel is essential for 3a - mediated [interleukin-1, beta] / il - 1beta [Process of secretion] / secretion ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are viroporins?",
    "new_text": "What are [Viroporin Proteins] / viroporins ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the genus of the sars coronavirus?",
    "new_text": "What is the genus of the sars coronavirus ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the family of the sars coronavirus?",
    "new_text": "What is the [Family] / family of the [SARS coronavirus] / sars coronavirus ?",
    "n_kge": 2
  },
  {
    "raw_text": "Is the sars coronavirus enveloped?",
    "new_text": "Is the [SARS coronavirus] / sars coronavirus enveloped ?",
    "n_kge": 1
  },
  {
    "raw_text": "Is the sars coronavirus single-stranded or double-stranded?",
    "new_text": "Is the [SARS coronavirus] / sars coronavirus single - stranded or double - stranded ?",
    "n_kge": 1
  },
  {
    "raw_text": "How many laboratory-confirmed cases of sars coronavirus infections were reported between november 2002 and july 2003?",
    "new_text": "How [Numerous] / many [Laboratory] / laboratory - confirmed cases of sars coronavirus infections were [Report (document)] / reported between november 2002 and july 2003 ?",
    "n_kge": 3
  },
  {
    "raw_text": "What was the fatality rate of the sars coronavirus outbreak between november 2002 and july 2003?",
    "new_text": "What was the fatality rate of the [SARS coronavirus] / sars coronavirus [Disease Outbreaks] / outbreak between november 2002 and july 2003 ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are examples of proinflammatory cytokines?",
    "new_text": "What are examples of proinflammatory cytokines ?",
    "n_kge": 0
  },
  {
    "raw_text": "How does nlrp3 detect rna viral infection?",
    "new_text": "How does [NLRP3 gene] / nlrp3 detect rna viral infection ?",
    "n_kge": 1
  },
  {
    "raw_text": "How many amino acids are in the sars-cov e protein?",
    "new_text": "How many [Amino Acids] / amino acids are in the sars - cov e protein ?",
    "n_kge": 1
  },
  {
    "raw_text": "What type of ion channels are formed by the sars-cov e protein?",
    "new_text": "What [Type - attribute] / type of ion channels are formed by the sars - cov e protein ?",
    "n_kge": 1
  },
  {
    "raw_text": "What does the sars-cov protein activate?",
    "new_text": "What does the [SARS coronavirus] / sars - cov [Proteins] / protein activate ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is critical to the development of a protective granuloma in tuberculosis infections?",
    "new_text": "What is critical to the development of a protective [Granuloma] / granuloma in tuberculosis infections ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is tumor necrosis factor-alpha?",
    "new_text": "What is [Alpha tumour necrosis factor measurement] / tumor necrosis factor - alpha ?",
    "n_kge": 1
  },
  {
    "raw_text": "What regulates the activity of mapk activity?",
    "new_text": "What regulates the activity of mapk activity ?",
    "n_kge": 0
  },
  {
    "raw_text": "What causes tuberculosis?",
    "new_text": "What [Etiology aspects] / causes [Tuberculosis] / tuberculosis ?",
    "n_kge": 2
  },
  {
    "raw_text": "What percentage of the world has been infected by tuberculosis?",
    "new_text": "What [Percent (qualifier value)] / percentage of the world has been [Infected] / infected by [Tuberculosis] / tuberculosis ?",
    "n_kge": 3
  },
  {
    "raw_text": "How many new tuberculosis cases are there each year worldwide?",
    "new_text": "How many [New] / new tuberculosis cases are there each year worldwide ?",
    "n_kge": 1
  },
  {
    "raw_text": "What are some mitogen activated protein kinases?",
    "new_text": "What are some [Mitogen-Activated Protein Kinases] / mitogen activated protein kinases ?",
    "n_kge": 1
  },
  {
    "raw_text": "How is mapk activated?",
    "new_text": "How is mapk activated ?",
    "n_kge": 0
  },
  {
    "raw_text": "What enzymes are involved with phosphorylation?",
    "new_text": "What [Enzymes] / enzymes are [Involvement with] / involved with [Phosphorylation] / phosphorylation ?",
    "n_kge": 3
  },
  {
    "raw_text": "How many mapk phosphatases exist?",
    "new_text": "How many [Mitogen-Activated Protein Kinase Phosphatases] / mapk phosphatases exist ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is lipopolysaccharide?",
    "new_text": "What is [Lipopolysaccharides] / lipopolysaccharide ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is staph aureus?",
    "new_text": "What is staph aureus ?",
    "n_kge": 0
  },
  {
    "raw_text": "What protein is in the critical path of immunity and cytokine expression?",
    "new_text": "What [Proteins] / protein is in the critical path of [Immune response] / immunity and [cytokine] / cytokine [Expression procedure] / expression ?",
    "n_kge": 4
  },
  {
    "raw_text": "What diminishes the effectiveness of annual influenza vaccinations?",
    "new_text": "What diminishes the [Effectiveness] / effectiveness of [Annual] / annual influenza vaccinations ?",
    "n_kge": 2
  },
  {
    "raw_text": "What new type of influenza vaccines are needed?",
    "new_text": "What new type of [Influenza virus vaccine] / influenza vaccines are needed ?",
    "n_kge": 1
  },
  {
    "raw_text": "What alternatives to classical vectored vaccines are needed?",
    "new_text": "What alternatives to [Conventional] / classical vectored vaccines are needed ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the advantage of virus vectored vaccine?",
    "new_text": "What is the advantage of [Virus] / virus vectored vaccine ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the advantage of virus vectored vaccines?",
    "new_text": "What is the advantage of [Virus] / virus vectored vaccines ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is one of the issues with present vaccines?",
    "new_text": "What is [One] / one of the issues with [Present] / present [Vaccines] / vaccines ?",
    "n_kge": 3
  },
  {
    "raw_text": "What general types of vaccines are available?",
    "new_text": "What general types of vaccines are available ?",
    "n_kge": 0
  },
  {
    "raw_text": "What inactivated vaccines are available?",
    "new_text": "What inactivated [Vaccines] / vaccines are available ?",
    "n_kge": 1
  },
  {
    "raw_text": "How is the split virus inactivated?",
    "new_text": "How is the split [Virus] / virus inactivated ?",
    "n_kge": 1
  },
  {
    "raw_text": "How is the tiv administered?",
    "new_text": "How is the tiv administered ?",
    "n_kge": 0
  },
  {
    "raw_text": "What does the tiv contain?",
    "new_text": "What does the tiv contain ?",
    "n_kge": 0
  },
  {
    "raw_text": "How is the tiv efficacy measured?",
    "new_text": "How is the tiv [Effectiveness] / efficacy [Measured] / measured ?",
    "n_kge": 2
  },
  {
    "raw_text": "Which is the major surface and attachment glycoprotein on influenza virus?",
    "new_text": "Which is the [Severe (severity modifier)] / major [Surface] / surface and attachment [Glycoproteins] / glycoprotein on influenza virus ?",
    "n_kge": 3
  },
  {
    "raw_text": "How is the serum antibody response measured?",
    "new_text": "How is the serum antibody response [Measured] / measured ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is a gold standard for correlation with immunity to influenza?",
    "new_text": "What is a gold standard for correlation with [Immune response] / immunity to [Influenza] / influenza ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the indication for protection to influenza?",
    "new_text": "What is the [Indication of (contextual qualifier)] / indication for protection to [Influenza] / influenza ?",
    "n_kge": 2
  },
  {
    "raw_text": "What gives protection against clinical disease?",
    "new_text": "What gives protection against clinical [Disease] / disease ?",
    "n_kge": 1
  },
  {
    "raw_text": "What can give protection against clinical disease?",
    "new_text": "What can give protection against clinical [Disease] / disease ?",
    "n_kge": 1
  },
  {
    "raw_text": "How is the laiv administered?",
    "new_text": "How is the laiv administered ?",
    "n_kge": 0
  },
  {
    "raw_text": "What does the laiv contain?",
    "new_text": "What does the laiv contain ?",
    "n_kge": 0
  },
  {
    "raw_text": "Do laiv replicate at body temperature?",
    "new_text": "Do laiv replicate at [Body Temperature] / body temperature ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is a characteristic of laiv?",
    "new_text": "What is a [Characteristics] / characteristic of laiv ?",
    "n_kge": 1
  },
  {
    "raw_text": "Where do the laiv replicate?",
    "new_text": "Where do the laiv replicate ?",
    "n_kge": 0
  },
  {
    "raw_text": "What does laiv immunization do?",
    "new_text": "What does laiv immunization do ?",
    "n_kge": 0
  },
  {
    "raw_text": "What do the inactivated vaccines rely on?",
    "new_text": "What do the inactivated vaccines rely on ?",
    "n_kge": 0
  },
  {
    "raw_text": "What enables virus invasion from immunity?",
    "new_text": "What enables [Virus] / virus [Tumor Cell Invasion] / invasion from [Immune response] / immunity ?",
    "n_kge": 3
  },
  {
    "raw_text": "When does the vaccine strain selection occur in the northern hemisphere?",
    "new_text": "When does the [Vaccines] / vaccine [Muscle strain] / strain [Genetic Selection] / selection occur in the northern hemisphere ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the efficacy of laiv?",
    "new_text": "What is the [Effectiveness] / efficacy of laiv ?",
    "n_kge": 1
  },
  {
    "raw_text": "What does laiv rely on?",
    "new_text": "What does laiv rely on ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the laiv replacement schedule?",
    "new_text": "What is the laiv [Surgical Replantation] / replacement [Schedule (document type)] / schedule ?",
    "n_kge": 2
  },
  {
    "raw_text": "Why laiv may provide broader broader protection than tiv?",
    "new_text": "Why laiv may provide broader broader protection than tiv ?",
    "n_kge": 0
  },
  {
    "raw_text": "What has raised the possibility of universal influenza vaccine?",
    "new_text": "What has raised the possibility of universal influenza vaccine ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the advantage of recombinant dna systems?",
    "new_text": "What is the advantage of [Recombinant DNA] / recombinant dna systems ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the advantage of recombinant dna system?",
    "new_text": "What is the advantage of [Recombinant DNA] / recombinant dna [Drug Delivery Systems] / system ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the advantage of recombinant dna systems?",
    "new_text": "What is the advantage of [Recombinant DNA] / recombinant dna systems ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the issue with each of these vaccines?",
    "new_text": "What is the [Problem] / issue with each of these [Vaccines] / vaccines ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is a concern with these vaccines?",
    "new_text": "What is a concern with these [Vaccines] / vaccines ?",
    "n_kge": 1
  },
  {
    "raw_text": "How many serotypes of adenovirus are there?",
    "new_text": "How [Numerous] / many serotypes of adenovirus are there ?",
    "n_kge": 1
  },
  {
    "raw_text": "Why adenovirus may be the safest vaccine vector?",
    "new_text": "Why [Adenoviruses] / adenovirus may be the safest [Vaccines] / vaccine [Disease Vectors] / vector ?",
    "n_kge": 3
  },
  {
    "raw_text": "Which is the most studied serotype?",
    "new_text": "Which is the most studied [Serotype] / serotype ?",
    "n_kge": 1
  },
  {
    "raw_text": "Why is ad5 is the most studied serotype?",
    "new_text": "Why is [Presenilin-2] / ad5 is the most studied [Serotype] / serotype ?",
    "n_kge": 2
  },
  {
    "raw_text": "Why are adenovirus vectors most attractive?",
    "new_text": "Why are adenovirus vectors most attractive ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the advantage of the adenovirus ?",
    "new_text": "What is the advantage of the [Adenoviruses] / adenovirus ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the advantage of adenovirus vector?",
    "new_text": "What is the advantage of [Adenovirus Vector] / adenovirus vector ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the advantage of adenovirus?",
    "new_text": "What is the advantage of [Adenoviruses] / adenovirus ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the advantage of adenovirus vaccines?",
    "new_text": "What is the advantage of adenovirus vaccines ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the advantage of oral capsule and intranasal deliveries?",
    "new_text": "What is the advantage of oral capsule and intranasal deliveries ?",
    "n_kge": 0
  },
  {
    "raw_text": "What did the first report on adenovirus as a vector demonstrate?",
    "new_text": "What did the first [Report (document)] / report on [Adenoviruses] / adenovirus as a [Disease Vectors] / vector demonstrate ?",
    "n_kge": 3
  },
  {
    "raw_text": "Which rad5 delivery has been tested?",
    "new_text": "Which rad5 [Obstetric Delivery] / delivery has been [Tests (qualifier value)] / tested ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was the result of the rad5-ha testing?",
    "new_text": "What was the [Result] / result of the rad5 - ha [Testing] / testing ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the result of rad5 trials?",
    "new_text": "What is the [Result] / result of rad5 trials ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is an example of failure of rad5?",
    "new_text": "What is [Aniridia type 1] / an example of [Failure (biologic function)] / failure of rad5 ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was the failure of rad5 vaccine for inducing hiv-1 specific t cell response?",
    "new_text": "What was the failure of rad5 vaccine for inducing [HIV-1] / hiv - 1 specific [T-Lymphocyte] / t cell response ?",
    "n_kge": 2
  },
  {
    "raw_text": "What does immunization with adenovirus induce?",
    "new_text": "What does immunization with adenovirus induce ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the advantage of inclusion of non-ha antigens to ha based vaccines?",
    "new_text": "What is the advantage of [Inclusion Bodies] / inclusion of non - ha [Antigens] / antigens to ha based [Vaccines] / vaccines ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the disadvantage of inclusion of non-ha antigens to ha based vaccines?",
    "new_text": "What is the disadvantage of [Inclusion Bodies] / inclusion of non - ha [Antigens] / antigens to ha based [Vaccines] / vaccines ?",
    "n_kge": 3
  },
  {
    "raw_text": "What was the first reported baculovirus vector based vaccine for influenza?",
    "new_text": "What was the first [Report (document)] / reported [Baculoviridae] / baculovirus [Disease Vectors] / vector based vaccine for influenza ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is a drawback of ad5 vector?",
    "new_text": "What is a drawback of [Presenilin-2] / ad5 [Disease Vectors] / vector ?",
    "n_kge": 2
  },
  {
    "raw_text": "What alternatives to ad5 vector have been explored?",
    "new_text": "What alternatives to [Presenilin-2] / ad5 [Disease Vectors] / vector have been explored ?",
    "n_kge": 2
  },
  {
    "raw_text": "What animal adenoviruses have been shown to induce immunity comparable to rda5-ha?",
    "new_text": "What [Animals] / animal [Adenoviruses] / adenoviruses have been shown [Tryptophanase] / to induce [Immune response] / immunity comparable [Tryptophanase] / to rda5 - ha ?",
    "n_kge": 5
  },
  {
    "raw_text": "What can evade anti-ad5 response and also provide effective antigen delivery and immunogenicity?",
    "new_text": "What can evade anti - [Presenilin-2] / ad5 response and also provide [Effectiveness] / effective [Antigens] / antigen [Obstetric Delivery] / delivery and immunogenicity ?",
    "n_kge": 4
  },
  {
    "raw_text": "What additional strategies have been explored to avoid preexisting immunity?",
    "new_text": "What additional strategies have been explored [Tryptophanase] / to avoid preexisting [Immune response] / immunity ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the advantage of aav vector?",
    "new_text": "What is the advantage of aav vector ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the advantage of the aav vector?",
    "new_text": "What is the advantage of the aav vector ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the advantage of aav vector?",
    "new_text": "What is the advantage of aav vector ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the advantage of aav vector?",
    "new_text": "What is the advantage of aav vector ?",
    "n_kge": 0
  },
  {
    "raw_text": "Has aav been studied as vectors for influenza?",
    "new_text": "Has [AAVS1 gene] / aav been studied as [Cloning Vectors] / vectors for [Influenza] / influenza ?",
    "n_kge": 3
  },
  {
    "raw_text": "What are alphaviruses?",
    "new_text": "What are [Alphavirus] / alphaviruses ?",
    "n_kge": 1
  },
  {
    "raw_text": "What are some alphavirus vectors that have been developed?",
    "new_text": "What are some [Alphavirus] / alphavirus [Cloning Vectors] / vectors that have been developed ?",
    "n_kge": 2
  },
  {
    "raw_text": "How do the alphavirus vectors work?",
    "new_text": "How do the [Alphavirus] / alphavirus [Cloning Vectors] / vectors [Work] / work ?",
    "n_kge": 3
  },
  {
    "raw_text": "How do the alphavirus vectors work?",
    "new_text": "How do the [Alphavirus] / alphavirus [Cloning Vectors] / vectors [Work] / work ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is an important feature of the replicon system?",
    "new_text": "What is [Aniridia type 1] / an important [Characteristics] / feature of the [Replicon] / replicon [Drug Delivery Systems] / system ?",
    "n_kge": 4
  },
  {
    "raw_text": "How did the vee based replicon system incorporating ha from pr8perform?",
    "new_text": "How did the [Venezuelan equine encephalitis virus] / vee based [Replicon] / replicon [Drug Delivery Systems] / system incorporating ha from pr8perform ?",
    "n_kge": 3
  },
  {
    "raw_text": "Why is the vee replicon system particularly appealing?",
    "new_text": "Why is the [Venezuelan equine encephalitis virus] / vee [Replicon] / replicon [Drug Delivery Systems] / system particularly appealing ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the advantage of the vee replicon system?",
    "new_text": "What is the advantage of the [Venezuelan equine encephalitis virus] / vee [Replicon] / replicon [Drug Delivery Systems] / system ?",
    "n_kge": 3
  },
  {
    "raw_text": "What were the vrps derived from vee developed for?",
    "new_text": "What were the vrps derived from [Venezuelan equine encephalitis virus] / vee developed for ?",
    "n_kge": 1
  },
  {
    "raw_text": "What did the clinical trial with cmv vrp show?",
    "new_text": "What did the [Clinical Trials] / clinical trial with cmv [Vascular Endothelial Growth Factor C] / vrp show ?",
    "n_kge": 2
  },
  {
    "raw_text": "What did the clinical trial with vrp show?",
    "new_text": "What did the [Clinical Trials] / clinical trial with [Vascular Endothelial Growth Factor C] / vrp show ?",
    "n_kge": 2
  },
  {
    "raw_text": "Which baculovirus vaccine has been approved for human use?",
    "new_text": "Which [Baculoviridae] / baculovirus [Vaccines] / vaccine has been approved for human use ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the advantage of baculoviruses?",
    "new_text": "What is the advantage of [Baculoviridae] / baculoviruses ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the advantage of baculovirus vectors?",
    "new_text": "What is the advantage of [Baculoviridae] / baculovirus [Cloning Vectors] / vectors ?",
    "n_kge": 2
  },
  {
    "raw_text": "How can baculovirus vectors be improved?",
    "new_text": "How can [Baculoviridae] / baculovirus [Cloning Vectors] / vectors be [Improved] / improved ?",
    "n_kge": 3
  },
  {
    "raw_text": "What baculovirus vector based immunization provided protection from lethal challenge?",
    "new_text": "What [Baculoviridae] / baculovirus [Disease Vectors] / vector based immunization provided protection from lethal [Challenge:Type:Point in time:^Patient:Nominal] / challenge ?",
    "n_kge": 3
  },
  {
    "raw_text": "What was the benefit of the robust innate immune response to baculovirus vector?",
    "new_text": "What was the benefit of the [Robust] / robust innate immune response to [Baculoviridae] / baculovirus [Disease Vectors] / vector ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the newcastle disease virus?",
    "new_text": "What is the [Newcastle disease virus] / newcastle disease virus ?",
    "n_kge": 1
  },
  {
    "raw_text": "What are the appealing qualities of the ndv vector?",
    "new_text": "What are the appealing qualities of the [Newcastle disease virus] / ndv [Disease Vectors] / vector ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the appealing quality of the ndv vector?",
    "new_text": "What is the appealing [Quality] / quality of the [Newcastle disease virus] / ndv [Disease Vectors] / vector ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the appealing quality of the ndv vector?",
    "new_text": "What is the appealing [Quality] / quality of the [Newcastle disease virus] / ndv [Disease Vectors] / vector ?",
    "n_kge": 3
  },
  {
    "raw_text": "What did the first report on the ndv vector test conclude?",
    "new_text": "What did the first [Report (document)] / report on the [Newcastle disease virus] / ndv [Disease Vectors] / vector [Laboratory Procedures] / test [Conclude Resin] / conclude ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is the added protection of ndv vector?",
    "new_text": "What is the added protection of [Newcastle disease virus] / ndv [Disease Vectors] / vector ?",
    "n_kge": 2
  },
  {
    "raw_text": "What have the limited ndv human trails shown?",
    "new_text": "What have the limited [Newcastle disease virus] / ndv [Homo sapiens] / human trails shown ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are the attractive features of the piv5 vector?",
    "new_text": "What are the attractive [Characteristics] / features of the piv5 [Disease Vectors] / vector ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was the result of the test of efficacy of piv5 in murine challenge?",
    "new_text": "What was the result of the test of [Effectiveness] / efficacy of piv5 in [Mus] / murine [Challenge:Type:Point in time:^Patient:Nominal] / challenge ?",
    "n_kge": 3
  },
  {
    "raw_text": "What opportunity has the termination of smallpox vaccination provided?",
    "new_text": "What opportunity has the termination of [Vaccination against smallpox] / smallpox vaccination provided ?",
    "n_kge": 1
  },
  {
    "raw_text": "What vaccinia vectors were created to address safety concerns?",
    "new_text": "What [Vaccinia] / vaccinia [Cloning Vectors] / vectors were created [Tryptophanase] / to address [Safety] / safety concerns ?",
    "n_kge": 4
  },
  {
    "raw_text": "How safe is mva?",
    "new_text": "How safe is [doxorubicin/mitomycin/vinblastine protocol] / mva ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the status of mva influenza vaccine?",
    "new_text": "What is the status of [doxorubicin/mitomycin/vinblastine protocol] / mva influenza vaccine ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is nyvac?",
    "new_text": "What is nyvac ?",
    "n_kge": 0
  },
  {
    "raw_text": "How is nyvac grown?",
    "new_text": "How is nyvac grown ?",
    "n_kge": 0
  },
  {
    "raw_text": "How safe is nyvac?",
    "new_text": "How safe is nyvac ?",
    "n_kge": 0
  },
  {
    "raw_text": "What would limit the use of poxvirus vectored vaccines?",
    "new_text": "What would limit the use of poxvirus vectored [Vaccines] / vaccines ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the advantage of the nyvac as an influenza virus?",
    "new_text": "What is the advantage of the nyvac as an [Orthomyxoviridae] / influenza virus ?",
    "n_kge": 1
  },
  {
    "raw_text": "Where is poxvirus vaccine being used?",
    "new_text": "Where is [Poxviridae] / poxvirus [Vaccines] / vaccine being [Used by] / used ?",
    "n_kge": 3
  },
  {
    "raw_text": "What have the studies on np shown for the protection against influenza challege?",
    "new_text": "What have the studies on [Measles Virus Nucleoprotein] / np shown for the protection against [Influenza] / influenza challege ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the goal of vaccine?",
    "new_text": "What is the [objective (goal)] / goal of [Vaccines] / vaccine ?",
    "n_kge": 2
  },
  {
    "raw_text": "What has enabled the development of one size fits all vaccine?",
    "new_text": "What has enabled the development of [One] / one [size] / size [Seizures] / fits all [Vaccines] / vaccine ?",
    "n_kge": 4
  },
  {
    "raw_text": "Why is a revision of current vaccines is needed?",
    "new_text": "Why is a [Revision] / revision of current [Vaccines] / vaccines is needed ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is an example of an improved vaccine regime?",
    "new_text": "What is [Aniridia type 1] / an example of [Aniridia type 1] / an [Improved] / improved [Vaccines] / vaccine regime ?",
    "n_kge": 4
  },
  {
    "raw_text": "What can provide an improved vaccine regime?",
    "new_text": "What can provide an [Improved] / improved [Vaccines] / vaccine regime ?",
    "n_kge": 2
  },
  {
    "raw_text": "What features can be created for creating vectored vaccines?",
    "new_text": "What [Characteristics] / features can be created for creating vectored vaccines ?",
    "n_kge": 1
  },
  {
    "raw_text": "How can sustained immunity be generated?",
    "new_text": "How can sustained [Immune response] / immunity be generated ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the advantage of vectored vaccines?",
    "new_text": "What is the advantage of vectored vaccines ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the enhanced memory immune response linked to?",
    "new_text": "What is the enhanced [Memory] / memory [Immune response] / immune response linked [Tryptophanase] / to ?",
    "n_kge": 3
  },
  {
    "raw_text": "What cellular process is the tat protein essential to?",
    "new_text": "What cellular process is the [tat Protein] / tat protein essential to ?",
    "n_kge": 1
  },
  {
    "raw_text": "Where does the tat protein move to in cells?",
    "new_text": "Where does the [tat Protein] / tat protein [Moving] / move [Tryptophanase] / to in [Cell Count] / cells ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is a nucleolus?",
    "new_text": "What is a [Cell Nucleolus] / nucleolus ?",
    "n_kge": 1
  },
  {
    "raw_text": "Where are rrna and ribosomes created?",
    "new_text": "Where are [Ribosomal RNA] / rrna and [Ribosomes] / ribosomes created ?",
    "n_kge": 2
  },
  {
    "raw_text": "How many proteins were shown to change the amount of jurkat t-cell nucleolus significantly?",
    "new_text": "How many [Proteins] / proteins were shown [Tryptophanase] / to [Changing] / change the [Quantity] / amount of jurkat t - cell nucleolus significantly ?",
    "n_kge": 4
  },
  {
    "raw_text": "What cellular processes occur in the nucleolus?",
    "new_text": "What cellular processes occur in the [Cell Nucleolus] / nucleolus ?",
    "n_kge": 1
  },
  {
    "raw_text": "Which viruses target the nucleolus as part of their replication strategy?",
    "new_text": "Which [Virus] / viruses target the nucleolus as part of their [DNA Replication] / replication strategy ?",
    "n_kge": 2
  },
  {
    "raw_text": "What nucleolar antigen is essential of localization of tat and rev proteins?",
    "new_text": "What nucleolar [Antigens] / antigen is essential of [localization] / localization of tat and [Gene Products, rev] / rev proteins ?",
    "n_kge": 3
  },
  {
    "raw_text": "What was studied in this report?",
    "new_text": "What was studied in this report ?",
    "n_kge": 0
  },
  {
    "raw_text": "What was studied in this report?",
    "new_text": "What was studied in this report ?",
    "n_kge": 0
  },
  {
    "raw_text": "Which isotope labeled arginine?",
    "new_text": "Which [Isotopes] / isotope labeled [arginine] / arginine ?",
    "n_kge": 2
  },
  {
    "raw_text": "Which isotope labeled lysine?",
    "new_text": "Which [Isotopes] / isotope labeled [lysine] / lysine ?",
    "n_kge": 2
  },
  {
    "raw_text": "How many cells were harvested from each culture?",
    "new_text": "How many [Cell Count] / cells were harvested from each [Anthropological Culture] / culture ?",
    "n_kge": 2
  },
  {
    "raw_text": "How long is the nuclear protein parp-1?",
    "new_text": "How [Long] / long is the [Nuclear Proteins] / nuclear protein [TIPARP gene] / parp - 1 ?",
    "n_kge": 3
  },
  {
    "raw_text": "How long is the protein alpha-tubulin?",
    "new_text": "How [Long] / long is the [Proteins] / protein [alpha-Tubulin] / alpha - tubulin ?",
    "n_kge": 3
  },
  {
    "raw_text": "Where was alpha-tubulin found most abundantly in the cell?",
    "new_text": "Where was [alpha-Tubulin] / alpha - tubulin [Present] / found most abundantly in the [Cells] / cell ?",
    "n_kge": 3
  },
  {
    "raw_text": "Where was alpha-tubulin found least abundantly in the cell?",
    "new_text": "Where was [alpha-Tubulin] / alpha - tubulin [Present] / found least abundantly in the [Cells] / cell ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is shown in table s1?",
    "new_text": "What is shown in table s1 ?",
    "n_kge": 0
  },
  {
    "raw_text": "What types of cells are used to study tat-mediated pathogenesis?",
    "new_text": "What types of cells are [Used by] / used [Tryptophanase] / to study tat - mediated pathogenesis ?",
    "n_kge": 2
  },
  {
    "raw_text": "How many proteins displayed a significant fold change?",
    "new_text": "How many [Proteins] / proteins displayed a [Statistical Significance] / significant [Fold Change] / fold change ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the significance of this study?",
    "new_text": "What is the [Statistical Significance] / significance of this study ?",
    "n_kge": 1
  },
  {
    "raw_text": "How are mammarenaviruses spread from rodents to humans?",
    "new_text": "How are [Mammarenavirus] / mammarenaviruses [Spreading (qualifier value)] / spread from [Rodent] / rodents to [Homo sapiens] / humans ?",
    "n_kge": 4
  },
  {
    "raw_text": "What are the main groups for mammarenaviruses?",
    "new_text": "What are the main groups for [Mammarenavirus] / mammarenaviruses ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the cause of lassa fever?",
    "new_text": "What is the [Etiology aspects] / cause of [Lassa Fever] / lassa fever ?",
    "n_kge": 2
  },
  {
    "raw_text": "What type of vaccine is junv, candid#1?",
    "new_text": "What type of vaccine is junv , candid # 1 ?",
    "n_kge": 0
  },
  {
    "raw_text": "Why was the human a549 cell line chosen for this study?",
    "new_text": "Why was the human a549 cell line chosen for this study ?",
    "n_kge": 0
  },
  {
    "raw_text": "For how long were the cells infected before analysis?",
    "new_text": "For how [Long] / long were the [Cell Count] / cells [Infected] / infected before analysis ?",
    "n_kge": 3
  },
  {
    "raw_text": "What drug is used to treat congestive heart failure?",
    "new_text": "What [Pharmaceutical Preparations] / drug is [Used by] / used [Tryptophanase] / to [Therapeutic procedure] / treat [Congestive heart failure] / congestive heart failure ?",
    "n_kge": 5
  },
  {
    "raw_text": "What does ouabain inhibit?",
    "new_text": "What does ouabain inhibit ?",
    "n_kge": 0
  },
  {
    "raw_text": "What method can significantly alleviate the emergence of drug-resistant variants in rna viral infections?",
    "new_text": "What [Methods] / method can significantly alleviate the emergence of drug - resistant variants in rna viral infections ?",
    "n_kge": 1
  },
  {
    "raw_text": "What factors did this study attribute to the efficient multiplication of mammarenaviruses?",
    "new_text": "What factors did this study [Concept Attribute] / attribute to the efficient multiplication of [Mammarenavirus] / mammarenaviruses ?",
    "n_kge": 2
  },
  {
    "raw_text": "How do the authors suggest that atp1a1 and phb contribute to the efficient multiplication of mammarenaviruses?",
    "new_text": "How do the [Author] / authors suggest that [ATP1A1 gene] / atp1a1 and [prohibitin] / phb contribute to the efficient multiplication of [Mammarenavirus] / mammarenaviruses ?",
    "n_kge": 4
  },
  {
    "raw_text": "Which are the most abundant biological entities on earth?",
    "new_text": "Which are the most abundant [biology (field)] / biological entities on [Earth, Planet] / earth ?",
    "n_kge": 2
  },
  {
    "raw_text": "What contributed to a large part of mammalian genomic sequence?",
    "new_text": "What contributed to a large part of [Mammals] / mammalian [Genome] / genomic [Base Sequence] / sequence ?",
    "n_kge": 3
  },
  {
    "raw_text": "What were the earliest replicating entities that fulfill several criteria for life?",
    "new_text": "What were the earliest replicating entities that fulfill [Numerous] / several criteria for [Life] / life ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are some examples of autonomous bacteria that lost their independence and became intracellular parasites or endosymbionts?",
    "new_text": "What are some examples of autonomous bacteria that lost their [Independence] / independence and became intracellular parasites or endosymbionts ?",
    "n_kge": 1
  },
  {
    "raw_text": "What entities with no genes satisfy the criteria for life?",
    "new_text": "What entities with no [Genes] / genes satisfy the criteria for [Life] / life ?",
    "n_kge": 2
  },
  {
    "raw_text": "Which group of rna quasispecies satisfy criteria for life?",
    "new_text": "Which group of [RNA] / rna [Quasispecies] / quasispecies satisfy criteria for [Life] / life ?",
    "n_kge": 3
  },
  {
    "raw_text": "How are the ribozymes able to replicate, join and create peptide bonds?",
    "new_text": "How are the [Catalytic RNA] / ribozymes [Ability] / able [Tryptophanase] / to replicate , join and create peptide bonds ?",
    "n_kge": 3
  },
  {
    "raw_text": "Does rna replication need polymerase enzymes?",
    "new_text": "Does rna [DNA Replication] / replication need polymerase [Enzymes] / enzymes ?",
    "n_kge": 2
  },
  {
    "raw_text": "How can dna arise chemically from rna?",
    "new_text": "How can [DNA] / dna arise [Chemicals] / chemically from [RNA] / rna ?",
    "n_kge": 3
  },
  {
    "raw_text": "What do ribozymes consist of?",
    "new_text": "What do [Catalytic RNA] / ribozymes [Consistency] / consist of ?",
    "n_kge": 2
  },
  {
    "raw_text": "What do ribozymes lack?",
    "new_text": "What do [Catalytic RNA] / ribozymes lack ?",
    "n_kge": 1
  },
  {
    "raw_text": "What do ribozymes exhibit?",
    "new_text": "What do [Catalytic RNA] / ribozymes [Exhibits as Topic] / exhibit ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is chikv marked by?",
    "new_text": "What is chikv marked by ?",
    "n_kge": 0
  },
  {
    "raw_text": "What does chikungunya cause?",
    "new_text": "What does [Chikungunya Fever] / chikungunya [Etiology aspects] / cause ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is chikungunya virus?",
    "new_text": "What is [Chikungunya virus] / chikungunya virus ?",
    "n_kge": 1
  },
  {
    "raw_text": "Is there a treatment?",
    "new_text": "Is there a [therapeutic aspects] / treatment ?",
    "n_kge": 1
  },
  {
    "raw_text": "What conclusion is drawn in this report?",
    "new_text": "What conclusion is drawn in this [Report (document)] / report ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is chikungunya virus?",
    "new_text": "What is [Chikungunya virus] / chikungunya virus ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is chikv?",
    "new_text": "What is chikv ?",
    "n_kge": 0
  },
  {
    "raw_text": "How is chikv propagated to humans?",
    "new_text": "How is chikv propagated to [Homo sapiens] / humans ?",
    "n_kge": 1
  },
  {
    "raw_text": "From what language the disease gets its name?",
    "new_text": "From what [Languages] / language the [Disease] / disease gets its [Name] / name ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the word chikungunya mean?",
    "new_text": "What is the word [Chikungunya Fever] / chikungunya mean ?",
    "n_kge": 1
  },
  {
    "raw_text": "What does chikungunya mean in swahili?",
    "new_text": "What does [Chikungunya Fever] / chikungunya mean in swahili ?",
    "n_kge": 1
  },
  {
    "raw_text": "How is chikv maintained in africa?",
    "new_text": "How is chikv maintained in [Africa] / africa ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is it vectored by, in asia?",
    "new_text": "What is it vectored by , in [Asia] / asia ?",
    "n_kge": 1
  },
  {
    "raw_text": "How does the transmission in asia occur?",
    "new_text": "How does the [disease transmission qualifier] / transmission in [Asia] / asia occur ?",
    "n_kge": 2
  },
  {
    "raw_text": "What spurred the discovery of the new vector ae albopictus?",
    "new_text": "What spurred the discovery of the [New] / new [Disease Vectors] / vector ae albopictus ?",
    "n_kge": 2
  },
  {
    "raw_text": "In the epidemic peak how many cases per week were there on the island?",
    "new_text": "In the [Epidemic] / epidemic peak how [Numerous] / many [Case (situation)] / cases per [Weekly] / week were there on the [Islands] / island ?",
    "n_kge": 5
  },
  {
    "raw_text": "What does this review detail?",
    "new_text": "What does this review detail ?",
    "n_kge": 0
  },
  {
    "raw_text": "What dose this review describe?",
    "new_text": "What [Dosage] / dose this review describe ?",
    "n_kge": 1
  },
  {
    "raw_text": "How many genotypes of chikv have been isilated?",
    "new_text": "How [Numerous] / many [Genotype] / genotypes of chikv have been isilated ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are the genotypes based on?",
    "new_text": "What are the [Genotype] / genotypes based on ?",
    "n_kge": 1
  },
  {
    "raw_text": "Hen did asian genotype emerge?",
    "new_text": "Hen did [Asians] / asian [Genotype] / genotype emerge ?",
    "n_kge": 2
  },
  {
    "raw_text": "When didthe asian genotype diverge from african genotype?",
    "new_text": "When didthe [Asians] / asian [Genotype] / genotype diverge from [African race] / african [Genotype] / genotype ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is the status of asian chikv since its emergence?",
    "new_text": "What is the [Status] / status of [Asians] / asian chikv since its emergence ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are the recent activities of chikv?",
    "new_text": "What are the [Recent] / recent [Activities] / activities of chikv ?",
    "n_kge": 2
  },
  {
    "raw_text": "How was the italian isolation found to have evolved from?",
    "new_text": "How was the italian [Isolation procedure] / isolation [Present] / found [Tryptophanase] / to have evolved from ?",
    "n_kge": 3
  },
  {
    "raw_text": "How many days is the incubation period?",
    "new_text": "How many [day] / days is the incubation period ?",
    "n_kge": 1
  },
  {
    "raw_text": "In how many days do the symptoms arise?",
    "new_text": "In how many [day] / days do the symptoms arise ?",
    "n_kge": 1
  },
  {
    "raw_text": "What are exhibited in the two phases?",
    "new_text": "What are exhibited in the [Two] / two phases ?",
    "n_kge": 1
  },
  {
    "raw_text": "What are consequences of infection?",
    "new_text": "What are consequences of [Communicable Diseases] / infection ?",
    "n_kge": 1
  },
  {
    "raw_text": "What percentage of the patients still have the chikv igm after eighteen months?",
    "new_text": "What [Percent (qualifier value)] / percentage of the [Patients] / patients still have the chikv [CD40LG wt Allele] / igm after [Eighteen] / eighteen months ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is te chronic stage characterized by?",
    "new_text": "What is [tellurium] / te chronic stage characterized by ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is affected by chikv?",
    "new_text": "What is [Affecting] / affected by chikv ?",
    "n_kge": 1
  },
  {
    "raw_text": "What explains the pain associated with chikv?",
    "new_text": "What explains the [Pain] / pain associated with chikv ?",
    "n_kge": 1
  },
  {
    "raw_text": "What percentage of people suffering from the chikf are over 65 years old?",
    "new_text": "What [Percent (qualifier value)] / percentage of [Persons] / people [Mental Suffering] / suffering from the chikf are over 65 years old ?",
    "n_kge": 3
  },
  {
    "raw_text": "What percentage die?",
    "new_text": "What [Percent (qualifier value)] / percentage die ?",
    "n_kge": 1
  },
  {
    "raw_text": "What other group is disproportionately affected?",
    "new_text": "What other group is disproportionately [Affecting] / affected ?",
    "n_kge": 1
  },
  {
    "raw_text": "What complications are associated with chikv?",
    "new_text": "What [Complication] / complications are associated with chikv ?",
    "n_kge": 1
  },
  {
    "raw_text": "What happens after host infection?",
    "new_text": "What happens after [Host (organism)] / host [Communicable Diseases] / infection ?",
    "n_kge": 2
  },
  {
    "raw_text": "What did the ae aegypti which is responsible for epidemics in kenya, comoros and seychelles carry?",
    "new_text": "What did the ae aegypti which is [Responsible to (attribute)] / responsible for [Epidemic] / epidemics in [Kenya] / kenya , [Comoros] / comoros and [Seychelles] / seychelles carry ?",
    "n_kge": 5
  },
  {
    "raw_text": "What was the result of the decline in population of ae aegyptus when the virus struck the reunion islands, due to massive use dichlorodiphenyltrichloroethane usage?",
    "new_text": "What was the [Result] / result of the decline [Present] / in [geographic population] / population of ae aegyptus when the [Virus] / virus [Struck] / struck the reunion islands , due to massive [utilization qualifier] / use [DDT (Insecticide)] / dichlorodiphenyltrichloroethane [Usage] / usage ?",
    "n_kge": 8
  },
  {
    "raw_text": "What did this mutation allow?",
    "new_text": "What did this [Mutation] / mutation allow ?",
    "n_kge": 1
  },
  {
    "raw_text": "What vectored the large epidemic in la reunion islands?",
    "new_text": "What vectored the large [Epidemic] / epidemic in [lanthanum] / la reunion islands ?",
    "n_kge": 2
  },
  {
    "raw_text": "What percentage of population was affected?",
    "new_text": "What [Percent (qualifier value)] / percentage of [geographic population] / population was [Affecting] / affected ?",
    "n_kge": 3
  },
  {
    "raw_text": "Where were the chikv strain found?",
    "new_text": "Where were the chikv [Muscle strain] / strain [Present] / found ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the finding on e1-a226v in indian ocean?",
    "new_text": "What is the [Signs and Symptoms] / finding on [VACUOLAR-TYPE PROTON-TRANSLOCATING ATPase SUBUNIT E1] / e1 - a226v in indian ocean ?",
    "n_kge": 2
  },
  {
    "raw_text": "What has the e1-a226v enabled?",
    "new_text": "What has the [VACUOLAR-TYPE PROTON-TRANSLOCATING ATPase SUBUNIT E1] / e1 - a226v enabled ?",
    "n_kge": 1
  },
  {
    "raw_text": "What has become the preferred and lethal vector?",
    "new_text": "What has become the preferred and lethal [Disease Vectors] / vector ?",
    "n_kge": 1
  },
  {
    "raw_text": "What was the finding on the green fluorescent tagged e1-a226v?",
    "new_text": "What was the [Signs and Symptoms] / finding on the [Green color] / green fluorescent tagged [VACUOLAR-TYPE PROTON-TRANSLOCATING ATPase SUBUNIT E1] / e1 - a226v ?",
    "n_kge": 3
  },
  {
    "raw_text": "What became the main vector in the indian ocean within 1-2 y after chikv was introduced?",
    "new_text": "What became the main [Disease Vectors] / vector in the indian ocean within 1 - 2 y after chikv was introduced ?",
    "n_kge": 1
  },
  {
    "raw_text": "How long ae aegypti been established in north america?",
    "new_text": "How [Long] / long ae aegypti been established in [North America] / north america ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the presence of ae albopictus in north america?",
    "new_text": "What is the [Present] / presence of ae albopictus in [North America] / north america ?",
    "n_kge": 2
  },
  {
    "raw_text": "What percentage of newborns were infected from their mother?",
    "new_text": "What [Percent (qualifier value)] / percentage of [Infant, Newborn] / newborns were [Infected] / infected from their [Mother (person)] / mother ?",
    "n_kge": 4
  },
  {
    "raw_text": "What has been some instances of mother to fetus transmission?",
    "new_text": "What has been some instances of [Mother (person)] / mother to fetus [disease transmission qualifier] / transmission ?",
    "n_kge": 2
  },
  {
    "raw_text": "What did the studies reveal regarding transmission from mothers during perinatal period?",
    "new_text": "What did the studies reveal regarding transmission from mothers during perinatal period ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is theorized regarding transmission?",
    "new_text": "What is theorized regarding [disease transmission qualifier] / transmission ?",
    "n_kge": 1
  },
  {
    "raw_text": "What did the study report?",
    "new_text": "What did the study report ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is a conclusion of this report?",
    "new_text": "What is a conclusion of this [Report (document)] / report ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is a conclusion of this report?",
    "new_text": "What is a conclusion of this [Report (document)] / report ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the niaid designation of chikv?",
    "new_text": "What is the niaid [Identifier] / designation of chikv ?",
    "n_kge": 1
  },
  {
    "raw_text": "What are the strengths and advantages of dna based vaccine?",
    "new_text": "What are the strengths and advantages of [DNA] / dna based [Vaccines] / vaccine ?",
    "n_kge": 2
  },
  {
    "raw_text": "How many facilities were monitored in this study?",
    "new_text": "How many facilities were monitored in this study ?",
    "n_kge": 0
  },
  {
    "raw_text": "What percentage of facilities believed they were adequately equipped to handle ebola virus disease?",
    "new_text": "What [Percent (qualifier value)] / percentage of facilities believed they were adequately equipped to handle [Hemorrhagic Fever, Ebola] / ebola virus disease ?",
    "n_kge": 2
  },
  {
    "raw_text": "How many facilities believed they were adequately equipped to handle ebla virus disease?",
    "new_text": "How many facilities believed they were adequately equipped to handle [Epidermolysis bullosa, lethal acantholytic] / ebla [Virus Diseases] / virus disease ?",
    "n_kge": 2
  },
  {
    "raw_text": "How many healthcare workers would be willing to continue working during the ebola virus outbreak?",
    "new_text": "How many [Health Personnel] / healthcare workers would be willing [Tryptophanase] / to [Continuous] / continue [Work] / working during the [Ebola virus] / ebola virus [Disease Outbreaks] / outbreak ?",
    "n_kge": 6
  },
  {
    "raw_text": "What does the study suggest would make healthcare workers more willing to care for patients during an ebola virus outbreak?",
    "new_text": "What does the study suggest would make [Health Personnel] / healthcare workers more willing [Tryptophanase] / to care for patients during an [Ebola virus] / ebola virus [Disease Outbreaks] / outbreak ?",
    "n_kge": 4
  },
  {
    "raw_text": "What causes avian infectious bronchitis?",
    "new_text": "What [Etiology aspects] / causes [Avian infectious bronchitis] / avian infectious bronchitis ?",
    "n_kge": 2
  },
  {
    "raw_text": "What differentiated the two chicken lines used in this study?",
    "new_text": "What [Cell Differentiation process] / differentiated the [Two] / two [Chickens] / chicken [Linear] / lines used in this study ?",
    "n_kge": 4
  },
  {
    "raw_text": "Which organ was used for the rna sequencing samples?",
    "new_text": "Which [Organ] / organ was [Used by] / used for the rna sequencing samples ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is needed to elucidate zoonotic emergence?",
    "new_text": "What is needed [Tryptophanase] / to elucidate zoonotic emergence ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the conclusion of this report?",
    "new_text": "What is the conclusion of this [Report (document)] / report ?",
    "n_kge": 1
  },
  {
    "raw_text": "Why have bats received attention in recent years?",
    "new_text": "Why have [Chiroptera] / bats received [Attention] / attention in [Recent] / recent years ?",
    "n_kge": 3
  },
  {
    "raw_text": "What difference bats demonstrate compared to most non-chiropteran mammals?",
    "new_text": "What [Delta (difference)] / difference [Chiroptera] / bats demonstrate compared to most non - chiropteran [Mammals] / mammals ?",
    "n_kge": 3
  },
  {
    "raw_text": "What suite of species-specific mechanisms do bats have to limit viral load?",
    "new_text": "What suite of species - specific [Mechanism (attribute)] / mechanisms do [Chiroptera] / bats have [Tryptophanase] / to limit [Viral Load result] / viral load ?",
    "n_kge": 4
  },
  {
    "raw_text": "How are mammalian cells typically rendered antiviral?",
    "new_text": "How are mammalian cells typically rendered [Antiviral Agents] / antiviral ?",
    "n_kge": 1
  },
  {
    "raw_text": "In non-flying mammals, what what would be elicited by ifn expression upon viral infection?",
    "new_text": "In non - flying [Mammals] / mammals , what what would be elicited by ifn [Expression procedure] / expression upon [Virus Diseases] / viral infection ?",
    "n_kge": 3
  },
  {
    "raw_text": "What do the bats do instead?",
    "new_text": "What do the [Chiroptera] / bats do instead ?",
    "n_kge": 1
  },
  {
    "raw_text": "Why may the bats have this unique adaptation?",
    "new_text": "Why may the [Chiroptera] / bats have this unique [Acclimatization] / adaptation ?",
    "n_kge": 2
  },
  {
    "raw_text": "Why was the field of virus dynamics developed?",
    "new_text": "Why was the field of [Virus] / virus dynamics developed ?",
    "n_kge": 1
  },
  {
    "raw_text": "How are bats connected to fatal viral diseases?",
    "new_text": "How are [Chiroptera] / bats connected to [Fatal] / fatal [Virus Diseases] / viral diseases ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is an example of anti-viral defense in bats?",
    "new_text": "What is [Aniridia type 1] / an example of [Antiviral Agents] / anti - viral defense in [Chiroptera] / bats ?",
    "n_kge": 3
  },
  {
    "raw_text": "What would be caused by this hyper-vigilance in most other mammals?",
    "new_text": "What would be caused by this [Hyperactive behavior] / hyper - [Wakefulness] / vigilance in most other [Mammals] / mammals ?",
    "n_kge": 3
  },
  {
    "raw_text": "How are bats different?",
    "new_text": "How are [Chiroptera] / bats different ?",
    "n_kge": 1
  },
  {
    "raw_text": "What bat species cells were compared?",
    "new_text": "What [Chiroptera] / bat species [Cell Count] / cells were compared ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was the conclusion of the study ?",
    "new_text": "What was the conclusion of the study ?",
    "n_kge": 0
  },
  {
    "raw_text": "What would be the benefit of learning more about bat's defenses and how they drive virus evolution?",
    "new_text": "What would be the benefit of [Knowledge acquisition] / learning more about bat's defenses and how they [Intrinsic drive] / drive [Virus] / virus [Biological Evolution] / evolution ?",
    "n_kge": 4
  },
  {
    "raw_text": "Which cells are ifn-defective and therefore limited in antiviral capacity?",
    "new_text": "Which [Cell Count] / cells are ifn - defective and therefore limited in [Antiviral Agents] / antiviral [Capacity] / capacity ?",
    "n_kge": 3
  },
  {
    "raw_text": "What cells demonstrate idiosyncratic interferon response?",
    "new_text": "What [Cell Count] / cells demonstrate idiosyncratic interferon response ?",
    "n_kge": 1
  },
  {
    "raw_text": "Which cells express constitutive ifn-a?",
    "new_text": "Which [Cell Count] / cells express constitutive ifn - a ?",
    "n_kge": 1
  },
  {
    "raw_text": "How were the spread of gfp-expressing virus-infected cells across tissue monolayers tracked via inverted fluorescence microscopy?",
    "new_text": "How were the spread of [Green Fluorescent Proteins] / gfp - expressing virus - infected cells across [Body tissue] / tissue monolayers tracked via inverted [Microscopy, Fluorescence] / fluorescence microscopy ?",
    "n_kge": 3
  },
  {
    "raw_text": "How were the spread of gfp-expressing virus-infected cells tracked?",
    "new_text": "How were the spread of [Green Fluorescent Proteins] / gfp - expressing virus - infected cells tracked ?",
    "n_kge": 1
  },
  {
    "raw_text": "How was the modeling carried out?",
    "new_text": "How was the modeling carried out ?",
    "n_kge": 0
  },
  {
    "raw_text": "What was the finding in this study?",
    "new_text": "What was the [Signs and Symptoms] / finding in this study ?",
    "n_kge": 1
  },
  {
    "raw_text": "What supports the results?",
    "new_text": "What supports the results ?",
    "n_kge": 0
  },
  {
    "raw_text": "What was additionally demonstrated?",
    "new_text": "What was additionally demonstrated ?",
    "n_kge": 0
  },
  {
    "raw_text": "What do the studies suggest?",
    "new_text": "What do the studies suggest ?",
    "n_kge": 0
  },
  {
    "raw_text": "What was the methodology for this study?",
    "new_text": "What was the methodology for this study ?",
    "n_kge": 0
  },
  {
    "raw_text": "What was demonstrated in deriving the equation for r 0?",
    "new_text": "What was demonstrated in deriving the equation for r 0 ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is a conclusion of the modeling?",
    "new_text": "What is a conclusion of the modeling ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is a conclusion of the study?",
    "new_text": "What is a conclusion of the study ?",
    "n_kge": 0
  },
  {
    "raw_text": "What do fits to rvsv-marv infections on pakit01 cells suggest?",
    "new_text": "What do [Seizures] / fits to rvsv - marv [Infection] / infections on pakit01 [Cell Count] / cells suggest ?",
    "n_kge": 3
  },
  {
    "raw_text": "What do the findings indicate?",
    "new_text": "What do the findings indicate ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is presented in this study?",
    "new_text": "What is [Presentation] / presented in this study ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is a conclusion of this study?",
    "new_text": "What is a conclusion of this study ?",
    "n_kge": 0
  },
  {
    "raw_text": "What age group has the highest rate of severe outcomes?",
    "new_text": "What [Human Age Group] / age group has the highest rate of [Severe (severity modifier)] / severe outcomes ?",
    "n_kge": 2
  },
  {
    "raw_text": "How is covid-19 spread?",
    "new_text": "How is [COVID-19] / covid - 19 [Spreading (qualifier value)] / spread ?",
    "n_kge": 2
  },
  {
    "raw_text": "How many states in the u s have reported cases of covid-19?",
    "new_text": "How [Numerous] / many [Geographic state] / states in the [United States] / u s have reported cases of covid - 19 ?",
    "n_kge": 3
  },
  {
    "raw_text": "When did the white house launch the \"15 days to slow the spread\" program?",
    "new_text": "When did the [Caucasoid Race] / white [Home environment] / house launch the \" 15 [day] / days to slow the [Spreading (qualifier value)] / spread \" program ?",
    "n_kge": 4
  },
  {
    "raw_text": "What should mildly-ill patients do?",
    "new_text": "What should mildly - [Malaise] / ill [Patients] / patients do ?",
    "n_kge": 2
  },
  {
    "raw_text": "What type of virus is sars-cov-2?",
    "new_text": "What type of virus is [2019 novel coronavirus] / sars - cov - 2 ?",
    "n_kge": 1
  },
  {
    "raw_text": "What viruses are similar to the covid-19 coronavirus?",
    "new_text": "What [Virus] / viruses are similar to the [COVID-19] / covid - 19 [Genus: Coronavirus] / coronavirus ?",
    "n_kge": 3
  },
  {
    "raw_text": "What are the phases of a pandemic?",
    "new_text": "What are the phases of a [Pandemics] / pandemic ?",
    "n_kge": 1
  },
  {
    "raw_text": "At which phase does the peak of the pandemic occur?",
    "new_text": "At which phase does the peak of the [Pandemics] / pandemic occur ?",
    "n_kge": 1
  },
  {
    "raw_text": "People with which medical conditions have a higher rate of severe illness?",
    "new_text": "[Persons] / People with which medical conditions have a [High] / higher rate of [Severe (severity modifier)] / severe [Illness (finding)] / illness ?",
    "n_kge": 4
  },
  {
    "raw_text": "What kind of test can diagnose covid-19?",
    "new_text": "What [Type - attribute] / kind of test can [Diagnosis] / diagnose [COVID-19] / covid - 19 ?",
    "n_kge": 3
  },
  {
    "raw_text": "In what species did the covid-19 virus likely originate?",
    "new_text": "In what species did the [2019 novel coronavirus] / covid - 19 virus [Probable diagnosis] / likely originate ?",
    "n_kge": 2
  },
  {
    "raw_text": "What risk factors should be considered in addition to clinical symptoms?",
    "new_text": "What [risk factors] / risk factors should be considered in addition to clinical symptoms ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the acronym sars-cov-2?",
    "new_text": "What is the [Acronyms] / acronym [2019 novel coronavirus] / sars - cov - 2 ?",
    "n_kge": 2
  },
  {
    "raw_text": "When was sars-cov-2 first identified?",
    "new_text": "When was [2019 novel coronavirus] / sars - cov - 2 first identified ?",
    "n_kge": 1
  },
  {
    "raw_text": "Where was sars-cov-2 first identified?",
    "new_text": "Where was [2019 novel coronavirus] / sars - cov - 2 first identified ?",
    "n_kge": 1
  },
  {
    "raw_text": "What factor positively correlates with imported-and-reported cases counts of sars-cov-2 infection?",
    "new_text": "What [Factor] / factor positively correlates with imported - and - [Report (document)] / reported [Case (situation)] / cases counts of sars - cov - 2 infection ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the doubling time of the covid-19 pandemic?",
    "new_text": "What is the [Doubling Time] / doubling time of the [COVID-19] / covid - 19 pandemic ?",
    "n_kge": 2
  },
  {
    "raw_text": "When did the first known cases of middle east respiratory syndrome (mers) occur?",
    "new_text": "When did the first [Known] / known [Case (situation)] / cases of [Middle East Respiratory Syndrome] / middle east respiratory syndrome occur ?",
    "n_kge": 3
  },
  {
    "raw_text": "Where did the first known cases of middle east respiratory syndrome (mers) occur?",
    "new_text": "Where did the first [Known] / known [Case (situation)] / cases of [Middle East Respiratory Syndrome] / middle east respiratory syndrome ( [Middle East Respiratory Syndrome] / middle east respiratory syndrome ) occur ?",
    "n_kge": 4
  },
  {
    "raw_text": "Where was the the case first to be publicly reported was from ?",
    "new_text": "Where [Wiskott-Aldrich Syndrome] / was the the [Case (situation)] / case first [Tryptophanase] / to be publicly [Report (document)] / reported [Wiskott-Aldrich Syndrome] / was from ?",
    "n_kge": 5
  },
  {
    "raw_text": "In what animals mers-cov sequences have been found ?",
    "new_text": "In what [Animals] / animals [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov [DNA Sequence] / sequences have been [Present] / found ?",
    "n_kge": 4
  },
  {
    "raw_text": "Where is mers-cov is enzootic in dc?",
    "new_text": "Where is [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov is enzootic in dc ?",
    "n_kge": 1
  },
  {
    "raw_text": "What does mers-cov cause?",
    "new_text": "What does [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov [Etiology aspects] / cause ?",
    "n_kge": 2
  },
  {
    "raw_text": "Precisely how does the virus transmit to humans?",
    "new_text": "Precisely how does the [Virus] / virus transmit to [Homo sapiens] / humans ?",
    "n_kge": 2
  },
  {
    "raw_text": "What appears to be a requirement for transmission?",
    "new_text": "What appears [Tryptophanase] / to be a requirement for [disease transmission qualifier] / transmission ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is a focal point of mers?",
    "new_text": "What is a [Focal] / focal point of [Middle East Respiratory Syndrome] / middle east respiratory syndrome ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is mers mostly known as?",
    "new_text": "What is [Middle East Respiratory Syndrome] / middle east respiratory syndrome mostly [Known] / known as ?",
    "n_kge": 2
  },
  {
    "raw_text": "What does the mers lrt disease involve?",
    "new_text": "What does the [Middle East Respiratory Syndrome] / middle east respiratory syndrome lrt [Disease] / disease involve ?",
    "n_kge": 2
  },
  {
    "raw_text": "Where else mers-cov has also been detected?",
    "new_text": "Where else [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov has also been detected ?",
    "n_kge": 1
  },
  {
    "raw_text": "Who suffers severe diseases from mers?",
    "new_text": "Who [Mental Suffering] / suffers severe diseases from [Middle East Respiratory Syndrome] / middle east respiratory syndrome ?",
    "n_kge": 2
  },
  {
    "raw_text": "Compared to severe acute respiratory syndrome (sars) and another sometimes- fatal zoonotic coronavirus disease, how does mers affect the patients?",
    "new_text": "Compared to [Severe Acute Respiratory Syndrome] / severe acute respiratory syndrome ( [Severe Acute Respiratory Syndrome] / sars ) and another sometimes - [Fatal] / fatal zoonotic [Genus: Coronavirus] / coronavirus disease , how does [Middle East Respiratory Syndrome] / middle east respiratory syndrome [Affect (mental function)] / affect the [Patients] / patients ?",
    "n_kge": 7
  },
  {
    "raw_text": "To what have most human cases of mers been linked?",
    "new_text": "To what have most [Homo sapiens] / human [Case (situation)] / cases of [Middle East Respiratory Syndrome] / middle east respiratory syndrome been linked ?",
    "n_kge": 3
  },
  {
    "raw_text": "Among whom 20% of the virus detection are reported?",
    "new_text": "Among whom 20 % of the virus detection are [Report (document)] / reported ?",
    "n_kge": 1
  },
  {
    "raw_text": "What have sero-surveys of mers virus found?",
    "new_text": "What have sero - surveys of [Middle East Respiratory Syndrome] / middle east respiratory syndrome [Virus] / virus [Present] / found ?",
    "n_kge": 3
  },
  {
    "raw_text": "How was the first culture of the new coronavirus announced?",
    "new_text": "How was the first [Anthropological Culture] / culture of the new coronavirus announced ?",
    "n_kge": 1
  },
  {
    "raw_text": "Where was the email published?",
    "new_text": "Where was the [Email] / email published ?",
    "n_kge": 1
  },
  {
    "raw_text": "When was the email published?",
    "new_text": "When was the [Email] / email published ?",
    "n_kge": 1
  },
  {
    "raw_text": "Whose was the first reported case?",
    "new_text": "Whose was the first [Report (document)] / reported [Case (situation)] / case ?",
    "n_kge": 2
  },
  {
    "raw_text": "How many viral rna or virus-specific antibodies been detected?",
    "new_text": "How many viral rna or virus - specific antibodies been detected ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the death rate from mers-cov?",
    "new_text": "What is the [Mortality Vital Statistics] / death rate from [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov ?",
    "n_kge": 2
  },
  {
    "raw_text": "What did the discovery process over two to three years reveal?",
    "new_text": "What did the discovery process over [Two] / two to [Three] / three years reveal ?",
    "n_kge": 2
  },
  {
    "raw_text": "What does subsequent transmission of mers-cov to other humans require?",
    "new_text": "What does [Following] / subsequent [disease transmission qualifier] / transmission of [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov to other [Homo sapiens] / humans require ?",
    "n_kge": 4
  },
  {
    "raw_text": "What would restrict access to both the virus and to viral diagnostics ?",
    "new_text": "What would restrict access to both the [Virus] / virus and to [Viral] / viral diagnostics ?",
    "n_kge": 2
  },
  {
    "raw_text": "How was the virus then made freely available?",
    "new_text": "How was the [Virus] / virus then made freely available ?",
    "n_kge": 1
  },
  {
    "raw_text": "What has epidemiology and research identified the mers-cov's cell receptor is?",
    "new_text": "What has [Epidemiology] / epidemiology and [research] / research identified the [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov's cell receptor is ?",
    "n_kge": 3
  },
  {
    "raw_text": "How does mers-cov compare with sars-cov?",
    "new_text": "How does [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov compare with [SARS coronavirus] / sars - cov ?",
    "n_kge": 2
  },
  {
    "raw_text": "How does mers-cov compare with sars-cov?",
    "new_text": "How does [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov compare with [SARS coronavirus] / sars - cov ?",
    "n_kge": 2
  },
  {
    "raw_text": "How does mers-cov spread among people?",
    "new_text": "How does [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov [Spreading (qualifier value)] / spread among [Persons] / people ?",
    "n_kge": 3
  },
  {
    "raw_text": "Who gets more severe disease from mers?",
    "new_text": "Who gets more severe disease from [Middle East Respiratory Syndrome] / middle east respiratory syndrome ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the spread of mers-cov among humans, associated with?",
    "new_text": "What is the [Spreading (qualifier value)] / spread of [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov among [Homo sapiens] / humans , associated with ?",
    "n_kge": 3
  },
  {
    "raw_text": "What do the dcs suffer with mers-cov infection?",
    "new_text": "What do the [cycloserine] / dcs [Mental Suffering] / suffer with [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov [Communicable Diseases] / infection ?",
    "n_kge": 4
  },
  {
    "raw_text": "What happens to humans infected by mers-cov virus?",
    "new_text": "What happens to [Homo sapiens] / humans [Infected] / infected by [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov [Virus] / virus ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is the incubation period of mers?",
    "new_text": "What is the incubation period of [Middle East Respiratory Syndrome] / middle east respiratory syndrome ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the duration between when illness begins in one person and subsequently spreads to another?",
    "new_text": "What is the [Duration (temporal concept)] / duration between when [Illness (finding)] / illness begins in [One] / one [Persons] / person and subsequently spreads to another ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is the median time to death in case of progressive illness?",
    "new_text": "What is the median time to death in case of [Progressive] / progressive [Illness (finding)] / illness ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the progression of symptoms to disease?",
    "new_text": "What is the progression of symptoms to [Disease] / disease ?",
    "n_kge": 1
  },
  {
    "raw_text": "What did the later who definition of mers clearly state?",
    "new_text": "What did the later [World Health Organization] / world health organization definition of [Middle East Respiratory Syndrome] / middle east respiratory syndrome clearly [Geographic state] / state ?",
    "n_kge": 3
  },
  {
    "raw_text": "What percentage of cases ksa has been a source of?",
    "new_text": "What [Percent (qualifier value)] / percentage of [Case (situation)] / cases [EPCAM gene] / ksa has been a [Source] / source of ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is severe mars noted for?",
    "new_text": "What is [Severe (severity modifier)] / severe mars noted for ?",
    "n_kge": 1
  },
  {
    "raw_text": "What symptoms appear among the confirmed cases of mers?",
    "new_text": "What symptoms [Appearance] / appear among the confirmed cases of [Middle East Respiratory Syndrome] / middle east respiratory syndrome ?",
    "n_kge": 2
  },
  {
    "raw_text": "What do patients often present to a hospital with, in cases of mers?",
    "new_text": "What do [Patients] / patients often [Present] / present to a [Hospitals] / hospital with , [Present] / in [Case (situation)] / cases of [Middle East Respiratory Syndrome] / middle east respiratory syndrome ?",
    "n_kge": 6
  },
  {
    "raw_text": "What can mers disease progress to?",
    "new_text": "What can [Middle East Respiratory Syndrome] / middle east respiratory syndrome [Disease] / disease [status - In progress] / progress [Tryptophanase] / to ?",
    "n_kge": 4
  },
  {
    "raw_text": "What percentage of all reported cases has mers reportedly killed ?",
    "new_text": "What [Percent (qualifier value)] / percentage of all reported cases has [Middle East Respiratory Syndrome] / middle east respiratory syndrome reportedly [Killing] / killed ?",
    "n_kge": 3
  },
  {
    "raw_text": "What percentage of of all reported cases has mers reportedly killed in ksa?",
    "new_text": "What [Percent (qualifier value)] / percentage of of all reported cases has [Middle East Respiratory Syndrome] / middle east respiratory syndrome reportedly [Killing] / killed in [EPCAM gene] / ksa ?",
    "n_kge": 4
  },
  {
    "raw_text": "What was mortality in south korea from mers disease?",
    "new_text": "What was [Mortality Vital Statistics] / mortality in south korea from [Middle East Respiratory Syndrome] / middle east respiratory syndrome [Disease] / disease ?",
    "n_kge": 3
  },
  {
    "raw_text": "Which are the preferred method for mers-cov detection?",
    "new_text": "Which are the preferred method for [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov detection ?",
    "n_kge": 1
  },
  {
    "raw_text": "What have become a key diagnostic and taxonomic target for cov species identification?",
    "new_text": "What have become a key [Diagnosis] / diagnostic and [Taxonomic] / taxonomic target for cov species [Identification (Psychology)] / identification ?",
    "n_kge": 3
  },
  {
    "raw_text": "Why it can be concluded that mers-cov is a novel and distinct virus?",
    "new_text": "Why it can be concluded that [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov is a [New] / novel and distinct [Virus] / virus ?",
    "n_kge": 3
  },
  {
    "raw_text": "What indicates the likely presence of infectious virus?",
    "new_text": "What indicates the [Probable diagnosis] / likely presence of infectious virus ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the sensitivity with which immunochromatographic tool could detect recombinant mers-cov nucleocapsid protein?",
    "new_text": "What is the [Hypersensitivity] / sensitivity with which immunochromatographic tool could detect recombinant [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov nucleocapsid protein ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the specificity with which immunochromatographic tool could detect recombinant mers-cov nucleocapsid protein?",
    "new_text": "What is the specificity with which immunochromatographic tool could detect recombinant [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov nucleocapsid protein ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is a different approach for the detection?",
    "new_text": "What is a different approach for the [Detection] / detection ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is usual in serology testing?",
    "new_text": "What is usual in [Study of serum] / serology [Testing] / testing ?",
    "n_kge": 2
  },
  {
    "raw_text": "How have some sero-assays bypassed the risks of working with infectious virus?",
    "new_text": "How have some [Serology (antibodies and most antigens except blood bank and infectious agents)] / sero - assays bypassed the [Risk] / risks of [Work] / working with infectious [Virus] / virus ?",
    "n_kge": 4
  },
  {
    "raw_text": "How have some sero-assays bypassed the risks of working with infectious virus?",
    "new_text": "How have some [Serology (antibodies and most antigens except blood bank and infectious agents)] / sero - assays bypassed the [Risk] / risks of [Work] / working with infectious [Virus] / virus ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is the detection of mers-cov infection using elisa or s1 subunit protein microarray [84] is usually followed by?",
    "new_text": "What is the [Detection] / detection of [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov [Communicable Diseases] / infection [Use of] / using [Enzyme-Linked Immunosorbent Assay] / elisa or s1 [Protein Subunits] / subunit protein microarray [ [84] / 84 ] is usually followed by ?",
    "n_kge": 7
  },
  {
    "raw_text": "What does the confirmatory process aim to ensure?",
    "new_text": "What does the confirmatory process aim [Tryptophanase] / to ensure ?",
    "n_kge": 1
  },
  {
    "raw_text": "When does generally mers infection does not trigger a detectable immune response?",
    "new_text": "When does generally [Middle East Respiratory Syndrome] / middle east respiratory syndrome [Communicable Diseases] / infection does not [Precipitating Factors] / trigger a detectable [Immune response] / immune response ?",
    "n_kge": 4
  },
  {
    "raw_text": "When does the who recommend samlinf from the lrt?",
    "new_text": "When does the [World Health Organization] / world health organization recommend samlinf from the lrt ?",
    "n_kge": 1
  },
  {
    "raw_text": "What do the recommended samples include?",
    "new_text": "What do the recommended samples include ?",
    "n_kge": 0
  },
  {
    "raw_text": "What are recommended when urt sampling is to be conducted?",
    "new_text": "What are recommended when urt [Sampling - Surgical action] / sampling is [Tryptophanase] / to be conducted ?",
    "n_kge": 2
  },
  {
    "raw_text": "What paired sera are preferable?",
    "new_text": "What paired [Serum] / sera are preferable ?",
    "n_kge": 1
  },
  {
    "raw_text": "When is a single sample suggested to be sufficient?",
    "new_text": "When is a [Unmarried person] / single [Specimen] / sample suggested [Tryptophanase] / to be sufficient ?",
    "n_kge": 3
  },
  {
    "raw_text": "How long human urine and stool have been found to contain mers-cov rna?",
    "new_text": "How [Long] / long [human urine] / human urine and [Feces] / stool have been [Present] / found [Tryptophanase] / to contain [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov [RNA] / rna ?",
    "n_kge": 7
  },
  {
    "raw_text": "What do individual studies report on viral shedding?",
    "new_text": "What do [Persons] / individual studies [Report (document)] / report on viral shedding ?",
    "n_kge": 2
  },
  {
    "raw_text": "What fraction of mers cases shed viral rna in their lrt specimens (tracheal aspirates and sputum) ?",
    "new_text": "What fraction of [Middle East Respiratory Syndrome] / middle east respiratory syndrome [Case (situation)] / cases shed viral rna in their lrt [Specimen] / specimens ( tracheal aspirates and [Sputum] / sputum ) ?",
    "n_kge": 4
  },
  {
    "raw_text": "How long mers cases shed viral rna in their lrt specimens (tracheal aspirates and sputum)?",
    "new_text": "How [Long] / long [Middle East Respiratory Syndrome] / middle east respiratory syndrome [Case (situation)] / cases shed viral rna in their lrt [Specimen] / specimens ( tracheal aspirates and [Sputum] / sputum ) ?",
    "n_kge": 5
  },
  {
    "raw_text": "What percentage of contacts were still shedding rna in their urt specimens?",
    "new_text": "What [Percent (qualifier value)] / percentage of contacts were still shedding [RNA] / rna in their urt [Specimen] / specimens ?",
    "n_kge": 3
  },
  {
    "raw_text": "What samples returned the highest mers viral load values?",
    "new_text": "What samples returned the highest [Middle East Respiratory Syndrome] / middle east respiratory syndrome [Viral Load result] / viral load values ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is npa?",
    "new_text": "What is npa ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is npa?",
    "new_text": "What is npa ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is bal?",
    "new_text": "What is bal ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the the proportion of deaths among those infected with mers-cov?",
    "new_text": "What is the the proportion of [Cessation of life] / deaths among those [Infected] / infected with [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the the proportion of deaths among those infected with mers-cov?",
    "new_text": "What is the the proportion of [Cessation of life] / deaths among those [Infected] / infected with [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov ?",
    "n_kge": 3
  },
  {
    "raw_text": "What has prevented worldwide spread of mers-cov?",
    "new_text": "What has prevented worldwide [Spreading (qualifier value)] / spread of [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov ?",
    "n_kge": 2
  },
  {
    "raw_text": "What must be reported to the world organization for animal health as an emerging disease ?",
    "new_text": "What must be [Report (document)] / reported to the world organization for animal health as an emerging [Disease] / disease ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are juvenile dcs more often positive for?",
    "new_text": "What are [Juvenile] / juvenile [cycloserine] / dcs more often [percent positive cells] / positive for ?",
    "n_kge": 3
  },
  {
    "raw_text": "What are older dcs are more likely to be positive for?",
    "new_text": "What are older [cycloserine] / dcs are [More] / more [Probable diagnosis] / likely [Tryptophanase] / to be [percent positive cells] / positive for ?",
    "n_kge": 5
  },
  {
    "raw_text": "When does the camel calving season?",
    "new_text": "When does the [Camels] / camel calving [Seasons] / season ?",
    "n_kge": 2
  },
  {
    "raw_text": "Why is there an increased risk to humans of spill-over during calving season?",
    "new_text": "Why is there [Aniridia type 1] / an increased risk to [Homo sapiens] / humans of spill - over during calving [Seasons] / season ?",
    "n_kge": 3
  },
  {
    "raw_text": "Which may be an occupational group with significantly higher incidence of seropositivity to mers-cov ?",
    "new_text": "Which may be [Aniridia type 1] / an occupational group with significantly higher [Incidence] / incidence of seropositivity to [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov ?",
    "n_kge": 3
  },
  {
    "raw_text": "How long after infectious mers-cov added to dc, goat or cow milk and stored at 4\u00b0c could be recovered?",
    "new_text": "How [Long] / long after infectious [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov added to dc , [Capra hircus] / goat or [Cow's milk] / cow milk and [Storage] / stored at 4 \u00b0 c could be recovered ?",
    "n_kge": 5
  },
  {
    "raw_text": "How long after infectious mers-cov added to dc, goat or cow milk and stored at 22\u00b0c could be recovered?",
    "new_text": "How [Long] / long after infectious [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov added to dc , [Capra hircus] / goat or [Cow's milk] / cow milk and [Storage] / stored at 22 \u00b0 c could be recovered ?",
    "n_kge": 5
  },
  {
    "raw_text": "What ablated mers-cov infection completely?",
    "new_text": "What ablated [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov [Communicable Diseases] / infection [Complete] / completely ?",
    "n_kge": 3
  },
  {
    "raw_text": "How long mers-cov remained viable at high ambient temperature (30\u00b0c) and low rh (30 %) ?",
    "new_text": "How [Long] / long [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov remained viable at high ambient temperature ( 30 \u00b0 c ) and low [rhodium] / rh ( 30 % ) ?",
    "n_kge": 3
  },
  {
    "raw_text": "How long can pathogenic bacteria remain viable and airborne in a coughed aerosol?",
    "new_text": "How [Long] / long can [Pathogenic organism] / pathogenic bacteria remain viable and airborne in a coughed aerosol ?",
    "n_kge": 2
  },
  {
    "raw_text": "How far can pathogenic bacteria spread in a coughed aerosol?",
    "new_text": "How [Distal (qualifier value)] / far can [Pathogenic organism] / pathogenic bacteria [Spreading (qualifier value)] / spread in a coughed aerosol ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is considered the mechanism of human-to-human transmission of mers-cov?",
    "new_text": "What is considered the [Mechanism (attribute)] / mechanism of human - to - human transmission of [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the transmission of mers-cov is defined as?",
    "new_text": "What is the [disease transmission qualifier] / transmission of [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov is defined as ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the transmission of mers-cov is defined as?",
    "new_text": "What is the [disease transmission qualifier] / transmission of [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov is defined as ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the transmission of mers-cov is defined as?",
    "new_text": "What is the [disease transmission qualifier] / transmission of [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov is defined as ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the transmission of mers-cov is defined as?",
    "new_text": "What is the [disease transmission qualifier] / transmission of [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov is defined as ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the transmission of mers-cov is defined as?",
    "new_text": "What is the [disease transmission qualifier] / transmission of [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov is defined as ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the the rate of general transmission, even in outbreaks?",
    "new_text": "What is the the rate of general [disease transmission qualifier] / transmission , even in [Disease Outbreaks] / outbreaks ?",
    "n_kge": 2
  },
  {
    "raw_text": "What do the majority of human cases of mers-cov seem not to do?",
    "new_text": "What do the majority of [Homo sapiens] / human [Case (situation)] / cases of [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov seem not to do ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the basic reproduction number (r 0)?",
    "new_text": "What is the basic reproduction number ( [Right] / r 0 ) ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the basic reproduction number (r 0 ) for mers-cov?",
    "new_text": "What is the basic reproduction number ( [Right] / r 0 ) for [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov ?",
    "n_kge": 2
  },
  {
    "raw_text": "Why has mers had a constant presence in the arabian peninsula?",
    "new_text": "Why has [Middle East Respiratory Syndrome] / middle east respiratory syndrome had a constant [Present] / presence in the arabian peninsula ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was the first known mers human-to-human transmission event was one characterized by?",
    "new_text": "What was the first [Known] / known [Middle East Respiratory Syndrome] / middle east respiratory syndrome human - to - human transmission [Event] / event was [One] / one characterized by ?",
    "n_kge": 4
  },
  {
    "raw_text": "Where was the first known mers human-to-human transmission event?",
    "new_text": "Where was the first [Known] / known [Middle East Respiratory Syndrome] / middle east respiratory syndrome human - to - human transmission [Event] / event ?",
    "n_kge": 3
  },
  {
    "raw_text": "Approximately what percentage of mers cases were fatal in ksa?",
    "new_text": "Approximately what [Percent (qualifier value)] / percentage of [Middle East Respiratory Syndrome] / middle east respiratory syndrome [Case (situation)] / cases were [Fatal] / fatal in [EPCAM gene] / ksa ?",
    "n_kge": 5
  },
  {
    "raw_text": "Approximately what percentage of mers cases were died outside ksa?",
    "new_text": "Approximately what [Percent (qualifier value)] / percentage of [Middle East Respiratory Syndrome] / middle east respiratory syndrome [Case (situation)] / cases were [Cessation of life] / died [Extrinsic] / outside [EPCAM gene] / ksa ?",
    "n_kge": 6
  },
  {
    "raw_text": "What percentage of hcws comprised of mers cases in the ksa and south korea?",
    "new_text": "What [Percent (qualifier value)] / percentage of hcws comprised of [Middle East Respiratory Syndrome] / middle east respiratory syndrome [Case (situation)] / cases in the [EPCAM gene] / ksa and south korea ?",
    "n_kge": 4
  },
  {
    "raw_text": "How has most of the analysis of mers-cov genetics been performed?",
    "new_text": "How has most of the analysis of [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov [Science of genetics] / genetics been [Performed] / performed ?",
    "n_kge": 3
  },
  {
    "raw_text": "What does clade a contain?",
    "new_text": "What does clade a contain ?",
    "n_kge": 0
  },
  {
    "raw_text": "What does clade b comprise?",
    "new_text": "What does clade b comprise ?",
    "n_kge": 0
  },
  {
    "raw_text": "How many clades have become apparent in genome of mers-cov from humans and dcs?",
    "new_text": "How many clades have become apparent in [Genome] / genome of [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov from [Homo sapiens] / humans and [cycloserine] / dcs ?",
    "n_kge": 4
  },
  {
    "raw_text": "Which city has had has had more mers cases than any other region of the ksa ?",
    "new_text": "Which [Cities] / city has had has had [More] / more [Middle East Respiratory Syndrome] / middle east respiratory syndrome [Case (situation)] / cases than any [Other] / other [Geographic Locations] / region of the [EPCAM gene] / ksa ?",
    "n_kge": 7
  },
  {
    "raw_text": "Which city harbours a wide range of mers-cov variants?",
    "new_text": "Which [Cities] / city harbours a wide range of [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov variants ?",
    "n_kge": 2
  },
  {
    "raw_text": "How has the vast majority of mers-cov transmission occurred?",
    "new_text": "How has the vast majority of [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov [disease transmission qualifier] / transmission occurred ?",
    "n_kge": 2
  },
  {
    "raw_text": "How were the transmission circumstances created?",
    "new_text": "How were the [disease transmission qualifier] / transmission circumstances created ?",
    "n_kge": 1
  },
  {
    "raw_text": "What percentage of humans have died among all humans reported to be infected?",
    "new_text": "What [Percent (qualifier value)] / percentage of [Homo sapiens] / humans have [Cessation of life] / died among all [Homo sapiens] / humans [Report (document)] / reported [Tryptophanase] / to be [Infected] / infected ?",
    "n_kge": 7
  },
  {
    "raw_text": "What would aid accurate calculation of a case fatality ratio?",
    "new_text": "What would aid accurate calculation of a case fatality ratio ?",
    "n_kge": 0
  },
  {
    "raw_text": "How does mars-cov differ from sars-cov?",
    "new_text": "How does mars - cov differ from [SARS coronavirus] / sars - cov ?",
    "n_kge": 1
  },
  {
    "raw_text": "Is there any evidence that mers-cov is a virus of pandemic concern?",
    "new_text": "Is there any evidence that [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov is a [Virus] / virus of [Pandemics] / pandemic concern ?",
    "n_kge": 3
  },
  {
    "raw_text": "How did the first who case definition define probable cases of mers?",
    "new_text": "How did the first [World Health Organization] / world health organization case definition define probable cases of [Middle East Respiratory Syndrome] / middle east respiratory syndrome ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is pheic?",
    "new_text": "What is pheic ?",
    "n_kge": 0
  },
  {
    "raw_text": "How is pheic defined?",
    "new_text": "How is pheic defined ?",
    "n_kge": 0
  },
  {
    "raw_text": "What platform was instrumental in rapid sharing of covid-19 information?",
    "new_text": "What platform was instrumental in rapid sharing of [COVID-19] / covid - 19 information ?",
    "n_kge": 1
  },
  {
    "raw_text": "What's the recommended procedure to disinfect at ct scanner after a covid-19 exposure?",
    "new_text": "What's the recommended [Interventional procedure] / procedure to disinfect at computed tomography scanner after a [COVID-19] / covid - 19 [Injury due to exposure to external cause] / exposure ?",
    "n_kge": 3
  },
  {
    "raw_text": "What's the recommended method to disinfect floors for covid-19?",
    "new_text": "What's the recommended [Methods] / method to disinfect [floor (object)] / floors for [COVID-19] / covid - 19 ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the role of computed tomography (ct) in covid-19?",
    "new_text": "What is the [Social Role] / role of [X-Ray Computed Tomography] / computed tomography in [COVID-19] / covid - 19 ?",
    "n_kge": 3
  },
  {
    "raw_text": "What kind of masks are recommended to protect healthcare workers from covid-19 exposure?",
    "new_text": "What [Type - attribute] / kind of [Masks] / masks are recommended [Tryptophanase] / to protect [Health Personnel] / healthcare workers from [COVID-19] / covid - 19 [Injury due to exposure to external cause] / exposure ?",
    "n_kge": 6
  },
  {
    "raw_text": "What thickness of layers is recommended for ct image reconstruction in covid-19 assessment?",
    "new_text": "What [Thick] / thickness of [anatomical layer] / layers is recommended for [X-Ray Computed Tomography] / computed tomography [Optical Image Reconstruction] / image reconstruction in [COVID-19] / covid - 19 [Evaluation procedure] / assessment ?",
    "n_kge": 6
  },
  {
    "raw_text": "What must the data gathering include?",
    "new_text": "What must the [Data] / data gathering include ?",
    "n_kge": 1
  },
  {
    "raw_text": "What must be done to assist in recognition of the disease on images and to allow accurate reporting of these findings?",
    "new_text": "What must be done [Tryptophanase] / to [Helping Behavior] / assist in [Recognition, Psychology] / recognition of the [Disease] / disease on images and [Tryptophanase] / to allow accurate reporting of these findings ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is the major role of chest ct?",
    "new_text": "What is the [Severe (severity modifier)] / major [Social Role] / role of chest computed tomography ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the reason to adopt low-dose ct?",
    "new_text": "What is the [Indication of (contextual qualifier)] / reason [Tryptophanase] / to [Personal status - Adopted] / adopt low - dose computed tomography ?",
    "n_kge": 3
  },
  {
    "raw_text": "What did the emict responsibilities include?",
    "new_text": "What did the emict responsibilities include ?",
    "n_kge": 0
  },
  {
    "raw_text": "How were the radiology department areas divided?",
    "new_text": "How were the radiology department areas divided ?",
    "n_kge": 0
  },
  {
    "raw_text": "How was the contaminated area connected to the ct room and other facilities?",
    "new_text": "How was the contaminated [Geographic Locations] / area connected to the [X-Ray Computed Tomography] / computed tomography [Room] / room and other facilities ?",
    "n_kge": 3
  },
  {
    "raw_text": "What does the clean area include?",
    "new_text": "What does the [Cleaning (activity)] / clean [Geographic Locations] / area include ?",
    "n_kge": 2
  },
  {
    "raw_text": "What does the semicontaminated area include?",
    "new_text": "What does the semicontaminated [Geographic Locations] / area include ?",
    "n_kge": 1
  },
  {
    "raw_text": "What does the buffer area include?",
    "new_text": "What does the buffer [Geographic Locations] / area include ?",
    "n_kge": 1
  },
  {
    "raw_text": "How was the wearing and removing of the equipment performed?",
    "new_text": "How was the wearing and removing of the equipment [Performed] / performed ?",
    "n_kge": 1
  },
  {
    "raw_text": "What can lower the physical and mental stress levels of staff members?",
    "new_text": "What can lower the [Physical Examination] / physical and [Psyche structure] / mental stress levels of staff members ?",
    "n_kge": 2
  },
  {
    "raw_text": "Who must be assigned to the clean area?",
    "new_text": "Who must be assigned to the [Cleaning (activity)] / clean [Geographic Locations] / area ?",
    "n_kge": 2
  },
  {
    "raw_text": "What responses must emict consider once a disease has been identified?",
    "new_text": "What responses must emict consider once a [Disease] / disease has been identified ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the conclusion of the report?",
    "new_text": "What is the conclusion of the [Report (document)] / report ?",
    "n_kge": 1
  },
  {
    "raw_text": "What were the number of cases in mainland china as of march 11th?",
    "new_text": "What were the [Numbers] / number of [Case (situation)] / cases [Present] / in mainland china as of [Hydranencephaly with Renal Aplasia-Dysplasia] / march 11th ?",
    "n_kge": 4
  },
  {
    "raw_text": "How many covid deaths occurred in chinese mainland as of march 11th?",
    "new_text": "How many covid [Cessation of life] / deaths occurred in chinese mainland as of [Hydranencephaly with Renal Aplasia-Dysplasia] / march 11th ?",
    "n_kge": 2
  },
  {
    "raw_text": "How many people have come in contact and how many of these are in observation?",
    "new_text": "How [Numerous] / many [Persons] / people have come in contact and how [Numerous] / many of these are [Present] / in observation ?",
    "n_kge": 4
  },
  {
    "raw_text": "When was the novel coronavirus first reported?",
    "new_text": "When was the [2019 novel coronavirus] / novel coronavirus first [Report (document)] / reported ?",
    "n_kge": 2
  },
  {
    "raw_text": "When did china detect the first human case of h7n9 infection?",
    "new_text": "When did [China] / china detect the first [Homo sapiens] / human [Case (situation)] / case of [Influenza in Birds] / h7n9 [Communicable Diseases] / infection ?",
    "n_kge": 5
  },
  {
    "raw_text": "How many deaths were associated with mers-cov as of july 2014?",
    "new_text": "How many [Cessation of life] / deaths were associated with [Middle East Respiratory Syndrome] / middle east respiratory syndrome - cov as of july 2014 ?",
    "n_kge": 2
  },
  {
    "raw_text": "What illness is caused by the 2019-ncov coronavirus?",
    "new_text": "What [Illness (finding)] / illness is caused by the [2019 novel coronavirus] / 2019 - ncov [Genus: Coronavirus] / coronavirus ?",
    "n_kge": 3
  },
  {
    "raw_text": "In addition to oral swabs, which tests detected the presence of 2019-ncov virus?",
    "new_text": "In addition to oral swabs , which [Laboratory Procedures] / tests detected the presence of [2019 novel coronavirus] / 2019 - ncov virus ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the relationship between the presence of virus in blood and anal swabs and disease severity?",
    "new_text": "What is the [Relationships] / relationship between the presence of virus in [Blood] / blood and anal swabs and disease severity ?",
    "n_kge": 2
  },
  {
    "raw_text": "Which patients were classified as severe in chinese guidelines?",
    "new_text": "Which [Patients] / patients were [Classification] / classified as [Severe (severity modifier)] / severe in chinese [Guidelines] / guidelines ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is the relationship between the presence of virus in blood sample and disease severity?",
    "new_text": "What is the [Relationships] / relationship between the presence of virus in [Blood specimen] / blood sample and disease severity ?",
    "n_kge": 2
  },
  {
    "raw_text": "What test could give an indication for special care for 2019-ncov patients?",
    "new_text": "What [Laboratory Procedures] / test could give [Aniridia type 1] / an [Indication of (contextual qualifier)] / indication for special care for [2019 novel coronavirus] / 2019 - ncov [Patients] / patients ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is the relationship between the presence of virus in anal swabs and disease severity in 2019-ncov?",
    "new_text": "What is the [Relationships] / relationship between the presence of virus in anal swabs and disease [Severities] / severity in 2019 - ncov ?",
    "n_kge": 2
  },
  {
    "raw_text": "What could be the implication of 2019-ncov virus in anal swabs?",
    "new_text": "What could be the implication of [2019 novel coronavirus] / 2019 - ncov [Virus] / virus in anal swabs ?",
    "n_kge": 2
  },
  {
    "raw_text": "What could account for the high transmission rate of the 2019-ncov virus?",
    "new_text": "What could [Account number:Identifier:Point in time:^Patient:Nominal] / account for the [High] / high [disease transmission qualifier] / transmission rate of the [2019 novel coronavirus] / 2019 - ncov [Virus] / virus ?",
    "n_kge": 5
  },
  {
    "raw_text": "What could account for the dissemination of the 2019-ncov virus across the whole body?",
    "new_text": "What could [Account number:Identifier:Point in time:^Patient:Nominal] / account for the dissemination of the [2019 novel coronavirus] / 2019 - ncov [Virus] / virus across the [Entire body as a whole] / whole body ?",
    "n_kge": 4
  },
  {
    "raw_text": "When did the world health organization declare the ebola epidemic in west africa as a public health emergency of international concern?",
    "new_text": "When did the [World Health Organization] / world health organization declare the [Hemorrhagic Fever, Ebola] / ebola [Epidemic] / epidemic in west africa as a [public health medicine (field)] / public health [Emergency Situation] / emergency of international concern ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is ppe?",
    "new_text": "What is ppe ?",
    "n_kge": 0
  },
  {
    "raw_text": "Where did the 2014 ebola epidemic in west africa spread to?",
    "new_text": "Where did the 2014 [Hemorrhagic Fever, Ebola] / ebola [Epidemic] / epidemic in west africa [Spreading (qualifier value)] / spread [Tryptophanase] / to ?",
    "n_kge": 4
  },
  {
    "raw_text": "What are the prerequisites for successful emergency preparedness for an epidemic?",
    "new_text": "What are the prerequisites for [Success] / successful emergency preparedness for an [Epidemic] / epidemic ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the structure of a coronavirus?",
    "new_text": "What is the structure of a [Genus: Coronavirus] / coronavirus ?",
    "n_kge": 1
  },
  {
    "raw_text": "What method is developed in this study?",
    "new_text": "What [Methods] / method is developed in this study ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the model simplified to?",
    "new_text": "What is the [Model] / model simplified [Tryptophanase] / to ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the estimate of r 0?",
    "new_text": "What is the [Estimated] / estimate of r 0 ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the conclusion of this study?",
    "new_text": "What is the conclusion of this study ?",
    "n_kge": 0
  },
  {
    "raw_text": "What was the focus of the study?",
    "new_text": "What was the [Focal] / focus of the study ?",
    "n_kge": 1
  },
  {
    "raw_text": "What were the model assumptions?",
    "new_text": "What were the [Model] / model assumptions ?",
    "n_kge": 1
  },
  {
    "raw_text": "What compartments were the bats divided into?",
    "new_text": "What [Anatomical compartments] / compartments were the [Chiroptera] / bats divided into ?",
    "n_kge": 2
  },
  {
    "raw_text": "What compartments were the host animals divided into?",
    "new_text": "What [Anatomical compartments] / compartments were the [Host (organism)] / host [Animals] / animals divided into ?",
    "n_kge": 3
  },
  {
    "raw_text": "What was the sars-cov-2 reservoir?",
    "new_text": "What was the [2019 novel coronavirus] / sars - cov - 2 reservoir ?",
    "n_kge": 1
  },
  {
    "raw_text": "What were the people divided into?",
    "new_text": "What were the [Persons] / people divided into ?",
    "n_kge": 1
  },
  {
    "raw_text": "What was the mean incubation period?",
    "new_text": "What was the mean incubation period ?",
    "n_kge": 0
  },
  {
    "raw_text": "What was the mean delay from symptom onset to detection/hospitalization of a case?",
    "new_text": "What was the mean [Deferred] / delay from symptom onset [Tryptophanase] / to [Detection] / detection / hospitalization of a [Case (situation)] / case ?",
    "n_kge": 4
  },
  {
    "raw_text": "How long after onset, the cases detected in thailand and japan were hospitalized?",
    "new_text": "How [Long] / long after [Age of Onset] / onset , the [Case (situation)] / cases detected in [Thailand] / thailand and [Japan] / japan were [Patient in hospital] / hospitalized ?",
    "n_kge": 6
  },
  {
    "raw_text": "What was the duration from illness onset to first medical visit ?",
    "new_text": "What was the duration from illness [Age of Onset] / onset to first medical [Visit] / visit ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was the assumption of transmissibility of asymptomatic infection?",
    "new_text": "What was the assumption of transmissibility of asymptomatic infection ?",
    "n_kge": 0
  },
  {
    "raw_text": "As of january 17, how many people were tested for body temperature?",
    "new_text": "As of january 17 , how many [Persons] / people were tested for body temperature ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is mobile population in wuhan?",
    "new_text": "What is mobile [geographic population] / population in wuhan ?",
    "n_kge": 1
  },
  {
    "raw_text": "What was the r0 of sars?",
    "new_text": "What was the r0 of [Severe Acute Respiratory Syndrome] / sars ?",
    "n_kge": 1
  },
  {
    "raw_text": "What was the value of r0 in other researches?",
    "new_text": "What was the value of r0 in other researches ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the reported value of r0 for mers?",
    "new_text": "What is the [Report (document)] / reported value of r0 for [Middle East Respiratory Syndrome] / middle east respiratory syndrome ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was r0 for the high transmissibility in south korea?",
    "new_text": "What was r0 for the [High] / high transmissibility in south korea ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is important for containing the transmission?",
    "new_text": "What is important for containing the [disease transmission qualifier] / transmission ?",
    "n_kge": 1
  },
  {
    "raw_text": "What did this model show?",
    "new_text": "What did this [Model] / model show ?",
    "n_kge": 1
  },
  {
    "raw_text": "What was the objective of the study?",
    "new_text": "What was the objective of the study ?",
    "n_kge": 0
  },
  {
    "raw_text": "What are coronaviruses?",
    "new_text": "What are [Genus: Coronavirus] / coronaviruses ?",
    "n_kge": 1
  },
  {
    "raw_text": "What animals can carry coronavirus?",
    "new_text": "What [Animals] / animals can carry [Genus: Coronavirus] / coronavirus ?",
    "n_kge": 2
  },
  {
    "raw_text": "How many covid-19 cases were confirmed on the diamond princess cruise ship?",
    "new_text": "How many [COVID-19] / covid - 19 [Case (situation)] / cases were confirmed on the [diamond] / diamond princess cruise [Ships] / ship ?",
    "n_kge": 4
  },
  {
    "raw_text": "What was the time period of peak infection of covid-19 on the diamond princess cruise ship?",
    "new_text": "What was the [Period (temporal qualifier)] / time period of peak [Communicable Diseases] / infection of [COVID-19] / covid - 19 on the [diamond] / diamond princess cruise [Ships] / ship ?",
    "n_kge": 5
  },
  {
    "raw_text": "With the intervention of movement restrictions starting on 5th february 2020, what were the confirmed cases for covid-19, were limited to?",
    "new_text": "With the [Interventional procedure] / intervention of movement restrictions starting on 5th february 2020 , what were the confirmed cases for [COVID-19] / covid - 19 , were limited [Tryptophanase] / to ?",
    "n_kge": 3
  },
  {
    "raw_text": "Who was the first covid-19 identified case patient on the diamond princess cruise ship?",
    "new_text": "Who was the first [COVID-19] / covid - 19 identified [Case (situation)] / case [Patients] / patient on the [diamond] / diamond princess cruise [Ships] / ship ?",
    "n_kge": 5
  },
  {
    "raw_text": "When was the first passenger patient on the diamond princess cruise ship diagnosed with covid-19?",
    "new_text": "When was the first passenger [Patients] / patient on the [diamond] / diamond princess cruise [Ships] / ship [Diagnosis] / diagnosed with [COVID-19] / covid - 19 ?",
    "n_kge": 5
  },
  {
    "raw_text": "How many covid-19 cases were confirmed on the diamond princess cruise ship?",
    "new_text": "How many [COVID-19] / covid - 19 [Case (situation)] / cases were confirmed on the [diamond] / diamond princess cruise [Ships] / ship ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is the estimated mean incubation period for covid-19 infection on the diamond princess cruise ship?",
    "new_text": "What is the [Estimated] / estimated mean incubation period for [COVID-19] / covid - 19 [Communicable Diseases] / infection on the [diamond] / diamond princess cruise [Ships] / ship ?",
    "n_kge": 5
  },
  {
    "raw_text": "What was the effect of movement restriction policy on the diamond princess cruise ship started on 5th february 2020?",
    "new_text": "What was the effect of movement restriction [Policy] / policy on the [diamond] / diamond princess cruise [Ships] / ship [Started] / started on 5th february 2020 ?",
    "n_kge": 4
  },
  {
    "raw_text": "What would have the number of confirmed cases on the diamond princess cruise ship, without a movement restriction starting on the 5th february 2020?",
    "new_text": "What would have the [Numbers] / number of confirmed cases on the [diamond] / diamond princess cruise [Ships] / ship , without a movement restriction starting on the 5th february 2020 ?",
    "n_kge": 3
  },
  {
    "raw_text": "When was the a cluster of pneumonia cases were first reported ?",
    "new_text": "When was the a cluster of [Pneumonia] / pneumonia [Case (situation)] / cases were first [Report (document)] / reported ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the number of inbound passengers from china?",
    "new_text": "What is the [Numbers] / number of inbound passengers from [China] / china ?",
    "n_kge": 2
  },
  {
    "raw_text": "What percent of inbound passengers from china were from wuhan?",
    "new_text": "What [Percent (qualifier value)] / percent of inbound passengers from [China] / china were from wuhan ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the mechanism of action for rupintrivir?",
    "new_text": "What is the mechanism of action for [rupintrivir] / rupintrivir ?",
    "n_kge": 1
  },
  {
    "raw_text": "Has rupintrivir been shown to reduce the symptoms of a rhinoviral infection?",
    "new_text": "Has [rupintrivir] / rupintrivir been shown [Tryptophanase] / to reduce the symptoms of a rhinoviral infection ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the primary etiology of acute respiratory infection?",
    "new_text": "What is the primary etiology of [Acute respiratory infections] / acute respiratory infection ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is rsv?",
    "new_text": "What is [Respiratory syncytial virus] / respiratory syncytial virus ?",
    "n_kge": 1
  },
  {
    "raw_text": "What virus is most commonly associated with acute respiratory infections?",
    "new_text": "What [Virus] / virus is most commonly associated with [Acute respiratory infections] / acute respiratory infections ?",
    "n_kge": 2
  },
  {
    "raw_text": "What viruses are most frequently associated with acute respiratory infections?",
    "new_text": "What [Virus] / viruses are most frequently associated with [Acute respiratory infections] / acute respiratory infections ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are the clinical characteristics of asthma?",
    "new_text": "What are the clinical characteristics of [Asthma] / asthma ?",
    "n_kge": 1
  },
  {
    "raw_text": "What risk factor was associated with hospitalization and death during the 2009 h1n1 influence pandemic?",
    "new_text": "What [risk factors] / risk factor was associated with hospitalization and [Cessation of life] / death during the 2009 [H1N1] / h1n1 influence [Pandemics] / pandemic ?",
    "n_kge": 4
  },
  {
    "raw_text": "How many surface proteins are on the h1n1 influenza virus?",
    "new_text": "How many [Membrane Proteins] / surface proteins are on the [Orthomyxovirus Type A, Porcine] / h1n1 influenza virus ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are the 2 surface proteins on the h1n1 influenza virus?",
    "new_text": "What are the 2 [Membrane Proteins] / surface proteins on the [Orthomyxovirus Type A, Porcine] / h1n1 influenza virus ?",
    "n_kge": 2
  },
  {
    "raw_text": "What pharmaceutical targets the na glycoprotein of the h1n1 influenza virus?",
    "new_text": "What [Pharmaceutical Preparations] / pharmaceutical targets the [Doxorubicin/Vinorelbine Regimen] / na [Glycoproteins] / glycoprotein of the [Orthomyxovirus Type A, Porcine] / h1n1 influenza virus ?",
    "n_kge": 4
  },
  {
    "raw_text": "What genetic mutation decreases a person's susceptibility to the h1n1 influenza virus?",
    "new_text": "What genetic mutation decreases a person's [Disease susceptibility] / susceptibility to the h1n1 influenza virus ?",
    "n_kge": 1
  },
  {
    "raw_text": "Why is ribavirin treatment limited?",
    "new_text": "Why is [ribavirin] / ribavirin [therapeutic aspects] / treatment limited ?",
    "n_kge": 2
  },
  {
    "raw_text": "To what the lack of exposure report could be attributed?",
    "new_text": "To what the lack of [Injury due to exposure to external cause] / exposure [Report (document)] / report could be attributed ?",
    "n_kge": 2
  },
  {
    "raw_text": "Why is the determination of asymptomatic or pre-symptomatic transmission, an urgent priority?",
    "new_text": "Why is the determination of [Asymptomatic (finding)] / asymptomatic or pre - symptomatic [disease transmission qualifier] / transmission , an [Urgent] / urgent [Priority] / priority ?",
    "n_kge": 4
  },
  {
    "raw_text": "When does the infectivity of sars-cov peak?",
    "new_text": "When does the infectivity of sars - cov peak ?",
    "n_kge": 0
  },
  {
    "raw_text": "How can the 2019-ncov spread?",
    "new_text": "How can the [2019 novel coronavirus] / 2019 - ncov [Spreading (qualifier value)] / spread ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the estimate of the basic reproduction number?",
    "new_text": "What is the [Estimated] / estimate of the basic reproduction number ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is assumed for the mean serial interval?",
    "new_text": "What is assumed for the mean serial interval ?",
    "n_kge": 0
  },
  {
    "raw_text": "What would a shorter mean serial interval mean?",
    "new_text": "What would a shorter mean serial interval mean ?",
    "n_kge": 0
  },
  {
    "raw_text": "What should have reduced the basic reproduction number in january?",
    "new_text": "What should have reduced the basic reproduction number in january ?",
    "n_kge": 0
  },
  {
    "raw_text": "What are the delays between infection to illness and illness to laboratory confirmatiion?",
    "new_text": "What are the delays between [Communicable Diseases] / infection to [Illness (finding)] / illness and [Illness (finding)] / illness to [Laboratory] / laboratory confirmatiion ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is the estimate of number of infections in wuhan on 25 january 2020?",
    "new_text": "What is the [Estimated] / estimate of [Numbers] / number of [Infection] / infections [Present] / in wuhan on 25 january 2020 ?",
    "n_kge": 4
  },
  {
    "raw_text": "When is viral shedding the highest?",
    "new_text": "When is viral shedding the highest ?",
    "n_kge": 0
  },
  {
    "raw_text": "How does the transmission of the respiratory virus happen?",
    "new_text": "How does the [disease transmission qualifier] / transmission of the respiratory virus happen ?",
    "n_kge": 1
  },
  {
    "raw_text": "How do some respiratory viruses spread?",
    "new_text": "How do some respiratory viruses [Spreading (qualifier value)] / spread ?",
    "n_kge": 1
  },
  {
    "raw_text": "What can also play a role?",
    "new_text": "What can also [Play] / play a [Social Role] / role ?",
    "n_kge": 2
  },
  {
    "raw_text": "What can play a role in the infection of gastrointestinal tract?",
    "new_text": "What can [Play] / play a [Social Role] / role in the infection of gastrointestinal tract ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was attributed to the spread of sars-cov at amoy gardens?",
    "new_text": "What was attributed to the [Spreading (qualifier value)] / spread of [SARS coronavirus] / sars - cov at amoy [Gardening] / gardens ?",
    "n_kge": 3
  },
  {
    "raw_text": "How were the first human infections identified?",
    "new_text": "How were the first [Homo sapiens] / human [Infection] / infections identified ?",
    "n_kge": 2
  },
  {
    "raw_text": "What do mild clinical presentations of 2019-ncov indicate?",
    "new_text": "What do [Mild (qualifier value)] / mild clinical presentations of [2019 novel coronavirus] / 2019 - ncov indicate ?",
    "n_kge": 2
  },
  {
    "raw_text": "Why is important to determine the spectrum of clinical manifestations of 2019-ncov infections?",
    "new_text": "Why is important [Tryptophanase] / to determine the spectrum of clinical manifestations of [COVID-19] / 2019 - ncov infections ?",
    "n_kge": 2
  },
  {
    "raw_text": "What, beyond the assessment of severity, is important?",
    "new_text": "What , beyond the [Evaluation procedure] / assessment of [Severities] / severity , is important ?",
    "n_kge": 2
  },
  {
    "raw_text": "For whom would the infections be more severe?",
    "new_text": "For whom would the [Infection] / infections be [More] / more [Severe (severity modifier)] / severe ?",
    "n_kge": 3
  },
  {
    "raw_text": "When is this especially true?",
    "new_text": "When is this especially true ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the current understanding on viral-induced exacerbations?",
    "new_text": "What is the current [Comprehension] / understanding on [Viral] / viral - induced exacerbations ?",
    "n_kge": 2
  },
  {
    "raw_text": "What have evoked new understandings as to the mechanisms of viral exacerbations?",
    "new_text": "What have [Triggered by] / evoked [New] / new understandings as to the [Mechanism (attribute)] / mechanisms of [Viral] / viral exacerbations ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is one of the major sources of exacerbation of chronic airway inflammatory diseases?",
    "new_text": "What is [One] / one of the [Severe (severity modifier)] / major sources of exacerbation of [chronic] / chronic airway inflammatory diseases ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the focus of this review?",
    "new_text": "What is the [Focal] / focus of this review ?",
    "n_kge": 1
  },
  {
    "raw_text": "What have the authors reviewed?",
    "new_text": "What have the [Author] / authors reviewed ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is summarized?",
    "new_text": "What is summarized ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is highlighted by the authors?",
    "new_text": "What is highlighted by the [Author] / authors ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is consolidated in this review?",
    "new_text": "What is consolidated in this review ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is this disease characterized by ?",
    "new_text": "What is this [Disease] / disease characterized by ?",
    "n_kge": 1
  },
  {
    "raw_text": "Where can this disease manifest?",
    "new_text": "Where can this [Disease] / disease [Manifest] / manifest ?",
    "n_kge": 2
  },
  {
    "raw_text": "Why do treatment and management vary in efficacy?",
    "new_text": "Why do [therapeutic aspects] / treatment and [Administration occupational activities] / management vary in [Effectiveness] / efficacy ?",
    "n_kge": 3
  },
  {
    "raw_text": "What complicates this further?",
    "new_text": "What complicates this further ?",
    "n_kge": 0
  },
  {
    "raw_text": "What are such exacerbations due to?",
    "new_text": "What are such exacerbations [Due to] / due to ?",
    "n_kge": 1
  },
  {
    "raw_text": "What do the acute exacerbations cause?",
    "new_text": "What do the acute exacerbations [Etiology aspects] / cause ?",
    "n_kge": 1
  },
  {
    "raw_text": "What are acute exacerbations usually due to ?",
    "new_text": "What are acute exacerbations usually [Due to] / due to ?",
    "n_kge": 1
  },
  {
    "raw_text": "What does the immune response elicited by these agents lead to?",
    "new_text": "What does the [Immune response] / immune response elicited by these agents [lead] / lead [Tryptophanase] / to ?",
    "n_kge": 3
  },
  {
    "raw_text": "Among these agents which is a major driver?",
    "new_text": "Among these agents which is a [Severe (severity modifier)] / major driver ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the viral involvement in copd exacerbation?",
    "new_text": "What is the [Viral] / viral [Involvement with] / involvement in copd exacerbation ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the reason for the involvement of respiratory viruses in exacerbation?",
    "new_text": "What is the [Indication of (contextual qualifier)] / reason for the [Involvement with] / involvement of respiratory viruses in exacerbation ?",
    "n_kge": 2
  },
  {
    "raw_text": "What does the involvement of respiratory viruses contribute to?",
    "new_text": "What does the [Involvement with] / involvement of respiratory viruses contribute [Tryptophanase] / to ?",
    "n_kge": 2
  },
  {
    "raw_text": "Why is it important to identify the exact mechanisms underpinning viral exacerbations in susceptible subjects?",
    "new_text": "Why is it important [Tryptophanase] / to identify the exact [Mechanism (attribute)] / mechanisms underpinning [Viral] / viral exacerbations in susceptible subjects ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the lower airway the site of?",
    "new_text": "What is the lower airway the site of ?",
    "n_kge": 0
  },
  {
    "raw_text": "Where is the the first point of contact with sources of exacerbation?",
    "new_text": "Where is the the first point of contact with [Source] / sources of exacerbation ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the focus of this review?",
    "new_text": "What is the [Focal] / focus of this review ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is complied by the authors?",
    "new_text": "What is complied by the [Author] / authors ?",
    "n_kge": 1
  },
  {
    "raw_text": "Before linking respiratory viruses, what was linked to acute exacerbations?",
    "new_text": "Before linking respiratory viruses , what was linked to acute exacerbations ?",
    "n_kge": 0
  },
  {
    "raw_text": "What did the advent of pcr technology lead to?",
    "new_text": "What did the advent of [Polymerase Chain Reaction] / pcr [Technology] / technology [lead] / lead [Tryptophanase] / to ?",
    "n_kge": 4
  },
  {
    "raw_text": "What are the predominant viruses linked to airway inflammatory diseases?",
    "new_text": "What are the predominant [Virus] / viruses linked to airway inflammatory diseases ?",
    "n_kge": 1
  },
  {
    "raw_text": "What other viruses are implicated in acute exacerbations but to a much lesser extent?",
    "new_text": "What other [Virus] / viruses are implicated in acute exacerbations [Butting] / but to a much [Smaller] / lesser [Extent] / extent ?",
    "n_kge": 4
  },
  {
    "raw_text": "What other viruses have been recently reported as contributing to acute exacerbations?",
    "new_text": "What other [Virus] / viruses have been [Recent] / recently [Report (document)] / reported as contributing to acute exacerbations ?",
    "n_kge": 3
  },
  {
    "raw_text": "What are the common feature of these viruses share?",
    "new_text": "What are the common [Characteristics] / feature of these [Virus] / viruses share ?",
    "n_kge": 2
  },
  {
    "raw_text": "Where do the respiratory viruses primarily infect and replicate?",
    "new_text": "Where do the respiratory viruses primarily [Infected] / infect and replicate ?",
    "n_kge": 1
  },
  {
    "raw_text": "What happens during the replication process?",
    "new_text": "What happens during the replication process ?",
    "n_kge": 0
  },
  {
    "raw_text": "What does the inflammation lead to in healthy airways?",
    "new_text": "What does the [Inflammation] / inflammation [lead] / lead [Tryptophanase] / to in healthy airways ?",
    "n_kge": 3
  },
  {
    "raw_text": "How may the responses be different in a chronically inflamed airway?",
    "new_text": "How may the responses be different in a chronically [Inflammatory] / inflamed airway ?",
    "n_kge": 1
  },
  {
    "raw_text": "What will the review focus on?",
    "new_text": "What will the review [Focal] / focus on ?",
    "n_kge": 1
  },
  {
    "raw_text": "How will this review serve?",
    "new_text": "How will this review serve ?",
    "n_kge": 0
  },
  {
    "raw_text": "Why is this approach significant?",
    "new_text": "Why is this approach [Statistical Significance] / significant ?",
    "n_kge": 1
  },
  {
    "raw_text": "What happens upon infection?",
    "new_text": "What happens upon [Communicable Diseases] / infection ?",
    "n_kge": 1
  },
  {
    "raw_text": "How does the infected airway cell respond?",
    "new_text": "How does the [Infected] / infected airway [Cells] / cell respond ?",
    "n_kge": 2
  },
  {
    "raw_text": "What does the epithelial proteins cause?",
    "new_text": "What does the epithelial [Proteins] / proteins [Etiology aspects] / cause ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the effect of these factors?",
    "new_text": "What is the effect of these factors ?",
    "n_kge": 0
  },
  {
    "raw_text": "What additional effects are caused in patients with asthma and patients with crs with nasal polyp ?",
    "new_text": "What additional effects are caused in [Patients] / patients with [Asthma] / asthma and [Patients] / patients with [Craniosynostosis] / crs with [Nasal Polyps] / nasal polyp ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is the result of increased eosinophilia?",
    "new_text": "What is the [Result] / result of increased eosinophilia ?",
    "n_kge": 1
  },
  {
    "raw_text": "What are the effects for patients with copd and patients with crs without nasal polyp (crssnp) ?",
    "new_text": "What are the effects for [Patients] / patients with [Chronic Obstructive Airway Disease] / copd and [Patients] / patients with [Craniosynostosis] / crs without [Nasal Polyps] / nasal polyp ( crssnp ) ?",
    "n_kge": 5
  },
  {
    "raw_text": "Which are the type 2 inflammatory cytokines expressed by the epithelial cells upon injury to the epithelial barrier?",
    "new_text": "Which are the type 2 [Inflammatory] / inflammatory [cytokine] / cytokines expressed by the [Epithelial Cells] / epithelial cells upon [Traumatic AND/OR non-traumatic injury] / injury to the epithelial barrier ?",
    "n_kge": 4
  },
  {
    "raw_text": "Which cells lacking both b and t cell receptors but play a crucial role in secreting type 2 cytokines to perpetuate type 2 inflammation when activated ?",
    "new_text": "Which [Cell Count] / cells lacking both b and [T-Cell Receptor] / t cell receptors but [Play] / play a crucial [Social Role] / role in [Cell secretion] / secreting [Type - attribute] / type 2 [cytokine] / cytokines [Tryptophanase] / to perpetuate [Type - attribute] / type 2 [Inflammation] / inflammation when activated ?",
    "n_kge": 10
  },
  {
    "raw_text": "What is the effect cell death and injury to the epithelial barrier due to infection?",
    "new_text": "What is the effect [Cell Death] / cell death and [Traumatic AND/OR non-traumatic injury] / injury to the epithelial barrier due to [Communicable Diseases] / infection ?",
    "n_kge": 3
  },
  {
    "raw_text": "What happens when the 3 cytokines are expressed?",
    "new_text": "What happens when the 3 [cytokine] / cytokines are expressed ?",
    "n_kge": 1
  },
  {
    "raw_text": "What happens in the case of copd?",
    "new_text": "What happens in the [Case (situation)] / case of [Chronic Obstructive Airway Disease] / copd ?",
    "n_kge": 2
  },
  {
    "raw_text": "What happens during viral infection of healthy individuals?",
    "new_text": "What happens during [Virus Diseases] / viral infection of healthy individuals ?",
    "n_kge": 1
  },
  {
    "raw_text": "What happens upon viral infection in the airway?",
    "new_text": "What happens upon [Virus Diseases] / viral infection in the airway ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the effect of the inflammation of the airway?",
    "new_text": "What is the effect of the [Inflammation] / inflammation of the airway ?",
    "n_kge": 1
  },
  {
    "raw_text": "What increases the severity of exacerbations in the airway?",
    "new_text": "What [Increased] / increases the [Severities] / severity of exacerbations in the airway ?",
    "n_kge": 2
  },
  {
    "raw_text": "Why viruses do not need to directly infect the lower airway to cause an acute exacerbation?",
    "new_text": "Why [Virus] / viruses do not need [Tryptophanase] / to directly [Infected] / infect the lower airway [Tryptophanase] / to [Etiology aspects] / cause an acute exacerbation ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is suggested by the fact that not all viral infections of the airway lead to acute exacerbations?",
    "new_text": "What is suggested by the fact that not [All] / all [Virus Diseases] / viral infections of the airway [lead] / lead to acute exacerbations ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the effect of chronic airway inflammatory disease in patients?",
    "new_text": "What is the effect of chronic airway inflammatory disease in [Patients] / patients ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the effect of chronic airway inflammatory disease?",
    "new_text": "What is the effect of chronic airway inflammatory disease ?",
    "n_kge": 0
  },
  {
    "raw_text": "Why should future studies be performed using metagenomics in addition to pcr analysis ?",
    "new_text": "Why should future studies be [Performed] / performed [Use of] / using [Metagenomics] / metagenomics in addition to [Polymerase chain reaction analysis] / pcr analysis ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is highlighted by the authors in this review?",
    "new_text": "What is highlighted by the [Author] / authors in this review ?",
    "n_kge": 1
  },
  {
    "raw_text": "Who has impaired or reduced ability of viral clearance ?",
    "new_text": "Who has [Impaired] / impaired or reduced [Ability] / ability of [Viral] / viral [Clearance] / clearance ?",
    "n_kge": 4
  },
  {
    "raw_text": "What does their impairment stems from?",
    "new_text": "What does their [Impaired] / impairment stems from ?",
    "n_kge": 1
  },
  {
    "raw_text": "Where is this especially evident?",
    "new_text": "Where is this especially evident ?",
    "n_kge": 0
  },
  {
    "raw_text": "What are other effects?",
    "new_text": "What are other effects ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the effect of viral components remaining in the airway?",
    "new_text": "What is the effect of viral components remaining in the airway ?",
    "n_kge": 0
  },
  {
    "raw_text": "What do these factors do?",
    "new_text": "What do these factors do ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is also linked with the chronic inflammation that precedes the malignancies?",
    "new_text": "What is also linked with the [Chronic inflammation] / chronic inflammation that precedes the [Malignant Neoplasms] / malignancies ?",
    "n_kge": 2
  },
  {
    "raw_text": "What should be investigated in the future?",
    "new_text": "What should be investigated in the future ?",
    "n_kge": 0
  },
  {
    "raw_text": "What further can viral persistence lead to?",
    "new_text": "What further can [Viral] / viral persistence [lead] / lead [Tryptophanase] / to ?",
    "n_kge": 3
  },
  {
    "raw_text": "What effect the use of steroids to suppress inflammation can have?",
    "new_text": "What effect the use of steroids [Tryptophanase] / to suppress [Inflammation] / inflammation can have ?",
    "n_kge": 2
  },
  {
    "raw_text": "What should be further focus of research?",
    "new_text": "What should be further [Focal] / focus of [research] / research ?",
    "n_kge": 2
  },
  {
    "raw_text": "Which viruses may not cause prolonged inflammation due to strong induction of antiviral clearance?",
    "new_text": "Which [Virus] / viruses may not [Etiology aspects] / cause [Prolonged] / prolonged [Inflammation] / inflammation [Due to] / due to strong induction of [Antiviral Agents] / antiviral [Clearance] / clearance ?",
    "n_kge": 7
  },
  {
    "raw_text": "What do these infections cause?",
    "new_text": "What do these [Infection] / infections [Etiology aspects] / cause ?",
    "n_kge": 2
  },
  {
    "raw_text": "What do the necroptotic factors such as rip3 do?",
    "new_text": "What do the necroptotic factors such as rip3 do ?",
    "n_kge": 0
  },
  {
    "raw_text": "What may the destruction of the epithelial barrier cause?",
    "new_text": "What may the [Destructive procedure (surgical)] / destruction of the epithelial barrier [Etiology aspects] / cause ?",
    "n_kge": 2
  },
  {
    "raw_text": "What may the epithelial destruction cause?",
    "new_text": "What may the epithelial [Destructive procedure (surgical)] / destruction [Etiology aspects] / cause ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is recommended that patients with chronic airway inflammatory disease?",
    "new_text": "What is recommended that [Patients] / patients with chronic airway inflammatory disease ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is another mechanism that viral infections use to drive acute exacerbations?",
    "new_text": "What is another [Mechanism (attribute)] / mechanism that [Virus Diseases] / viral infections [utilization qualifier] / use [Tryptophanase] / to [Intrinsic drive] / drive acute exacerbations ?",
    "n_kge": 5
  },
  {
    "raw_text": "What does infection of respiratory viruses cause?",
    "new_text": "What does infection of respiratory viruses [Etiology aspects] / cause ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is an example of this?",
    "new_text": "What is [Aniridia type 1] / an example of this ?",
    "n_kge": 1
  },
  {
    "raw_text": "What are also associated with viral infections and pneumonia development, which may worsen inflammation in the lower airway?",
    "new_text": "What are also associated with [Virus Diseases] / viral infections and pneumonia development , which may worsen [Inflammation] / inflammation in the lower airway ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is another area of interest?",
    "new_text": "What is another [Geographic Locations] / area of [Interested] / interest ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is usually linked with the development of chronic airway inflammatory diseases?",
    "new_text": "What is usually linked with the development of chronic airway inflammatory diseases ?",
    "n_kge": 0
  },
  {
    "raw_text": "What follows in the event of a viral infection such as rv infection?",
    "new_text": "What [Followed by] / follows in the [Event] / event of a [Virus Diseases] / viral infection such as [Residual volume] / rv [Communicable Diseases] / infection ?",
    "n_kge": 5
  },
  {
    "raw_text": "What does the viral infection alter?",
    "new_text": "What does the [Virus Diseases] / viral infection alter ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the destabilization is further compounded by?",
    "new_text": "What is the destabilization is further compounded by ?",
    "n_kge": 0
  },
  {
    "raw_text": "What does all this gradually lead to?",
    "new_text": "What does all this gradually [lead] / lead [Tryptophanase] / to ?",
    "n_kge": 2
  },
  {
    "raw_text": "Why do these changes may result in more severe and frequent acute exacerbations ?",
    "new_text": "Why do these [Changing] / changes may [Result] / result in more [Severe (severity modifier)] / severe and frequent acute exacerbations ?",
    "n_kge": 3
  },
  {
    "raw_text": "How effective are microbiome based trial therapies?",
    "new_text": "How [Effectiveness] / effective are [Microbiome] / microbiome based [Clinical Trials] / trial [Therapeutic procedure] / therapies ?",
    "n_kge": 4
  },
  {
    "raw_text": "What can viral infections cause?",
    "new_text": "What can [Virus Diseases] / viral infections [Etiology aspects] / cause ?",
    "n_kge": 2
  },
  {
    "raw_text": "Which is the primary contact/infection site of most respiratory viruses?",
    "new_text": "Which is the primary contact / infection site of most respiratory viruses ?",
    "n_kge": 0
  },
  {
    "raw_text": "What does the destruction of epithelial barrier, mucociliary function and cell death of the epithelial cells do?",
    "new_text": "What does the [Destructive procedure (surgical)] / destruction of epithelial barrier , mucociliary [physiological aspects] / function and [Cell Death] / cell death of the [Epithelial Cells] / epithelial cells do ?",
    "n_kge": 4
  },
  {
    "raw_text": "What are viral infections are usually accompanied with?",
    "new_text": "What are [Virus Diseases] / viral infections are usually accompanied with ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the dysregulation of inflammation can be further compounded by?",
    "new_text": "What is the dysregulation of [Inflammation] / inflammation can be further compounded by ?",
    "n_kge": 1
  },
  {
    "raw_text": "What does the change in the local airway environment and inflammation promote?",
    "new_text": "What does the change in the [Local] / local airway [Environment] / environment and [Inflammation] / inflammation [Promotion (action)] / promote ?",
    "n_kge": 4
  },
  {
    "raw_text": "What does the the inflammatory environment dispersal of upper airway commensals into the lower airway cause?",
    "new_text": "What does the the [Inflammatory] / inflammatory [Environment] / environment dispersal of [Structure of upper respiratory tract cavity] / upper airway commensals into the lower airway [Etiology aspects] / cause ?",
    "n_kge": 4
  },
  {
    "raw_text": "Which are the most commonly studied viruses in chronic airway inflammatory diseases?",
    "new_text": "Which are the most commonly studied [Virus] / viruses in chronic airway inflammatory diseases ?",
    "n_kge": 1
  },
  {
    "raw_text": "What do the infections such as rsv are shown to do?",
    "new_text": "What do the infections such as respiratory syncytial virus are shown to do ?",
    "n_kge": 0
  },
  {
    "raw_text": "What does mucus overproduction do?",
    "new_text": "What does [Mucous body substance] / mucus overproduction do ?",
    "n_kge": 1
  },
  {
    "raw_text": "What does the disruption of the ciliary movement during viral infection may cause?",
    "new_text": "What does the disruption of the ciliary [Movement] / movement during [Virus Diseases] / viral infection may [Etiology aspects] / cause ?",
    "n_kge": 3
  },
  {
    "raw_text": "What are micrornas(mirna)?",
    "new_text": "What are [MicroRNAs] / micrornas ( [MicroRNAs] / mirna ) ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are mirnas found to be induced by?",
    "new_text": "What are [MicroRNAs] / mirnas [Present] / found [Tryptophanase] / to be induced by ?",
    "n_kge": 3
  },
  {
    "raw_text": "What were linked to the exacerbation of the airway inflammation disease?",
    "new_text": "What were linked to the exacerbation of the airway inflammation disease ?",
    "n_kge": 0
  },
  {
    "raw_text": "Where might such mirna changes have originated from?",
    "new_text": "Where might such [MicroRNAs] / mirna [Changing] / changes have originated from ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are both ifv and rsv infections shown to do?",
    "new_text": "What are both ifv and respiratory syncytial virus infections shown to do ?",
    "n_kge": 0
  },
  {
    "raw_text": "What are ifv infection shown to do?",
    "new_text": "What are ifv [Communicable Diseases] / infection shown to do ?",
    "n_kge": 1
  },
  {
    "raw_text": "What happens in in asthmatic epithelium in ifv infection?",
    "new_text": "What happens [Present] / in [Present] / in [Asthma] / asthmatic [Epithelium] / epithelium [Present] / in ifv [Communicable Diseases] / infection ?",
    "n_kge": 6
  },
  {
    "raw_text": "What do non-coding rnas present as?",
    "new_text": "What do non - coding rnas [Present] / present as ?",
    "n_kge": 1
  },
  {
    "raw_text": "What mechanisms, other than mirna modulation play a role?",
    "new_text": "What [Mechanism (attribute)] / mechanisms , other than [MicroRNAs] / mirna [Modulated] / modulation [Play] / play a [Social Role] / role ?",
    "n_kge": 5
  },
  {
    "raw_text": "What have recent epigenetic studies indicated?",
    "new_text": "What have [Recent] / recent [study of epigenetics] / epigenetic studies indicated ?",
    "n_kge": 2
  },
  {
    "raw_text": "What have these studies also shown?",
    "new_text": "What have these studies also shown ?",
    "n_kge": 0
  },
  {
    "raw_text": "What has spalluto et al have shown?",
    "new_text": "What has spalluto [Thrombocythemia, Essential] / et [Aluminum measurement] / al have shown ?",
    "n_kge": 2
  },
  {
    "raw_text": "What infections such as rv and rsv that weakly induce antiviral responses may result in?",
    "new_text": "What [Infection] / infections such as [Residual volume] / rv and [Respiratory syncytial virus] / respiratory syncytial virus that weakly induce antiviral responses may [Result] / result in ?",
    "n_kge": 4
  },
  {
    "raw_text": "What can viral infection result in?",
    "new_text": "What can [Virus Diseases] / viral infection [Result] / result in ?",
    "n_kge": 2
  },
  {
    "raw_text": "What sustains the inflammation in the airway?",
    "new_text": "What sustains the [Inflammation] / inflammation in the airway ?",
    "n_kge": 1
  },
  {
    "raw_text": "What may viral infections of the respiratory epithelium by viruses such as ifv, rv, rsv and hsv do?",
    "new_text": "What may viral infections of the respiratory epithelium [Belarus] / by [Virus] / viruses such as ifv , [Residual volume] / rv , [Respiratory syncytial virus] / respiratory syncytial virus and [Herpes Simplex Infections] / hsv do ?",
    "n_kge": 5
  },
  {
    "raw_text": "What can happen in response to the infection such as neutrophils?",
    "new_text": "What can happen in response [Tryptophanase] / to the [Communicable Diseases] / infection such as [neutrophil] / neutrophils ?",
    "n_kge": 3
  },
  {
    "raw_text": "In addition to worsening disease symptoms, what do viral-induced exacerbations do?",
    "new_text": "In addition to worsening [Disease] / disease symptoms , what do [Viral] / viral - induced exacerbations do ?",
    "n_kge": 2
  },
  {
    "raw_text": "What may studies in natural exacerbations and in viral-challenge models using rna-sequencing (rna-seq) or single cell rna-seq on a range of time-points provide?",
    "new_text": "What may studies in [Natural] / natural exacerbations and in [Viral] / viral - [Challenge:Type:Point in time:^Patient:Nominal] / challenge [Model] / models [Use of] / using rna - sequencing or single cell rna - sequencing on a range of time - points provide ?",
    "n_kge": 5
  },
  {
    "raw_text": "What analysis functions may be useful?",
    "new_text": "What analysis [Function (attribute)] / functions may be useful ?",
    "n_kge": 1
  },
  {
    "raw_text": "For what purpose animal based models aare developed for?",
    "new_text": "For what [Purpose] / purpose animal based models [acylaminoacyl-peptidase] / aare developed for ?",
    "n_kge": 2
  },
  {
    "raw_text": "What can be used unravel the immune profile of a viral infection in healthy and diseased condition?",
    "new_text": "What can be [Used by] / used unravel the immune profile of a [Virus Diseases] / viral infection in healthy and diseased [Disease] / condition ?",
    "n_kge": 3
  },
  {
    "raw_text": "For what purpose controlled in vivo human infections can be performed for mild viruses?",
    "new_text": "For what [Purpose] / purpose controlled in vivo [Homo sapiens] / human [Infection] / infections can be [Performed] / performed for [Mild (qualifier value)] / mild [Virus] / viruses ?",
    "n_kge": 6
  },
  {
    "raw_text": "Why may the mechanisms of exacerbation vary considerably?",
    "new_text": "Why may the [Mechanism (attribute)] / mechanisms of exacerbation vary considerably ?",
    "n_kge": 1
  },
  {
    "raw_text": "What clinical condition is caused by hantaan virus?",
    "new_text": "What clinical condition is caused by [Hantaan virus] / hantaan virus ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the structure of hantaan virus?",
    "new_text": "What is the structure of hantaan virus ?",
    "n_kge": 0
  },
  {
    "raw_text": "What the animal vector reservoir for hantaan virus?",
    "new_text": "What the [Animals] / animal [Disease Vectors] / vector reservoir for [Hantaan virus] / hantaan virus ?",
    "n_kge": 3
  },
  {
    "raw_text": "What diagnostic test is correlated with the severity of hfrs?",
    "new_text": "What [Diagnostic tests] / diagnostic test is correlated with the [Severities] / severity of [Hemorrhagic Fever with Renal Syndrome] / hfrs ?",
    "n_kge": 3
  },
  {
    "raw_text": "How is interferon used in practice?",
    "new_text": "How is [Interferons] / interferon [Used by] / used in practice ?",
    "n_kge": 2
  },
  {
    "raw_text": "What genotypes are associated with the severity of hfrs?",
    "new_text": "What [Genotype] / genotypes are associated with the [Severities] / severity of [Hemorrhagic Fever with Renal Syndrome] / hfrs ?",
    "n_kge": 3
  },
  {
    "raw_text": "Which ifitm proteins have been shown to possess antiviral activity?",
    "new_text": "Which ifitm [Proteins] / proteins have been shown [Tryptophanase] / to [Possessed] / possess antiviral activity ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the hypothesized mechanism by which ifitms work?",
    "new_text": "What is the hypothesized [Mechanism (attribute)] / mechanism by which ifitms [Work] / work ?",
    "n_kge": 2
  },
  {
    "raw_text": "What genotype causes truncation of the ifitm3 protein?",
    "new_text": "What [Genotype] / genotype [Etiology aspects] / causes truncation of the [IFITM3 gene] / ifitm3 protein ?",
    "n_kge": 3
  },
  {
    "raw_text": "What can cause a slowing growth in daily reported deaths?",
    "new_text": "What can [Etiology aspects] / cause a slowing [Growth] / growth in [Daily] / daily [Report (document)] / reported [Cessation of life] / deaths ?",
    "n_kge": 5
  },
  {
    "raw_text": "When did italy go into iockdown?",
    "new_text": "When did [Italy] / italy [GORAB gene] / go into iockdown ?",
    "n_kge": 2
  },
  {
    "raw_text": "Approximately how many deaths have been averted in western europe with current non-pharmaceutical interventions remaining in place until the end of march?",
    "new_text": "Approximately how many [Cessation of life] / deaths have been averted in [Western Europe] / western europe with current non - pharmaceutical interventions remaining in [Place] / place until the end of [Hydranencephaly with Renal Aplasia-Dysplasia] / march ?",
    "n_kge": 4
  },
  {
    "raw_text": "What are some non-pharmaceutical interventions?",
    "new_text": "What are some non - pharmaceutical interventions ?",
    "n_kge": 0
  },
  {
    "raw_text": "Type of model used to infer the impact non-pharmaceutical interventions?",
    "new_text": "[Type - attribute] / Type of [Model] / model [Used by] / used [Tryptophanase] / to infer the [IMPACT gene] / impact non - pharmaceutical interventions ?",
    "n_kge": 5
  },
  {
    "raw_text": "How can a semi-mechanistic bayesian hierarchical model estimate changes to the reproductive number?",
    "new_text": "How can a semi - mechanistic bayesian hierarchical model [Estimated] / estimate [Changing] / changes to the [Reproduction] / reproductive number ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is a key assumption of a semi-mechanistic bayesian hierarchical model used for coronavirus?",
    "new_text": "What is a key assumption of a semi - mechanistic bayesian hierarchical [Model] / model [Used by] / used for [Genus: Coronavirus] / coronavirus ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the time lag between when transmission changes occur and when their impact can be observed in trends in mortality?",
    "new_text": "What is the [Time] / time [STMN1 gene] / lag between when [disease transmission qualifier] / transmission [Changing] / changes occur and when their [IMPACT gene] / impact can be observed in [trends qualifier] / trends in [Mortality Vital Statistics] / mortality ?",
    "n_kge": 7
  },
  {
    "raw_text": "What is the key aim of non-pharmaceutical interventions?",
    "new_text": "What is the key aim of non - pharmaceutical interventions ?",
    "n_kge": 0
  },
  {
    "raw_text": "What happens if the reproduction number is greater then 1?",
    "new_text": "What happens if the [Reproduction] / reproduction [Numbers] / number is greater then 1 ?",
    "n_kge": 2
  },
  {
    "raw_text": "When did china introduce strict movement restrictions and other measures including case isolation and quarantine?",
    "new_text": "When did [China] / china introduce strict movement restrictions and other [Measures] / measures including [Case (situation)] / case [Isolation procedure] / isolation and [Quarantine] / quarantine ?",
    "n_kge": 5
  },
  {
    "raw_text": "What was the result of china's interventions introduced in january?",
    "new_text": "What was the [Result] / result of china's interventions introduced in january ?",
    "n_kge": 1
  },
  {
    "raw_text": "What are examples of social distancing?",
    "new_text": "What are examples of [Physical Distancing] / social distancing ?",
    "n_kge": 1
  },
  {
    "raw_text": "What was the estimated effect on china's reproduction number in march based on the intervention introduced in january?",
    "new_text": "What was the [Estimated] / estimated effect on china's [Reproduction] / reproduction [Numbers] / number in [Hydranencephaly with Renal Aplasia-Dysplasia] / march based on the [Interventional procedure] / intervention introduced in january ?",
    "n_kge": 5
  },
  {
    "raw_text": "Why is it challenging to estimate the reproduction number?",
    "new_text": "Why is it challenging [Tryptophanase] / to [Estimated] / estimate the [Reproduction] / reproduction [Numbers] / number ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is an alternative way to estimate the course of an epidemic?",
    "new_text": "What is an alternative way [Tryptophanase] / to [Estimated] / estimate the [Course] / course of an [Epidemic] / epidemic ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is the estimated attack rate in italy?",
    "new_text": "What is the [Estimated] / estimated [Incidence Proportion] / attack rate in [Italy] / italy ?",
    "n_kge": 3
  },
  {
    "raw_text": "As of the end of march what is the proportion of spain's population to be infected?",
    "new_text": "As of the end of [Hydranencephaly with Renal Aplasia-Dysplasia] / march what is the proportion of spain's [geographic population] / population [Tryptophanase] / to be [Infected] / infected ?",
    "n_kge": 4
  },
  {
    "raw_text": "Which western european country is estimated to have the lowest attack rate?",
    "new_text": "Which western european [Country] / country is [Estimated] / estimated [Tryptophanase] / to have the lowest [Incidence Proportion] / attack rate ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is austria's estimated mean percentage [95% credible interval] of total population infected as of 28th march?",
    "new_text": "What is austria's [Estimated] / estimated mean [Percent (qualifier value)] / percentage [ [95] / 95 % credible interval ] of total population [Infected] / infected as of 28th [Hydranencephaly with Renal Aplasia-Dysplasia] / march ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is belgium's estimated mean percentage [95% credible interval] of total population infected as of 28th march?",
    "new_text": "What is belgium's [Estimated] / estimated mean [Percent (qualifier value)] / percentage [ [95] / 95 % credible interval ] of total population [Infected] / infected as of 28th [Hydranencephaly with Renal Aplasia-Dysplasia] / march ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is denmark's estimated mean percentage [95% credible interval] of total population infected as of 28th march?",
    "new_text": "What is denmark's [Estimated] / estimated mean [Percent (qualifier value)] / percentage [ [95] / 95 % credible interval ] of total population [Infected] / infected as of 28th [Hydranencephaly with Renal Aplasia-Dysplasia] / march ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is france's estimated mean percentage [95% credible interval] of total population infected as of 28th march?",
    "new_text": "What is france's [Estimated] / estimated mean [Percent (qualifier value)] / percentage [ [95] / 95 % credible interval ] of total population [Infected] / infected as of 28th [Hydranencephaly with Renal Aplasia-Dysplasia] / march ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is germany's estimated mean percentage [95% credible interval] of total population infected as of 28th march?",
    "new_text": "What is germany's [Estimated] / estimated mean [Percent (qualifier value)] / percentage [ [95] / 95 % credible interval ] of total population [Infected] / infected as of 28th [Hydranencephaly with Renal Aplasia-Dysplasia] / march ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is italy's estimated mean percentage [95% credible interval] of total population infected as of 28th march?",
    "new_text": "What is italy's [Estimated] / estimated mean [Percent (qualifier value)] / percentage [ [95] / 95 % credible interval ] of total population [Infected] / infected as of 28th [Hydranencephaly with Renal Aplasia-Dysplasia] / march ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is norway's estimated mean percentage [95% credible interval] of total population infected as of 28th march?",
    "new_text": "What is norway's [Estimated] / estimated mean [Percent (qualifier value)] / percentage [ [95] / 95 % credible interval ] of total population [Infected] / infected as of 28th [Hydranencephaly with Renal Aplasia-Dysplasia] / march ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is spain's estimated mean percentage [95% credible interval] of total population infected as of 28th march?",
    "new_text": "What is spain's [Estimated] / estimated mean [Percent (qualifier value)] / percentage [ [95] / 95 % credible interval ] of total population [Infected] / infected as of 28th [Hydranencephaly with Renal Aplasia-Dysplasia] / march ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is spain's estimated mean percentage [95% credible interval] of total population infected as of 28th march?",
    "new_text": "What is spain's [Estimated] / estimated mean [Percent (qualifier value)] / percentage [ [95] / 95 % credible interval ] of total population [Infected] / infected as of 28th [Hydranencephaly with Renal Aplasia-Dysplasia] / march ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is switzerland's estimated mean percentage [95% credible interval] of total population infected as of 28th march?",
    "new_text": "What is switzerland's [Estimated] / estimated mean [Percent (qualifier value)] / percentage [ [95] / 95 % credible interval ] of total population [Infected] / infected as of 28th [Hydranencephaly with Renal Aplasia-Dysplasia] / march ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is united kingdom's estimated mean percentage [95% credible interval] of total population infected as of 28th march?",
    "new_text": "What is united kingdom's [Estimated] / estimated mean [Percent (qualifier value)] / percentage [ [95] / 95 % credible interval ] of total population [Infected] / infected as of 28th [Hydranencephaly with Renal Aplasia-Dysplasia] / march ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is the estimated averaged initial reproduction number [95% credible interval] for western europe as of 28th march?",
    "new_text": "What is the [Estimated] / estimated averaged initial reproduction [Numbers] / number [ [95] / 95 % credible interval ] for [Western Europe] / western europe as of 28th [Hydranencephaly with Renal Aplasia-Dysplasia] / march ?",
    "n_kge": 5
  },
  {
    "raw_text": "Why is there high uncertainty in estimating the impact of interventions against the coronavirus?",
    "new_text": "Why is there [High] / high [Uncertainty] / uncertainty in [Estimated] / estimating the [IMPACT gene] / impact of interventions against the [Genus: Coronavirus] / coronavirus ?",
    "n_kge": 5
  },
  {
    "raw_text": "Why is it statistically impossible to determine which individual intervention had the greatest effect on reducing the coronavirus reproduction number?",
    "new_text": "Why is it statistically impossible [Tryptophanase] / to determine which [Persons] / individual [Interventional procedure] / intervention had the greatest effect on reducing the [Genus: Coronavirus] / coronavirus [Reproduction] / reproduction [Numbers] / number ?",
    "n_kge": 6
  },
  {
    "raw_text": "What is estimated to drop immediately after an introduction of a non-pharmaceutical intervention?",
    "new_text": "What is [Estimated] / estimated [Tryptophanase] / to drop [Stat (do immediately)] / immediately after an introduction of a non - pharmaceutical intervention ?",
    "n_kge": 3
  },
  {
    "raw_text": "One way to understand the impact of interventions?",
    "new_text": "One way [Tryptophanase] / to [Comprehension] / understand the [IMPACT gene] / impact of interventions ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is a lockdown?",
    "new_text": "What is a lockdown ?",
    "n_kge": 0
  },
  {
    "raw_text": "Why is it hard to know the true incidence of infections number?",
    "new_text": "Why is it [Hardness] / hard [Tryptophanase] / to know the true [Incidence] / incidence of [Infection] / infections [Numbers] / number ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is an example of a case-based measure against coronavirus?",
    "new_text": "What is [Aniridia type 1] / an example of a case - based [Measures] / measure against [Genus: Coronavirus] / coronavirus ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is an example of containment phase intervention?",
    "new_text": "What is [Aniridia type 1] / an example of containment phase intervention ?",
    "n_kge": 1
  },
  {
    "raw_text": "What does a public events ban intervention mean?",
    "new_text": "What does a public [Event] / events ban [Interventional procedure] / intervention mean ?",
    "n_kge": 2
  },
  {
    "raw_text": "An example of social distancing?",
    "new_text": "[Aniridia type 1] / An example of [Physical Distancing] / social distancing ?",
    "n_kge": 2
  },
  {
    "raw_text": "Example of social distancing?",
    "new_text": "Example of [Physical Distancing] / social distancing ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is a lockdown?",
    "new_text": "What is a lockdown ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is an infection-to-onset-distribution?",
    "new_text": "What is an [Communicable Diseases] / infection - to - [Age of Onset] / onset - [Distributing] / distribution ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is an onset-to-death distribution?",
    "new_text": "What is an [Age of Onset] / onset - to - [Cessation of life] / death [Distributing] / distribution ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the population-averaged infection fatality ratio?",
    "new_text": "What is the [geographic population] / population - averaged [Communicable Diseases] / infection fatality [Ratio] / ratio ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the time-varying reproduction number a function of?",
    "new_text": "What is the time - varying [Reproduction] / reproduction [Numbers] / number a [physiological aspects] / function of ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is an incubation period?",
    "new_text": "What is an incubation period ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is an incubation period?",
    "new_text": "What is an incubation period ?",
    "n_kge": 0
  },
  {
    "raw_text": "What are the descriptive statistics for the onset-to-death for coronavirus?",
    "new_text": "What are the descriptive statistics for the [Age of Onset] / onset - to - [Cessation of life] / death for [Genus: Coronavirus] / coronavirus ?",
    "n_kge": 3
  },
  {
    "raw_text": "What are the descriptive statistics for the incubation period for coronavirus?",
    "new_text": "What are the descriptive statistics for the incubation period for [Genus: Coronavirus] / coronavirus ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the estimated infection-to-death distribution's mean for coronavirus?",
    "new_text": "What is the [Estimated] / estimated infection - to - [Cessation of life] / death distribution's mean for coronavirus ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is a well known approach to model the true number of infected individuals?",
    "new_text": "What is a well known approach to [Model] / model the true number of [Infected] / infected individuals ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is a way to measure virus transmission?",
    "new_text": "What is a way [Tryptophanase] / to [Measures] / measure virus transmission ?",
    "n_kge": 2
  },
  {
    "raw_text": "What term describes when a majority of the population has built an immunity to a virus?",
    "new_text": "What [Term Birth] / term describes when a majority of the [geographic population] / population has built [Aniridia type 1] / an [Immune response] / immunity to a [Virus] / virus ?",
    "n_kge": 5
  },
  {
    "raw_text": "What is the estimated number of people in italy infected with coronavirus by march 28th?",
    "new_text": "What is the [Estimated] / estimated [Numbers] / number of [Persons] / people in [Italy] / italy [Infected] / infected with [Genus: Coronavirus] / coronavirus by [Hydranencephaly with Renal Aplasia-Dysplasia] / march 28th ?",
    "n_kge": 7
  },
  {
    "raw_text": "In 2009 what was the reported h1n1 vaccination rate in china?",
    "new_text": "In 2009 what was the [Report (document)] / reported [H1N1] / h1n1 vaccination rate in [China] / china ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the highest alert level given by the world health organization to a pandemic?",
    "new_text": "What is the highest alert level given by the [World Health Organization] / world health organization to a [Pandemics] / pandemic ?",
    "n_kge": 2
  },
  {
    "raw_text": "What does it mean for a pandemic to have a who alert level of 6?",
    "new_text": "What does it mean for a [Pandemics] / pandemic [Tryptophanase] / to have a [World Health Organization] / world health organization alert level of 6 ?",
    "n_kge": 3
  },
  {
    "raw_text": "What was the estimated economic impact in the u s from the 2009 sars pandemic?",
    "new_text": "What was the [Estimated] / estimated economic impact in the [United States] / u s from the 2009 [Severe Acute Respiratory Syndrome] / sars [Pandemics] / pandemic ?",
    "n_kge": 4
  },
  {
    "raw_text": "How is 2019-ncov transmitted?",
    "new_text": "How is [2019 novel coronavirus] / 2019 - ncov [disease transmission] / transmitted ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are ways in which 2019-ncov is transmitted?",
    "new_text": "What are ways in which [2019 novel coronavirus] / 2019 - ncov is [disease transmission] / transmitted ?",
    "n_kge": 2
  },
  {
    "raw_text": "Is oral swab for detecting 2019-ncov infection, sufficient?",
    "new_text": "Is oral swab for detecting [COVID-19] / 2019 - ncov infection , sufficient ?",
    "n_kge": 1
  },
  {
    "raw_text": "Is oral swab for detecting 2019-ncov infection, sufficient?",
    "new_text": "Is oral swab for detecting [COVID-19] / 2019 - ncov infection , sufficient ?",
    "n_kge": 1
  },
  {
    "raw_text": "What other tests should be considered for 2019-ncov epidemiology?",
    "new_text": "What other [Laboratory Procedures] / tests should be considered for [2019 novel coronavirus] / 2019 - ncov [Epidemiology] / epidemiology ?",
    "n_kge": 3
  },
  {
    "raw_text": "What tests should be done before a 2019-ncov infected patient is discharged?",
    "new_text": "What [Laboratory Procedures] / tests should be [Done (qualifier value)] / done before a [2019 novel coronavirus] / 2019 - ncov [Infected] / infected [Patients] / patient is [Patient Discharge] / discharged ?",
    "n_kge": 6
  },
  {
    "raw_text": "What is a hantavirus?",
    "new_text": "What is a [Hantavirus] / hantavirus ?",
    "n_kge": 1
  },
  {
    "raw_text": "What plays a role in innate immunity to hantavirus infection?",
    "new_text": "What [Play] / plays a [Social Role] / role in [Immunity, Innate] / innate immunity to hantavirus infection ?",
    "n_kge": 3
  },
  {
    "raw_text": "What evidence suggests that rig-i and ddx60 collaborate to exert antiviral effects?",
    "new_text": "What evidence suggests that [DDX58 protein, human] / rig - i and [DDX60 gene] / ddx60 collaborate [Tryptophanase] / to [Exertion] / exert [Antiviral Agents] / antiviral effects ?",
    "n_kge": 5
  },
  {
    "raw_text": "What was the major contribution of this study?",
    "new_text": "What was the [Severe (severity modifier)] / major contribution of this study ?",
    "n_kge": 1
  },
  {
    "raw_text": "What symptoms were reported?",
    "new_text": "What symptoms were [Report (document)] / reported ?",
    "n_kge": 1
  },
  {
    "raw_text": "What did the collected data include?",
    "new_text": "What did the collected data include ?",
    "n_kge": 0
  },
  {
    "raw_text": "When was covid surveillance implemented in european region?",
    "new_text": "When was covid surveillance [Implemented] / implemented in [ethnic european] / european [Geographic Locations] / region ?",
    "n_kge": 3
  },
  {
    "raw_text": "As of 21 february, how many cases were reported?",
    "new_text": "As of 21 february , how many [Case (situation)] / cases were [Report (document)] / reported ?",
    "n_kge": 2
  },
  {
    "raw_text": "Where were the cases that were studied?",
    "new_text": "Where were the [Case (situation)] / cases that were studied ?",
    "n_kge": 1
  },
  {
    "raw_text": "What was the median case age?",
    "new_text": "What was the median [Case (situation)] / case [Age] / age ?",
    "n_kge": 2
  },
  {
    "raw_text": "How many were male?",
    "new_text": "How many were [Males] / male ?",
    "n_kge": 1
  },
  {
    "raw_text": "How many cases were there on 5 march?",
    "new_text": "How many [Case (situation)] / cases were there on 5 [Hydranencephaly with Renal Aplasia-Dysplasia] / march ?",
    "n_kge": 2
  },
  {
    "raw_text": "When did the chinese authorities share the sequence of a novel coronavirus ?",
    "new_text": "When did the chinese authorities share the [Base Sequence] / sequence of a [2019 novel coronavirus] / novel coronavirus ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the name of the disease caused buy sars-cov-2?",
    "new_text": "What is the [Name] / name of the [Disease] / disease caused buy [2019 novel coronavirus] / sars - cov - 2 ?",
    "n_kge": 3
  },
  {
    "raw_text": "What country does this study exclude?",
    "new_text": "What [Country] / country does this study exclude ?",
    "n_kge": 1
  },
  {
    "raw_text": "What does the study include?",
    "new_text": "What does the study include ?",
    "n_kge": 0
  },
  {
    "raw_text": "What did the ecdc and who regional office ask the countries?",
    "new_text": "What did the ecdc and [World Health Organization] / world health organization regional office [Arsenical keratosis] / ask the [Country] / countries ?",
    "n_kge": 3
  },
  {
    "raw_text": "What was the overall aim of the surveillance?",
    "new_text": "What was the overall aim of the surveillance ?",
    "n_kge": 0
  },
  {
    "raw_text": "What were the surveillance objectives?",
    "new_text": "What were the surveillance [objective (goal)] / objectives ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the adopted who case definition?",
    "new_text": "What is the [Personal status - Adopted] / adopted [World Health Organization] / world health organization case definition ?",
    "n_kge": 2
  },
  {
    "raw_text": "When was the first reported death in france?",
    "new_text": "When was the first [Report (document)] / reported [Cessation of life] / death in [France] / france ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the presumed incubation period?",
    "new_text": "What is the presumed incubation period ?",
    "n_kge": 0
  },
  {
    "raw_text": "What were the places of infection?",
    "new_text": "What were the [Place] / places of [Communicable Diseases] / infection ?",
    "n_kge": 2
  },
  {
    "raw_text": "What places were linked to these?",
    "new_text": "What [Place] / places were linked to these ?",
    "n_kge": 1
  },
  {
    "raw_text": "How many cases were hospitalised?",
    "new_text": "How many [Case (situation)] / cases were hospitalised ?",
    "n_kge": 1
  },
  {
    "raw_text": "Why were they hospitalised?",
    "new_text": "Why were they hospitalised ?",
    "n_kge": 0
  },
  {
    "raw_text": "What was time from onset to hospitalisation?",
    "new_text": "What was time from onset to [Hospitalization] / hospitalisation ?",
    "n_kge": 1
  },
  {
    "raw_text": "What was the duration of hospitalisation?",
    "new_text": "What was the [Duration (temporal concept)] / duration of [Hospitalization] / hospitalisation ?",
    "n_kge": 2
  },
  {
    "raw_text": "Why was this?",
    "new_text": "Why was this ?",
    "n_kge": 0
  },
  {
    "raw_text": "How many cases reported symptoms at this point?",
    "new_text": "How many [Case (situation)] / cases [Report (document)] / reported symptoms at this point ?",
    "n_kge": 2
  },
  {
    "raw_text": "How many cases were asymptomatic?",
    "new_text": "How many [Case (situation)] / cases were [Asymptomatic (finding)] / asymptomatic ?",
    "n_kge": 2
  },
  {
    "raw_text": "What were the asymptomatic cases tested as?",
    "new_text": "What were the [Asymptomatic (finding)] / asymptomatic [Case (situation)] / cases [Tests (qualifier value)] / tested as ?",
    "n_kge": 3
  },
  {
    "raw_text": "For how many cases fever reported as the sole symptom?",
    "new_text": "For how many [Case (situation)] / cases [Fever] / fever [Report (document)] / reported as the [Sole of Foot] / sole [Symptoms] / symptom ?",
    "n_kge": 5
  },
  {
    "raw_text": "In how many cases the symptoms at diagnosis were consistent with the case definition for acute respiratory infection?",
    "new_text": "In how many [Case (situation)] / cases the symptoms at [Diagnosis] / diagnosis were consistent with the case definition for [Acute respiratory infections] / acute respiratory infection ?",
    "n_kge": 3
  },
  {
    "raw_text": "How many cases had data on preexisting conditions?",
    "new_text": "How many [Case (situation)] / cases had [Data] / data on preexisting conditions ?",
    "n_kge": 2
  },
  {
    "raw_text": "How many cases had no pre-existing conditions?",
    "new_text": "How many [Case (situation)] / cases had no pre - existing conditions ?",
    "n_kge": 1
  },
  {
    "raw_text": "What other data on pre-existing conditions were reported?",
    "new_text": "What [Other] / other [Data] / data on pre - existing conditions were [Report (document)] / reported ?",
    "n_kge": 3
  },
  {
    "raw_text": "How many reported viral pneumonia?",
    "new_text": "How many [Report (document)] / reported [Pneumonia, Viral] / viral pneumonia ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was the clinical evolution of the hospitalised cases?",
    "new_text": "What was the clinical [Biological Evolution] / evolution of the hospitalised [Case (situation)] / cases ?",
    "n_kge": 2
  },
  {
    "raw_text": "What happened to three cases who were aged 65 years or over?",
    "new_text": "What happened to [Three] / three [Case (situation)] / cases [World Health Organization] / world health organization were [Age] / aged 65 years or over ?",
    "n_kge": 4
  },
  {
    "raw_text": "What happened to the case who died?",
    "new_text": "What happened to the [Case (situation)] / case [World Health Organization] / world health organization [Cessation of life] / died ?",
    "n_kge": 3
  },
  {
    "raw_text": "What was the duration of hospitalisation reported for 16 cases ?",
    "new_text": "What was the [Duration (temporal concept)] / duration of [Hospitalization] / hospitalisation reported for 16 cases ?",
    "n_kge": 2
  },
  {
    "raw_text": "How were the assays confirmed?",
    "new_text": "How were the assays confirmed ?",
    "n_kge": 0
  },
  {
    "raw_text": "What were the specimen types for 21 cases?",
    "new_text": "What were the specimen types for 21 [Case (situation)] / cases ?",
    "n_kge": 1
  },
  {
    "raw_text": "As of 5 march 2020, what are the cases in the who european region?",
    "new_text": "As of 5 [Hydranencephaly with Renal Aplasia-Dysplasia] / march 2020 , what are the [Case (situation)] / cases in the [World Health Organization] / world health organization [ethnic european] / european [Geographic Locations] / region ?",
    "n_kge": 5
  },
  {
    "raw_text": "What were the two contexts for transmission?",
    "new_text": "What were the [Two] / two [Context] / contexts for [disease transmission qualifier] / transmission ?",
    "n_kge": 3
  },
  {
    "raw_text": "What does the analysis show on the difference between locally acquired cases vs imported cases?",
    "new_text": "What does the analysis show on the [Delta (difference)] / difference between locally acquired [Case (situation)] / cases vs imported [Case (situation)] / cases ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is required for locally acquired cases?",
    "new_text": "What is required for locally acquired [Case (situation)] / cases ?",
    "n_kge": 1
  },
  {
    "raw_text": "What was common to all imported cases?",
    "new_text": "What was common to all imported [Case (situation)] / cases ?",
    "n_kge": 1
  },
  {
    "raw_text": "What testing and detection are needed?",
    "new_text": "What [Testing] / testing and [Detection] / detection are needed ?",
    "n_kge": 2
  },
  {
    "raw_text": "What did the finding prompt ecdc to do?",
    "new_text": "What did the [Signs and Symptoms] / finding prompt ecdc to do ?",
    "n_kge": 1
  },
  {
    "raw_text": "Why is understanding the infection-severity critical ?",
    "new_text": "Why is [Comprehension] / understanding the infection - severity critical ?",
    "n_kge": 1
  },
  {
    "raw_text": "Why are serological tests vital?",
    "new_text": "Why are [Serologic tests] / serological tests vital ?",
    "n_kge": 1
  },
  {
    "raw_text": "How can hospital based surveillance help?",
    "new_text": "How can hospital based surveillance help ?",
    "n_kge": 0
  },
  {
    "raw_text": "How can present systems of surveillance be used?",
    "new_text": "How can [Present] / present systems of surveillance be [Used by] / used ?",
    "n_kge": 2
  },
  {
    "raw_text": "How will this approach used?",
    "new_text": "How will this approach [Used by] / used ?",
    "n_kge": 1
  },
  {
    "raw_text": "Why is additional research needed?",
    "new_text": "Why is additional [research] / research needed ?",
    "n_kge": 1
  },
  {
    "raw_text": "What growing dysjunction has been witnessed?",
    "new_text": "What growing dysjunction has been [Witnesses] / witnessed ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is aiming to incorporate pathways to translation at the earliest stages?",
    "new_text": "What is aiming [Tryptophanase] / to incorporate pathways [Tryptophanase] / to translation at the earliest stages ?",
    "n_kge": 2
  },
  {
    "raw_text": "How much have the number of biomedical research publications targeting 'translational' concepts has increased ?",
    "new_text": "How much have the [Numbers] / number of [Biomedical Research] / biomedical research [Publications] / publications targeting ' [Genetic Translation Process] / translational ' concepts has [Increased] / increased ?",
    "n_kge": 5
  },
  {
    "raw_text": "What ways to solve the issues are outlined?",
    "new_text": "What ways [Tryptophanase] / to solve the issues are outlined ?",
    "n_kge": 1
  },
  {
    "raw_text": "How do these exact processes ultimately restrict viral infectivity?",
    "new_text": "How do these exact processes ultimately restrict viral infectivity ?",
    "n_kge": 0
  },
  {
    "raw_text": "What does the author coin this evolutionary dilemma as?",
    "new_text": "What does the [Author] / author [Coins] / coin this evolutionary dilemma as ?",
    "n_kge": 2
  },
  {
    "raw_text": "How do many viruses resolve this ?",
    "new_text": "How do many [Virus] / viruses resolve this ?",
    "n_kge": 1
  },
  {
    "raw_text": "How may this \"achilles heel\" be safely targeted?",
    "new_text": "How may this \" [Structure of achilles tendon] / achilles [Heel] / heel \" be safely targeted ?",
    "n_kge": 2
  },
  {
    "raw_text": "Why may mmhp-targeting therapies exhibit both robust and broadspectrum antiviral efficacy?",
    "new_text": "Why may mmhp - targeting [Therapeutic procedure] / therapies [Exhibits as Topic] / exhibit both [Robust] / robust and broadspectrum [Antiviral Agents] / antiviral [Effectiveness] / efficacy ?",
    "n_kge": 5
  },
  {
    "raw_text": "What will achieving this through drug repurposing do?",
    "new_text": "What will achieving this through drug repurposing do ?",
    "n_kge": 0
  },
  {
    "raw_text": "What are also discussed by the author?",
    "new_text": "What are also discussed by the [Author] / author ?",
    "n_kge": 1
  },
  {
    "raw_text": "What does the author anticipate international efforts will do?",
    "new_text": "What does the [Author] / author anticipate international efforts will do ?",
    "n_kge": 1
  },
  {
    "raw_text": "What do pathogens do upon infection?",
    "new_text": "What [ART4 gene] / do pathogens [ART4 gene] / do upon [Communicable Diseases] / infection ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the flip side ?",
    "new_text": "What is the [CFLAR gene] / flip [Side] / side ?",
    "n_kge": 2
  },
  {
    "raw_text": "What do rbps do?",
    "new_text": "What do rbps do ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is included in rbps?",
    "new_text": "What is included in rbps ?",
    "n_kge": 0
  },
  {
    "raw_text": "What do tristetraprolin and auf1, do?",
    "new_text": "What do [Tristetraprolin] / tristetraprolin and [HNRNPD gene] / auf1 , do ?",
    "n_kge": 2
  },
  {
    "raw_text": "What do rbps include?",
    "new_text": "What do rbps include ?",
    "n_kge": 0
  },
  {
    "raw_text": "What domembers of the roquin and regnase families do?",
    "new_text": "What domembers of the [RC3H1 gene] / roquin and regnase families do ?",
    "n_kge": 1
  },
  {
    "raw_text": "What do the rbps include?",
    "new_text": "What do the rbps include ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the increasingly apparent role of rna methylation machinery ?",
    "new_text": "What is the increasingly apparent [Social Role] / role of rna methylation machinery ?",
    "n_kge": 1
  },
  {
    "raw_text": "Where do these activities take place?",
    "new_text": "Where do these [Activities] / activities take [Place] / place ?",
    "n_kge": 2
  },
  {
    "raw_text": "What happens to these activities during infection?",
    "new_text": "What happens to these [Activities] / activities during [Communicable Diseases] / infection ?",
    "n_kge": 2
  },
  {
    "raw_text": "In this way, what do the mrna-destabilising rbps constitute ?",
    "new_text": "In this way , what do the [RNA, Messenger] / mrna - destabilising rbps constitute ?",
    "n_kge": 1
  },
  {
    "raw_text": "What can be done with the 'brake' on the immune system?",
    "new_text": "What can be [Done (qualifier value)] / done with the ' brake ' on the [Immune system] / immune system ?",
    "n_kge": 2
  },
  {
    "raw_text": "What does the author anticipate that continued efforts will lead to?",
    "new_text": "What does the [Author] / author anticipate that [Continuous] / continued efforts will [lead] / lead [Tryptophanase] / to ?",
    "n_kge": 4
  },
  {
    "raw_text": "What is another mrna under post-transcriptional regulation by regnase-1 and roquin?",
    "new_text": "What is another [RNA, Messenger] / mrna under post - transcriptional regulation by regnase - 1 and [RC3H1 gene] / roquin ?",
    "n_kge": 2
  },
  {
    "raw_text": "What does furin encode?",
    "new_text": "What does [paired basic amino acid cleaving enzyme] / furin encode ?",
    "n_kge": 1
  },
  {
    "raw_text": "What are furin, along with other pcsk family members implicated in?",
    "new_text": "What are [paired basic amino acid cleaving enzyme] / furin , along with other pcsk [Family member] / family members implicated in ?",
    "n_kge": 2
  },
  {
    "raw_text": "What do braun and sauter review?",
    "new_text": "What do braun and sauter review ?",
    "n_kge": 0
  },
  {
    "raw_text": "What dis their recent work reveal?",
    "new_text": "What dis their [Recent] / recent [Work] / work reveal ?",
    "n_kge": 2
  },
  {
    "raw_text": "What has the increasing abundance of affordable, sensitive, high-throughput genome sequencing technologies led to?",
    "new_text": "What has the increasing abundance of affordable , [Hypersensitivity] / sensitive , high - throughput genome sequencing technologies led [Tryptophanase] / to ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was this system used for the first time for?",
    "new_text": "What was this [Drug Delivery Systems] / system [Used by] / used for the first time for ?",
    "n_kge": 2
  },
  {
    "raw_text": "What have decades of basic immunology research provided ?",
    "new_text": "What have decades of basic [Immunology] / immunology research provided ?",
    "n_kge": 1
  },
  {
    "raw_text": "What has this focus on mammalian defences and pathologies sidelined?",
    "new_text": "What has this [Focal] / focus on [Mammals] / mammalian defences and [Pathology] / pathologies sidelined ?",
    "n_kge": 3
  },
  {
    "raw_text": "What has crispr/cas antiviral immune system of prokaryotes been repurposed as?",
    "new_text": "What has crispr / cas [Antiviral Agents] / antiviral immune system of [Prokaryote] / prokaryotes been repurposed as ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is another case in point?",
    "new_text": "What is another case in point ?",
    "n_kge": 0
  },
  {
    "raw_text": "What are the ancient lineage of ncldvs?",
    "new_text": "What are the ancient lineage of ncldvs ?",
    "n_kge": 0
  },
  {
    "raw_text": "What do the recent efforts indicate regarding hundreds of human and avian infectious viruses?",
    "new_text": "What do the [Recent] / recent efforts indicate regarding hundreds of [Homo sapiens] / human and [Aves] / avian infectious viruses ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is neo-virology?",
    "new_text": "What is neo - [Science of Virology] / virology ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is predicted these efforts on neo-virology will unlock?",
    "new_text": "What is [Prediction] / predicted these efforts on neo - [Science of Virology] / virology will unlock ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are the two of the four pillars of the national innovation and science agenda?",
    "new_text": "What are the [Two] / two of the [Four] / four pillars of the national innovation and [Science] / science agenda ?",
    "n_kge": 3
  },
  {
    "raw_text": "What do australia's medical research and innovation priorities include?",
    "new_text": "What do australia's medical research and innovation [Priorities] / priorities include ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is essential for these priority outcomes?",
    "new_text": "What is essential for these [Priority] / priority outcomes ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the japan amed tasked with?",
    "new_text": "What is the [Japan] / japan amed tasked with ?",
    "n_kge": 1
  },
  {
    "raw_text": "What serious question was raised?",
    "new_text": "What serious question was raised ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is a recent discovery?",
    "new_text": "What is a [Recent] / recent discovery ?",
    "n_kge": 1
  },
  {
    "raw_text": "Which bat virus have been found to be linked with diseases?",
    "new_text": "Which [Chiroptera] / bat [Virus] / virus have been [Present] / found [Tryptophanase] / to be linked with [Disease] / diseases ?",
    "n_kge": 5
  },
  {
    "raw_text": "What assay played an important role?",
    "new_text": "What [Biological Assay] / assay played an important [Social Role] / role ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was the death toll in the 1918-1919 spanish influenza epidemic?",
    "new_text": "What was the [Cessation of life] / death [TLR4 protein, human] / toll in the 1918 - 1919 spanish [Influenza] / influenza [Epidemic] / epidemic ?",
    "n_kge": 4
  },
  {
    "raw_text": "How many people were infected during the 1918 spanish influenza epidemic?",
    "new_text": "How many [Persons] / people were [Infected] / infected during the 1918 spanish [Influenza] / influenza [Epidemic] / epidemic ?",
    "n_kge": 4
  },
  {
    "raw_text": "What was the case fatality rate in the 1918 spanish influenza epidemic?",
    "new_text": "What was the [Case Fatality Rate] / case fatality rate in the 1918 spanish [Influenza] / influenza [Epidemic] / epidemic ?",
    "n_kge": 3
  },
  {
    "raw_text": "What was the death toll in the 1918-1919 spanish influenza epidemic?",
    "new_text": "What was the [Cessation of life] / death [TLR4 protein, human] / toll in the 1918 - 1919 spanish [Influenza] / influenza [Epidemic] / epidemic ?",
    "n_kge": 4
  },
  {
    "raw_text": "Are the modern day influenza viruses related to the 1918 spanish influenza virus?",
    "new_text": "Are the modern [Daily] / day [Orthomyxoviridae] / influenza viruses [Relationships] / related to the 1918 spanish [Orthomyxoviridae] / influenza virus ?",
    "n_kge": 4
  },
  {
    "raw_text": "Why is the spanish influenza virus the mother of the modern influenza viruses?",
    "new_text": "Why is the spanish [Orthomyxoviridae] / influenza virus the [Mother (person)] / mother of the modern [Orthomyxoviridae] / influenza viruses ?",
    "n_kge": 3
  },
  {
    "raw_text": "When was it determined that the 1918 pandemic was caused by the h1n1 influenza virus?",
    "new_text": "When was it determined that the 1918 [Pandemics] / pandemic was caused by the [Orthomyxovirus Type A, Porcine] / h1n1 influenza virus ?",
    "n_kge": 2
  },
  {
    "raw_text": "Did the spanish influenza or swine flu or the h1n1 virus disappear in humans for some time?",
    "new_text": "Did the spanish [Influenza] / influenza or swine flu or the [Influenza A Virus, H1N1 Subtype] / h1n1 virus disappear in [Homo sapiens] / humans for some [Time] / time ?",
    "n_kge": 4
  },
  {
    "raw_text": "When did the swine flu (spanish influenza) virus reappear in humans?",
    "new_text": "When did the swine flu ( spanish [Orthomyxoviridae] / influenza ) virus reappear in [Homo sapiens] / humans ?",
    "n_kge": 2
  },
  {
    "raw_text": "What descendant lineages of the swine flu (spanish influenza) virus were identified in 2006?",
    "new_text": "What descendant lineages of the swine flu ( spanish [Orthomyxoviridae] / influenza ) virus were identified in 2006 ?",
    "n_kge": 1
  },
  {
    "raw_text": "Are the modern descendant influenza viruses as dangerous as the 1918 parent swine flu (spanish influenza) h1n1 virus?",
    "new_text": "Are the modern descendant [Orthomyxoviridae] / influenza viruses as dangerous as the 1918 [parent] / parent swine flu ( spanish influenza ) h1n1 virus ?",
    "n_kge": 2
  },
  {
    "raw_text": "How dangerous are the modern h1n1 (swine flu) and the h3n2 (influenza a) viruses compared to the 1918 h1n1 (swine flu spanish influenza) viruses?",
    "new_text": "How dangerous are the modern [H1N1] / h1n1 ( swine [Influenza] / flu ) and the h3n2 ( influenza a ) viruses compared to the 1918 [H1N1] / h1n1 ( swine [Influenza] / flu spanish influenza ) viruses ?",
    "n_kge": 4
  },
  {
    "raw_text": "Are the descendant h1n1 strains of the 1918 h1n1 swine flu (spanish influenza) virus, still prevalent?",
    "new_text": "Are the descendant [H1N1] / h1n1 [Muscle strain] / strains of the 1918 [H1N1] / h1n1 [Family suidae] / swine flu ( spanish [Orthomyxoviridae] / influenza ) virus , still prevalent ?",
    "n_kge": 5
  },
  {
    "raw_text": "Is the origin and epidemiology of the 1918 swine flu (spanish influenza) known?",
    "new_text": "Is the origin and [Epidemiology] / epidemiology of the 1918 swine flu ( spanish [Influenza] / influenza ) [Known] / known ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is the geographical origin of the h1n1 swine flu ?",
    "new_text": "What is the geographical origin of the h1n1 [Family suidae] / swine flu ?",
    "n_kge": 1
  },
  {
    "raw_text": "Is the geographical origin of the 1918 h1n1 swine flu known?",
    "new_text": "Is the geographical origin of the 1918 h1n1 [Family suidae] / swine flu [Known] / known ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is an unique feature of the 1918 swine flu?",
    "new_text": "What is [Aniridia type 1] / an unique [Characteristics] / feature of the 1918 swine flu ?",
    "n_kge": 2
  },
  {
    "raw_text": "What season or time of the year do the new strains of influenza emerge?",
    "new_text": "What [Seasons] / season or time of the year do the [New] / new [Muscle strain] / strains of [Influenza] / influenza emerge ?",
    "n_kge": 4
  },
  {
    "raw_text": "Once appeared, when do the influenza like diseases occur in subsequent years?",
    "new_text": "Once appeared , when do the influenza like diseases occur in [Following] / subsequent years ?",
    "n_kge": 1
  },
  {
    "raw_text": "When did the first wave of the h1n1 swine flu (spanish influenza) occur?",
    "new_text": "When did the first wave of the h1n1 [Family suidae] / swine flu ( spanish [Influenza] / influenza ) occur ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was the death rate in the first wave of the 1918 swine flu pandemic?",
    "new_text": "What was the [Mortality Vital Statistics] / death rate in the first wave of the 1918 swine flu [Pandemics] / pandemic ?",
    "n_kge": 2
  },
  {
    "raw_text": "When were the second and the third wave of the 1918-1919 swine flu pandemic?",
    "new_text": "When were the second and the third wave of the 1918 - 1919 swine flu [Pandemics] / pandemic ?",
    "n_kge": 1
  },
  {
    "raw_text": "What was the primary difference between the first wave and the 2nd and 3rd wave of the 1918-1919 swine flu pandemic?",
    "new_text": "What was the primary difference between the first wave and the 2nd and 3rd wave of the 1918 - 1919 swine flu [Pandemics] / pandemic ?",
    "n_kge": 1
  },
  {
    "raw_text": "Why the human influenza viruses do not disappear after herd immunity is developed?",
    "new_text": "Why the human influenza viruses do not disappear after herd immunity is developed ?",
    "n_kge": 0
  },
  {
    "raw_text": "What are the circumstances that promote the spread of influenza virus?",
    "new_text": "What are the circumstances that [Promotion (action)] / promote the [Spreading (qualifier value)] / spread of [Orthomyxoviridae] / influenza virus ?",
    "n_kge": 3
  },
  {
    "raw_text": "Do seasonal temperatures and humidity explain the appearance of the three waves of the 1918 swine flu?",
    "new_text": "Do [Seasonal course] / seasonal [Temperature] / temperatures and [Humidity] / humidity explain the [Personal appearance] / appearance of the [Three] / three waves of the 1918 swine flu ?",
    "n_kge": 5
  },
  {
    "raw_text": "Which virus samples from the 1918 swine flu pandemic have been identified?",
    "new_text": "Which virus samples from the 1918 swine flu [Pandemics] / pandemic have been identified ?",
    "n_kge": 1
  },
  {
    "raw_text": "Are viruses in the first and third waves of the 1918 swine flu pandemic same or derived from the virus from the second wave of the swine flu?",
    "new_text": "Are [Virus] / viruses in the first and third waves of the 1918 swine flu [Pandemics] / pandemic [Same] / same or derived from the [Virus] / virus from the second wave of the swine flu ?",
    "n_kge": 4
  },
  {
    "raw_text": "Was the 1918 swine flu virus novel to humans are was it derived from older viruses?",
    "new_text": "Was the 1918 swine flu virus [New] / novel to [Homo sapiens] / humans are was it derived from older [Virus] / viruses ?",
    "n_kge": 3
  },
  {
    "raw_text": "Do avian flu viruses change over long periods?",
    "new_text": "Do avian flu viruses change over [Long] / long periods ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the typical age profile of mortality in influenza diseases?",
    "new_text": "What is the typical [Age] / age profile of [Mortality Vital Statistics] / mortality in [Influenza] / influenza [Disease] / diseases ?",
    "n_kge": 4
  },
  {
    "raw_text": "What was the age profile of mortality in the 1918 swine flu?",
    "new_text": "What was the [Age] / age profile of [Mortality Vital Statistics] / mortality in the 1918 swine flu ?",
    "n_kge": 2
  },
  {
    "raw_text": "Which age group was most susceptible to die during the 1918 swine flu pandemic?",
    "new_text": "Which [Human Age Group] / age group was most susceptible [Tryptophanase] / to die during the 1918 swine flu [Pandemics] / pandemic ?",
    "n_kge": 3
  },
  {
    "raw_text": "What was the death rate among children during the 1918 swine flu pandemic?",
    "new_text": "What was the death rate among children during the 1918 swine flu [Pandemics] / pandemic ?",
    "n_kge": 1
  },
  {
    "raw_text": "What theory provides partial explanation for the age-specific profile of the death rate in the 1918 swine flu pandemic?",
    "new_text": "What theory provides partial explanation for the age - specific profile of the death rate in the 1918 swine flu [Pandemics] / pandemic ?",
    "n_kge": 1
  },
  {
    "raw_text": "Is there a difference in the pathologic feature and course of disease between modern influenza pandemics and the 1918 swine flu pandemic?",
    "new_text": "Is there a [Delta (difference)] / difference in the pathologic [Characteristics] / feature and course of disease between modern [Influenza] / influenza [Pandemics] / pandemics and the 1918 swine flu [Pandemics] / pandemic ?",
    "n_kge": 5
  },
  {
    "raw_text": "Could the 1918 swine flu virus been controlled by modern day drugs or vaccines?",
    "new_text": "Could the 1918 swine flu virus been controlled by modern [Daily] / day drugs or [Vaccines] / vaccines ?",
    "n_kge": 2
  },
  {
    "raw_text": "Why was there such a high death rate in the 19118 swine flu pandemic?",
    "new_text": "Why was there such a [High] / high [Mortality Vital Statistics] / death rate in the 19118 swine flu [Pandemics] / pandemic ?",
    "n_kge": 3
  },
  {
    "raw_text": "Is the molecular basis of human adaptation of a virus understood?",
    "new_text": "Is the molecular basis of human [Acclimatization] / adaptation of a virus [Comprehension] / understood ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was the initial growth phase pattern?",
    "new_text": "What was the initial growth phase pattern ?",
    "n_kge": 0
  },
  {
    "raw_text": "What was the result of under-reporting?",
    "new_text": "What was the [Result] / result of under - reporting ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is r0?",
    "new_text": "What is r0 ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is likely increase of the reporting rate after the 17th january 2020?",
    "new_text": "What is [Probable diagnosis] / likely [Increase] / increase of the reporting rate after the 17th january 2020 ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the estimated value of r0?",
    "new_text": "What is the [Estimated] / estimated value of r0 ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the likely period of under-reporting?",
    "new_text": "What is the [Probable diagnosis] / likely period of under - reporting ?",
    "n_kge": 1
  },
  {
    "raw_text": "Where and when was 2019-ncov first identified?",
    "new_text": "Where and when was [2019 novel coronavirus] / 2019 - ncov first identified ?",
    "n_kge": 1
  },
  {
    "raw_text": "What are some of the symptoms caused by the virus?",
    "new_text": "What are some of the symptoms caused by the [Virus] / virus ?",
    "n_kge": 1
  },
  {
    "raw_text": "What was the cumulative number of reported cases by 1 january 2020?",
    "new_text": "What was the cumulative [Numbers] / number of [Report (document)] / reported cases by 1 january 2020 ?",
    "n_kge": 2
  },
  {
    "raw_text": "As of 26 january 2020, what had the outbreak resulted in?",
    "new_text": "As of 26 january 2020 , what had the [Disease Outbreaks] / outbreak resulted in ?",
    "n_kge": 1
  },
  {
    "raw_text": "As of 26 january 2020, what countries had sporadic cases?",
    "new_text": "As of 26 january 2020 , what [Country] / countries had sporadic [Case (situation)] / cases ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was the result of the imperial college estimation?",
    "new_text": "What was the [Result] / result of the imperial college estimation ?",
    "n_kge": 1
  },
  {
    "raw_text": "Who release the time series data from 10th to 20th january 2020?",
    "new_text": "Who [Patient Discharge] / release the time series [Data] / data from 10th to 20th january 2020 ?",
    "n_kge": 2
  },
  {
    "raw_text": "Who released the time series data from after 21st january 2020?",
    "new_text": "Who released the time series [Data] / data from after 21st january 2020 ?",
    "n_kge": 1
  },
  {
    "raw_text": "How was the epidemic curve modelled?",
    "new_text": "How was the [Epidemic] / epidemic curve modelled ?",
    "n_kge": 1
  },
  {
    "raw_text": "How was the epidemic curve modeled?",
    "new_text": "How was the [Epidemic] / epidemic curve modeled ?",
    "n_kge": 1
  },
  {
    "raw_text": "What study is reported in this report?",
    "new_text": "What study is [Report (document)] / reported in this report ?",
    "n_kge": 1
  },
  {
    "raw_text": "How does the genome of 2019-vcov compare with sars like viruses and sars-cov?",
    "new_text": "How does the [Genome] / genome of 2019 - vcov compare with [Severe Acute Respiratory Syndrome] / sars like [Virus] / viruses and [SARS coronavirus] / sars - cov ?",
    "n_kge": 4
  },
  {
    "raw_text": "How different is it from sars-related viruses?",
    "new_text": "How different is it from sars - [Relationships] / related viruses ?",
    "n_kge": 1
  },
  {
    "raw_text": "What novel features does the genome have?",
    "new_text": "What [New] / novel [Characteristics] / features does the [Genome] / genome have ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is important for understanding the origin and evolution of this novel lineage b betacoronavirus?",
    "new_text": "What is important for [Comprehension] / understanding the origin and [Biological Evolution] / evolution of this [New] / novel lineage b [Betacoronavirus] / betacoronavirus ?",
    "n_kge": 4
  },
  {
    "raw_text": "What are coronaviruses?",
    "new_text": "What are [Genus: Coronavirus] / coronaviruses ?",
    "n_kge": 1
  },
  {
    "raw_text": "What are four generas?",
    "new_text": "What are [Four] / four generas ?",
    "n_kge": 1
  },
  {
    "raw_text": "What do evolutionary analyses show?",
    "new_text": "What do evolutionary analyses show ?",
    "n_kge": 0
  },
  {
    "raw_text": "What are the examples that have emerged as human pathogens?",
    "new_text": "What are the examples that have emerged as [Homo sapiens] / human pathogens ?",
    "n_kge": 1
  },
  {
    "raw_text": "Where did these viruses originate before crossing the barrier to infect humans?",
    "new_text": "Where did these [Virus] / viruses originate [Before] / before crossing the barrier [Tryptophanase] / to [Infected] / infect [Homo sapiens] / humans ?",
    "n_kge": 5
  },
  {
    "raw_text": "What covs were known to infect humans before december 2019?",
    "new_text": "What covs were [Known] / known [Tryptophanase] / to [Infected] / infect [Homo sapiens] / humans before december 2019 ?",
    "n_kge": 4
  },
  {
    "raw_text": "What do hcov-oc43 and hcov-hku1 cause?",
    "new_text": "What do hcov - oc43 and hcov - hku1 [Etiology aspects] / cause ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the contrast with sars-cov and mers=cov?",
    "new_text": "What is the [Contrast Media] / contrast with [SARS coronavirus] / sars - cov and [Middle East Respiratory Syndrome] / middle east respiratory syndrome = cov ?",
    "n_kge": 3
  },
  {
    "raw_text": "What was the authors' recent report on?",
    "new_text": "What was the [Author] / authors ' [Recent] / recent [Report (document)] / report on ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is analyzed in this study?",
    "new_text": "What is analyzed in this study ?",
    "n_kge": 0
  },
  {
    "raw_text": "What genome sequence was available for this study?",
    "new_text": "What genome sequence was available for this study ?",
    "n_kge": 0
  },
  {
    "raw_text": "What strains were included in this study?",
    "new_text": "What [Muscle strain] / strains were included in this study ?",
    "n_kge": 1
  },
  {
    "raw_text": "How was the phylogenetic construction done?",
    "new_text": "How was the phylogenetic [Construction worker] / construction done ?",
    "n_kge": 1
  },
  {
    "raw_text": "How were the evolutionary distances computed?",
    "new_text": "How were the evolutionary distances computed ?",
    "n_kge": 0
  },
  {
    "raw_text": "How was the structural analysis of orf8 done?",
    "new_text": "How was the structural analysis of orf8 done ?",
    "n_kge": 0
  },
  {
    "raw_text": "What was done for the prediction of protein secondary structures?",
    "new_text": "What was [Done (qualifier value)] / done for the [Prediction] / prediction of protein secondary structures ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the rna of the 2019-ncov?",
    "new_text": "What is the [RNA] / rna of the [2019 novel coronavirus] / 2019 - ncov ?",
    "n_kge": 2
  },
  {
    "raw_text": "What was the g+c content?",
    "new_text": "What was the g + c content ?",
    "n_kge": 0
  },
  {
    "raw_text": "How are 2019-ncov and sars-cov similar?",
    "new_text": "How are [2019 novel coronavirus] / 2019 - ncov and [SARS coronavirus] / sars - cov similar ?",
    "n_kge": 2
  },
  {
    "raw_text": "Where is the major distinction?",
    "new_text": "Where is the [Severe (severity modifier)] / major distinction ?",
    "n_kge": 1
  },
  {
    "raw_text": "What do the s1 and s2 subunits of spike glycoprotein contain?",
    "new_text": "What do the s1 and s2 subunits of spike [Glycoproteins] / glycoprotein contain ?",
    "n_kge": 1
  },
  {
    "raw_text": "What are the chacateristics of the s2 subunit?",
    "new_text": "What are the chacateristics of the s2 [Protein Subunits] / subunit ?",
    "n_kge": 1
  },
  {
    "raw_text": "What would be the benefit of the identity of the s2 unit?",
    "new_text": "What would be the benefit of the [Sense of identity (observable entity)] / identity of the s2 [Unit] / unit ?",
    "n_kge": 2
  },
  {
    "raw_text": "How do the s1 subunits compare with that of sars-likecov and human sars-cov?",
    "new_text": "How do the s1 subunits compare with that of [Severe Acute Respiratory Syndrome] / sars - likecov and [Homo sapiens] / human [SARS coronavirus] / sars - cov ?",
    "n_kge": 3
  },
  {
    "raw_text": "Where are the amino acid differences?",
    "new_text": "Where are the amino acid differences ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is responsible for the interaction with host receptor?",
    "new_text": "What is [Responsible to (attribute)] / responsible for the interaction with [Host (organism)] / host [receptor] / receptor ?",
    "n_kge": 3
  },
  {
    "raw_text": "What will the investigation of external subdomain reveal?",
    "new_text": "What will the [Evaluation] / investigation of [Extrinsic] / external subdomain reveal ?",
    "n_kge": 2
  },
  {
    "raw_text": "How do most bat sarsr-cov differ from 2019-ncov and human sars-cov?",
    "new_text": "How do most [Chiroptera] / bat sarsr - cov differ from [2019 novel coronavirus] / 2019 - ncov and [Homo sapiens] / human [SARS coronavirus] / sars - cov ?",
    "n_kge": 4
  },
  {
    "raw_text": "Which strains do not have such deletions?",
    "new_text": "Which [Muscle strain] / strains do not have such deletions ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the consequence of lack of deletions in yunnan strains?",
    "new_text": "What is the consequence of lack of deletions in yunnan [Muscle strain] / strains ?",
    "n_kge": 1
  },
  {
    "raw_text": "Being closest to 2019-ncov, which species do the two bat sars-related coronavirus zxc21 and zc45 infect?",
    "new_text": "Being closest to [2019 novel coronavirus] / 2019 - ncov , which species do the [Two] / two [Chiroptera] / bat sars - related coronavirus zxc21 and zc45 [Infected] / infect ?",
    "n_kge": 4
  },
  {
    "raw_text": "What would lessen the likelihood of jumping the barrier?",
    "new_text": "What would lessen the [Probability] / likelihood of [Jumping] / jumping the barrier ?",
    "n_kge": 2
  },
  {
    "raw_text": "What do the results indicate?",
    "new_text": "What do the results indicate ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is orf8?",
    "new_text": "What is orf8 ?",
    "n_kge": 0
  },
  {
    "raw_text": "What orf8 length do human sars-covs isolated from early-phase patients, all civet sars-covs, and other bat sars-related covs contain?",
    "new_text": "What orf8 [Length] / length do [Homo sapiens] / human sars - covs isolated from early - phase [Patients] / patients , all civet sars - covs , and other [Chiroptera] / bat sars - [Relationships] / related covs contain ?",
    "n_kge": 5
  },
  {
    "raw_text": "From where have the original sars-con orf8 been acquired?",
    "new_text": "From where have the [Original] / original [Severe Acute Respiratory Syndrome] / sars - con orf8 been acquired ?",
    "n_kge": 2
  },
  {
    "raw_text": "What does the orf8 derived from 2019-ncov belong to?",
    "new_text": "What does the orf8 derived from [2019 novel coronavirus] / 2019 - ncov belong [Tryptophanase] / to ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the relation between the new2019-ncov and the conserved orf8?",
    "new_text": "What is the [Relative (related person)] / relation between the new2019 - [2019 novel coronavirus] / ncov and the conserved orf8 ?",
    "n_kge": 2
  },
  {
    "raw_text": "Orf8 was shown to do what?",
    "new_text": "Orf8 was shown to do what ?",
    "n_kge": 0
  },
  {
    "raw_text": "What high possibility does the novel orf8 have?",
    "new_text": "What [High] / high possibility does the [New] / novel orf8 have ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the summary of this report?",
    "new_text": "What is the summary of this report ?",
    "n_kge": 0
  },
  {
    "raw_text": "Where was covid19 first discovered?",
    "new_text": "Where was [COVID-19] / covid19 first discovered ?",
    "n_kge": 1
  },
  {
    "raw_text": "Where can published genomic sequences be found for the 2019-ncov virus?",
    "new_text": "Where can published [Genome] / genomic [DNA Sequence] / sequences be found for the [2019 novel coronavirus] / 2019 - ncov virus ?",
    "n_kge": 3
  },
  {
    "raw_text": "What genes have been targeted for the diagnostic rt-pcr tests in 2019-ncov?",
    "new_text": "What [Genes] / genes have been targeted for the [Diagnosis] / diagnostic [Reverse Transcriptase Polymerase Chain Reaction] / rt - pcr [Laboratory Procedures] / tests in [2019 novel coronavirus] / 2019 - ncov ?",
    "n_kge": 5
  },
  {
    "raw_text": "How does being a smoker impact covid-19 patient outcomes?",
    "new_text": "How does being a [Smoker] / smoker [IMPACT gene] / impact [COVID-19] / covid - 19 patient outcomes ?",
    "n_kge": 3
  },
  {
    "raw_text": "Are smokers more likely to contract influenza?",
    "new_text": "Are [Smoker] / smokers more [Probable diagnosis] / likely [Tryptophanase] / to [Contract agreement] / contract [Influenza] / influenza ?",
    "n_kge": 5
  },
  {
    "raw_text": "Why might we underestimate the spread of covid19?",
    "new_text": "Why might we underestimate the [Spreading (qualifier value)] / spread of [COVID-19] / covid19 ?",
    "n_kge": 2
  },
  {
    "raw_text": "Where was the first imported case of covid19 in the united states?",
    "new_text": "Where was the first imported [Case (situation)] / case of [COVID-19] / covid19 in the [United States] / united states ?",
    "n_kge": 3
  },
  {
    "raw_text": "When was the first case of covid19 confirmed in the usa?",
    "new_text": "When was the first [Case (situation)] / case of [COVID-19] / covid19 confirmed in the [United States] / usa ?",
    "n_kge": 3
  },
  {
    "raw_text": "When was the second covid19 case reported in the us?",
    "new_text": "When was the second [COVID-19] / covid19 [Case (situation)] / case [Report (document)] / reported in the us ?",
    "n_kge": 3
  },
  {
    "raw_text": "Where was the second reported case of covid in the united states?",
    "new_text": "Where was the second reported case of covid in the [United States] / united states ?",
    "n_kge": 1
  },
  {
    "raw_text": "When was the first local transmission of covid reported in the united states?",
    "new_text": "When was the first [Local] / local [disease transmission qualifier] / transmission of covid [Report (document)] / reported in the [United States] / united states ?",
    "n_kge": 4
  },
  {
    "raw_text": "When did the who declare covid to be a public health emergency of international concern?",
    "new_text": "When did the [World Health Organization] / world health organization declare covid [Tryptophanase] / to be a [public health medicine (field)] / public health [Emergency Situation] / emergency of international concern ?",
    "n_kge": 4
  },
  {
    "raw_text": "When did the united states declare covid19 a public health emergency?",
    "new_text": "When did the [United States] / united states declare [COVID-19] / covid19 a [public health medicine (field)] / public health [Emergency Situation] / emergency ?",
    "n_kge": 4
  },
  {
    "raw_text": "What are the most common symptoms of covid19?",
    "new_text": "What are the most common symptoms of [COVID-19] / covid19 ?",
    "n_kge": 1
  },
  {
    "raw_text": "What symptoms might people experience with covid19?",
    "new_text": "What symptoms might [Persons] / people [Practice Experience] / experience with [COVID-19] / covid19 ?",
    "n_kge": 3
  },
  {
    "raw_text": "Who is at greater risk of dying from covid19?",
    "new_text": "Who is at greater [Risk] / risk of [Dying Process] / dying from [COVID-19] / covid19 ?",
    "n_kge": 3
  },
  {
    "raw_text": "How long is the incubation time for covid19?",
    "new_text": "How [Long] / long is the incubation time for [COVID-19] / covid19 ?",
    "n_kge": 2
  },
  {
    "raw_text": "How does covid19 get spread?",
    "new_text": "How does [COVID-19] / covid19 get [Spreading (qualifier value)] / spread ?",
    "n_kge": 2
  },
  {
    "raw_text": "Is it possible to get infected with covid and another virus?",
    "new_text": "Is it possible [Tryptophanase] / to get [Infected] / infected with covid and another [Virus] / virus ?",
    "n_kge": 3
  },
  {
    "raw_text": "How many people are estimated to need humanitarian assistance in 2020?",
    "new_text": "How many [Persons] / people are [Estimated] / estimated [Tryptophanase] / to need humanitarian assistance in 2020 ?",
    "n_kge": 3
  },
  {
    "raw_text": "For whom does the sars-cov-2 pose a great threat?",
    "new_text": "For whom does the [2019 novel coronavirus] / sars - cov - 2 pose a great threat ?",
    "n_kge": 1
  },
  {
    "raw_text": "What can undermine interventions?",
    "new_text": "What can undermine interventions ?",
    "n_kge": 0
  },
  {
    "raw_text": "Who are expected to be particularly susceptible?",
    "new_text": "Who are expected [Tryptophanase] / to be particularly susceptible ?",
    "n_kge": 1
  },
  {
    "raw_text": "Why populations may be particularly susceptible?",
    "new_text": "Why [geographic population] / populations may be particularly susceptible ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the impact of disease outbreaks?",
    "new_text": "What is the [IMPACT gene] / impact of disease outbreaks ?",
    "n_kge": 1
  },
  {
    "raw_text": "What represents a barrier to testing?",
    "new_text": "What represents a barrier to [Testing] / testing ?",
    "n_kge": 1
  },
  {
    "raw_text": "Where are difficulties are exacerbated during humanitarian crises?",
    "new_text": "Where are [Has difficulty doing (qualifier value)] / difficulties are [Symptom aggravating factors] / exacerbated during humanitarian crises ?",
    "n_kge": 2
  },
  {
    "raw_text": "What can prevent contact tracing?",
    "new_text": "What can prevent [Infectious Disease Contact Tracing] / contact tracing ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is an example of intractable structural challenge?",
    "new_text": "What is [Aniridia type 1] / an example of [Unresponsive to Treatment] / intractable structural [Challenge:Type:Point in time:^Patient:Nominal] / challenge ?",
    "n_kge": 3
  },
  {
    "raw_text": "What should be the priority of the national and international bodies trying to prevent the pandemic?",
    "new_text": "What should be the [Priority] / priority of the national and international [Human body] / bodies trying [Tryptophanase] / to prevent the [Pandemics] / pandemic ?",
    "n_kge": 4
  },
  {
    "raw_text": "What resources need to be identified?",
    "new_text": "What [Resources] / resources need [Tryptophanase] / to be identified ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is an effective public health hygiene?",
    "new_text": "What is an [Effectiveness] / effective [public health medicine (field)] / public health [Hygiene] / hygiene ?",
    "n_kge": 3
  },
  {
    "raw_text": "What has been demonstrated to be effective for prevention?",
    "new_text": "What has been demonstrated [Tryptophanase] / to be effective for prevention ?",
    "n_kge": 1
  },
  {
    "raw_text": "What has increased hand washing?",
    "new_text": "What has [Increased] / increased [Handwashing] / hand washing ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is hand washing to protect one's own health consistent with?",
    "new_text": "What is [Handwashing] / hand washing [Tryptophanase] / to protect one's own [Health] / health consistent with ?",
    "n_kge": 3
  },
  {
    "raw_text": "What is possible in many resource -limited settings?",
    "new_text": "What is possible in many resource - limited settings ?",
    "n_kge": 0
  },
  {
    "raw_text": "What is the foremost authority on minimum standards for humanitarian assistance?",
    "new_text": "What is the foremost authority on minimum [standards characteristics] / standards for humanitarian assistance ?",
    "n_kge": 1
  },
  {
    "raw_text": "For what there is evidence for the efficacy of hand washing?",
    "new_text": "For what there is evidence for the [Effectiveness] / efficacy of [Handwashing] / hand washing ?",
    "n_kge": 2
  },
  {
    "raw_text": "What are humanitarian wash standards based on?",
    "new_text": "What are humanitarian [Wash (cleansing action)] / wash [standards characteristics] / standards based on ?",
    "n_kge": 2
  },
  {
    "raw_text": "What confers a high risk of gender based violence?",
    "new_text": "What confers a high risk of [Gender-Based Violence] / gender based violence ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is the deterrent effect of gender based violence around latrines?",
    "new_text": "What is the deterrent effect of [Gender-Based Violence] / gender based violence around [Latrines] / latrines ?",
    "n_kge": 2
  },
  {
    "raw_text": "What will maximize the effectiveness of interventions?",
    "new_text": "What will maximize the effectiveness of interventions ?",
    "n_kge": 0
  },
  {
    "raw_text": "What will happen without the adaptation of existing standards?",
    "new_text": "What will happen without the [Acclimatization] / adaptation of existing [standards characteristics] / standards ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is essential when pandemics threaten vulnerable populations?",
    "new_text": "What is essential when [Pandemics] / pandemics threaten vulnerable populations ?",
    "n_kge": 1
  },
  {
    "raw_text": "What is a necessary component of effective health governance?",
    "new_text": "What is a necessary component of [Effectiveness] / effective [Health] / health governance ?",
    "n_kge": 2
  },
  {
    "raw_text": "Approximately how many people died during the 1918-1919 influenza pandemic?",
    "new_text": "Approximately how many [Persons] / people [Cessation of life] / died during the 1918 - 1919 [Influenza] / influenza [Pandemics] / pandemic ?",
    "n_kge": 4
  },
  {
    "raw_text": "What social and economic factors contributed to the large fatality rate in the 1918 influenza pandemic?",
    "new_text": "What social and [Economic Factors] / economic factors contributed to the large fatality rate in the 1918 [Influenza] / influenza [Pandemics] / pandemic ?",
    "n_kge": 3
  },
  {
    "raw_text": "What problems were faced by medical staff during the 1918 epidemic?",
    "new_text": "What problems were faced by medical staff during the 1918 [Epidemic] / epidemic ?",
    "n_kge": 1
  },
  {
    "raw_text": "What helpful drugs are available now to control the disease or to provide palliative care for influenza patients?",
    "new_text": "What helpful [Pharmaceutical Preparations] / drugs are available now [Tryptophanase] / to control the [Disease] / disease or [Tryptophanase] / to provide [Palliative Care] / palliative care for [Influenza] / influenza [Patients] / patients ?",
    "n_kge": 7
  },
  {
    "raw_text": "How has the mortality rate due to influenza declined in usa over past decades?",
    "new_text": "How has the [Mortality Vital Statistics] / mortality rate [Due to] / due to [Influenza] / influenza declined in [United States] / usa over [In the past] / past decades ?",
    "n_kge": 5
  },
  {
    "raw_text": "Is there an influenza vaccine?",
    "new_text": "Is there an [Influenza virus vaccine] / influenza vaccine ?",
    "n_kge": 1
  },
  {
    "raw_text": "For the 2009 influenza pandemic, what were the case fatality rates?",
    "new_text": "For the 2009 [Influenza] / influenza [Pandemics] / pandemic , what were the [Case Fatality Rate] / case fatality rates ?",
    "n_kge": 3
  },
  {
    "raw_text": "What factors would contribute now to the faster rates of influenza infections?",
    "new_text": "What factors would contribute now to the faster rates of [Influenza] / influenza [Infection] / infections ?",
    "n_kge": 2
  },
  {
    "raw_text": "What factors would be responsible in future for the prevention of an influenza pandemic?",
    "new_text": "What factors would be [Responsible to (attribute)] / responsible in future for the [Prophylactic treatment] / prevention of an [Influenza] / influenza [Pandemics] / pandemic ?",
    "n_kge": 4
  },
  {
    "raw_text": "What was the detected fatality rate of h7n9 avian flu?",
    "new_text": "What was the detected fatality rate of [Influenza in Birds] / h7n9 [Influenza in Birds] / avian flu ?",
    "n_kge": 2
  },
  {
    "raw_text": "Why would real case fatality rate for the h7n9 be lower than detected rate?",
    "new_text": "Why would real [Case Fatality Rate] / case fatality rate for the [Influenza in Birds] / h7n9 be lower than detected rate ?",
    "n_kge": 2
  },
  {
    "raw_text": "What is the structure of the ebolavirus?",
    "new_text": "What is the structure of the [Ebolavirus] / ebolavirus ?",
    "n_kge": 1
  },
  {
    "raw_text": "When was the west african ebolavirus outbreak?",
    "new_text": "When was the west african [Ebolavirus] / ebolavirus [Disease Outbreaks] / outbreak ?",
    "n_kge": 2
  },
  {
    "raw_text": "What animals are considered to be maintenance hosts to the ebolavirus?",
    "new_text": "What [Animals] / animals are considered [Tryptophanase] / to be [Maintenance] / maintenance [Host (organism)] / hosts [Tryptophanase] / to the [Ebolavirus] / ebolavirus ?",
    "n_kge": 6
  },
  {
    "raw_text": "What do circles indicate in figure 1?",
    "new_text": "What do circles indicate in figure 1 ?",
    "n_kge": 0
  },
  {
    "raw_text": "What do arrows indicate in figure 1?",
    "new_text": "What do arrows indicate in figure 1 ?",
    "n_kge": 0
  }
]